

## Edit Saved Searches for User *cnichols*

Queries 10 through 39.

S #	Comment	Database	Query String
S39	<input type="text"/>	PGPB,USPT,USOC,EPAB,JPAB,DWPI	(somatotropin OR growth-hormone OR hGH OR human growth hormone AND insulin ) AND @PY somatotropin OR growth-hormone OR hGH OR human growth hormone AND fusion protein AND chimera
S38	<input type="text"/>	PGPB,USPT,USOC,EPAB,JPAB,DWPI	(somatotropin OR growth-hormone OR hGH OR human growth hormone AND insulin ) AND @PY somatotropin OR growth-hormone OR hGH OR human growth hormone AND fusion protein AND chimera
S37	<input type="text"/>	PGPB,USPT,USOC,EPAB,JPAB,DWPI	(somatotropin OR growth-hormone OR hGH OR human growth hormone AND insulin ) AND @PY somatotropin OR growth-hormone OR hGH OR human growth hormone AND fusion protein
S36	<input type="text"/>	PGPB,USPT,USOC,EPAB,JPAB,DWPI	( somatotropin OR growth-hormone OR hGH OR human growth hormone AND insulin ) AND @PY

			<= 1998
S35		PGPB,USPT,USOC,EPAB,JPAB,DWPI	somatotropin OR growth-hormone OR hGH OR human growth hormone AND insulin
S34		PGPB,USPT,USOC,EPAB,JPAB,DWPI	somatotropin OR growth-hormone OR hGH OR human growth hormone
S33		PGPB,USPT,USOC,EPAB,JPAB,DWPI	(somatotropin)
S32		PGPB,USPT,USOC,EPAB,JPAB,DWPI	536/23.4,23.5,23.51.CCLS. AND insulin AND human growth hormone AND @AYL21 AND fusion protein AND somatotropin
S31		PGPB,USPT,USOC,EPAB,JPAB,DWPI	536/23.4,23.5,23.51.CCLS. AND insulin AND human growth hormone AND @AYL21 AND fusion protein
S30		PGPB,USPT,USOC,EPAB,JPAB,DWPI	536/23.4,23.5,23.51.CCLS. AND insulin AND human growth hormone AND @AY<=1998
S29		PGPB,USPT,USOC,EPAB,JPAB,DWPI	((435/252.1,325.CCLS.) AND insulin AND human growth hormone OR hGH OR somatotropin ) AND @AY 536/23.4,23.5,23.51.CCLS. AND insulin AND chimeric protein
S28		PGPB,USPT,USOC,EPAB,JPAB,DWPI	( (435/252.1,325.CCLS.) AND insulin AND human growth hormone OR hGH OR somatotropin ) AND @AY <= 1998
S27		PGPB,USPT,USOC,EPAB,JPAB,DWPI	( (435/252.1,325.CCLS.) AND insulin AND human growth hormone OR hGH OR somatotropin ) AND @AD <= 1998
S26		PGPB,USPT,USOC,EPAB,JPAB,DWPI	( 536/23.4,23.5,23.51.CCLS. AND insulin AND human

			growth hormone ) AND @AD <= 1998
S25		PGPB,USPT,USOC,EPAB,JPAB,DWPI	536/23.4,23.5,23.51.CCLS. AND insulin AND human growth hormone
S24		PGPB,USPT,USOC,EPAB,JPAB,DWPI	536/23.4,23.5,23.51.CCLS. AND insulin
S23		PGPB,USPT,USOC,EPAB,JPAB,DWPI	536/23.4,23.5,23.51.CCLS.
S22		PGPB,USPT,USOC,EPAB,JPAB,DWPI	536/23.4,23.5,23.
S21		PGPB,USPT,USOC,EPAB,JPAB,DWPI	(435/252.1,325.CCLS.) AND insulin AND human growth hormone OR hGH OR somatotropin AND fusion protein AND chimeric protein AND human-growth-hormone AND human-insulin
S20		PGPB,USPT,USOC,EPAB,JPAB,DWPI	(435/252.1,325.CCLS.) AND insulin AND human growth hormone OR hGH OR somatotropin AND fusion protein AND chimeric protein
S19		PGPB,USPT,USOC,EPAB,JPAB,DWPI	(435/252.1,325.CCLS.) AND insulin AND human growth hormone OR hGH OR somatotropin AND fusion protein
S18		PGPB,USPT,USOC,EPAB,JPAB,DWPI	(435/252.1,325.CCLS.) AND insulin AND human growth hormone OR hGH OR somatotropin
S17		PGPB,USPT,USOC,EPAB,JPAB,DWPI	human growth hormone OR hGH OR somatotropin
S16		PGPB,USPT,USOC,EPAB,JPAB,DWPI	(435/252.1,325.CCLS.) AND insulin
S15		PGPB,USPT,USOC,EPAB,JPAB,DWPI	(435/252.1,325.CCLS.)
S14		PGPB,USPT,USOC,EPAB,JPAB,DWPI	Gan.IN.
S13		PGPB,USPT,USOC,EPAB,JPAB,DWPI	Gan-Z-R.IN.



S12		PGPB,USPT,USOC,EPAB,JPAB,DWPI	Gan-Zhong.IN.
S11		PGPB,USPT,USOC,EPAB,JPAB,DWPI	Gan-Zhong-R.IN.
S10		PGPB,USPT,USOC,EPAB,JPAB,DWPI	(Gan-Zhong-Ru.IN.)



Untitled

JP402138298A  
EP000338634A2  
JP403197495A  
20020164712

5399489  
5618697  
5814618  
5846711  
5830462



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for insulin AND growth hormone AND fusion protein Go Clear Save Search

Limits Preview/Index History Clipboard Details

Display Summary Show 500 Sort by Send to

About Entrez

Text Version

All: 14 Review: 1

Items 1 - 14 of 14

One page.

#### Entrez PubMed

Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

#### PubMed Services

Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
My NCBI (Cubby)

#### Related Resources

Order Documents  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

☐ 1: [Sandoval C, Stojanova A, DiFalco MR, Congote LF.](#)

[Related Articles, Links](#)

The fusion of IGF I with stromal cell-derived factor I or alpha1 proteinase inhibitor alters their mitogenic or chemotactic activities while keeping their ability to inhibit HIV-1-gp120 binding.

Biochem Pharmacol. 2003 Jun 15;65(12):2055-63.

PMID: 12787886 [PubMed - indexed for MEDLINE]

☐ 2: [Ohkubo K, Naito Y, Fujiwara T, Miyazaki J, Ikehara Y, Ono J.](#)

[Related Articles, Links](#)

Inhibitory effect of the alpha1-antitrypsin Pittsburgh type-mutant (alpha1-PIM/R) on proinsulin processing in the regulated secretory pathway of the pancreatic beta-cell line MIN6.

Endocr J. 2003 Feb;50(1):9-20.

PMID: 12733705 [PubMed - indexed for MEDLINE]

☐ 3: [Lien S, Milner SJ, Graham LD, Wallace JC, Francis GL.](#)

[Related Articles, Links](#)

Linkers for improved cleavage of fusion proteins with an engineered alpha-lytic protease.

Biotechnol Bioeng. 2001 Aug 20;74(4):335-43.

PMID: 11410858 [PubMed - indexed for MEDLINE]

☐ 4: [Zhang X, Lu X, Jing N, Zhu S.](#)

[Related Articles, Links](#)

cDNA cloning and functional expression of growth hormone receptor from soft-shelled turtle (*Pelodiscus sinensis japonicus*).

Gen Comp Endocrinol. 2000 Sep;119(3):265-75.

PMID: 11017774 [PubMed - indexed for MEDLINE]

☐ 5: [Adams TE, Epa VC, Garrett TP, Ward CW.](#)

[Related Articles, Links](#)

Structure and function of the type 1 insulin-like growth factor receptor.

Cell Mol Life Sci. 2000 Jul;57(7):1050-93. Review.

PMID: 10961344 [PubMed - indexed for MEDLINE]

☐ 6: [Costa C, Solanes G, Visa J, Bosch F.](#)

[Related Articles, Links](#)

Transgenic rabbits overexpressing growth hormone develop acromegaly and diabetes mellitus.

FASEB J. 1998 Nov;12(14):1455-60.

PMID: 9806754 [PubMed - indexed for MEDLINE]

☐ 7: [Kim SO, Jiang J, Yi W, Feng GS, Frank SJ.](#)

[Related Articles, Links](#)

Involvement of the Src homology 2-containing tyrosine phosphatase SHP-2 in growth hormone signaling.

J Biol Chem. 1998 Jan 23;273(4):2344-54.  
PMID: 9442080 [PubMed - indexed for MEDLINE]

- ☐ 8: [Polyak SW, Forsberg G, Forbes BE, McNeil KA, Aplin SE, Wallace JC.](#) [Related Articles, Links](#)



Introduction of spacer peptides N-terminal to a cleavage recognition motif in recombinant fusion proteins can improve site-specific cleavage.  
Protein Eng. 1997 Jun;10(6):615-9.  
PMID: 9278273 [PubMed - indexed for MEDLINE]

- ☐ 9: [Kilgour E, Gout I, Anderson NG.](#) [Related Articles, Links](#)



Requirement for phosphoinositide 3-OH kinase in growth hormone signalling to the mitogen-activated protein kinase and p70s6k pathways.  
Biochem J. 1996 Apr 15;315 ( Pt 2):517-22.  
PMID: 8615823 [PubMed - indexed for MEDLINE]

- ☐ 10: [Serra D, Fillat C, Matas R, Bosch F, Hegardt FG.](#) [Related Articles, Links](#)



Tissue-specific expression and dietary regulation of chimeric mitochondrial 3-hydroxy-3-methylglutaryl coenzyme A synthase/human growth hormone gene in transgenic mice.  
J Biol Chem. 1996 Mar 29;271(13):7529-34.  
PMID: 8631784 [PubMed - indexed for MEDLINE]

- ☐ 11: [Puri NK, Crivelli E, Cardamone M, Fiddes R, Bertolini J, Ninham B, Brandon MR.](#) [Related Articles, Links](#)



Solubilization of growth hormone and other recombinant proteins from Escherichia coli inclusion bodies by using a cationic surfactant.  
Biochem J. 1992 Aug 1;285 ( Pt 3):871-9.  
PMID: 1497625 [PubMed - indexed for MEDLINE]

- ☐ 12: [Francis GL, Ross M, Ballard FJ, Milner SJ, Senn C, McNeil KA, Wallace JC, King R, Wells JR.](#) [Related Articles, Links](#)



Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency.  
J Mol Endocrinol. 1992 Jun;8(3):213-23.  
PMID: 1378742 [PubMed - indexed for MEDLINE]

- ☐ 13: [Nishikawa S, Yanase K, Tokunaga-Doi T, Kodama K, Gomi H, Uesugi S, Ohtsuka E, Kato Y, Suzuki F, Ikehara M.](#) [Related Articles, Links](#)



Efficient cleavage by alpha-thrombin of a recombinant fused protein which contains insulin-like growth factor I.  
Protein Eng. 1987 Dec;1(6):487-92.  
PMID: 3334100 [PubMed - indexed for MEDLINE]



- ☐ 14: [Bayne ML, Cascieri MA, Kelder B, Applebaum J, Chicchi G, Shapiro JA, Pasleau F, Kopchick JJ.](#) [Related Articles, Links](#)



Expression of a synthetic gene encoding human insulin-like growth factor I in cultured mouse fibroblasts.  
Proc Natl Acad Sci U S A. 1987 May;84(9):2638-42.  
PMID: 3033657 [PubMed - indexed for MEDLINE]

Display  ☒ Show  ☒ Sort by  ☒ Send to  ☒

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)  
[Department of Health & Human Services](#)



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for   

Limits Preview/Index History Clipboard Details

Display Abstract Show 20 Sort by Send to

About Entrez

Text Version

All: 1 Review: 0 

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: Biochem J. 1992 Aug 1;285 ( Pt 3):871-9.[Related Articles, Links](#)

### **Solubilization of growth hormone and other recombinant proteins from Escherichia coli inclusion bodies by using a cationic surfactant.**

**Puri NK, Crivelli E, Cardamone M, Fiddes R, Bertolini J, Ninham B, Brandon MR.**

Bunge Scientific and Technical Services Division, North Melbourne, Victoria, Australia.

Recombinant pig growth hormone (rPGH) was solubilized from inclusion bodies by using the cationic surfactant cetyltrimethylammonium chloride (CTAC). The solubilizing action of CTAC appeared to be dependent on the presence of a positively charged head group, as a non-charged variant was inactive. Relatively low concentrations of CTAC were required for rapid solubilization, and protein-bound CTAC was easily removed by ion-exchange chromatography. Compared with solubilization and recovery of rPGH from inclusion bodies with 7.5 M-urea and 6 M-guanidinium chloride, the relative efficiency of solubilization was lower with CTAC. However, superior refolding efficiency resulted in final yields of purified rPGH being in the order of CTAC greater than urea greater than or equal to guanidinium chloride. Detailed comparison of the different rPGH preparations as well as pituitary-derived growth hormone by h.p.l.c., native PAGE, c.d. spectral analysis and radioreceptor-binding assay showed that the CTAC-derived rPGH was essentially indistinguishable from the urea and guanidinium chloride preparations. The CTAC-derived rPGH was of greater biopotency than pituitary-derived growth hormone. The advantages of CTAC over urea and guanidinium chloride for increasing recovery of monomeric rPGH by minimizing aggregation during refolding in vitro were also found with recombinant sheep interleukin-I beta and a sheep insulin-like growth factor II fusion protein. In addition, the bioactivity of the CTAC-derived recombinant interleukin-1 beta was approximately ten-fold greater than that of an equivalent amount obtained from urea and guanidinium chloride preparations. It is concluded that CTAC represents, in general, an excellent additional approach or a superior alternative to urea and in particular guanidinium chloride for solubilization and recovery of

bioactive recombinant proteins from inclusion bodies.

PMID: 1497625 [PubMed - indexed for MEDLINE]

---

Display  Show  Sort by  Send to



[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 29 2005 17:30:14



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed ☒ for   

Limits Preview/Index History Clipboard Details

Display Abstract ☒ Show 20 ☒ Sort by ☒ Send to ☒

All: 1 Review: 0

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: Protein Eng. 1997 Jun;10(6):615-9.

Related Articles, Links

FREE full text article at  
peds.oupjournals.org**Introduction of spacer peptides N-terminal to a cleavage recognition motif in recombinant fusion proteins can improve site-specific cleavage.****Polyak SW, Forsberg G, Forbes BE, McNeil KA, Aplin SE, Wallace JC.**



Co-operative Research Centre for Tissue Growth and Repair, Department of Biochemistry, University of Adelaide, Australia.

To improve site-specific cleavage of a methionyl porcine growth hormone [[Met1]-pGH(1-46)-IGF-II] fusion protein by the enzyme H64A subtilisin, a series of flexible, unstructured spacer peptides were introduced N-terminal to the cleavage site. When enzymatic digestion preceded refolding of the fusion proteins, IGF-II could only be liberated from substrates which contained spacer peptides. Compared with the parent construct, the yield of IGF-II from refolded fusion proteins containing spacers was improved up to two-fold. Furthermore, this cleavage rate was improved by removing a competing protease recognition motif from the fusion partner. These data show that fusion partners can influence site-specific proteolysis of fusion proteins. Introduction of flexible spacers between the moieties can alleviate these interactions.

PMID: 9278273 [PubMed - indexed for MEDLINE]

Display Abstract ☒ Show 20 ☒ Sort by ☒ Send to ☒[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 29 2005 17:30:14



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search  for

Limits Preview/Index History Clipboard Details

Display  Show  Sort by  Send to

About Entrez

Text Version

Entrez PubMed

Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

PubMed Services

Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
My NCBI (Cubby)

Related Resources

Order Documents  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

Items 1 - 6 of 6

One page.

☐ 1: [Ohkubo K, Naito Y, Fujiwara T, Miyazaki J, Ikehara Y, Ono J.](#) Related Articles, Links



Inhibitory effect of the alpha1-antitrypsin Pittsburgh type-mutant (alpha1-PIM/R) on proinsulin processing in the regulated secretory pathway of the pancreatic beta-cell line MIN6.

Endocr J. 2003 Feb;50(1):9-20.

PMID: 12733705 [PubMed - indexed for MEDLINE]



☐ 2: [Noel S, Herman A, Johnson GA, Gray CA, Stewart MD, Bazer FW, Gertler A, Spencer TE.](#) Related Articles, Links



Ovine placental lactogen specifically binds to endometrial glands of the ovine uterus.

Biol Reprod. 2003 Mar;68(3):772-80.

PMID: 12604625 [PubMed - indexed for MEDLINE]



☐ 3: [Adams TE, Epa VC, Garrett TP, Ward CW.](#) Related Articles, Links



Structure and function of the type 1 insulin-like growth factor receptor.

Cell Mol Life Sci. 2000 Jul;57(7):1050-93. Review.

PMID: 10961344 [PubMed - indexed for MEDLINE]



☐ 4: [Costa C, Solanes G, Visa J, Bosch F.](#) Related Articles, Links



Transgenic rabbits overexpressing growth hormone develop acromegaly and diabetes mellitus.

FASEB J. 1998 Nov;12(14):1455-60.

PMID: 9806754 [PubMed - indexed for MEDLINE]



☐ 5: [Serra D, Fillat C, Matas R, Bosch F, Hegardt FG.](#) Related Articles, Links



Tissue-specific expression and dietary regulation of chimeric mitochondrial 3-hydroxy-3-methylglutaryl coenzyme A synthase/human growth hormone gene in transgenic mice.

J Biol Chem. 1996 Mar 29;271(13):7529-34.

PMID: 8631784 [PubMed - indexed for MEDLINE]



☐ 6: [Baumann G, Davila N, Shaw MA, Ray J, Liebhaber SA, Cooke NE.](#) Related Articles, Links





Binding of human growth hormone (GH)-variant (placental GH) to GH-binding proteins in human plasma.

J Clin Endocrinol Metab. 1991 Dec;73(6):1175-9.

PMID: 1955498 [PubMed - indexed for MEDLINE]

Display  Show  Sort by  Send to

[Write to the Help Desk](#)



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search  for

Limits Preview/Index History Clipboard Details

Display  Show  Sort by  Send to

About Entrez

Text Version

All: 9 Review: 1

Items 1 - 9 of 9

One page.

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: [Sandoval C, Stojanova A, DiFalco MR, Congote LF.](#) Related Articles, Links

The fusion of IGF I with stromal cell-derived factor I or alpha1 proteinase inhibitor alters their mitogenic or chemotactic activities while keeping their ability to inhibit HIV-1-gp120 binding.

Biochem Pharmacol. 2003 Jun 15;65(12):2055-63.

PMID: 12787886 [PubMed - indexed for MEDLINE]

☐ 2: [Ohkubo K, Naito Y, Fujiwara T, Miyazaki J, Ikehara Y, Ono J.](#) Related Articles, Links

Inhibitory effect of the alpha1-antitrypsin Pittsburgh type-mutant (alpha1-PIM/R) on proinsulin processing in the regulated secretory pathway of the pancreatic beta-cell line MIN6.

Endocr J. 2003 Feb;50(1):9-20.

PMID: 12733705 [PubMed - indexed for MEDLINE]

☐ 3: [Kim SO, Loesch K, Wang X, Jiang J, Mei L, Cunnick JM, Wu J, Frank SJ.](#) Related Articles, Links

A role for Grb2-associated binder-1 in growth hormone signaling.

Endocrinology. 2002 Dec;143(12):4856-67.

PMID: 12446613 [PubMed - indexed for MEDLINE]

☐ 4: [Townes R, Kostyo JL, Vogel T, Sakal E, Tchelet A, Maher R, Gertler A.](#) Related Articles, Links

Evidence that the N-terminus of human growth hormone is involved in expression of its growth promoting, diabetogenic, and insulin-like activities.

Endocrinology. 1992 Mar;130(3):1225-30.

PMID: 1537288 [PubMed - indexed for MEDLINE]

☐ 5: [Baumann G, Davila N, Shaw MA, Ray J, Liebhaber SA, Cooke NE.](#) Related Articles, Links

Binding of human growth hormone (GH)-variant (placental GH) to GH-binding proteins in human plasma.

J Clin Endocrinol Metab. 1991 Dec;73(6):1175-9.

PMID: 1955498 [PubMed - indexed for MEDLINE]

☐ 6: [McGrane MM, Yun JS, Moorman AF, Lamers WH, Hendrick GK, Arafah BM, Park EA, Wagner TE, Hanson RW.](#) Related Articles, Links

Metabolic effects of developmental, tissue-, and cell-specific expression of a chimeric phosphoenolpyruvate carboxykinase (GTP)/bovine growth hormone gene in transgenic mice.

J Biol Chem. 1990 Dec 25;265(36):22371-9.

PMID: 1702419 [PubMed - indexed for MEDLINE]



- ☐ 7: [McGrane MM, Yun JS, Roesler WJ, Park EA, Wagner TE, Hanson RW.](#) [Related Articles, Links](#)



Developmental regulation and tissue-specific expression of a chimaeric phosphoenolpyruvate carboxykinase/bovine growth hormone gene in transgenic animals.

J Reprod Fertil Suppl. 1990;41:17-23. Review.

PMID: 2213709 [PubMed - indexed for MEDLINE]

- ☐ 8: [Hatzoglou M, Park E, Wynshaw-Boris A, Kaung HL, Hanson RW.](#) [Related Articles, Links](#)



Hormonal regulation of chimeric genes containing the phosphoenolpyruvate carboxykinase promoter regulatory region in hepatoma cells infected by murine retroviruses.

J Biol Chem. 1988 Nov 25;263(33):17798-808.

PMID: 2846579 [PubMed - indexed for MEDLINE]

- ☐ 9: [McGrane MM, de Vente J, Yun J, Bloom J, Park E, Wynshaw-Boris A, Wagner T, Rottman FM, Hanson RW.](#) [Related Articles, Links](#)



Tissue-specific expression and dietary regulation of a chimeric phosphoenolpyruvate carboxykinase/bovine growth hormone gene in transgenic mice.

J Biol Chem. 1988 Aug 15;263(23):11443-51.

PMID: 2841327 [PubMed - indexed for MEDLINE]

Display  ☐ Show  ☐ Sort by  ☐ Send to  ☐



[Write to the Help Desk](#)



[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 29 2005 17:30:14






My NC  
[Sign In] [Regis]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search PubMed for

Limits Preview/Index History Clipboard Details

Display Abstract Show 20 Sort by Send to

All: 1 Review: 0 

Entrez PubMed

Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

PubMed Services

Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
My NCBI (Cubby)

Related Resources

Order Documents  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

☐ 1: Endocrinology. 1992 Mar;130(3):1225-30.

Related Articles, Links

FREE full text article at  
[endo.endojournals.org](http://endo.endojournals.org)

**Evidence that the N-terminus of human growth hormone is involved in expression of its growth promoting, diabetogenic, and insulin-like activities.**

**Towns R, Kostyo JL, Vogel T, Sakal E, Tchelet A, Maher R, Gertler A.**

Department of Physiology, University of Michigan Medical School, Ann Arbor 48109.

Recent work with various point and deletion mutants of human GH (hGH) has suggested that the proximal N-terminal end of the hormone molecule is important for its growth promoting action. This study was conducted to examine the growth promoting, diabetogenic, and insulin-like activities of two N-terminal mutants of hGH, the deletion mutant Des-7 hGH (met8, ala11), and a chimeric mutant of bovine GH (bGH) and hGH containing the N-terminal 13 amino acids of bGH (met, ala 1-13/14-191, asp11). The CD spectra of these mutants are similar to that of wild-type hGH and they retain lactogenic activity on Nb2 lymphoma cells, whereas their ability to bind to somatogenic receptors on IM-9 lymphocytes and bovine liver membranes is markedly reduced. In this study, growth promoting activity of the mutants was assessed using the 9-day weight gain test in hypophysectomized rats. Des-7 hGH had a potency of 0.03 IU/mg protein in this assay, whereas the potency of the bGH/hGH chimera was 0.71 IU/mg. Diabetogenic activity was tested in the ob/ob mouse, using the elevation of fasting blood glucose and the worsening of glucose tolerance after a 3-day course of treatment as end-points. Both Des-7 hGH and the bGH/hGH chimera had reduced diabetogenic activity compared to that of biosynthetic wild-type hGH, consistent with their reduced growth activity. Insulin-like activity was assessed by testing the in vitro ability of the mutants to stimulate [14C] glucose oxidation by epididymal adipose tissue of hypophysectomized rats. Des-7 hGH had about 1% the activity of wild-type hGH, whereas the chimera was about 20% as active. When Des-7 hGH was added to the incubation medium along with wild-type hGH in ratios of 5, 12.5, or 25:1 (Des-7 hGH:hGH), the insulin-like action of hGH was significantly inhibited, indicating that the mutant is a modest antagonist of the insulin-

like action of hGH. When the ability of Des-7 hGH to compete with [125I] hGH for binding to isolated rat adipocytes was tested, the mutant was about 10% as effective as wild-type hGH. Thus, Des-7 hGH appears to be more effective in binding to adipocyte GH receptors than in triggering an insulin-like response, perhaps accounting for its modest antagonistic activity. The results of this study suggest that the proximal N-terminal end of the hGH molecule is involved in the expression of the growth promoting, diabetogenic and insulin-like activities of GH.



PMID: 1537288 [PubMed - indexed for MEDLINE] .

---

Display  Show  Sort by  Send to

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)  
Department of Health & Human Services  
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 29 2005 17:30:14



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search  for

Limits Preview/Index History Clipboard Details  
 Display  Show  Sort by  Send to

About Entrez

Text Version

Entrez PubMed

Overview  
 Help | FAQ  
 Tutorial  
 New/Noteworthy  
 E-Utilities

PubMed Services

Journals Database  
 MeSH Database  
 Single Citation Matcher  
 Batch Citation Matcher  
 Clinical Queries  
 LinkOut

My NCBI (Cubby)

Related Resources

Order Documents  
 NLM Catalog  
 NLM Gateway  
 TOXNET  
 Consumer Health  
 Clinical Alerts  
 ClinicalTrials.gov  
 PubMed Central

Items 1 - 58 of 58

One page.

☐ 1: [Vanderschueren D, Vandenput L, Boonen S.](#) [Related Articles, Links](#)

Reversing sex steroid deficiency and optimizing skeletal development in the adolescent with gonadal failure.  
 Endocr Dev. 2005;8:150-65.  
 PMID: 15722623 [PubMed - in process]

☐ 2: [Mauras N, Welch S, Rini A, Klein KO.](#) [Related Articles, Links](#)

An open label 12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys.  
 J Pediatr Endocrinol Metab. 2004 Dec;17(12):1597-606.  
 PMID: 15645693 [PubMed - in process]

☐ 3: [Jorgensen L, Kim DH, Vermehren C, Bjerregaard S, Frokjaer S.](#) [Related Articles, Links](#)

Micropipette manipulation: a technique to evaluate the stability of water-in-oil emulsions containing proteins.  
 J Pharm Sci. 2004 Dec;93(12):2994-3003.  
 PMID: 15468333 [PubMed - indexed for MEDLINE]

☐ 4: [Pursel VG, Mitchell AD, Bee G, Elsasser TH, McMurtry JP, Wall RJ, Coleman ME, Schwartz RJ.](#) [Related Articles, Links](#)

Growth and tissue accretion rates of swine expressing an insulin-like growth factor I transgene.  
 Anim Biotechnol. 2004 May;15(1):33-45.  
 PMID: 15248599 [PubMed - indexed for MEDLINE]

☐ 5: [Nishimura G, Hasegawa T, Kinoshita E, Tanaka Y, Kurosawa K, Yoshimoto M.](#) [Related Articles, Links](#)

Newly recognized syndrome of metaphyseal undermodeling, spondylar dysplasia, and overgrowth: report of two adolescents and a child.  
 Am J Med Genet A. 2004 Jul 15;128(2):204-8.  
 PMID: 15214018 [PubMed - indexed for MEDLINE]

☐ 6: [Lilja L, Johansson JU, Gromada J, Mandic SA, Fried G, Berggren PO, Bark C.](#) [Related Articles, Links](#)

Cyclin-dependent kinase 5 associated with p39 promotes Munc18-1 phosphorylation and Ca(2+)-dependent exocytosis.  
 J Biol Chem. 2004 Jul 9;279(28):29534-41. Epub 2004 Apr 26.  
 PMID: 15123626 [PubMed - indexed for MEDLINE]

☐ 7: [Eshet R, Gil-Ad I, Apelboym O, Segev Y, Phillip M, Werner H.](#) [Related Articles, Links](#)

Modulation of brain insulin-like growth factor I (IGF-I) binding sites and

hypothalamic GHRH and somatostatin levels by exogenous growth hormone and IGF-I in juvenile rats.

J Mol Neurosci. 2004;22(3):179-88.

PMID: 14997011 [PubMed - indexed for MEDLINE]

- ☐ **8:** [Wang Y, Price SE, Jiang H.](#) Related Articles, Links



Cloning and characterization of the bovine class 1 and class 2 insulin-like growth factor-I mRNAs.

Domest Anim Endocrinol. 2003 Nov;25(4):315-28.

PMID: 14652133 [PubMed - indexed for MEDLINE]

- ☐ **9:** [Vong QP, Chan KM, Leung K, Cheng CH.](#) Related Articles, Links



Common carp insulin-like growth factor-I gene: complete nucleotide sequence and functional characterization of the 5'-flanking region.

Gene. 2003 Dec 11;322:145-56.

PMID: 14644506 [PubMed - indexed for MEDLINE]

- ☐ **10:** [Cheviet S, Coppola T, Haynes LP, Burgoyne RD, Regazzi R.](#) Related Articles, Links



The Rab-binding protein Noc2 is associated with insulin-containing secretory granules and is essential for pancreatic beta-cell exocytosis.

Mol Endocrinol. 2004 Jan;18(1):117-26. Epub 2003 Oct 30.

PMID: 14593078 [PubMed - indexed for MEDLINE]

- ☐ **11:** [Brown CW, Li L, Houston-Hawkins DE, Matzuk MM.](#) Related Articles, Links



Activins are critical modulators of growth and survival.

Mol Endocrinol. 2003 Dec;17(12):2404-17. Epub 2003 Oct 9.

PMID: 14551263 [PubMed - indexed for MEDLINE]

- ☐ **12:** [Gu F, Dube N, Kim JW, Cheng A, Ibarra-Sanchez Mde J, Tremblay ML, Boisclair YR.](#) Related Articles, Links



Protein tyrosine phosphatase 1B attenuates growth hormone-mediated JAK2-STAT signaling.

Mol Cell Biol. 2003 Jun;23(11):3753-62.

PMID: 12748279 [PubMed - indexed for MEDLINE]

- ☐ **13:** [Sjogren K, Jansson JO, Isaksson OG, Ohlsson C.](#) Related Articles, Links



A transgenic model to determine the physiological role of liver-derived insulin-like growth factor I.

Minerva Endocrinol. 2002 Dec;27(4):299-311. Review.

PMID: 12511852 [PubMed - indexed for MEDLINE]

- ☐ **14:** [Osborn BL, Sekut L, Corcoran M, Poortman C, Sturm B, Chen G, Mather D, Lin HL, Parry TJ.](#) Related Articles, Links



Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys.

Eur J Pharmacol. 2002 Dec 5;456(1-3):149-58.

PMID: 12450581 [PubMed - indexed for MEDLINE]

- ☐ **15:** [Kim SO, Loesch K, Wang X, Jiang J, Mei L, Cunnick JM, Wu J, Frank SJ.](#) Related Articles, Links



A role for Grb2-associated binder-1 in growth hormone signaling.

Endocrinology. 2002 Dec;143(12):4856-67.

PMID: 12446613 [PubMed - indexed for MEDLINE]

- ☐ **16:** [Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, Leroith D, Cherman N, Bianco P, Wientroub S, Robey PG.](#) Related Articles, Links

Collins MT.



Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome.

J Clin Endocrinol Metab. 2002 Nov;87(11):5104-12.

PMID: 12414879 [PubMed - indexed for MEDLINE]

☐ 17: Robson H, Siebler T, Shalet SM, Williams GR.

Related Articles, Links



Interactions between GH, IGF-I, glucocorticoids, and thyroid hormones during skeletal growth.

Pediatr Res. 2002 Aug;52(2):137-47. Review.

PMID: 12149488 [PubMed - indexed for MEDLINE]

☐ 18: Wu XH, Chen X, Zhang SL, Pang L, To C, Wang TT, Hohman TC, Filep JG, Chan JS.

Related Articles, Links



Molecular mechanism(s) of insulin action on the expression of the angiotensinogen gene in kidney proximal tubular cells.

J Renin Angiotensin Aldosterone Syst. 2000 Jun;1(2):166-74.

PMID: 11967809 [PubMed - indexed for MEDLINE]

☐ 19: Juul A.

Related Articles, Links



The effects of oestrogens on linear bone growth.

Hum Reprod Update. 2001 May-Jun;7(3):303-13. Review.

PMID: 11392377 [PubMed - indexed for MEDLINE]

☐ 20: Chen X, Zhang SL, Pang L, Filep JG, Tang SS, Ingelfinger JR, Chan JS.

Related Articles, Links



Characterization of a putative insulin-responsive element and its binding protein(s) in rat angiotensinogen gene promoter: regulation by glucose and insulin.

Endocrinology. 2001 Jun;142(6):2577-85.

PMID: 11356707 [PubMed - indexed for MEDLINE]

☐ 21: Mauras N, Hayes V, O'Brien KO.

Related Articles, Links



Estrogen treatment and estrogen suppression: metabolic effects in adolescence.

J Pediatr Endocrinol Metab. 2000;13 Suppl 6:1431-7. Review.

PMID: 11202220 [PubMed - indexed for MEDLINE]

☐ 22: Zhang X, Lu X, Jing N, Zhu S.

Related Articles, Links



cDNA cloning and functional expression of growth hormone receptor from soft-shelled turtle (*Pelodiscus sinensis japonicus*).

Gen Comp Endocrinol. 2000 Sep;119(3):265-75.

PMID: 11017774 [PubMed - indexed for MEDLINE]

☐ 23: Wada S, Minagawa A, Imamaki K, Suda S, Yamanaka K, Jitaka M, Katayama S.

Related Articles, Links



A patient of hypogonadotropic hypogonadism accompanied by growth hormone deficiency and decreased bone mineral density who attained normal growth.

Intern Med. 2000 Aug;39(8):641-5.

PMID: 10939538 [PubMed - indexed for MEDLINE]

☐ 24: Aridor M, Balch WE.

Related Articles, Links



Perspectives: drug delivery. Regulating export of ER cargo.

Science. 2000 Feb 4;287(5454):816-7. No abstract available.

PMID: 10691557 [PubMed - indexed for MEDLINE]

- ☐ **25:** [Rivera VM, Wang X, Wardwell S, Courage NL, Volchuk A, Keenan T, Holt DA, Gilman M, Orci L, Cerasoli F Jr, Rothman JE, Clackson T.](#) [Related Articles, Links](#)



Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum.

Science. 2000 Feb 4;287(5454):826-30.

PMID: 10657290 [PubMed - indexed for MEDLINE]

- ☐ **26:** [Benbassat C, Shoba LN, Newman M, Adamo ML, Frank SJ, Lowe WL Jr.](#) [Related Articles, Links](#)



Growth hormone-mediated regulation of insulin-like growth factor I promoter activity in C6 glioma cells.

Endocrinology. 1999 Jul;140(7):3073-81.

PMID: 10385399 [PubMed - indexed for MEDLINE]

- ☐ **27:** [Liang L, Zhou T, Jiang J, Pierce JH, Gustafson TA, Frank SJ.](#) [Related Articles, Links](#)



Insulin receptor substrate-1 enhances growth hormone-induced proliferation.

Endocrinology. 1999 May;140(5):1972-83.

PMID: 10218944 [PubMed - indexed for MEDLINE]

- ☐ **28:** [Niiori-Onishi A, Iwasaki Y, Mutsuga N, Oiso Y, Inoue K, Saito H.](#) [Related Articles, Links](#)



Molecular mechanisms of the negative effect of insulin-like growth factor-I on growth hormone gene expression in MtT/S somatotroph cells.

Endocrinology. 1999 Jan;140(1):344-9.

PMID: 9886844 [PubMed - indexed for MEDLINE]

- ☐ **29:** [Swift GH, Liu Y, Rose SD, Bischof LJ, Steelman S, Buchberg AM, Wright CV, MacDonald RJ.](#) [Related Articles, Links](#)



An endocrine-exocrine switch in the activity of the pancreatic homeodomain protein PDX1 through formation of a trimeric complex with PBX1b and MRG1 (MEIS2).

Mol Cell Biol. 1998 Sep;18(9):5109-20.

PMID: 9710595 [PubMed - indexed for MEDLINE]

- ☐ **30:** [Lund PK.](#) [Related Articles, Links](#)



The alpha-smooth muscle actin promoter: a useful tool to analyse autocrine and paracrine roles of mesenchymal cells in normal and diseased bowel.

Gut. 1998 Mar;42(3):320-2. Review.

PMID: 9577334 [PubMed - indexed for MEDLINE]

- ☐ **31:** [Kim SO, Jiang J, Yi W, Feng GS, Frank SJ.](#) [Related Articles, Links](#)



Involvement of the Src homology 2-containing tyrosine phosphatase SHP-2 in growth hormone signaling.








J Biol Chem. 1998 Jan 23;273(4):2344-54.

PMID: 9442080 [PubMed - indexed for MEDLINE]

- ☐ **32:** [Blackburn A, Dressendorfer RA, Blum WF, Erhard M, Brem G, Strasburger CJ, Wolf E.](#) [Related Articles, Links](#)












Interactions of insulin-like growth factor (IGF)-II and growth hormone in vivo: circulating levels of IGF-I and IGF-binding proteins in transgenic mice.

- Eur J Endocrinol. 1997 Dec;137(6):701-8.  
PMID: 9437240 [PubMed - indexed for MEDLINE]
- ☐ **33:** [Ye P, Umayahara Y, Ritter D, Bunting T, Auman H, Rotwein P, D'Ercole AJ.](#) Related Articles, Links  
 Regulation of insulin-like growth factor I (IGF-I) gene expression in brain of transgenic mice expressing an IGF-I-luciferase fusion gene.  
Endocrinology. 1997 Dec;138(12):5466-75.  
PMID: 9389533 [PubMed - indexed for MEDLINE]
- ☐ **34:** [Jacobs ML, Chandrashekar V, Bartke A, Weber RF.](#) Related Articles, Links  
 Early effects of streptozotocin-induced diabetes on insulin-like growth factor-I in the kidneys of growth hormone-transgenic and growth hormone-deficient dwarf mice.  
Exp Nephrol. 1997 Jul-Aug;5(4):337-44.  
PMID: 9259189 [PubMed - indexed for MEDLINE]
- ☐ **35:** [Polyak SW, Forsberg G, Forbes BE, McNeil KA, Aplin SE, Wallace JC.](#) Related Articles, Links  
 Introduction of spacer peptides N-terminal to a cleavage recognition motif in recombinant fusion proteins can improve site-specific cleavage.  
Protein Eng. 1997 Jun;10(6):615-9.  
PMID: 9278273 [PubMed - indexed for MEDLINE]
- ☐ **36:** [Klein KO, Martha PM Jr, Blizzard RM, Herbst T, Rogol AD.](#) Related Articles, Links  
 A longitudinal assessment of hormonal and physical alterations during normal puberty in boys. II. Estrogen levels as determined by an ultrasensitive bioassay.  
J Clin Endocrinol Metab. 1996 Sep;81(9):3203-7.  
PMID: 8784070 [PubMed - indexed for MEDLINE]
- ☐ **37:** [Kilgour E, Gout I, Anderson NG.](#) Related Articles, Links  
 Requirement for phosphoinositide 3-OH kinase in growth hormone signalling to the mitogen-activated protein kinase and p70s6k pathways.  
Biochem J. 1996 Apr 15;315 ( Pt 2):517-22.  
PMID: 8615823 [PubMed - indexed for MEDLINE]
- ☐ **38:** [Szabo M, Butz MR, Banerjee SA, Chikaraishi DM, Frohman LA.](#) Related Articles, Links  
 Autofeedback suppression of growth hormone (GH) secretion in transgenic mice expressing a human GH reporter targeted by tyrosine hydroxylase 5'-flanking sequences to the hypothalamus.  
Endocrinology. 1995 Sep;136(9):4044-8.  
PMID: 7649113 [PubMed - indexed for MEDLINE]
- ☐ **39:** [Berlin I, Chalon S, Payan C, Schollnhammer G, Cesselin F, Varoquaux O, Puech AJ.](#) Related Articles, Links  
 Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine.  
Br J Clin Pharmacol. 1995 Mar;39(3):243-9.  
PMID: 7619663 [PubMed - indexed for MEDLINE]
- ☐ **40:** [Liang Y, Jetton TL, Zimmerman EC, Najafi H, Berner DK, Matschinsky FM, Magnuson MA.](#) Related Articles, Links

Effects of glucose on insulin secretion, glucokinase activity, and



-  transgene expression in transgenic mouse islets containing an upstream glucokinase promoter-human growth hormone fusion gene.  
Diabetes. 1994 Sep;43(9):1138-45.  
PMID: 8070614 [PubMed - indexed for MEDLINE]
- ☐ **41:** Moller C, Emtner M, Arner P, Norstedt G. [Related Articles, Links](#)
-  Growth hormone regulation of lipid metabolism in cells transfected with growth hormone receptor cDNA.  
Mol Cell Endocrinol. 1994 Feb;99(1):111-7.  
PMID: 8187953 [PubMed - indexed for MEDLINE]
- ☐ **42:** Valera A, Rodriguez-Gil JE, Yun JS, McGrane MM, Hanson RW, Bosch F. [Related Articles, Links](#)
-  Glucose metabolism in transgenic mice containing a chimeric P-enolpyruvate carboxykinase/bovine growth hormone gene.  
FASEB J. 1993 Jun;7(9):791-800.  
PMID: 8330686 [PubMed - indexed for MEDLINE]
- ☐ **43:** Lloyd RV, Jin L, Chang A, Kulig E, Camper SA, Ross BD, Downs TR, Frohman LA. [Related Articles, Links](#)
-  Morphologic effects of hGRH gene expression on the pituitary, liver, and pancreas of MT-hGRH transgenic mice. An in situ hybridization analysis.  
Am J Pathol. 1992 Oct;141(4):895-906.  
PMID: 1415483 [PubMed - indexed for MEDLINE]
- ☐ **44:** Puri NK, Crivelli E, Cardamone M, Fiddes R, Bertolini J, Ninham B, Brandon MR. [Related Articles, Links](#)
-  Solubilization of growth hormone and other recombinant proteins from Escherichia coli inclusion bodies by using a cationic surfactant.  
Biochem J. 1992 Aug 1;285 ( Pt 3):871-9.  
PMID: 1497625 [PubMed - indexed for MEDLINE]
- ☐ **45:** Hall LJ, Kajimoto Y, Bichell D, Kim SW, James PL, Counts D, Nixon LJ, Tobin G, Rotwein P. [Related Articles, Links](#)
-  Functional analysis of the rat insulin-like growth factor I gene and identification of an IGF-I gene promoter.  
DNA Cell Biol. 1992 May;11(4):301-13.  
PMID: 1605853 [PubMed - indexed for MEDLINE]
- ☐ **46:** Lewis UJ, Lewis LJ, Salem MA, Staten NR, Galosy SS, Krivi GG. [Related Articles, Links](#)
-  A recombinant-DNA-derived modification of human growth hormone (hGH44-191) with enhanced diabetogenic activity.  
Mol Cell Endocrinol. 1991 Jun;78(1-2):45-54.  
PMID: 1936524 [PubMed - indexed for MEDLINE]
- ☐ **47:** Wolf E, Rapp K, Brem G. [Related Articles, Links](#)
-  Expression of metallothionein-human growth hormone fusion genes in transgenic mice results in disproportionate skeletal gigantism.  
Growth Dev Aging. 1991 Summer;55(2):117-27.  
PMID: 1938045 [PubMed - indexed for MEDLINE]
- ☐ **48:** Pursel VG, Hammer RE, Bolt DJ, Palmiter RD, Brinster RL. [Related Articles, Links](#)
-  Integration, expression and germ-line transmission of growth-related genes in pigs.  
J Reprod Fertil Suppl. 1990;41:77-87. Review.

PMID: 2213718 [PubMed - indexed for MEDLINE]

- ☐ **49:** Miller KF, Bolt DJ, Pursel VG, Hammer RE, Pinkert CA, Palmiter RD, Brinster RL. [Related Articles, Links](#)



Expression of human or bovine growth hormone gene with a mouse metallothionein-1 promoter in transgenic swine alters the secretion of porcine growth hormone and insulin-like growth factor-I.

J Endocrinol. 1989 Mar;120(3):481-8.

PMID: 2926315 [PubMed - indexed for MEDLINE]

- ☐ **50:** Vigneron P, Dainat J, Bacou F. [Related Articles, Links](#)



[Properties of skeletal muscle fibers. II. Hormonal influences]

Reprod Nutr Dev. 1989;29(1):27-53. Review. French.

PMID: 2648515 [PubMed - indexed for MEDLINE]

- ☐ **51:** Mathews LS, Hammer RE, Brinster RL, Palmiter RD. [Related Articles, Links](#)



Expression of insulin-like growth factor I in transgenic mice with elevated levels of growth hormone is correlated with growth.

Endocrinology. 1988 Jul;123(1):433-7.

PMID: 3383777 [PubMed - indexed for MEDLINE]

- ☐ **52:** Ebert KM, Low MJ, Overstrom EW, Buonomo FC, Baile CA, Roberts TM, Lee A, Mandel G, Goodman RH. [Related Articles, Links](#)



A Moloney MLV-rat somatotropin fusion gene produces biologically active somatotropin in a transgenic pig.

Mol Endocrinol. 1988 Mar;2(3):277-83.

PMID: 3398854 [PubMed - indexed for MEDLINE]

- ☐ **53:** Pursel VG, Rexroad CE Jr, Bolt DJ, Miller KF, Wall RJ, Hammer RE, Pinkert CA, Palmiter RD, Brinster RL. [Related Articles, Links](#)



Progress on gene transfer in farm animals.

Vet Immunol Immunopathol. 1987 Dec;17(1-4):303-12.

PMID: 3481144 [PubMed - indexed for MEDLINE]

- ☐ **54:** Welsh M, Hammer RE, Brinster RL, Steiner DF. [Related Articles, Links](#)



Stimulation of growth hormone synthesis by glucose in islets of Langerhans isolated from transgenic mice.

J Biol Chem. 1986 Oct 5;261(28):12915-7.

PMID: 3531193 [PubMed - indexed for MEDLINE]

- ☐ **55:** Binoux M, Gourmelen M, Girard F. [Related Articles, Links](#)



Serum levels of insulin-like growth factor (IGF) and IGF-binding protein in constitutionally short children and adolescents.

Acta Endocrinol (Copenh). 1986 Sep;113(1):145-52.

PMID: 2429488 [PubMed - indexed for MEDLINE]

- ☐ **56:** Ornitz DM, Palmiter RD, Hammer RE, Brinster RL, Swift GH, MacDonald RJ. [Related Articles, Links](#)



Specific expression of an elastase-human growth hormone fusion gene in pancreatic acinar cells of transgenic mice.

Nature. 1985 Feb 14-20;313(6003):600-2.

PMID: 3844051 [PubMed - indexed for MEDLINE]

- ☐ **57:** Palmiter RD, Norstedt G, Gelinas RE, Hammer RE, Brinster RL. [Related Articles, Links](#)



Metallothionein-human GH fusion genes stimulate growth of mice.

Science. 1983 Nov 18;222(4625):809-14. Review.  
PMID: 6356363 [PubMed - indexed for MEDLINE]

☐ 58: [Acher R.](#)

[Related Articles, Links](#)



Molecular evolution of the polypeptide hormones.

Ciba Found Symp. 1976;41:31-59. Review.

PMID: 780077 [PubMed - indexed for MEDLINE]

Display  ☒ Show  ☒ Sort by  ☒ Send to  ☒



[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 29 2005 17:30:14



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed ☒ for insulin AND somatotropin AND chimera

Limits Preview/Index History Clipboard Details

Display Summary ☒ Show 20

About Entrez

Text Version

All: 7 Review: 1 ☒

Items 1 - 7 of 7

One page.

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: [Ohkubo K, Naito Y, Fujiwara T, Miyazaki J, Ikehara Y, Ono J.](#) Related Articles, Links



Inhibitory effect of the alpha1-antitrypsin Pittsburgh type-mutant (alpha1-PIM/R) on proinsulin processing in the regulated secretory pathway of the pancreatic beta-cell line MIN6.

Endocr J. 2003 Feb;50(1):9-20.

PMID: 12733705 [PubMed - indexed for MEDLINE]

☐ 2: [Kim SO, Loesch K, Wang X, Jiang J, Mei L, Cunnick JM, Wu J, Frank SJ.](#) Related Articles, Links



A role for Grb2-associated binder-1 in growth hormone signaling.

Endocrinology. 2002 Dec;143(12):4856-67.

PMID: 12446613 [PubMed - indexed for MEDLINE]

☐ 3: [Towns R, Kostyo JL, Vogel T, Sakal E, Tchelet A, Maher R, Gertler A.](#) Related Articles, Links



Evidence that the N-terminus of human growth hormone is involved in expression of its growth promoting, diabetogenic, and insulin-like activities.

Endocrinology. 1992 Mar;130(3):1225-30.

PMID: 1537288 [PubMed - indexed for MEDLINE]

☐ 4: [Baumann G, Davila N, Shaw MA, Ray J, Liebhaber SA, Cooke NE.](#) Related Articles, Links



Binding of human growth hormone (GH)-variant (placental GH) to GH-binding proteins in human plasma.

J Clin Endocrinol Metab. 1991 Dec;73(6):1175-9.

PMID: 1955498 [PubMed - indexed for MEDLINE]

☐ 5: [McGrane MM, Yun JS, Moorman AF, Lamers WH, Hendrick GK, Arafah BM, Park EA, Wagner TE, Hanson RW.](#) Related Articles, Links



Metabolic effects of developmental, tissue-, and cell-specific expression of a chimeric phosphoenolpyruvate carboxykinase (GTP)/bovine growth hormone gene in transgenic mice.

J Biol Chem. 1990 Dec 25;265(36):22371-9.

PMID: 1702419 [PubMed - indexed for MEDLINE]

☐ 6: [McGrane MM, Yun JS, Roesler WJ, Park EA, Wagner TE, Hanson RW.](#) Related Articles, Links



Developmental regulation and tissue-specific expression of a chimaeric phosphoenolpyruvate carboxykinase/bovine growth hormone gene in transgenic animals.

J Reprod Fertil Suppl. 1990;41:17-23. Review.

PMID: 2213709 [PubMed - indexed for MEDLINE]

- ☐ 7: [McGrane MM, de Vente J, Yun J, Bloom J, Park E, Wynshaw-Boris A, Wagner T, Rottman FM, Hanson RW.](#) [Related Articles, Links](#)



Tissue-specific expression and dietary regulation of a chimeric phosphoenolpyruvate carboxykinase/bovine growth hormone gene in transgenic mice.

J Biol Chem. 1988 Aug 15;263(23):11443-51.

PMID: 2841327 [PubMed - indexed for MEDLINE]

Display  Show  Sort by  Send to



[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 29 2005 17:30:14



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for insulin AND somatotropin AND chimeric Go Clear Save Search

Limits Preview/Index History Clipboard Details

Display Summary Show 20 Sort by Send to

About Entrez

Text Version

All: 18 Review: 0

Items 1 - 18 of 18

One page.

#### Entrez PubMed

Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

#### PubMed Services

Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
My NCBI (Cubby)

#### Related Resources

Order Documents  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

☐ 1: [Ohkubo K, Naito Y, Fujiwara T, Miyazaki J, Ikehara Y, Ono J.](#) Related Articles, Links

Inhibitory effect of the alpha1-antitrypsin Pittsburgh type-mutant (alpha1-PIM/R) on proinsulin processing in the regulated secretory pathway of the pancreatic beta-cell line MIN6.  
Endocr J. 2003 Feb;50(1):9-20.  
PMID: 12733705 [PubMed - indexed for MEDLINE]

☐ 2: [Noel S, Herman A, Johnson GA, Gray CA, Stewart MD, Bazer FW, Gertler A, Spencer TE.](#) Related Articles, Links

Ovine placental lactogen specifically binds to endometrial glands of the ovine uterus.  
Biol Reprod. 2003 Mar;68(3):772-80.  
PMID: 12604625 [PubMed - indexed for MEDLINE]

☐ 3: [Costa C, Solanes G, Visa J, Bosch F.](#) Related Articles, Links

Transgenic rabbits overexpressing growth hormone develop acromegaly and diabetes mellitus.  
FASEB J. 1998 Nov;12(14):1455-60.  
PMID: 9806754 [PubMed - indexed for MEDLINE]

☐ 4: [Ikeda A, Chang KT, Matsumoto Y, Furuhashi Y, Nishihara M, Sasaki F, Takahashi M.](#) Related Articles, Links

Obesity and insulin resistance in human growth hormone transgenic rats.  
Endocrinology. 1998 Jul;139(7):3057-63.  
PMID: 9645676 [PubMed - indexed for MEDLINE]


☐ 5: [Serra D, Fillat C, Matas R, Bosch F, Hegardt FG.](#) Related Articles, Links

Tissue-specific expression and dietary regulation of chimeric mitochondrial 3-hydroxy-3-methylglutaryl coenzyme A synthase/human growth hormone gene in transgenic mice.  
J Biol Chem. 1996 Mar 29;271(13):7529-34.  
PMID: 8631784 [PubMed - indexed for MEDLINE]

☐ 6: [Friedman JE, Yun JS, Patel YM, McGrane MM, Hanson RW.](#) Related Articles, Links

Glucocorticoids regulate the induction of phosphoenolpyruvate carboxykinase (GTP) gene transcription during diabetes.  
J Biol Chem. 1993 Jun 15;268(17):12952-7.  
PMID: 7685354 [PubMed - indexed for MEDLINE]

☐ 7: [Valera A, Rodriguez-Gil JE, Yun JS, McGrane MM, Hanson RW, Bosch F.](#) Related Articles, Links

-  Glucose metabolism in transgenic mice containing a chimeric P-enolpyruvate carboxykinase/bovine growth hormone gene.  
FASEB J. 1993 Jun;7(9):791-800.  
PMID: 8330686 [PubMed - indexed for MEDLINE]
- ☐ **8:** [Hall LJ, Kajimoto Y, Bichell D, Kim SW, James PL, Counts D, Nixon LJ, Tobin G, Rotwein P.](#) Related Articles, Links  
Functional analysis of the rat insulin-like growth factor I gene and identification of an IGF-I gene promoter.  
DNA Cell Biol. 1992 May;11(4):301-13.  
PMID: 1605853 [PubMed - indexed for MEDLINE]
- ☐ **9:** [Townes R, Kostyo JL, Vogel T, Sakal E, Tchelet A, Maher R, Gertler A.](#) Related Articles, Links  
Evidence that the N-terminus of human growth hormone is involved in expression of its growth promoting, diabetogenic, and insulin-like activities.  
Endocrinology. 1992 Mar;130(3):1225-30.  
PMID: 1537288 [PubMed - indexed for MEDLINE]
- ☐ **10:** [Baumann G, Davila N, Shaw MA, Ray J, Liebhaber SA, Cooke NE.](#) Related Articles, Links  
Binding of human growth hormone (GH)-variant (placental GH) to GH-binding proteins in human plasma.  
J Clin Endocrinol Metab. 1991 Dec;73(6):1175-9.  
PMID: 1955498 [PubMed - indexed for MEDLINE]
- ☐ **11:** [Spatola E, Pescovitz OH, Marsh K, Johnson NB, Berry SA, Gelato MC.](#) Related Articles, Links  
Interaction of growth hormone-releasing hormone with the insulin-like growth-factors during prenatal development in the rat.  
Endocrinology. 1991 Sep;129(3):1193-200.  
PMID: 1651841 [PubMed - indexed for MEDLINE]
- ☐ **12:** [Rexroad CE Jr, Mayo K, Bolt DJ, Elsasser TH, Miller KF, Behringer RR, Palmiter RD, Brinster RL.](#) Related Articles, Links  
Transferrin- and albumin-directed expression of growth-related peptides in transgenic sheep.  
J Anim Sci. 1991 Jul;69(7):2995-3004.  
PMID: 1715850 [PubMed - indexed for MEDLINE]
- ☐ **13:** [Hatzoglou M, Bosch F, Park EA, Hanson RW.](#) Related Articles, Links  
Hormonal control of interacting promoters introduced into cells by retroviruses.  
J Biol Chem. 1991 May 5;266(13):8416-25.  
PMID: 2022656 [PubMed - indexed for MEDLINE]
- ☐ **14:** [Bchini O, Andres AC, Schubaur B, Mehtali M, LeMeur M, Lathe R, Gerlinger P.](#) Related Articles, Links  
Precocious mammary gland development and milk protein synthesis in transgenic mice ubiquitously expressing human growth hormone.  
Endocrinology. 1991 Jan;128(1):539-46.  
PMID: 1986943 [PubMed - indexed for MEDLINE]
- ☐ **15:** [McGrane MM, Yun JS, Moorman AF, Lamers WH, Hendrick GK, Arafah BM, Park EA, Wagner TE, Hanson RW.](#) Related Articles, Links  
Metabolic effects of developmental, tissue-, and cell-specific expression



of a chimeric phosphoenolpyruvate carboxykinase (GTP)/bovine growth hormone gene in transgenic mice.

J Biol Chem. 1990 Dec 25;265(36):22371-9.

PMID: 1702419 [PubMed - indexed for MEDLINE]



☐ 16: [Quaife CJ, Mathews LS, Pinkert CA, Hammer RE, Brinster RL, Palmiter RD.](#) Related Articles, Links



Histopathology associated with elevated levels of growth hormone and insulin-like growth factor I in transgenic mice.

Endocrinology. 1989 Jan;124(1):40-8.

PMID: 2642417 [PubMed - indexed for MEDLINE]



☐ 17: [Mathews LS, Hammer RE, Behringer RR, D'Ercole AJ, Bell GI, Brinster RL, Palmiter RD.](#) Related Articles, Links



Growth enhancement of transgenic mice expressing human insulin-like growth factor I.

Endocrinology. 1988 Dec;123(6):2827-33.

PMID: 3197646 [PubMed - indexed for MEDLINE]



☐ 18: [McGrane MM, de Vente J, Yun J, Bloom J, Park E, Wynshaw-Boris A, Wagner T, Rottman FM, Hanson RW.](#) Related Articles, Links



Tissue-specific expression and dietary regulation of a chimeric phosphoenolpyruvate carboxykinase/bovine growth hormone gene in transgenic mice.

J Biol Chem. 1988 Aug 15;263(23):11443-51.

PMID: 2841327 [PubMed - indexed for MEDLINE]

Display

Summary



Show

20



Sort by



Send to



[Write to the Help Desk](#)



[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 29 2005 17:30:14





All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for insulin AND human growth hormone AND confounding factors Go Clear Save Search

Limits Preview/Index History Clipboard Details

Display Summary Show 500 Sort by Send to

About Entrez

Text Version

All: 22 Review: 2

Items 1 - 22 of 22

One page.

Entrez PubMed

Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

PubMed Services

Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
My NCBI (Cubby)

Related Resources

Order Documents  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

☐ 1: [Iliev DI, Wittekindt NE, Ranke MB, Binder G.](#)

[Related Articles, Links](#)



Structural analysis of human growth hormone with respect to the dominant expression of growth hormone (GH) mutations in isolated GH deficiency type II.

Endocrinology. 2005 Mar;146(3):1411-7. Epub 2004 Dec 9.  
PMID: 15591149 [PubMed - indexed for MEDLINE]

☐ 2: [Spolaore B, Polverino de Laureto P, Zambonin M, Fontana A.](#)

[Related Articles, Links](#)



Limited proteolysis of human growth hormone at low pH: isolation, characterization, and complementation of the two biologically relevant fragments 1-44 and 45-191.

Biochemistry. 2004 Jun 1;43(21):6576-86.  
PMID: 15157090 [PubMed - indexed for MEDLINE]

☐ 3: [Vartiainen J, Poykko SM, Raisanen T, Kesaniemi YA, Ukkola O.](#)

[Related Articles, Links](#)



Sequencing analysis of the ghrelin receptor (growth hormone secretagogue receptor type 1a) gene.

Eur J Endocrinol. 2004 Apr;150(4):457-63.  
PMID: 15080774 [PubMed - indexed for MEDLINE]

☐ 4: [Obrepalska-Stepiowska A, Kedzia A, Trojan J, Gozdzińska-Jozefiak A.](#)

[Related Articles, Links](#)



Analysis of coding and promoter sequences of the IGF-I gene in children with growth disorders presenting with normal level of growth hormone.

J Pediatr Endocrinol Metab. 2003 Dec;16(9):1267-75.  
PMID: 14714750 [PubMed - indexed for MEDLINE]

☐ 5: [Baumann G.](#)

[Related Articles, Links](#)



Growth hormone binding protein. The soluble growth hormone receptor.

Minerva Endocrinol. 2002 Dec;27(4):265-76. Review.  
PMID: 12511849 [PubMed - indexed for MEDLINE]

☐ 6: [Pineda AO, Cantwell AM, Bush LA, Rose T, Di Cera E.](#)

[Related Articles, Links](#)




The thrombin epitope recognizing thrombomodulin is a highly cooperative hot spot in exosite I.

J Biol Chem. 2002 Aug 30;277(35):32015-9. Epub 2002 Jun 14.  
PMID: 12068020 [PubMed - indexed for MEDLINE]

☐ 7: [Tauber MT, Porra V, Dastot F, Molinas C, Amselem S, Cholin S, Rochiccioli P, Bieth E.](#)

[Related Articles, Links](#)


Heterozygous mutation in the WSXWS equivalent motif of the growth

-  hormone receptor in a child with poor response to growth hormone therapy.

Growth Horm IGF Res. 1998 Jun;8(3):211-6.  
PMID: 10984309 [PubMed - indexed for MEDLINE]

☐ 8: [Ohkura K, Hori H.](#)


[Related Articles, Links](#)

-  Analyses of insulin-potentiating fragments of human growth hormone by computational simulation; essential unit for insulin-involved biological responses.

Bioorg Med Chem. 2000 Jul;8(7):1733-40.  
PMID: 10976521 [PubMed - indexed for MEDLINE]

☐ 9: [Goh EL, Zhu T, Yakar S, LeRoith D, Lobie PE.](#)


[Related Articles, Links](#)

-  CrkII participation in the cellular effects of growth hormone and insulin-like growth factor-1. Phosphatidylinositol-3 kinase dependent and independent effects.

J Biol Chem. 2000 Jun 9;275(23):17683-92.  
PMID: 10748058 [PubMed - indexed for MEDLINE]

☐ 10: [Tollet-Egnell P, Flores-Morales A, Stavreus-Evers A, Sahlin L, Norstedt G.](#)


[Related Articles, Links](#)

-  Growth hormone regulation of SOCS-2, SOCS-3, and CIS messenger ribonucleic acid expression in the rat.

Endocrinology. 1999 Aug;140(8):3693-704.  
PMID: 10433229 [PubMed - indexed for MEDLINE]

☐ 11: [Milstein SJ, Leipold H, Sarubbi D, Leone-Bay A, Mlynek GM, Robinson JR, Kasimova M, Freire E.](#)


[Related Articles, Links](#)

-  Partially unfolded proteins efficiently penetrate cell membranes--implications for oral drug delivery.

J Control Release. 1998 Apr 30;53(1-3):259-67.  
PMID: 9741933 [PubMed - indexed for MEDLINE]

☐ 12: [Contreras JO, Faure R, Baquiran G, Bergeron JJ, Posner BI.](#)

[Related Articles, Links](#)

-  ATP-dependent desensitization of insulin binding and tyrosine kinase activity of the insulin receptor kinase. The role of endosomal acidification.

J Biol Chem. 1998 Aug 21;273(34):22007-13.  
PMID: 9705342 [PubMed - indexed for MEDLINE]

☐ 13: [Kim SO, Jiang J, Yi W, Feng GS, Frank SJ.](#)


[Related Articles, Links](#)

-  Involvement of the Src homology 2-containing tyrosine phosphatase SHP-2 in growth hormone signaling.

J Biol Chem. 1998 Jan 23;273(4):2344-54.  
PMID: 9442080 [PubMed - indexed for MEDLINE]

☐ 14: [Khosravi MJ, Diamandi A, Mistry J, Krishna RG, Khare A.](#)

[Related Articles, Links](#)


-  Acid-labile subunit of human insulin-like growth factor-binding protein complex: measurement, molecular, and clinical evaluation.

J Clin Endocrinol Metab. 1997 Dec;82(12):3944-51.  
PMID: 9398693 [PubMed - indexed for MEDLINE]


☐ 15: [Campbell GS.](#)

[Related Articles, Links](#)


Growth-hormone signal transduction.

 J Pediatr. 1997 Jul;131(1 Pt 2):S42-4. Review.  
PMID: 9255227 [PubMed - indexed for MEDLINE]


☐ **16:** [Higgins KA, Thompson PE, Hearn MT.](#) [Related Articles, Links](#)

 Conformational analysis of human growth hormone [6-13] peptide analogues.  
Int J Pept Protein Res. 1996 Jul;48(1):1-11.  
PMID: 8844258 [PubMed - indexed for MEDLINE]


☐ **17:** [Thompson P, Lim N, Ede NJ, Ng FM, Rae ID, Hearn MT.](#) [Related Articles, Links](#)

 Structure and in vivo activity of hypoglycaemic analogues of human growth hormone (6-13).  
Drug Des Discov. 1995 Aug;13(1):55-72.  
PMID: 8882901 [PubMed - indexed for MEDLINE]


☐ **18:** [Ede NJ, Rae ID, Hearn MT.](#) [Related Articles, Links](#)

 Synthesis and conformation of constrained peptides with hypoglycaemic activity derived from human growth hormone.  
Int J Pept Protein Res. 1994 Dec;44(6):568-81.  
PMID: 7705979 [PubMed - indexed for MEDLINE]


☐ **19:** [Townes R, Kostyo JL, Vogel T, Sakal E, Tchelet A, Maher R, Gertler A.](#) [Related Articles, Links](#)

 Evidence that the N-terminus of human growth hormone is involved in expression of its growth promoting, diabetogenic, and insulin-like activities.  
Endocrinology. 1992 Mar;130(3):1225-30.  
PMID: 1537288 [PubMed - indexed for MEDLINE]


☐ **20:** [Ede NJ, Lim N, Rae ID, Ng FM, Hearn MT.](#) [Related Articles, Links](#)

 Synthesis and evaluation of constrained peptide analogues related to the N-terminal region of human growth hormone.  
Pept Res. 1991 May-Jun;4(3):171-6.  
PMID: 1823187 [PubMed - indexed for MEDLINE]

☐ **21:** [Manzella JM, Rychlik W, Rhoads RE, Hershey JW, Blackshear PJ.](#) [Related Articles, Links](#)



 Insulin induction of ornithine decarboxylase. Importance of mRNA secondary structure and phosphorylation of eucaryotic initiation factors eIF-4B and eIF-4E.  
J Biol Chem. 1991 Feb 5;266(4):2383-9.  
PMID: 1989989 [PubMed - indexed for MEDLINE]

☐ **22:** [Doi T, Tokunaga T, Ohtsuka E, Hiraki Y, Suzuki F, Ikehara M.](#) [Related Articles, Links](#)

 Expression of the amino terminal part of synthetic human growth hormone gene and somatomedin-like activity of expressed protein.  
Protein Eng. 1986 Oct-Nov;1(1):17-21.  
PMID: 3333840 [PubMed - indexed for MEDLINE]

Display ☐ Summary ☒ Show ☐ 500 ☒ Sort by ☐ Send to ☒

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)  
[Department of Health & Human Services](#)  
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for [ ] Go Clear

Limits Preview/Index History Clipboard Details

Display Abstract Show 20 Sort by Send to

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Pept Res. 1991 May-Jun;4(3):171-6.

Related Articles, Links

**Synthesis and evaluation of constrained peptide analogues related to the N-terminal region of human growth hormone.****Ede NJ, Lim N, Rae ID, Ng FM, Hearn MT.**

Dept. of Biochemistry, Monash University, Clayton, Victoria, Australia.

The synthesis and incorporation of two different isomeric gamma-lactam structures into peptide analogues related to hGH [6-13] are described. These peptide analogues and the corresponding aspartimide analogue have been tested for hypoglycemic activity with the intravenous insulin tolerance test. One lactam structure is of the type developed by Freidinger and co-workers, while the isomeric gamma-lactam structure represents a new constrained synthon for use in peptide synthesis. We have found that the hGH [6-13] peptide analogue incorporating the Freidinger lactam was more potent and longer lasting than the aspartimide peptide analogue. The hGH [6-13] peptide analogue incorporating the new gamma-lactam has diminished hypoglycemic activity. The relative biological activities of the three peptide analogues and the possible conformational implications at the physiological site of action are discussed.

PMID: 1823187 [PubMed - indexed for MEDLINE]

Display Abstract Show 20 Sort by Send to

[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Department of Health &amp; Human Services

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 29 2005 17:30:14

Welcome to STN International! Enter x:x

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:07:00 ON 18 APR 2005

=> file BIOSCIENCE

FILE 'ADISCTI' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 16:09:11 ON 18 APR 2005

FILE 'ANABSTR' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (c) 2005 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT 2005 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 16:09:11 ON 18 APR 2005

Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserved

FILE 'DRUGB' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 International Federation of the Societies of Cosmetics Chemi:

FILE 'LIFESCI' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (c) 2005 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 16:09:11 ON 18 APR 2005

FILE 'NIOSHTIC' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 16:09:11 ON 18 APR 2005

Compiled and distributed by the NTIS, U.S. Department of Commerce.

It contains copyrighted material.

All rights reserved. (2005)

FILE 'NUTRACEUT' ENTERED AT 16:09:11 ON 18 APR 2005

Copyright 2005 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 16:09:11 ON 18 APR 2005

Any reproduction or dissemination in part or in full,

by means of any process and on any support whatsoever

is prohibited without the prior written agreement of INIST-CNRS.

FILE 'TOXCENTER' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 ACS

FILE 'USPATFULL' ENTERED AT 16:09:11 ON 18 APR 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:09:11 ON 18 APR 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPIFV' ENTERED AT 16:09:11 ON 18 APR 2005

COPYRIGHT (C) 2005 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s human growth hormone OR growth hormone OR hGH OR somatotropin

12 FILES SEARCHED...

18 FILES SEARCHED...

25 FILES SEARCHED...

32 FILES SEARCHED...

48 FILES SEARCHED...

53 FILES SEARCHED...

65 FILES SEARCHED...



'1998' NOT A VALID FIELD CODE

31 FILES SEARCHED...

'1998' NOT A VALID FIELD CODE

'1998' NOT A VALID FIELD CODE

44 FILES SEARCHED...

'1998' NOT A VALID FIELD CODE

48 FILES SEARCHED...

53 FILES SEARCHED...

'1998' NOT A VALID FIELD CODE

59 FILES SEARCHED...

'1998' NOT A VALID FIELD CODE

65 FILES SEARCHED...

66 FILES SEARCHED...

71 FILES SEARCHED...

L5 588 L4 AND PY<=1998

=> D 15 1-588

L5 ANSWER 1 OF 588 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation.  
on STN

AN 94:55839 BIOBUSINESS

DN 0636041

TI \*\*\*Growth\*\*\* \*\*\*hormone\*\*\* \*\*\*fusion\*\*\* \*\*\*proteins\*\*\* ,  
methods of production, and methods of treatment

AU Wells J R E; King R M; Francis G L

CS College Park, Australia.

PI US 5330971 19 July 1994

SO Official Gazette of the United States Patent and Trademark Office Patents,  
( \*\*\*1994\*\*\* ) Vol.1164, No.3, July 19, P.1919.  
ISSN: 0098-1133.

DT PATENT

FS UNIQUE

LA ENGLISH

TI Involvement of the Src homology 2-containing tyrosine phosphatase SHP-2 in  
\*\*\*growth\*\*\* \*\*\*hormone\*\*\* signaling.

AU Kim, Sung-Oh; Jiang, Jing; Yi, Woelsung; Feng, Gen-Sheng; Frank, Stuart J.  
[Reprint author]

CS Univ. Alabama Birmingham, Rm. 756, DREB, UAB Station, Birmingham, AL  
35294, USA

SO Journal of Biological Chemistry, (Jan. 23, 1998) Vol. 273, No. 4, pp.  
2344-2354. print.

CODEN: JBCHA3. ISSN: 0021-9258.

DT Article

LA English

ED Entered STN: 25 Feb 1998

Last Updated on STN: 6 Apr 1998

L5 ANSWER 5 OF 588 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on  
STN

AN 1996:237966 BIOSIS

DN PREV199698786095

TI Requirement for phosphoinositide 3-OH kinase in \*\*\*growth\*\*\*  
\*\*\*hormone\*\*\* signalling to the mitogen-activated protein kinase and  
p70-s6k pathways.

AU Kilgour, Elaine Vvan Gout; Anderson, Neil G. [Reprint author]

CS Hannah Res. Inst., Ayr KA6 5HL, UK

SO Biochemical Journal, (1996) Vol. 315, No. 2, pp. 517-522.

ISSN: 0264-6021.

DT Article

LA English

ED Entered STN: 28 May 1996

Last Updated on STN: 11 Jul 1996

L5 ANSWER 6 OF 588 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on  
STN

AN 1992:475605 BIOSIS

DN PREV199294106980; BA94:106980

L5 ANSWER 8 OF 588 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on  
STN

AN 1988:264670 BIOSIS

DN PREV198886003914; BA86:3914

TI EFFICIENT CLEAVAGE BY ALPHA THROMBIN OF A RECOMBINANT FUSED PROTEIN WHICH  
CONTAINS \*\*\*INSULIN\*\*\* -LIKE GROWTH FACTOR I.

AU NISHIKAWA S [Reprint author]; YANASE K; TOKUNAGA-DOI T; KODAMA K; GOMI H;  
UESUGI S; OTHSUKA E; KATO Y; SUZUKI F; IKEHARA M

CS FAC PHARMACEUTICAL SCI, CALCIFIED-TISSUE METABOLISM, FAC DENTISTRY, OSAKA  
UNIV, OSAKA 565

SO Protein Engineering, (1987) Vol. 1, No. 6, pp. 487-492.  
CODEN: PRENE9. ISSN: 0269-2139.

DT Article

FS BA

LA ENGLISH

ED Entered STN: 2 Jun 1988  
Last Updated on STN: 2 Jun 1988

L5 ANSWER 9 OF 588 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on  
STN

AN 1987:336944 BIOSIS

DN PREV198784045887; BA84:45887

TI EXPRESSION OF A SYNTHETIC GENE ENCODING HUMAN \*\*\*INSULIN\*\*\* -LIKE  
GROWTH FACTOR I IN CULTURED MOUSE FIBROBLASTS.

AU BAYNE M L [Reprint author]; CASCIERI M A; KELDER B; APPLEBAUM J; CHICCHI  
G; SHAPIRO J A; PASLEAU F; KOPCHICK J J

CS MERCK INST THERAP RES, MERCK SHARP AND DOHME RES LAB, MERCK AND CO INC,  
RAHWAY, NJ 07065, USA

SO Proceedings of the National Academy of Sciences of the United States of  
America, (1987) Vol. 84, No. 9, pp. 2638-2642.  
CODEN: PNASA6. ISSN: 0027-8424.

DT Article

FS BA

DT Patent  
LA English  
OS WPI: 1997-289224 [26]

L5 ANSWER 12 OF 588 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN  
AN 1996-09799 BIOTECHDS  
TI Production of extracellular proteins in bacteria with inner and outer  
cell membranes;

recombinant protein production using new vector containing DNA  
encoding a \*\*\*fusion\*\*\* \*\*\*protein\*\*\* of the prepro-peptide of  
a bacterium extracellular protease and the target protein

AU Fabricius Woldike H; Hastrup S  
PA Novo-Nordisk  
LO Bagsvaerd, Denmark.

PI WO 9617943 \*\*\*13 Jun 1996\*\*\*  
AI WO 1995-DK498 8 Dec 1995  
PRAI DK 1994-1411 9 Dec 1994

DT Patent  
LA English  
OS WPI: 1996-287187 [29]

L5 ANSWER 13 OF 588 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN  
AN 1996-07319 BIOTECHDS  
TI New Escherichia coli and Salmonella mutants;  
mutant strain as an improved host for recombinant protein expression  
and protein secretion

AU Georgiou G; Baneyx F  
PA Univ.Texas  
LO Austin, TX, USA.

PI US 5508192 \*\*\*16 Apr 1996\*\*\*  
AI US 1993-153855 18 Nov 1993  
PRAI US 1993-153855 18 Nov 1993

DT Patent  
LA English

AN 1993-05553 BIOTECHDS

TI Solubilization of \*\*\*growth\*\*\* \*\*\*hormone\*\*\* and other  
recombinant proteins from E. coli inclusion bodies using a cationic  
surfactant;  
use of cetyltrimethylammonium chloride for pig recombinant  
\*\*\*somatotropin\*\*\* protein renaturation from an Escherichia coli  
inclusion body (conference abstract)

AU Puri N K; Crivelli E; Cardamone M; Fiddes R; Bertolini J; Ninham B  
CS SK+Beecham; Bunge-Australia  
LO SmithKline Beecham Animal Health, Lincoln, Nebraska, USA.  
SO J.Cell.Biochem.; ( \*\*\*1993\*\*\* ) Suppl.17A, 48  
CODEN: JCEBD5

DT Journal  
LA English

L5 ANSWER 17 OF 588 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN  
AN 1992-10729 BIOTECHDS

TI Non-naturally occurring \*\*\*fusion\*\*\* \*\*\*protein\*\*\* prodrug;  
e.g. cattle recombinant somatoliberin \*\*\*fusion\*\*\* \*\*\*protein\*\*\*  
cleavage using dipeptidyl-peptidase-IV

PA Upjohn

PI WO 9210576 \*\*\*25 Jun 1992\*\*\*

AI WO 1991-US9152 12 Dec 1991

PRAI US 1990-626727 13 Dec 1990

DT Patent  
LA English

OS WPI: 1992-234631 [28]

L5 ANSWER 18 OF 588 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN  
AN 1992-08600 BIOTECHDS

TI High yield production of peptide with physiological activity;  
gene cloning and expression in Bacillus subtilis, and \*\*\*fusion\*\*\*  
\*\*\*protein\*\*\* cleavage at dipeptide site using an aminopeptidase or  
carboxypeptidase

DT Patent  
LA English  
OS WPI: 1991-007212 [01]

L5 ANSWER 21 OF 588 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN  
AN 1990-14580 BIOTECHDS

TI Recombinant yeast processing system;  
Saccharomyces cerevisiae alpha-factor, mouse salivary amylase,  
carboxypeptidase or yeast BAR1 signal peptide and leader peptide; DNA  
sequence and protein sequence; vector construction

PA Novo-Nordisk

PI WO 9010075 \*\*\*7 Sep 1990\*\*\*

AI WO 1990-DK58 1 Mar 1990

PRAI DK 1989-4941 6 Oct 1989; DK 1989-1054 3 Mar 1989

DT Patent  
LA English  
OS WPI: 1990-290356 [38]

L5 ANSWER 22 OF 588 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN  
AN 1990-14577 BIOTECHDS

TI Production of recombinant \*\*\*fusion\*\*\* \*\*\*protein\*\*\* ;  
recombinant beta-glucuronidase (GUS), glucose-isomerase,  
\*\*\*insulin\*\*\* , interferon, \*\*\*somatotropin\*\*\* , chymosin, toxin,  
virus protein production; vector plasmid pBG101-41 and plasmid pBG1;  
GUS promoter

PA Repligen

PI US 4952682 \*\*\*28 Aug 1990\*\*\*

AI US 1988-253351 30 Sep 1988

PRAI US 1988-253351 30 Sep 1988

DT Patent  
LA English  
OS WPI: 1990-282185 [37]

L5 ANSWER 23 OF 588 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN

PRAI US 1988-173231 24 Mar 1988

DT Patent

LA English

OS WPI: 1989-309634 [42]

L5 ANSWER 26 OF 588 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN  
AN 1989-11436 BIOTECHDS

TI The physiological consequences of \*\*\*growth\*\*\* \*\*\*hormone\*\*\*  
fusion gene expression in transgenic sheep;

sheep \*\*\*somatotropin\*\*\* \*\*\*fusion\*\*\* \*\*\*protein\*\*\* ,  
expression in transgenic sheep (conference abstract)

AU Ward K A; Nancarrow C D; Murray J D; Wynn P C; Speck P; Hales J R S  
LO CSIRO, Division of Animal Production, PO Box 239, Blacktown, NSW 2148,  
Australia.

SO J.Cell.Biochem.; ( \*\*\*1989\*\*\* ) Suppl.13B, 164  
CODEN: JCEBD5

DT Journal

LA English

L5 ANSWER 27 OF 588 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN  
AN 1989-11434 BIOTECHDS

TI Expression of growth-related fusion genes in pigs;  
cattle, human \*\*\*somatotropin\*\*\* , and human somatoliberin  
\*\*\*fusion\*\*\* \*\*\*protein\*\*\* expression in transgenic pig for  
improved feed utilization efficiency (conference abstract)

AU Pursel V G; Miller K F; Bolt D J; Pinkert C A; Hammer R E; Mayo K E  
LO Agricultural Research Service, USDA, Beltsville, MD 20705, USA.

SO J.Cell.Biochem.; ( \*\*\*1989\*\*\* ) Suppl.13B, 163  
CODEN: JCEBD5

DT Journal

LA English

L5 ANSWER 28 OF 588 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN  
AN 1989-08912 BIOTECHDS

SO Biochem.J.; ( \*\*\*1986\*\*\* ) 240, 1, 1-12

CODEN: BIJOAK

DT Journal

LA English

L5 ANSWER 31 OF 588 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN

AN 1987-02001 BIOTECHDS

TI Fused protein for enzyme immunoassay use;

comprising enzymatically active beta-galactosidase fused to an  
immunologically active peptide

PA Calif.Biotechnol.

PI WO 8606742 \*\*\*20 Nov 1986\*\*\*

AI WO 1986-US1002 7 May 1986

PRAI US 1985-731853 7 May 1985

DT Patent

LA English

OS WPI: 1986-318850 [48]

L5 ANSWER 32 OF 588 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN

AN 1986-07777 BIOTECHDS

TI Cleavage of peptides and proteins at the methionyl bond using cyanogen  
chloride;

e.g. \*\*\*insulin\*\*\* and interferon and \*\*\*somatotropin\*\*\*  
\*\*\*fusion\*\*\* \*\*\*protein\*\*\* separation

PA Hoechst

PI EP 180920 \*\*\*14 May 1986\*\*\*

AI EP 1985-113857 31 Oct 1985

PRAI DE 1984-440988 9 Nov 1984

DT Patent

LA German

OS WPI: 1986-126378 [20]

L5 ANSWER 33 OF 588 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN

AN 1986-03670 BIOTECHDS



LA English  
FS MEDLINE; Priority Journals  
OS MEDLINE 1998230078  
EM 199805  
ED Entered STN: 19980610  
Last Updated on STN: 19980610

L5 ANSWER 36 OF 588 CANCERLIT on STN  
AN 95122541 CANCERLIT  
DN 95122541 PubMed ID: 7822327  
TI Studies in transgenic mice reveal potential relationships between  
secretin-producing cells and other endocrine cell types.  
AU Lopez M J; Upchurch B H; Rindi G; Leiter A B  
CS Division of Gastroenterology, New England Medical Center, Tufts University  
School of Medicine, Boston, Massachusetts 02111.  
NC DK07471 (NIDDK)  
DK34928 (NIDDK)  
DK43673 (NIDDK)  
SO JOURNAL OF BIOLOGICAL CHEMISTRY, \*\*\* (1995 Jan 13)\*\*\* 270 (2) 885-91.  
Journal code: 2985121R. ISSN: 0021-9258.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS MEDLINE; Priority Journals  
OS MEDLINE 95122541  
EM 199502  
ED Entered STN: 19950313  
Last Updated on STN: 19950313

L5 ANSWER 37 OF 588 CANCERLIT on STN  
AN 94347214 CANCERLIT  
DN 94347214 PubMed ID: 7520703  
TI Primary sequence and functional analysis of the bovine galanin gene  
promoter in human neuroblastoma cells.

ED Entered STN: 19941107  
Last Updated on STN: 19941107

L5 ANSWER 39 OF 588 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:843634 CAPLUS

DN 142:50180

TI Improved expression of recombinant \*\*\*insulin\*\*\* -like growth factor I

IN Lee, Young Ik; Kim, Sun Ok; Hyun, Sang Won

PA KIST, S. Korea

SO Repub. Korea, No pp. given

CODEN: KRXXFC

DT Patent

LA Korean

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	KR 149254	B1	19980817	KR 1995-15125	19950609 <--
PRAI	KR 1995-15125		19950609		

L5 ANSWER 40 OF 588 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:261207 CAPLUS

DN 130:263121

TI Production of therapeutic proteins suitable for oral administration in  
low-nicotine, non-food crop plants

IN Kenward, Kimberley; Brandle, Jim; Davies, Peter

PA The Minister of Agriculture and Agri-Food Canada, Can.; Queen's University

SO Can. Pat. Appl., 30 pp.

CODEN: CPXXEB

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	CA 2188220	AA	19980418	CA 1996-2188220	19961018 <--

AN 1997:679258 CAPLUS  
 DN 127:314806  
 TI Compositions and methods for screening drug libraries  
 IN Spinella, Dominic Gregory; Becherer, Kathleen Ann; Brown, Steven Joel  
 PA Chugai Biopharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 79 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9737220	A1	19971009	WO 1997-US5821	19970402 <--
	W: AU, CA, JP, KR				
	US 5866341	A	19990202	US 1996-627151	19960403
	CA 2250870	AA	19971009	CA 1997-2250870	19970402 <--
	AU 9726619	A1	19971022	AU 1997-26619	19970402 <--
	AU 717289	B2	20000323		
	JP 2001503131	T2	20010306	JP 1997-535624	19970402
	EP 801307	A2	19971015	EP 1997-302302	19970403 <--
	EP 801307	A3	19981216		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
PRAI	US 1996-627151	A	19960403		
	WO 1997-US5821	W	19970402		

L5 ANSWER 43 OF 588 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:650465 CAPLUS  
 DN 127:304110

TI Genetic vectors comprising a gene of interest and a tetracycline-controlled activator gene and uses in tetracycline-regulated gene therapy or immunization systems  
 IN Hobart, Peter M.; Liang, Xiaowu  
 PA Vical Incorporated, USA  
 SO PCT Int. Appl., 37 pp.

MR, NE, SN, TD, TG

ZA 9610456	A	19970620	ZA 1996-10456	19961212 <--
CA 2241367	AA	19970626	CA 1996-2241367	19961218 <--
AU 9710935	A1	19970714	AU 1997-10935	19961218 <--
EP 868523	A1	19981007	EP 1996-941597	19961218 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,  
SI, LT, LV, FI, RO

CN 1207773	A	19990210	CN 1996-199732	19961218
CN 1125181	B	20031022		
JP 2000501617	T2	20000215	JP 1997-522315	19961218
PRAI DK 1995-1449	A	19951220		
WO 1996-DK542	W	19961218		

L5 ANSWER 45 OF 588 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:499238 CAPLUS

DN 127:186606

TI Recombinant preparation of amylin or other heterologous polypeptides in  
secretory mammalian cells and clinical applications

IN Newgard, Christopher B.; Halban, Philippe A.; Normington, Karl D.; Clark,  
Samuel A.; Thigpen, Anice E.; Quaade, Christian; Kruse, Fred; McGarry,  
Dennis

PA Board of Regents, University of Texas System, USA; Betagene, Inc.;  
Newgard, Christopher B.; Halban, Philippe A.; Normington, Karl D.; Clark,  
Samuel A.; Thigpen, Anice E.; Quaade, Christian; Kruse, Fred; McGarry,  
Dennis

SO PCT Int. Appl., 336 pp.  
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9726321	A2	19970724	WO 1997-US761	19970117 <--
	WO 9726321	A3	19980108		

CA 2165162	C	20000523		
US 5789156	A	19980804	US 1995-383754	19950203 <--
US 5589362	A	19961231	US 1995-485971	19950607 <--
US 5814618	A	19980929	US 1995-485978	19950607 <--
US 5859310	A	19990112	US 1995-481970	19950607
US 5866755	A	19990202	US 1995-486814	19950607
US 5888981	A	19990330	US 1995-479306	19950607
US 5912411	A	19990615	US 1995-487472	19950607
US 6004941	A	19991221	US 1995-485740	19950607
US 5922927	A	19990713	US 1997-897719	19970721
US 6136954	A	20001024	US 1998-162184	19980928
US 6242667	B1	20010605	US 1998-161902	19980928
US 6252136	B1	20010626	US 1998-163269	19980929
US 2004003417	A1	20040101	US 1999-241347	19990202
US 2002077307	A1	20020620	US 1999-281674	19990330
US 6783756	B2	20040831		
US 6271348	B1	20010807	US 2000-489777	20000124
US 2002086426	A1	20020704	US 2001-777317	20010205
US 2002152489	A1	20021017	US 2001-874389	20010604
US 2002152487	A1	20021017	US 2001-892227	20010625
PRAI US 1993-76327	B2	19930614		
US 1993-76726	A2	19930614		
US 1994-260452	A2	19940614		
US 1994-270637	B2	19940701		
US 1994-275876	A2	19940715		
US 1995-383754	A2	19950203		
US 1995-479306	A1	19950607		
US 1995-481970	A1	19950607		
US 1995-485978	A1	19950607		
US 1995-486814	A1	19950607		
US 1995-487472	A1	19950607		
US 1998-161902	A1	19980928		
US 1998-162184	A3	19980928		
US 1998-163269	A1	19980929		

PA Bionebraska, Inc., USA

SO U.S., 27 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 5595887	A	19970121	US 1990-552810	19900716 <--
	WO 9201707	A1	19920206	WO 1991-US4511	19910624 <--
	W: AU, CA, FI, JP, NO				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	AU 9189155	A1	19920218	AU 1991-89155	19910624 <--
	AU 662302	B2	19950831		
	EP 539530	A1	19930505	EP 1992-902529	19910624 <--
	EP 539530	B1	20000202		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 189478	E	20000215	AT 1992-902529	19910624
	JP 3129437	B2	20010129	JP 1992-500610	19910624
	CA 2087261	C	20021224	CA 1991-2087261	19910624
	ZA 9105307	A	19930224	ZA 1991-5307	19910709 <--
	US 6127150	A	20001003	US 1997-927128	19970905
PRAI	US 1990-552810	A	19900716		
	WO 1991-US4511	W	19910624		
	US 1996-680004	B1	19960715		

L5 ANSWER 49 OF 588 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:113481 CAPLUS

DN 124:137837

TI Host cells transformed with \*\*\*fusion\*\*\* \*\*\*protein\*\*\* gene and  
method for screening test samples with receptor-ligand interactions or  
peptide-binding activities

IN Young, Kathleen H.; Ozenberger, Bradley A.

PA American Cyanamid Co., USA

TI A receptor-activated reporter for use in the screening for receptor agonists

IN Czech, Michael P.; Corvera, Silvia

PA University of Massachusetts Medical Center, USA

SO PCT Int. Appl., 87 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9509240	A1	19950406	WO 1994-US10936	19940927 <--
	W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN			
	RW:	KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 5989893	A	19991123	US 1994-287537	19940808
	AU 9478448	A1	19950418	AU 1994-78448	19940927 <--
	EP 721508	A1	19960717	EP 1994-929363	19940927 <--
	R:	BE, CH, DE, DK, FR, GB, IT, LI, SE			
PRAI	US 1993-127316	A	19930927		
	US 1994-287537	A	19940808		
	WO 1994-US10936	W	19940927		
OS	MARPAT 123:25661				

L5 ANSWER 51 OF 588 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:503106 CAPLUS

DN 123:2763

TI Efficient secretion of foreign proteins from yeast expression hosts using the signal sequence of the YAP3 gene

IN Christiansen, Lars; Petersen, Jens G. Litske

PA Genentech, Inc., USA  
 SO PCT Int. Appl., 102 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9323550	A2	19931125	WO 1993-US4717	19930517 <--
	WO 9323550	A3	19940303		
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5316921	A	19940531	US 1992-884811	19920518 <--
	US 5328837	A	19940712	US 1992-885971	19920518 <--
	EP 642585	A1	19950315	EP 1993-911350	19930517 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 07508178	T2	19950914	JP 1993-503819	19930517 <--
	US 5580963	A	19961203	US 1994-194088	19940209 <--
	US 5684136	A	19971104	US 1995-435501	19950505 <--
	US 5763584	A	19980609	US 1995-435764	19950505 <--
	US 5770704	A	19980623	US 1997-792078	19970131 <--
	JP 2004000236	A2	20040108	JP 2003-172155	20030617
PRAI	US 1992-884811	A	19920518		
	US 1992-885971	A	19920518		
	US 1992-950572	A2	19920921		
	JP 1993-503790	A3	19930517		
	WO 1993-US4717	W	19930517		
	US 1993-87784	B1	19930713		
	US 1994-268880	B3	19940630		
	US 1995-423291	B1	19950417		

L5 ANSWER 53 OF 588 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1993:532910 CAPLUS  
 DN 119:132910



EP 564531	A1	19931013	EP 1992-902109	19911203 <--
EP 564531	B1	19980325		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
JP 07503600	T2	19950420	JP 1992-502710	19911203 <--
JP 3267293	B2	20020318		
AT 164395	E	19980415	AT 1992-902109	19911203 <--
ES 2113940	T3	19980516	ES 1992-902109	19911203 <--
JP 2002119294	A2	20020423	JP 2001-256931	19911203
JP 2002136295	A2	20020514	JP 2001-256932	19911203
US 5750373	A	19980512	US 1993-50058	19930430 <--
US 5780279	A	19980714	US 1995-418928	19950405 <--
US 5846765	A	19981208	US 1995-441871	19950516 <--
US 6040136	A	20000321	US 1997-923854	19970903
JP 2004121261	A2	20040422	JP 2003-403062	20031202
JP 2005065705	A2	20050317	JP 2004-327565	20041111
PRAI US 1990-621667	A	19901203		
US 1991-683400	A	19910410		
US 1991-715300	A	19910614		
US 1991-743614	A	19910808		
JP 1992-502710	A3	19911203		
JP 2001-256931	A3	19911203		
JP 2001-256932	A3	19911203		
WO 1991-US9133	W	19911203		
US 1992-864452	B1	19920419		
US 1993-50058	A2	19930430		
US 1993-161692	A1	19931203		
US 1995-418928	A3	19950405		
US 1995-463587	A3	19950605		
L5 ANSWER 55 OF 588 CAPLUS COPYRIGHT 2005 ACS on STN				
AN 1993:3439 CAPLUS				
DN 118:3439				
TI Expression of recombinant polypeptides with improved purification				
IN Tarnowski, S. Joseph; Hilliker, Sandra; Willett, W. Scott				

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 493926	A1	19920708	EP 1991-311690	19911217 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE				
	CA 2057715	AA	19920620	CA 1991-2057715	19911216 <--
	AU 9189782	A1	19920625	AU 1991-89782	19911217 <--
	HU 62336	A2	19930428	HU 1991-3990	19911217 <--
	JP 04293491	A2	19921019	JP 1991-334861	19911218 <--
PRAI	US 1990-629803	A	19901219		

L5 ANSWER 57 OF 588 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 1992:249895 CAPLUS  
DN 116:249895

TI Chimeric genes encoding hybrid soluble cellular receptors and use of the recombinant receptors for identification of agonists or antagonists and of ligand binding sites  
IN Kjeldsen, Thomas Boerglum; Andersen, Asser Sloth; Wiberg, Finn Christoph; Moeller, Niels Peter Hundahl; Rasmussen, Jesper Skou  
PA Novo-Nordisk A/S, Den.  
SO PCT Int. Appl., 98 pp.  
CODEN: PIXXD2

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9117252	A1	19911114	WO 1991-DK115	19910430 <--
	W: AU, BG, CA, FI, HU, JP, KR, NO, PL, RO, SU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	AU 9177921	A1	19911127	AU 1991-77921	19910430 <--
	AU 655767	B2	19950112		

AN 1992:144080 CAPLUS  
 DN 116:144080  
 TI Production and characterization of recombinant \*\*\*insulin\*\*\* -like growth factor-I (IGF-I) and potent analogs of IGF-I, with Gly or Arg substituted for Glu3, following their expression in Escherichia coli as \*\*\*fusion\*\*\* \*\*\*proteins\*\*\*  
 AU King, R.; Wells, J. R. E.; Krieg, P.; Snoswell, M.; Brazier, J.; Bagley, C. J.; Wallace, J. C.; Ballard, F. J.; Ross, M.; Francis, G. L.  
 CS Dep. Biochem., Univ. Adelaide, Adelaide, 5000, Australia  
 SO Journal of Molecular Endocrinology ( \*\*\*1992\*\*\* ), 8(1), 29-41  
 CODEN: JMLEEI; ISSN: 0952-5041  
 DT Journal  
 LA English

L5 ANSWER 60 OF 588 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1992:35160 CAPLUS

DN 116:35160

TI Method for treating gut dysfunction with \*\*\*insulin\*\*\* -like growth factor-1 or analogs thereof

IN Ballard, Francis John; Read, Leanna Christine

PA Gropep Pty. Ltd., Australia

SO PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9112018	A1	19910822	WO 1991-AU31	19910130 <--
	W: AU, CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	CA 2074166	AA	19910814	CA 1991-2074166	19910130 <--
	CA 2074166	C	20031125		
	AU 9172262	A1	19910903	AU 1991-72262	19910130 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE

JP 05506574 T2 19930930 JP 1991-507276 19910320 <--  
JP 3319594 B2 20020903  
AT 158615 E 19971015 AT 1991-906955 19910320 <--  
PRAI US 1990-496409 A2 19900320  
WO 1991-US1844 A 19910320

L5 ANSWER 62 OF 588 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1991:22478 CAPLUS

DN 114:22478

TI Thermostable ribonuclease T1 variant and its manufacture with recombinant  
Escherichia coli

IN Nishikawa, Ron; Uesugi, Haruichi; Nakagawa, Setsuko; Ikehara, Morio

PA Tanpaku Kogaku Kenkyusho K. K., Japan

SO Jpn. Kokai Tokkyo Koho, 13 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 02057181	A2	19900226	JP 1988-208905	19880823 <--
	JP 2641263	B2	19970813		
PRAI	JP 1988-208905		19880823		

L5 ANSWER 63 OF 588 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1989:451709 CAPLUS

DN 111:51709

TI Manufacture and secretion of biologically active proteins with recombinant  
bacteria and therapeutic use of said proteins

IN Dalboege, Henrik; Moelvig, Jens; Hejnaes, Kim Ry

PA Nordisk Gentofte, Den.

SO PCT Int. Appl., 35 pp.

CODEN: PIXXD2

AU 8659125	A1	19861224	AU 1986-59125	19860620 <--
JP 62036183	A2	19870217	JP 1986-144706	19860620 <--
PRAI US 1985-747152	A	19850620		

L5 ANSWER 65 OF 588 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1987:14227 CAPLUS

DN 106:14227

TI Streptavidin-like polypeptides

IN Meade, Harry M.; Garwin, Jeffrey L.

PA Biogen N. V., USA

SO PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 8602077	A1	19860410	WO 1985-US1901	19851001 <--
	W: JP				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	EP 198015	A1	19861022	EP 1985-905158	19851001 <--
	EP 198015	B1	19910828		
	EP 198015	B2	19950719		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 62500700	T2	19870326	JP 1985-504502	19851001 <--
	AT 66691	E	19910915	AT 1985-905158	19851001 <--
	US 5168049	A	19921201	US 1988-185329	19880421 <--
	US 5272254	A	19931221	US 1991-800158	19911127 <--
	JP 08228791	A2	19960910	JP 1996-47976	19960208 <--
PRAI	US 1984-656873	A	19841002		
	EP 1985-905158	A	19851001		
	WO 1985-US1901	W	19851001		
	US 1988-185329	A3	19880421		

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	AU 546092	B2	19850815	AU 1981-74484	19810824 <--
	AU 8174484	A1	19820114		
PRAI	AU 1981-74484		19810824		

L5 ANSWER 68 OF 588 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1983:570624 CAPLUS

DN 99:170624

TI Stabilizing and selecting cells

IN Hershberger, Charles Lee; Rosteck, Paul Robert, Jr.

PA Eli Lilly and Co., USA

SO Eur. Pat. Appl., 67 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 80848	A2	19830608	EP 1982-306207	19821122 <--
	EP 80848	A3	19850116		
	EP 80848	B1	19890823		
	R: BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 4436815	A	19840313	US 1981-325511	19811127 <--
	AU 8290130	A1	19830602	AU 1982-90130	19821103 <--
	AU 555637	B2	19861002		
	IL 67176	A1	19890228	IL 1982-67176	19821104 <--
	CA 1190490	A1	19850716	CA 1982-415169	19821109 <--
	GB 2110694	A1	19830622	GB 1982-33260	19821122 <--
	GB 2110694	B2	19850227		
	HU 31301	O	19840428	HU 1982-3792	19821125 <--
	HU 197043	B	19890228		
	DK 8205274	A	19830528	DK 1982-5274	19821126 <--
	JP 58107184	A2	19830625	JP 1982-208370	19821126 <--

BR 7807290	A	19790612	BR 1978-7290	19781106 <--
FR 2422717	A1	19791109	FR 1978-31350	19781106 <--
FR 2422717	B1	19851206		
JP 54145289	A2	19791113	JP 1978-137216	19781106 <--
JP 01023118	B4	19890501		
ES 474849	A1	19791201	ES 1978-474849	19781106 <--
AT 7807935	A	19830515	AT 1978-7935	19781106 <--
AT 373280	B	19840110		
IL 55890	A1	19840131	IL 1978-55890	19781106 <--
CA 1166983	A1	19840508	CA 1978-315864	19781106 <--
RO 80052	P	19850315	RO 1978-95604	19781106 <--
CH 656640	A	19860715	CH 1978-11417	19781106 <--
DD 145928	C	19810114	DD 1978-208917	19781107 <--
ZA 7806305	A	19791031	ZA 1978-6305	19781108 <--
FR 2422718	A1	19791109	FR 1979-16725	19790628 <--
FR 2422718	B1	19840518		
FR 2422719	A1	19791109	FR 1979-16726	19790628 <--
FR 2422719	B1	19841228		
US 4425437	A	19840110	US 1982-403674	19820730 <--
US 4431739	A	19840214	US 1982-403675	19820730 <--
US 4563424	A	19860107	US 1982-403676	19820730 <--
FI 8302334	A	19830627	FI 1983-2334	19830627 <--
FI 8302335	A	19830627	FI 1983-2335	19830627 <--
FI 8302336	A	19830627	FI 1983-2336	19830627 <--
FI 8302337	A	19830627	FI 1983-2337	19830627 <--
CA 1221324	A2	19870505	CA 1984-453083	19840427 <--
US 4812554	A	19890314	US 1985-787871	19851016 <--
NO 8505217	A	19790509	NO 1985-5217	19851220 <--
NO 8705114	A	19790509	NO 1987-5114	19871208 <--
JP 01027480	A2	19890130	JP 1988-173625	19880712 <--
JP 06057154	B4	19940803		
US 5420020	A	19950530	US 1994-279839	19940725 <--
PRAI US 1977-849591	A2	19771108		
US 1977-849691	A	19771108		

DE 1980-3012169        A        19800327  
DE 1980-3012170        A        19800327  
EP 1980-730038        A        19800530

L5     ANSWER 71 OF 588   CEABA-VTB   COPYRIGHT   2005   DECHEMA on STN  
AN     1991(06):7233   CEABA-VTB   FS   B  
DN     CEABA: 1991:4393890  
TI     \*\*\*Growth\*\*\*        \*\*\*hormone\*\*\*        \*\*\*fusion\*\*\*        \*\*\*proteins\*\*\*        .  
AU     Wells, J. R. E.; King, R. M.; Francis, G. L. (Groppe Pty. Ltd.,  
Thebarton, S. A., Australia)  
SO     PCT Patent Appl. (   \*\*\*1990\*\*\*   ) WO 9015142 (Appl. AU PJ4672, Filed 9 Jun  
1989)  
CODEN: PIXXD2  
DT     Patent  
LA     English

L5     ANSWER 72 OF 588   CEN   COPYRIGHT 2001 ACS on STN  
AN     1998:2155   CEN  
TI     GREAT EXPECTATIONS  
Biopharmaceutical industry expects success from new drug therapies and a  
full product development pipeline  
AU     Thayer, Ann M.  
SO     Chemical & Engineering News, (   \*\*\*10 Aug 1998\*\*\*   ) Vol. 76, No. 32, pp.  
19.  
CODEN: CENEAR, ISSN: 0009-2347.  
PB     American Chemical Society  
LA     English  
WC     5858

L5     ANSWER 73 OF 588   DGENE   COPYRIGHT 2005 The Thomson Corp on STN  
AN     AAW67492   Protein        DGENE  
TI     Inhibitors of interaction between   \*\*\*insulin\*\*\*   -like growth factor -  
useful for, e.g. treating or preventing hyperglycaemia, obesity and



PA (PENC-N) PENCE.

PI \*\*\*WO 9712988 A1 19970410 80\*\*\*

AI WO 1996-US16032 19961004

PRAI US 1995-540397 19951006

DT Patent

LA English

OS 1997-226231 [20]

DESC K-coil peptide.

L5 ANSWER 76 OF 588 DGENE COPYRIGHT 2005 The Thomson Corp on STN

AN AAW15765 Peptide DGENE

TI Nucleic acid segment encoding one subunit of a coiled dimer protein -  
also derived \*\*\*fusion\*\*\* \*\*\*proteins\*\*\* that can be detected or  
purified by reaction with the complementary second subunit

IN Bautista D; Cachia P J; Hodges R S; Houston M E; Irvin R T; Tripet B; Yu  
L

PA (PENC-N) PENCE.

PI \*\*\*WO 9712988 A1 19970410 80\*\*\*

AI WO 1996-US16032 19961004

PRAI US 1995-540397 19951006

DT Patent

LA English

OS 1997-226231 [20]

DESC E-coil (peptide 0993) coil peptide.

L5 ANSWER 77 OF 588 DGENE COPYRIGHT 2005 The Thomson Corp on STN

AN AAR10021 Protein DGENE

TI New plasmids encoding \*\*\*growth\*\*\* \*\*\*hormone\*\*\* \*\*\*fusion\*\*\*  
\*\*\*proteins\*\*\* - for treatment of protein accumulation deficiencies,  
e.g. associated with burns, infection, cancer and cystic fibrosis.

IN Wells J R; King R M; Francis G L

PA (GROP-N) GROPEP PTY LTD.

PI \*\*\*WO 9015142 A 19901213 42\*\*\*

AI WO 1990-AU210 19900522

L5 ANSWER 80 OF 588 DGENE COPYRIGHT 2005 The Thomson Corp on STN  
 AN AAP82123 protein DGENE  
 TI Human \*\*\*insulin\*\*\* -like growth factor I prodn. - by transforming  
 host bacteria with expression plasmid contg. gene coding IGF-I,  
 culturing, sepg. IGF-I etc.  
 PA (FUJI) FUJISAWA PHARM CO LTD.  
 PI \*\*\*JP 63263085 A 19881031 7\*\*\*  
 AI JP 1987-99285 19870422  
 PRAI JP 1987-99285 19870422  
 DT Patent  
 LA Japanese  
 OS 1988-350713 [49]  
 CR N-PSDB: AAN82058  
 DESC \*\*\*Fusion\*\*\* \*\*\*protein\*\*\* of \*\*\*insulin\*\*\* -like growth  
 factor-1 and peptide Cd.

L5 ANSWER 81 OF 588 DGENE COPYRIGHT 2005 The Thomson Corp on STN  
 AN AAT60577 DNA DGENE  
 TI Nucleic acid segment encoding one subunit of a coiled dimer protein -  
 also derived \*\*\*fusion\*\*\* \*\*\*proteins\*\*\* that can be detected or  
 purified by reaction with the complementary second subunit  
 IN Bautista D; Cachia P J; Hodges R S; Houston M E; Irvin R T; Tripet B; Yu  
 L  
 PA (PENC-N) PENCE.  
 PI \*\*\*WO 9712988 A1 19970410 80\*\*\*  
 AI WO 1996-US16032 19961004  
 PRAI US 1995-540397 19951006  
 DT Patent  
 LA English  
 OS 1997-226231 [20]  
 CR P-PSDB: AAW15766  
 DESC K-coil peptide DNA.

host bacteria with expression plasmid contg. gene coding IGF-I,  
culturing, sepg. IGF-I etc.

PA (FUJI) FUJISAWA PHARM CO LTD.

PI \*\*\*JP 63263085 A 19881031 7\*\*\*

AI JP 1987-99285 19870422

PRAI JP 1987-99285 19870422

DT Patent

LA Japanese

OS 1988-350713 [49]

CR P-PSDB: AAP82123

DESC DNA encoding \*\*\*fusion\*\*\* \*\*\*protein\*\*\* of IGF-1 and peptide Cd.

L5 ANSWER 85 OF 588 DISSABS COPYRIGHT (C) 2005 ProQuest Information and  
Learning Company; All Rights Reserved on STN

AN 88:36845 DISSABS Order Number: AAR8916838

TI TARGETING OF HORMONES TO THE REGULATED SECRETORY PATHWAY IN AN ANTERIOR  
PITUITARY CELL LINE

AU POWELL, SHARON KAY [PH.D.]

CS UNIVERSITY OF CALIFORNIA, BERKELEY (0028)

SO Dissertation Abstracts International, ( \*\*\*1988\*\*\* ) Vol. 50, No. 4B, p.  
1206. Order No.: AAR8916838. 125 pages.

DT Dissertation

FS DAI

LA English

ED Entered STN: 19921118

Last Updated on STN: 19921118

L5 ANSWER 86 OF 588 IFIPAT COPYRIGHT 2005 IFI on STN

AN 03444043 IFIPAT;IFIUDB;IFICDB

TI PROCESS FOR PRODUCING EXTRACELLULAR PROTEINS IN BACTERIA; TRANSFORMING  
BACTERIA HAVING CELL MEMBRANES WITH RECOMBINANT VECTOR ENCODING A

\*\*\*FUSION\*\*\* \*\*\*PROTEIN\*\*\* OF N-TERMINAL PREPROPEPTIDE OF  
ACRHOMOBACTER LYTICUS PROTEASE I FUSED TO DESIRED PROTEIN, CULTURING, AND  
RECOVERING PROTEINS

US 5750373  
 DT Utility  
 FS CHEMICAL  
 GRANTED  
 CLMN 73  
 GI 20 Drawing Sheet(s), 22 Figure(s).

L5 ANSWER 88 OF 588 IFIPAT COPYRIGHT 2005 IFI on STN  
 AN 03023328 IFIPAT;IFIUDB;IFICDB  
 TI AGROBACTERIUM TUMEFACIENS TRANSFORMATION OF MUSA SPECIES  
 IN Arntzen Charles J; May Gregory D  
 PA Texas A & M University System (6116)  
 PI US 5792935 A 19980811 (CITED IN 001 LATER PATENTS)  
 WO 9515678 19950615  
 AI US 1996-652521 19960605  
 WO 1994-US14210 19941209  
 19960605 PCT 371 date  
 19960605 PCT 102(e) date  
 RLI US 1993-164296 19931209 CONTINUATION ABANDONED  
 US 1994-341461 19941117 CONTINUATION ABANDONED  
 FI US 5792935 19980811  
 DT Utility; REASSIGNED  
 FS CHEMICAL  
 GRANTED  
 MRN 008132 MFN: 0010  
 009901 00356  
 CLMN 30  
 GI 2 Drawing Sheet(s), 4 Figure(s).

L5 ANSWER 89 OF 588 IFIPAT COPYRIGHT 2005 IFI on STN  
 AN 03009803 IFIPAT;IFIUDB;IFICDB  
 TI METHOD OF SELECTION OF PROTEOLYTIC CLEAVAGE SITES BY DIRECTED EVOLUTION  
 AND PHAGEMID DISPLAY  
 IN Matthews David J; Wells James A; Zoller Mark J

CLMN 50

GI 20 Drawing Sheet(s), 22 Figure(s).

L5 ANSWER 91 OF 588 IFIPAT COPYRIGHT 2005 IFI on STN

AN 02910850 IFIPAT;IFIUDB;IFICDB

TI PROCESS FOR PREPARING A DESIRED PROTEIN; EXPRESSING DNA SEQUENCE CODING A  
\*\*\*FUSION\*\*\* \*\*\*PROTEIN\*\*\* SYNTHESIS, CLEAVAGE USING DIPEPTIDYL  
AMINOPEPTIDASE I

IN Christensen Thorkild (DK); Dalboge Henrik (DK); Jessen Torben Ehler  
(DK); Pedersen John (DK); Ringsted Jorli Winnie (DK)

PA Novo Nordisk A/S DK (60996)

PI US 5691169 A 19971125 (CITED IN 001 LATER PATENTS)

AI US 1995-402455 19950310

RLI US 1988-215602 19880701 CONTINUATION ABANDONED

US 1991-759106 19910906 CONTINUATION ABANDONED

US 1992-959856 19921112 CONTINUATION ABANDONED

US 1995-372692 19950113 CONTINUATION 5618697

US 1986-910230 19861002 CONTINUATION-IN-PART ABANDONED

US 1994-640081 19940808 CONTINUATION-IN-PART ABANDONED

PRAI DK 1982-5493 19821210

DK 1985-556 19850207

FI US 5691169 19971125

US 5618697

DT Utility

FS CHEMICAL

GRANTED

CLMN 44

L5 ANSWER 92 OF 588 IFIPAT COPYRIGHT 2005 IFI on STN

AN 02854382 IFIPAT;IFIUDB;IFICDB

TI PROTEIN PRODUCTION AND PROTEIN DELIVERY; NEW TRANSCRIPTION UNIT COMPRISES  
EXOGENOUS REGULATORY SEQUENCE, EXOGENOUS EXON AND SPLICE-DONOR SITE,  
OPERATIVELY LINKED TO SECOND EXON OF ENDOGENOUS GENE

MRN 007396 MFN: 0676

011641 0962

CLMN 20

GI 4 Drawing Sheet(s), 5 Figure(s).

L5 ANSWER 94 OF 588 IFIPAT COPYRIGHT 2005 IFI on STN

AN 02827453 IFIPAT;IFIUDB;IFICDB

TI K. LACTIS TRANSALDOLASE GENE PROMOTER AND USE THEREOF; DNA SEQUENCE FOR  
PROTEIN OR ENZYME BIOSYNTHESIS

IN Bolotin Monique (FR); Menart Sandrine (FR)

PA Rhone-Poulenc Rorer S A FR (27977)

PI US 5616474 A 19970401 (CITED IN 001 LATER PATENTS)

WO 9403618 19940217

AI US 1995-374686 19950201

WO 1993-FR771 19930728

19950201 PCT 371 date

19950201 PCT 102(e) date

PRAI FR 1992-9432 19920730

FI US 5616474 19970401

DT Utility; REASSIGNED

FS CHEMICAL

GRANTED

MRN 007618 MFN: 0980

011641 0962

CLMN 19

GI 6 Drawing Sheet(s), 7 Figure(s).

L5 ANSWER 95 OF 588 IFIPAT COPYRIGHT 2005 IFI on STN

AN 02706440 IFIPAT;IFIUDB;IFICDB

TI METHOD OF PRODUCING PEPTIDES OR PROTEINS AS \*\*\*FUSION\*\*\*

\*\*\*PROTEINS\*\*\* ; LINKED TO CARRIER BY A DIPEPTIDE OF LYSINE-ARGININE

IN Yamamoto Hiroaki (JP); Yamashita Kunihiro (JP)

PA M & D Research Co Ltd JP (21716)

PI US 5506120 A 19960409 (CITED IN 004 LATER PATENTS)

\*\*\*FUSION\*\*\*      \*\*\*PROTEIN\*\*\*      CONTAINING CARRIER PROTEIN WITH PEPTIDI  
FUSED TO CLEAVAGE SITE; HIGH ISOELECTRIC POINT FACILITATES SEPARATION  
IN    Hilliker Sandra; Tarnowski S Joseph; Willett W Scott  
PA    Scios Nova Inc (30143)  
PI    US 5322930      A    19940621    (CITED IN 007 LATER PATENTS)  
AI    US 1992-974932      19921112  
RLI    US 1990-564259      19900807 DIVISION      5202239  
FI    US 5322930      19940621  
      US 5202239  
DT    Utility  
FS    CHEMICAL  
      GRANTED  
CLMN  8  
GI    10 Drawing Sheet(s),  13 Figure(s).

L5    ANSWER 98 OF 588    IFIPAT    COPYRIGHT 2005 IFI on STN  
AN    02350522    IFIPAT;IFIUDB;IFICDB  
TI    EXPRESSION OF RECOMBINANT POLYPEPTIDES WITH IMPROVED PURIFICATION;  
      \*\*\*FUSION\*\*\*      \*\*\*PROTEIN\*\*\*      CONTAINING PEPTIDE AND CARRIER  
IN    Hilliker Sandra; Tarnowski S Joseph; Willett W Scott  
PA    Scios Nova Inc (30143)  
PI    US 5202239      A    19930413    (CITED IN 008 LATER PATENTS)  
AI    US 1990-564259      19900807  
FI    US 5202239      19930413  
DT    Utility  
FS    CHEMICAL  
      GRANTED  
MRN    005460    MFN: 0278  
      006289      0014  
CLMN  8  
GI    10 Drawing Sheet(s),  13 Figure(s).

L5    ANSWER 99 OF 588    IFIPAT    COPYRIGHT 2005 IFI on STN  
AN    02230615    IFIPAT;IFIUDB;IFICDB

NC CA-21124 (NCI)  
 DK-27430 (NIDDK)  
 DK-42502 (NIDDK)  
 +  
 SO Molecular and cellular biology, \*\*\* (1998 Sep) \*\*\* 18 (9) 5109-20.  
 Journal code: 8109087. ISSN: 0270-7306.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199809  
 ED Entered STN: 19980917  
 Last Updated on STN: 20000303  
 Entered Medline: 19980910  
  
 L5 ANSWER 102 OF 588 MEDLINE on STN  
 AN 97403905 MEDLINE  
 DN PubMed ID: 9259189  
 TI Early effects of streptozotocin-induced diabetes on \*\*\*insulin\*\*\* -like  
 growth factor-I in the kidneys of \*\*\*growth\*\*\* \*\*\*hormone\*\*\*  
 -transgenic and \*\*\*growth\*\*\* \*\*\*hormone\*\*\* -deficient dwarf mice.  
 AU Jacobs M L; Chandrashekar V; Bartke A; Weber R F  
 CS Department of Internal Medicine, University of Dijkzigt, Rotterdam, The  
 Netherlands.  
 NC DK42137 (NIDDK)  
 HD2003 (NICHD)  
 SO Experimental nephrology, \*\*\* (1997 Jul-Aug) \*\*\* 5 (4) 337-44.  
 Journal code: 9302239. ISSN: 1018-7782.  
 CY Switzerland  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199709  
 ED Entered STN: 19971008



EM 199406  
 ED Entered STN: 19940629  
 Last Updated on STN: 19940629  
 Entered Medline: 19940623

L5 ANSWER 105 OF 588 MEDLINE on STN  
 AN 93321808 MEDLINE  
 DN PubMed ID: 8330686  
 TI Glucose metabolism in transgenic mice containing a chimeric P-enolpyruvate  
 carboxykinase/bovine \*\*\*growth\*\*\* \*\*\*hormone\*\*\* gene.  
 AU Valera A; Rodriguez-Gil J E; Yun J S; McGrane M M; Hanson R W; Bosch F  
 CS Department of Biochemistry, School of Veterinary Medicine, Autonomous  
 University of Barcelona, Spain.  
 NC DK-21859 (NIDDK)  
 DK-24451 (NIDDK)  
 SO FASEB journal : official publication of the Federation of American  
 Societies for Experimental Biology, \*\*\* (1993 Jun) \*\*\* 7 (9) 791-800.  
 Journal code: 8804484. ISSN: 0892-6638.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199308  
 ED Entered STN: 19930826  
 Last Updated on STN: 19980206  
 Entered Medline: 19930816

L5 ANSWER 106 OF 588 MEDLINE on STN  
 AN 92297156 MEDLINE  
 DN PubMed ID: 1605853  
 TI Functional analysis of the rat \*\*\*insulin\*\*\* -like growth factor I gene  
 and identification of an IGF-I gene promoter.  
 AU Hall L J; Kajimoto Y; Bichell D; Kim S W; James P L; Counts D; Nixon L J;  
 Tobin G; Rotwein P

ED Entered STN: 19920124  
 Last Updated on STN: 19920124  
 Entered Medline: 19911226

L5 ANSWER 108 OF 588 MEDLINE on STN  
 AN 88128506 MEDLINE  
 DN PubMed ID: 3481144  
 TI Progress on gene transfer in farm animals.  
 AU Pursel V G; Rexroad C E Jr; Bolt D J; Miller K F; Wall R J; Hammer R E;  
 Pinkert C A; Palmiter R D; Brinster R L  
 CS Laboratory of Reproductive Physiology, University of Pennsylvania.  
 NC HD 09172 (NICHD)  
 HD 19018 (NICHD)  
 SO Veterinary immunology and immunopathology, \*\*\* (1987 Dec)\*\*\* 17 (1-4)  
 303-12.  
 Journal code: 8002006. ISSN: 0165-2427.  
 CY Netherlands  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 198803  
 ED Entered STN: 19900308  
 Last Updated on STN: 19970203  
 Entered Medline: 19880315

L5 ANSWER 109 OF 588 PHARMAML COPYRIGHT 2005 MARKETLETTER on STN  
 AN 1635871 PHARMAML  
 TI Roche Enters New Product Phase With Bright Prospects  
 SO Marketletter February 17, 1997  
 DT Newsletter  
 WC 1315

L5 ANSWER 110 OF 588 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

4(1).

ISSN: 0892-1903.

PUBLISHER: BioVenture Publishing

DOCUMENT TYPE: Newsletter

LANGUAGE: English

WORD COUNT: 3806

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 114 OF 588 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:382726 PROMT

TITLE: PhRMA Pipeline Report

SOURCE: BioPharm, ( \*\*\*Jul 1998\*\*\* ) pp. 12.

ISSN: 1040-8304.

LANGUAGE: English

WORD COUNT: 453

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 115 OF 588 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation  
on STN

AN 1998:634881 SCISEARCH

GA The Genuine Article (R) Number: 110MZ

TI Platelet-derived growth factor (PDGF) stimulates the association of SH2-B  
beta with PDGF receptor and phosphorylation of SH2-B beta

AU Rui L Y; CarterSu C (Reprint)

CS UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 (Reprint); UNIV  
MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109

CYA USA

SO JOURNAL OF BIOLOGICAL CHEMISTRY, ( \*\*\*14 AUG 1998\*\*\* ) Vol. 273, No. 33,  
pp. 21239-21245.

Publisher: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE  
PIKE, BETHESDA, MD 20814.

ISSN: 0021-9258.

DT Article; Journal

AU Welham M J (Reprint); Bone H; Levings M; Learmonth L; Wang L M; Leslie K  
B; Pierce J H; Schrader J W

CS UNIV BATH, SCH PHARM & PHARMACOL, PHARMACOL GRP, CALVERTON DOWN, BATH BA2  
7AY, AVON, ENGLAND (Reprint); UNIV BRITISH COLUMBIA, BIOMED RES CTR,  
VANCOUVER, BC V6T 1Z3, CANADA; NIH, CELL & MOL BIOL LAB, BETHESDA, MD  
20892

CYA ENGLAND; CANADA; USA

SO JOURNAL OF BIOLOGICAL CHEMISTRY, ( \*\*\*10 JAN 1997\*\*\* ) Vol. 272, No. 2,  
pp. 1377-1381.  
Publisher: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE  
PIKE, BETHESDA, MD 20814.  
ISSN: 0021-9258.

DT Article; Journal

FS LIFE

LA English

REC Reference Count: 36

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L5 ANSWER 118 OF 588 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation  
on STN

AN 93:283691 SCISEARCH

GA The Genuine Article (R) Number: KZ609

TI CHARGE HETEROGENEITY OF \*\*\*INSULIN\*\*\* \*\*\*FUSION\*\*\*  
\*\*\*PROTEINS\*\*\* EXPRESSED IN ESCHERICHIA-COLI IS NOT DUE TO PROTEOLYTIC  
DEGRADATION

'AU MULLNER S (Reprint); KARBETHONGES B; TRIPIER D

CS HOECHST AG, POB 800320, W-6230 FRANKFURT 80, GERMANY (Reprint)

CYA GERMANY

SO ANALYTICAL BIOCHEMISTRY, ( \*\*\*01 MAY 1993\*\*\* ) Vol. 210, No. 2, pp.  
366-373.  
ISSN: 0003-2697.

DT Article; Journal

FS LIFE

LA ENGLISH

LA English

ED Entered STN: 20011116

Last Updated on STN: 20020924

L5 ANSWER 121 OF 588 USPATFULL on STN

AN 2005:71141 USPATFULL

TI Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies

IN Hsei, Vanessa, San Jose, CA, United States

Koumenis, Iphigenia, Winston-Salem, NC, United States

Leong, Steven R., Berkeley, CA, United States

Presta, Leonard G., San Francisco, CA, United States

Shahrokh, Zahra, San Francisco, CA, United States

Zapata, Gerarado A., Foster City, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

PI US 6870033 B1 20050322

WO 9837200 19980827

<--

AI US 1999-355014 19990913 (9)

WO 1998-US3337 19980220

19990913 PCT 371 date

RLI Continuation-in-part of Ser. No. US 1998-12116, filed on 22 Jan 1998, now abandoned Continuation of Ser. No. US 1997-804444, filed on 21 Feb 1997, now patented, Pat. No. US 6117980

DT Utility

FS GRANTED

LN.CNT 9269

INCL INCLM: 530/388.850

INCLS: 530/391.100; 530/387.300; 424/133.100

NCL NCLM: 530/388.850

NCLS: 530/391.100; 530/387.300; 424/133.100

IC [7]

ICM: C07K016-00

EXF 530/387.1; 530/387.3; 530/388.85; 530/391.5; 424/130.1; 424/133.1

TI Keratinocyte growth factor-2 products  
 IN Narhi, Linda Owers, Camarillo, CA, United States  
 Osslund, Timothy David, Camarillo, CA, United States  
 PA Amgen, Inc., Thousand Oaks, CA, United States (U.S. corporation)  
 PI US 6743422 B1 20040601  
 WO 9816642 19980423 <--  
 AI US 1999-284100 19990407 (9)  
 WO 1997-US18607 19971015  
 PRAI US 1996-33046P 19961210 (60)  
 US 1996-32781P 19961206 (60)  
 US 1996-28493P 19961015 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 3100  
 INCL INCLM: 424/085.100  
 INCLS: 514/002.000; 514/008.000; 514/012.000; 435/320.100; 435/252.300;  
 435/254.110; 435/325.000; 435/069.100; 435/069.400; 530/351.000;  
 530/350.000; 536/023.500; 536/023.100  
 NCL NCLM: 424/085.100  
 NCLS: 435/069.100; 435/069.400; 435/252.300; 435/254.110; 435/320.100;  
 435/325.000; 514/002.000; 514/008.000; 514/012.000; 530/350.000;  
 530/351.000; 536/023.100; 536/023.500  
 IC [7]  
 ICM: C07K014-475  
 ICS: C12N001-21; C12N005-16; C12N015-19; C12N015-63  
 EXF 530/399; 530/350; 530/351; 435/69.4; 435/71.1; 435/71.2; 435/325;  
 435/352.3; 435/254.11; 435/320.1; 435/69.1; 536/23.5; 536/23.51; 574/2;  
 574/5; 574/12; 424/85.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L5 ANSWER 124 OF 588 USPATFULL on STN  
 AN 2004:78914 USPATFULL  
 TI DNA glycosylases and their use  
 IN Krokan, Hans E., Unigen Center for Molecular Biology, University of

PI US 6689605 B1 20040210  
 WO 9852615 19981126 <--  
 AI US 2000-424281 20000102 (9)  
 WO 1998-US10381 19980522  
 PRAI US 1997-47426P 19970522 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 1634  
 INCL INCLM: 435/320.100  
 INCLS: 435/455.000; 435/325.000; 424/093.200; 424/093.210; 424/199.100  
 NCL NCLM: 435/320.100  
 NCLS: 424/093.200; 424/093.210; 424/199.100; 435/325.000; 435/455.000  
 IC [7]  
 ICM: C12N015-63  
 ICS: C12N005-00; C12N015-00; A61K048-00  
 EXF 435/320.1; 435/325; 435/455; 424/199.1; 424/93.2; 424/93.21; 514/44  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L5 ANSWER 126 OF 588 USPATFULL on STN  
 AN 2003:279230 USPATFULL  
 TI Ligand/lytic peptide compositions and methods of use  
 IN Enright, Frederick M., Baton Rouge, LA, United States  
 Jaynes, Jesse M., Baton Rouge, LA, United States  
 Hansel, William, Baton Rouge, LA, United States  
 Koonce, Kenneth L., Baton Rouge, LA, United States  
 McCann, Samuel M., Baton Rouge, LA, United States  
 Yu, Wen H., Baton Rouge, LA, United States  
 Melrose, Patricia A., Baton Rouge, LA, United States  
 Foil, Lane D., Baton Rouge, LA, United States  
 Elzer, Philip H., Baton Rouge, LA, United States  
 PA Board of Supervisors of Louisiana State University and Agricultural and  
 Mechanical College, Baton Rouge, LA, United States (U.S. corporation)  
 PI US 6635740 B1 20031021  
 WO 9842365 19981001 <--

INCL INCLM: 536/024.100  
INCLS: 435/194.000; 435/320.100  
NCL NCLM: 536/024.100  
NCLS: 435/194.000; 435/320.100  
IC [7]  
ICM: C07H021-04  
ICS: C12N009-12; C12N015-00  
EXF 435/194; 435/320.1; 536/24.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 128 OF 588 USPATFULL on STN  
AN 2003:216226 USPATFULL  
TI Method for producing a correctly folded, biological active recombinant  
protein  
IN Gustafsson, Jan-Gunnar, Uppsala, SWEDEN  
Ohman, Johan, Upplands-Vasby, SWEDEN  
PA Pharmacia AB, Stockholm, SWEDEN (non-U.S. corporation)  
PI US 6605706 B1 20030812  
WO 9718233 19970522 <--  
AI US 1998-51941 19980706 (9)  
WO 1996-SE1456 19961112  
PRAI SE 1995-4019 19951113  
DT Utility  
FS GRANTED

LN.CNT 367

INCL INCLM: 530/412.000  
INCLS: 530/413.000; 530/414.000; 530/416.000; 530/300.000; 530/350.000;  
530/399.000; 453/069.100; 453/069.400; 453/069.700; 453/252.300;  
453/252.800; 453/320.100  
NCL NCLM: 530/412.000  
NCLS: 435/069.100; 435/069.400; 435/069.700; 435/252.300; 435/252.800;  
435/320.100; 530/300.000; 530/350.000; 530/399.000; 530/413.000;  
530/414.000; 530/416.000  
IC [7]



AN 2003:115898 USPATFULL  
 TI LDL-receptor  
 IN Todd, John A., Cambridge, UNITED KINGDOM  
 Hess, John W., Lansdale, PA, United States  
 Caskey, Charles T., Houston, TX, United States  
 Cox, Roger D, Oxon, UNITED KINGDOM  
 Gerhold, David, Lansdale, PA, United States  
 Hammond, Holly, Telford, PA, United States  
 Hey, Patricia, Lansdale, PA, United States  
 Kawaguchi, Yoshihiko, Osaka, JAPAN  
 Merriman, Tony R., Dunedin, NEW ZEALAND  
 Metzker, Michael L., Ft. Washington, PA, United States  
 Nakagawa, Yusuke, Ikeda, JAPAN  
 Phillips, Michael S., Lansdale, PA, United States  
 Twells, Rebecca C. J., Oxon, UNITED KINGDOM  
 PA The Wellcome Trust Limited as Trustee for the Wellcome Trust, London,  
 UNITED KINGDOM (non-U.S. corporation)  
 PI US 6555654 B1 20030429  
 WO 9846743 19981022 <--  
 AI US 2000-402923 20000214 (9)  
 WO 1998-GB1102 19980415  
 PRAI US 1997-43553P 19970415 (60)  
 US 1997-48746P 19970605 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 8214  
 INCL INCLM: 530/350.000  
 INCLS: 530/300.000; 435/007.100; 435/320.100  
 NCL NCLM: 530/350.000  
 NCLS: 435/007.100; 435/320.100; 530/300.000  
 IC [7]  
 ICM: C07K014-00  
 ICS: C07K005-00; C12Q001-68  
 EXF 530/300; 530/350; 530/303; 435/7.1; 435/320.1

vectors

IN Jarvis, Donald L., Laramie, WY, United States

PA University of Wyoming, Laramie, WY, United States (U.S. corporation)

PI US 6461863 B1 20021008

WO 9806835 19980219 <--

AI US 1999-242435 19991129 (9)

WO 1997-US14428 19970815

19991129 PCT 371 date

PRAI US 1996-24078P 19960816 (60)

DT Utility

FS GRANTED

LN.CNT 7154

INCL INCLM: 435/320.100

INCLS: 435/069.100; 435/070.100; 435/325.000; 435/348.000

NCL NCLM: 435/320.100

NCLS: 435/069.100; 435/070.100; 435/325.000; 435/348.000

IC [7]

ICM: C12P021-06

ICS: C12P021-04; C12N005-00; C12N005-06; C12N015-00

EXF 435/320.1; 435/348; 435/325; 435/70.1; 435/69.1; 424/93.2; 536/23.1;

536/23.5; 536/24.1; 536/320.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 133 OF 588 USPATFULL on STN

AN 2002:254173 USPATFULL

TI Polynucleotides encoding IMP.18p myo-inositol monophosphatase and  
methods of detecting said polynucleotides

IN Detera-Wadleigh, Sevilla D., Bethesda, MD, United States

Yoshikawa, Takeo, Rockville, MD, United States

Sanders, Alan R., Washington, DC, United States

Esterling, Lisa E., Derwood, MD, United States

PA The United States of America as represented by the Secretary of the  
Department of Health and Human Services, Washington, DC, United States  
(U.S. government)

PRAI US 1996-31338P 19961121 (60)

DT Utility

FS GRANTED

LN.CNT 1771

INCL INCLM: 435/325.000

INCLS: 435/320.100; 435/455.000; 536/023.100; 536/023.500; 424/093.200;  
424/093.210

NCL NCLM: 435/325.000

NCLS: 424/093.200; 424/093.210; 435/320.100; 435/455.000; 536/023.100;  
536/023.500

IC [7]

ICM: C12N005-00

ICS: C12N015-00; C07H021-04; A01N063-00

EXF 435/320.1; 435/325; 435/455; 435/69.1; 536/23.1; 536/23.5; 424/93.2;  
424/93.21

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 135 OF 588 USPATFULL on STN

AN 2002:230807 USPATFULL

TI Human melanocyte stimulating hormone receptor polypeptide and DNA

IN Wikberg, Jarl, Trillvagen 13, S-905 92 Ume.ang., SWEDEN

Chhajlani, Vijay, Stigbergsvagen 8 A, S-752 42 Uppsala, SWEDEN

PI US 6448032 B1 20020910

WO 9404674 19940303

&lt;--

AI US 1995-387805 19950221 (8)

WO 1993-DK273 19930820

19950221 PCT 371 date

PRAI DK 1992-1046 19920821

DK 1992-1118 19920910

DK 1993-528 19930505

DT Utility

FS GRANTED

LN.CNT 3610

435/007.210; 435/174.000

IC [7]

ICM: C12Q001-02

ICS: C12Q001-00; G01N033-53; G01N033-567; A61K049-00

EXF 424/93.21; 424/277.1; 435/325; 435/1.1; 435/283.1; 800/3

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 137 OF 588 USPATFULL on STN

AN 2002:152860 USPATFULL

TI A-myb null mutant transgenic mice

IN Toscani, Antonio, late of Philadelphia, PA, United States deceased

Toscani, Donato, Teramo, ITALY heir

Toscani, Amelia, Teramo, ITALY heir

Hatton, Kimi, Fairfax, VA, United States

Reddy, E. Premkumar, Villanova, PA, United States

PA Temple University-Of The Commonwealth System of Higher Education,  
Philadelphia, PA, United States (U.S. corporation)

PI US 6410825 B1 20020625

WO 9846726 19981022

<--

AI US 2000-402929 20000322 (9)

WO 1998-US6896 19980407

20000322 PCT 371 date

PRAI US 1997-43353P 19970415 (60)

DT Utility

FS GRANTED

LN:CNT 1831

INCL INCLM: 800/018.000

INCLS: 800/008.000; 800/013.000; 800/021.000; 435/325.000; 435/455.000

NCL NCLM: 800/018.000

NCLS: 435/325.000; 435/455.000; 800/008.000; 800/013.000; 800/021.000

IC [7]

ICM: A01K067-00

ICS: C12N015-85; C12N015-09

EXF 536/23.1; 800/8; 800/21; 800/13; 800/14; 800/15; 800/16; 800/17; 800/18;

TI Process for preparing recombinant proteins using highly efficient  
expression vector from saccharomyces cerevisiae

IN Jang, Ki-Ryong, Yusong-ku, KOREA, REPUBLIC OF  
Moon, Jae-Woong, Yusong-ku, KOREA, REPUBLIC OF  
Bae, Cheon-Soon, Yusong-ku, KOREA, REPUBLIC OF  
Yang, Doo-Suk, Yusong-ku, KOREA, REPUBLIC OF  
Lee, Jee-Won, Yusong-ku, KOREA, REPUBLIC OF  
Seong, Baik-Lin, Yusong-ku, KOREA, REPUBLIC OF

PA Hanil Synthetic Fiber Co., Ltd., Masan-si, KOREA, REPUBLIC OF (non-U.S.  
corporation)

PI US 6391585 B1 20020521  
WO 9854339 19981203 <--

AI US 1999-424620 19991124 (9)  
WO 1997-KR97 19970527  
19991124 PCT 371 date

DT Utility

FS GRANTED

LN.CNT 1348

INCL INCLM: 435/069.100  
INCLS: 435/069.400; 435/069.500; 435/320.100; 435/254.210; 536/023.100;  
536/024.100

NCL NCLM: 435/069.100  
NCLS: 435/069.400; 435/069.500; 435/254.210; 435/320.100; 536/023.100;  
536/024.100

IC [7]  
ICM: C12N015-12  
ICS: C12N015-18; C12N015-19; C12N015-63; C12N001-19; C07H021-04

EXF 536/23.1; 536/24.1; 435/320.1; 435/254.21; 435/69.1; 435/69.4; 435/69.5

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 140 OF 588 USPATFULL on STN

AN 2002:108829 USPATFULL

TI Heregulin variants

IN Ballinger, Marcus D., Burlingame, CA, United States

63130

Braford-Goldberg, Sarah Ruth, 4111 W. Pine #10, St. Louis, MO, United States 63108

Caparon, Maire Helena, 109 Beechwood Ct., Chesterfield, MO, United States 63017

Easton, Alan Michael, 2317 Seven Pines Dr. #7, Maryland Heights, MO, United States 63146

Klein, Barbara Kure, 12917 Topping Estates, St. Louis, MO, United States 63131

McKearn, John P., 18612 Babler Meadows Dr., St. Louis, MO, United States 63038

Olins, Peter O., 17507 Summit View, Glencoe, MO, United States 63038

Paik, Kumnan, 1021 Alpine Ridge, Ballwin, MO, United States 63021

Thomas, John W., 13426 Mason Valley, Town & Country, MO, United States 63131

PI US 6361977 B1 20020326

WO 9521254 19950810

AI US 1995-446872 19950606 (8)

WO 1995-US1185 19950202

19950606 PCT 371 date

RLI Continuation-in-part of Ser. No. US 1994-192325, filed on 4 Feb 1994, now patented, Pat. No. US 6097133 Continuation-in-part of Ser. No. WO 1993-US11197, filed on 22 Nov 1993 Continuation-in-part of Ser. No. US 1992-981044, filed on 24 Nov 1992

DT Utility

FS GRANTED

LN.CNT 13951

INCL INCLM: 435/069.520

INCLS: 435/069.700; 424/085.100; 424/085.200

NCL NCLM: 435/069.520

NCLS: 424/085.100; 424/085.200; 435/069.700

IC [7]

ICM: C12P021-04

ICS: A61K045-00

use thereof, and methods of humanizing antibody peptides

IN do Couto, Fernando J. R., Pleasanton, CA, United States  
Ceriani, Roberto L., Lafayette, CA, United States  
Peterson, Jerry A., San Francisco, CA, United States

PA Cancer Research Institute of Contra Costa, San Francisco, CA, United States (U.S. corporation)

PI US 6309636 B1 20011030  
WO 9608565 19960321 <--

AI US 1995-525539 19950914 (8)  
WO 1995-US11683 19950914  
19950914 PCT 371 date  
19950914 PCT 102(e) date

DT Utility

FS GRANTED

LN.CNT 2130

INCL INCLM: 424/133.100  
INCLS: 424/134.100; 424/138.100; 424/141.100; 424/152.100; 424/172.100;  
424/174.100; 424/178.100; 424/183.100; 435/007.100; 530/350.000;  
530/388.100

NCL NCLM: 424/133.100  
NCLS: 424/134.100; 424/138.100; 424/141.100; 424/152.100; 424/172.100;  
424/174.100; 424/178.100; 424/183.100; 435/007.100; 530/350.000;  
530/388.100

IC [7]  
ICM: A61K033-395  
ICS: C07K001-00; C07K016-00; G01N033-53

EXF 435/7.1; 530/388.1; 530/388.2; 530/388.8; 530/388.85; 424/130.1;  
424/133.1; 424/141.1; 424/152.1; 424/155.1; 424/156.1; 424/174.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 144 OF 588 USPATFULL on STN

AN 2001:157994 USPATFULL

TI Cytosolic forms of beta-lactamase and uses thereof

IN Tsien, Roger Y., La Jolla, CA, United States

abandoned Continuation of Ser. No. US 1991-670352, filed on 13 Mar 1991,  
now abandoned Continuation of Ser. No. US 1990-530477, filed on 29 May  
1990, now abandoned Continuation of Ser. No. US 1987-139682, filed on 30  
Dec 1987, now abandoned

DT Reissue

FS GRANTED

LN.CNT 1199

INCL INCLM: 435/069.900

INCLS: 435/069.700; 435/069.800; 435/254.200; 435/254.110; 435/320.100;  
435/471.000; 435/483.000; 536/024.100; 536/024.200; 536/023.400

NCL NCLM: 435/069.900

NCLS: 435/069.700; 435/069.800; 435/254.110; 435/254.200; 435/320.100;  
435/471.000; 435/483.000; 536/023.400; 536/024.100; 536/024.200

IC [7]

ICM: C12N015-62

ICS: C12N015-09; C12N001-15; C12N015-63; C12N015-81

EXF 435/69.9; 435/254.2; 435/254.11; 435/320.1; 435/69.7; 435/69.8; 435/471;  
435/483; 536/23.4; 536/24.1; 536/24.2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 146 OF 588 USPATFULL on STN

AN 2001:107872 USPATFULL

TI Delivery of gene products by intestinal cell expression

IN German, Michael, San Francisco, CA, United States

Goldfine, Ira D., Kentfield, CA, United States

Rothman, Stephen S., Berkeley, CA, United States

PA The Regents of the University of California, Oakland, CA, United States  
(U.S. corporation)

PI US 6258789 B1 20010710

WO 9811779 19980326

<--

AI US 1999-254988 19990611 (9)

WO 1997-US16523 19970918

19990611 PCT 371 date

19990611 PCT 102(e) date



424/185.100; 424/190.100; 514/002.000; 514/012.000; 514/014.000;  
 514/016.000; 530/300.000; 530/350.000; 530/387.100; 530/388.100  
 NCL NCLM: 435/006.000  
 NCLS: 424/150.100; 424/185.100; 424/190.100; 424/234.100; 435/007.100;  
 435/069.100; 435/320.100; 514/002.000; 514/012.000; 514/014.000;  
 514/016.000; 530/300.000; 530/350.000; 530/387.100; 530/388.100  
 IC [7]  
 ICM: C12Q001-68  
 ICS: G01N033-53; A61K039-02; A61K038-16  
 EXF 530/300; 530/350; 530/388.1; 530/388.2; 530/387.1; 424/85.8; 424/150.1;  
 424/185.1; 424/234.1; 424/190.1; 424/800; 424/807; 536/23.1; 435/6;  
 435/7.1; 435/252.3; 435/325; 435/690.1; 435/71.1; 514/2; 514/12-16;  
 900/200; 900/DIG.530  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L5 ANSWER 148 OF 588 USPATFULL on STN  
 AN 2001:75153 USPATFULL  
 TI Oxygen-binding heme proteins incorporating circularly-permuted globins  
 IN Sligar, Stephen G., Urbana, IL, United States  
 Sanders, Kevin, Champaign, IL, United States  
 PA The Board of Trustees of the University of Illinois, Urbana, IL, United  
 States (U.S. corporation)  
 PI US 6235500 B1 20010522  
 WO 9813386 19980402 <--  
 AI US 1999-269592 19990628 (9)  
 WO 1997-US17294 19970926  
 19990628 PCT 371 date  
 19990628 PCT 102(e) date  
 PRAI US 1996-26831P 19960927 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 1994  
 INCL INCLM: 435/069.600  
 INCLS: 435/252.300; 435/320.100; 435/325.000; 536/023.500; 530/385.000

ICS: C12N015-09

EXF 435/252.3; 435/69.1; 435/471; 514/2; 424/93.4; 424/93.44

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 150 OF 588 USPATFULL on STN

AN 2001:51579 USPATFULL

TI DbpA compositions

IN Guo, Betty P., Boston, MA, United States

Hook, Magnus, Houston, TX, United States

PA Texas A & M University System, College Station, TX, United States (U.S. corporation)

PI US 6214355 B1 20010410

WO 9727301 19970731

<--

AI US 1998-117257 19980722 (9)

WO 1996-US17081 19961022

19981029 PCT 371 date

19981029 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 945476 Continuation-in-part of Ser. No. US 1996-589711, filed on 22 Jan 1996, now patented, Pat. No. US 5853987, issued on 29 Dec 1998 Continuation-in-part of Ser. No. US 1995-427023, filed on 24 Apr 1995, now abandoned

DT Utility

FS Granted

LN.CNT 5444

INCL INCLM: 424/234.100

INCLS: 530/388.400; 530/350.000; 514/002.000

NCL NCLM: 424/234.100

NCLS: 514/002.000; 530/350.000; 530/388.400

IC [7]

ICM: A16K039-02

ICS: A16K038-16; C07K014-20; C07K016-12

EXF 530/350; 530/388.4; 504/2; 424/234.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Erythropoietin receptor antibodies  
 IN Young, Peter Ronald, SmithKline Beecham Corporation Corporate  
 Intellectual Property - UW2220 P.O. Box 1539, King of Prussia, PA,  
 United States 19406-0939  
 Erickson-Miller, Connie L., SmithKline Beecham Corporation Corporate  
 Intellectual Property - UW2220 P.O. Box 1539, King of Prussia, PA,  
 United States 19406-0939  
 PI US 6153190 20001128  
 WO 9640231 19961219 <--  
 AI US 1997-776511 19970123 (8)  
 WO 1996-US9613 19960607  
 19970128 PCT 371 date  
 19970128 PCT 102(e) date  
 RLI Continuation-in-part of Ser. No. US 1995-474673, filed on 7 Jun 1995,  
 now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 1683  
 INCL INCLM: 424/141.100  
 INCLS: 435/325.000; 435/334.000; 530/388.100  
 NCL NCLM: 424/141.100  
 NCLS: 435/325.000; 435/334.000; 530/388.100  
 IC [7]  
 ICM: A61K039-395  
 ICS: C12N005-12; C12P021-08; C07K016-28  
 EXF 530/387.1; 530/387.3; 530/388.1; 530/388.23; 530/389.1; 530/389.2;  
 530/389.6; 424/141.1; 435/325; 435/334  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L5 ANSWER 153 OF 588 USPATFULL on STN  
 AN 2000:87749 USPATFULL  
 TI Oral peptide pharmaceutical products  
 IN Stern, William, Tenafly, NJ, United States  
 Gilligan, James P., Union, NJ, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

PI US 6025145 20000215

WO 9514930 19950601 <--

AI US 1995-374565 19950120 (8)

WO 1994-US13329 19941118

19950120 PCT 371 date

19950120 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1994-286305, filed on 5 Aug 1994, now patented, Pat. No. US 5766863 which is a continuation-in-part of Ser. No. US 1993-170558, filed on 20 Dec 1993 which is a continuation-in-part of Ser. No. US 1993-157563, filed on 23 Nov 1993, now abandoned

DT Utility

FS Granted

LN.CNT 2985

INCL INCLM: 435/007.200

INCLS: 435/015.000; 435/069.100; 435/194.000; 435/325.000

NCL NCLM: 435/007.200

NCLS: 435/015.000; 435/069.100; 435/194.000; 435/325.000

IC [7]

ICM: C12Q001-48

EXF 435/7.2; 435/69.1; 435/325; 435/240.2; 435/194; 435/15

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PL5 ANSWER 155 OF 588 USPATFULL on STN

AN 2000:12632 USPATFULL

TI Production of secreted foreign polypeptides in plant cell culture

IN Lee, James M., Pullman, WA, United States

Magnuson, Nancy S., Pullman, WA, United States

An, Gynheung, Pohang, Korea, Republic of

Reeves, Raymond, Pullman, WA, United States

PA Washington State University Research Foundation, Pullman, WA, United States (U.S. corporation)

DT Utility

FS Granted

LN.CNT 886

INCL INCLM: 435/069.100

INCLS: 435/252.300; 435/320.100; 530/380.000; 536/023.500

NCL NCLM: 435/069.100

NCLS: 435/252.300; 435/320.100; 530/380.000; 536/023.500

IC [6]

ICM: C07K014-705

ICS: C12N015-12

EXF 435/7.1; 435/69.1; 435/252.7; 435/320.1; 530/350; 536/23.5

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 157 OF 588 USPATFULL on STN

AN 1999:155685 USPATFULL

TI Human vascular IBP-like growth factor

IN Hastings, Greg A., Germantown, MD, United States

Rosen, Craig A., Laytonsville, MD, United States

PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.  
corporation)

PI US 5994302 19991130

WO 9617931 19960613

<--

AI US 1997-849107 19970925 (8)

WO 1994-US14388 19941209

19970925 PCT 371 date

19970925 PCT 102(e) date

DT Utility

FS Granted

LN.CNT 1514

INCL INCLM: 514/012.000

INCLS: 530/399.000; 530/402.000

NCL NCLM: 514/012.000

NCLS: 530/399.000; 530/402.000

IC [6]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 159 OF 588 USPATFULL on STN  
AN 1999:67348 USPATFULL  
TI Method for purification of a mixture of hydroxamate derivatized protein  
and native protein  
IN Wikstrom, Per, Upplands Vasby, Sweden  
PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)  
PI US 5912329 19990615  
WO 9514035 19950526 <--  
AI US 1996-635908 19960425 (8)  
WO 1994-SE1088 19941117  
19960425 PCT 371 date  
19960425 PCT 102(e) date  
PRAI SE 1993-3822 19931118  
DT Utility  
FS Granted  
LN.CNT 284  
INCL INCLM: 530/415.000  
INCLS: 530/399.000; 530/416.000; 530/417.000  
NCL NCLM: 530/415.000  
NCLS: 530/399.000; 530/416.000; 530/417.000  
IC [6]  
ICM: C07K007-10  
ICS: C07K001-14; C07K003-20  
EXF 530/399; 530/415; 530/416; 530/417  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 160 OF 588 USPATFULL on STN  
AN 1999:24489 USPATFULL  
TI Expression of surface layer proteins  
IN Deblaere, Rolf Y., Waarschoot, Belgium  
Desomer, Jan, Drongen, Belgium  
Dhaese, Patrick, Drongen, Belgium

PI US 5871934 19990216  
 WO 9507922 19950323 <--  
 AI US 1996-605002 19960415 (8)  
 WO 1994-US10529 19940916  
 19960415 PCT 371 date  
 19960415 PCT 102(e) date  
 RLI Continuation-in-part of Ser. No. US 1994-250975, filed on 31 May 1994,  
 now patented, Pat. No. US 5783664 which is a continuation-in-part of  
 Ser. No. US 1993-123175, filed on 17 Sep 1993, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 2149  
 INCL INCLM: 435/007.100  
 INCLS: 435/007.200; 435/069.700; 435/172.300; 436/501.000  
 NCL NCLM: 435/007.100  
 NCLS: 435/007.200; 435/069.700; 436/501.000  
 IC [6]  
 ICM: C12Q001-25  
 ICS: G01N033-53  
 EXF 435/7.1; 435/7.2; 435/69.7; 435/172.3; 436/501  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L5 ANSWER 162 OF 588 USPATFULL on STN  
 AN 1999:21891 USPATFULL  
 TI Methods for producing members of specific binding pairs  
 IN Winter, Gregory Paul, Cambridge, United Kingdom  
 Johnson, Kevin Stuart, Cambridge, United Kingdom  
 Griffiths, Andrew David, Cambridge, United Kingdom  
 Smith, Andrew John Hammond, Cambridge, United Kingdom  
 PA Medical Research Council, London, England (non-U.S. corporation)  
 Cambridge Antibody Technology Limited, Melbourn, England (non-U.S.  
 corporation)  
 PI US 5871907 19990216  
 WO 9220791 19921126 <--

INCLS: 514/021.000

NCL NCLM: 514/002.000

NCLS: 514/021.000

IC [6]

ICM: A01N037-18

ICS: A01N038-00

EXF 514/2; 514/21

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 164 OF 588 USPATFULL on STN

AN 1998:162337 USPATFULL

TI Hexokinase inhibitors

IN Newgard, Christopher B., Dallas, TX, United States

Han, He-Ping, Arlington, TX, United States

Normington, Karl D., Dallas, TX, United States

PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

Betagene, Inc., Dallas, TX, United States (U.S. corporation)

PI US 5854067 19981229 <--

AI US 1996-588983 19960119 (8)

DT Utility

FS Granted

LN.CNT 5377

INCL INCLM: 435/366.000

INCLS: 425/004.000; 425/006.000; 425/091.100; 425/091.310; 425/183.000;  
425/320.100; 425/325.000; 536/023.100; 536/024.310; 536/024.500

NCL NCLM: 435/366.000

NCLS: 435/004.000; 435/006.000; 435/091.100; 435/091.310; 435/183.000;  
435/320.100; 435/325.000; 536/023.100; 536/024.310; 536/024.500

IC [6]

ICM: C12N015-85

ICS: C12N015-00; C12N015-63; C12Q001-68

EXF 435/325; 435/4; 435/6; 435/69.1; 435/320.1; 435/172.3; 424/94.1;  
536/23.1; 536/24.5; 514/44; 576/24.31



L5 ANSWER 166 OF 588 USPATFULL on STN  
 AN 1998:162296 USPATFULL  
 TI IGF-II analogues  
 IN Edwards, Richard Mark, Oxford, England  
 Bawden, Lindsay, Oxford, England  
 PA British Biotech Pharmaceutical Limited, Oxford, England (non-U.S.  
 corporation)  
 PI US 5854025 19981229 <--  
 AI US 1995-462695 19950605 (8)  
 RLI Continuation of Ser. No. US 1994-190029, filed on 28 Feb 1994  
 PRAI GB 1991-16325 19910729  
 GB 1992-2401 19920205  
 DT Utility  
 FS Granted  
 LN.CNT 1116  
 INCL INCLM: 435/069.400  
 INCLS: 435/069.700; 435/243.000; 435/252.800; 435/325.000; 435/320.100;  
 536/023.510  
 NCL NCLM: 435/069.400  
 NCLS: 435/069.700; 435/243.000; 435/252.800; 435/320.100; 435/325.000;  
 536/023.510  
 IC [6]  
 ICM: C12N001-21  
 ICS: C12N005-10; C12N015-18; C12N015-70  
 EXF 530/399; 930/120; 435/69.1; 435/69.4; 435/69.7; 435/71.1; 435/240.1;  
 435/240.2; 435/320.1; 435/243; 435/252.8; 435/325; 536/23.1; 536/23.4;  
 536/23.51; 536/23.2; 935/13; 935/14; 935/47  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 167 OF 588 USPATFULL on STN  
 AN 1998:162289 USPATFULL  
 TI Expression of polypeptides in yeast  
 IN Hitzeman, Ronald A., Pacifica, CA, United States

L5 ANSWER 168 OF 588 USPATFULL on STN  
AN 1998:162259 USPATFULL  
TI Decorin binding protein compositions and methods of use  
IN Guo, Betty, Houston, TX, United States  
Hook, Magnus, Houston, TX, United States  
PA The Texas A & M University System, College Station, TX, United States  
(U.S. corporation)  
PI US 5853987 19981229 <--  
AI US 1996-589711 19960122 (8)  
RLI Continuation-in-part of Ser. No. US 1995-427023, filed on 24 Apr 1995,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 4684  
INCL INCLM: 435/006.000  
INCLS: 536/022.100; 536/023.100; 536/023.700; 536/024.330; 536/025.320;  
435/320.100; 435/091.200; 435/006.000; 530/350.000  
NCL NCLM: 435/006.000  
NCLS: 435/091.200; 435/320.100; 530/350.000; 536/022.100; 536/023.100;  
536/023.700; 536/024.330; 536/025.320  
IC [6]  
ICM: C07H021-04  
ICS: C07H021-02; C12P019-34; C12Q001-68  
EXF 536/22.1; 536/23.1; 536/23.7; 536/24.33; 536/25.32; 435/320.1; 435/6;  
435/91.2; 530/350  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 169 OF 588 USPATFULL on STN  
AN 1998:162251 USPATFULL  
TI Molecularly cloned acquired immunodeficiency syndrome polypeptides and  
methods of use  
IN Berman, Phillip W., Burlingame, CA, United States  
Capon, Daniel J., San Mateo, CA, United States

RLI Division of Ser. No. US 1994-205824, filed on 4 Mar 1994, now abandoned  
which is a continuation of Ser. No. US 1992-947910, filed on 21 Sep  
1992, now abandoned which is a continuation of Ser. No. US 1987-132942,  
filed on 6 Nov 1987, now abandoned

PRAI DK 1986-1455 19860326

DK 1986-6294 19861223

DT Utility

FS Granted

LN.CNT 2913

INCL INCLM: 424/093.200

INCLS: 435/252.300

NCL NCLM: 424/093.200

NCLS: 435/252.300

IC [6]

ICM: A61K039-02

ICS: A61K039-12; A61K039-002; A61K039-108

EXF 424/93.2; 435/252.3

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 171 OF 588 USPATFULL on STN

AN 1998:159916 USPATFULL

TI Method of enhancing proliferation or differentiation of hematopoietic  
stem cells using Wnt polypeptides

IN Matthews, William, Woodside, CA, United States

Austin, Timothy W., Morgan Hill, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S.  
corporation)

PI US 5851984 19981222

<--

AI US 1996-696566 19960816 (8)

DT Utility

FS Granted

LN.CNT 3923

INCL INCLM: 514/002.000

INCLS: 435/002.000; 424/085.100

Ser. No. US 1994-338730, filed on 14 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 726812

DT Utility

FS Granted

LN.CNT 4487

INCL INCLM: 435/368.000

INCLS: 435/325.000; 435/366.000; 435/383.000; 435/384.000

NCL NCLM: 435/368.000

NCLS: 435/325.000; 435/366.000; 435/377.000; 435/383.000; 435/384.000

IC [6]

ICM: C12N005-06

ICS: C12N005-08; C12N005-02

EXF 435/240.2; 435/325; 435/366; 435/368; 435/377; 435/383; 435/384

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 173 OF 588 USPATFULL on STN

AN 1998:157185 USPATFULL

TI Compositions and methods for the treatment and diagnosis of cardiovascular using RCHD528 as a target

IN Falb, Dean A., Massachusetts, MA, United States

PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

PI US 5849578 19981215 <--

AI US 1996-616844 19960315 (8)

RLI Division of Ser. No. US 1996-599654, filed on 9 Feb 1996 which is a continuation-in-part of Ser. No. US 1995-458873, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10 Feb 1995

DT Utility

FS Granted

LN.CNT 5753

INCL INCLM: 435/325.000

INCLS: 536/023.100; 536/024.100; 536/024.300; 435/006.000; 435/069.100; 435/320.100; 435/455.000

ICM: C12N015-18

ICS: C12N015-63; C12N001-21; C07K014-61

EXF 435/69.4; 435/325; 435/243; 435/320.1; 435/172.3; 530/399; 530/402;  
530/416; 536/23.51

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 175 OF 588 USPATFULL on STN

AN 1998:157111 USPATFULL

TI Screening assay for compounds stimulating somatostatin transcription  
factor -1 binding to an STF-1 binding site

IN Montminy, Marc, Wellsley, MA, United States  
Peers, Bernard, Waremmme, Belgium

PA Research Development Foundation, Carson City, NV, United States (U.S.  
corporation)

PI US 5849493 19981215 <--

AI US 1996-757316 19961127 (8)

PRAI US 1995-7722P 19951130 (60)

DT Utility

FS Granted

LN.CNT 1182

INCL INCLM: 435/006.000

INCLS: 435/004.000

NCL NCLM: 435/006.000

NCLS: 435/004.000

IC [6]

ICM: C12Q001-02

ICS: C12Q001-68

EXF 435/6; 435/4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 176 OF 588 USPATFULL on STN

AN 1998:157103 USPATFULL

TI Liver enriched transcription factor

IN Sladek, Frances M., Riverside, CA, United States

INCLS: 424/184.100; 424/231.100; 435/005.000; 536/023.720; 536/024.500  
NCL NCLM: 514/044.000  
NCLS: 424/184.100; 424/231.100; 435/005.000; 536/023.720; 536/024.500  
IC [6]  
ICM: A01N043-06  
ICS: A61K039-245; C07H021-04; C12Q001-68  
EXF 424/231.1; 424/184.1; 536/23.72; 536/24.5; 435/5; 514/44  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 178 OF 588 USPATFULL on STN  
AN 1998:154254 USPATFULL  
TI Compositions and methods for administering Borrelia DNA  
IN Huebner, Robert C., Stroudsburg, PA, United States  
Norman, Jon A., Poway, CA, United States  
Liang, Xiaowu, La Jolla, CA, United States  
Carner, Kristin R., San Diego, CA, United States  
Barbour, Alan G., San Antonio, TX, United States  
Luke, Catherine J., San Antonio, TX, United States  
PA Pasteur Merieux Serums et Vaccins, Lyon, France (non-U.S. corporation)  
Vical Inc., San Diego, CA, United States (U.S. corporation)  
University of Texas Health Science Center, San Antonio, TX, United States (U.S. corporation)  
PI US 5846946 19981208 <--  
AI US 1996-663998 19960614 (8)  
DT Utility  
FS Granted  
LN.CNT 1584

INCL INCLM: 514/044.000  
INCLS: 424/234.100; 435/006.000; 435/069.100; 435/172.300; 435/325.000;  
435/320.100; 935/062.000; 935/056.000; 935/034.000; 935/065.000  
NCL NCLM: 514/044.000  
NCLS: 424/234.100; 435/006.000; 435/069.100; 435/320.100; 435/325.000  
IC [6]  
ICM: A61K048-00

TI Invertebrate apoptosis gene `GRIM` and methods of producing the protein  
 encoded thereby  
 IN Abrams, John M., Dallas, TX, United States  
 Chen, Po, Dallas, TX, United States  
 Nordstrom, William, Dallas, TX, United States  
 PA Board of Regents, The University of Texas System, Austin, TX, United  
 States (U.S. corporation)  
 PI US 5846768 19981208 <--  
 AI US 1996-684101 19960722 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 2475  
 INCL INCLM: 435/069.100  
 INCLS: 435/320.100; 435/172.300; 435/252.300; 435/325.000; 435/348.000;  
 536/023.100; 536/024.300; 536/024.330; 536/024.100; 536/023.500  
 NCL NCLM: 435/069.100  
 NCLS: 435/252.300; 435/320.100; 435/325.000; 435/348.000; 536/023.100;  
 536/023.500; 536/024.100; 536/024.300; 536/024.330  
 IC [6]  
 ICM: C07K014-435  
 ICS: C12N001-21; C12N005-10; C12N015-12  
 EXF 536/23.1; 536/23.5; 536/24.3; 536/24.33; 536/24.1; 435/320.1; 435/69.1;  
 435/172.3; 435/252.3; 435/325; 435/348  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 181 OF 588 USPATFULL on STN  
 AN 1998:154082 USPATFULL  
 TI Identification of novel substrates  
 IN Matthews, David J., San Francisco, CA, United States  
 Wells, James A., Burlingame, CA, United States  
 Zoller, Mark J., San Francisco, CA, United States  
 PA Genentech, Inc., South San Francisco, CA, United States (U.S.  
 corporation)  
 PI US 5846765 19981208 <--

AI US 1994-222719 19940404 (8)  
RLI Continuation-in-part of Ser. No. US 1992-969136, filed on 30 Oct 1992,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 1810  
INCL INCLM: 435/006.000  
INCLS: 435/069.100; 435/069.700; 435/320.100; 435/325.000; 536/023.100  
NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/069.700; 435/320.100; 435/325.000; 536/023.100  
IC [6]  
ICM: C12Q001-68  
ICS: C12P021-06; C12N015-00; C07H017-00  
EXF 435/6; 435/69.7; 435/69.1; 435/240.1; 435/320.1; 530/350; 530/399;  
536/23.51; 536/23.4; 536/23.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
  
L5 ANSWER 183 OF 588 USPATFULL on STN  
AN 1998:151087 USPATFULL  
TI Genetically fused globin-like polypeptides having hemoglobin-like  
activity  
IN Hoffman, Stephen J., Denver, CO, United States  
Looker, Douglas L., Lafayette, CO, United States  
Rosendahl, Mary S., Broomfield, CO, United States  
Stetler, Gary L., Denver, CO, United States  
Wagenbach, Michael, Osaka, Japan  
Anderson, David C., Lafayette, CO, United States  
Mathews, Antony James, Louisville, CO, United States  
Nagai, Kiyoshi, Cambridge, England  
PA Somatogen, Inc., Boulder, CO, United States (U.S. corporation)  
PI US 5844089 19981201 <--  
AI US 1995-450733 19950525 (8)  
RLI Division of Ser. No. US 1991-789179, filed on 8 Nov 1991, now patented,  
Pat. No. US 5545727 which is a continuation-in-part of Ser. No. US



now abandoned And Ser. No. US 1989-349623, filed on 10 May 1989, now  
abandoned

DT Utility

FS Granted

LN.CNT 6872

INCL INCLM: 530/385.000

NCL NCLM: 530/385.000

IC [6]

ICM: C07K014-805

EXF 530/385

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 185 OF 588 USPATFULL on STN

AN 1998:151080 USPATFULL

TI Cytostatin I

IN Ni, Jian, Gaithersburg, MD, United States

Gentz, Reiner, Silver Spring, MD, United States

Yu, Guo-Liang, Darnestown, MD, United States

Rosen, Craig A., Laytonsville, MD, United States

PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.  
corporation)

PI US 5844081 19981201 <--

AI US 1995-470298 19950606 (8)

RLI Division of Ser. No. US 1995-409731, filed on 24 Mar 1995, now patented,  
Pat. No. US 5658758

DT Utility

FS Granted

LN.CNT 1577

INCL INCLM: 530/350.000

INCLS: 435/069.100; 435/071.100; 435/071.200; 435/252.300; 435/325.000;  
435/320.100

NCL NCLM: 530/350.000

NCLS: 435/069.100; 435/071.100; 435/071.200; 435/252.300; 435/320.100;  
435/325.000

dimerized polypeptide fusions

IN Sledziewski, Andrzej Z., Seattle, WA, United States

Bell, Lillian Anne, Seattle, WA, United States

Kindsvogel, Wayne R., Seattle, WA, United States

PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5843725 19981201 <--

AI US 1995-475458 19950607 (8)

RLI Division of Ser. No. US 1994-180195, filed on 11 Jan 1994, now patented,  
Pat. No. US 5567584 which is a continuation of Ser. No. US 1990-634510,  
filed on 27 Dec 1990, now abandoned which is a continuation-in-part of  
Ser. No. US 1989-347291, filed on 2 May 1989, now patented, Pat. No. US  
5155027 which is a continuation-in-part of Ser. No. US 1988-146877,  
filed on 22 Jan 1988, now abandoned

PRAI EP 1989-10087 19890118

DT Utility

FS Granted

LN.CNT 4072

INCL INCLM: 435/069.700

INCLS: 435/325.000; 435/320.100; 435/172.300; 530/387.100; 530/387.300;  
530/333.000; 530/350.000; 530/399.000

NCL NCLM: 435/069.700

NCLS: 435/320.100; 435/325.000; 530/333.000; 530/350.000; 530/387.100;  
530/387.300; 530/399.000

IC [6]

ICM: C12N015-10

ICS: C12N005-10; C07K016-46; C07K014-705

EXF 435/69.7; 435/320.1; 435/172.3; 435/325; 530/387.3; 530/399; 530/333;  
530/350; 530/387.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 188 OF 588 USPATFULL on STN

AN 1998:150739 USPATFULL

TI Alphavirus vector constructs

IN Dubensky, Jr., Thomas W., Rancho Sante Fe, CA, United States

corporation)

PI US 5842477 19981201 <--

AI US 1996-604284 19960221 (8)

DT Utility

FS Granted

LN.CNT 1467

INCL INCLM: 128/898.000

INCLS: 623/011.000; 623/013.000

NCL NCLM: 128/898.000

NCLS: 623/902.000

IC [6]

ICM: A61B019-00

ICS: A61F002-08

EXF 623/11; 623/13; 128/898

L5 ANSWER 190 OF 588 USPATFULL on STN

AN 1998:147590 USPATFULL

TI Receptor modulating agents

IN Morgan, Jr., A. Charles, Edmonds, WA, United States

Wilbur, D. Scott, Edmonds, WA, United States

PA Receptagen Corporation, Edmonds, WA, United States (U.S. corporation)

University of Washington, Seattle, WA, United States (U.S. corporation)

PI US 5840880 19981124 <--

AI US 1995-406191 19950316 (8)

RLI Continuation-in-part of Ser. No. US 1994-224831, filed on 8 Apr 1994,  
now abandoned

DT Utility

FS Granted

LN.CNT 2940

INCL INCLM: 536/026.400

INCLS: 536/026.440; 514/052.000

NCL NCLM: 536/026.400

NCLS: 536/026.440

IC [6]

Wilbur, D. Scott, Edmonds, WA, United States

Pathare, Pradip M., Seattle, WA, United States

PA Receptagen Corporation, Edmonds, WA, United States (U.S. corporation)

University of WA, Edmonds, WA, United States (U.S. corporation)

PI US 5840712 19981124 <--

AI US 1995-545151 19951019 (8)

RLI Continuation-in-part of Ser. No. US 1995-406191, filed on 16 Mar 1995  
Ser. No. Ser. No. US 1995-406192, filed on 16 Mar 1995, now patented,  
Pat. No. US 5739287 And Ser. No. US 1995-406194, filed on 16 Mar 1995 ,  
each Ser. No. US which is a continuation-in-part of Ser. No. US  
1994-224831, filed on 8 Apr 1994, now abandoned

DT Utility

FS Granted

LN.CNT 3615

INCL INCLM: 514/052.000

INCLS: 536/026.400; 536/026.440

NCL NCLM: 514/052.000

NCLS: 536/026.400; 536/026.440

IC [6]

ICM: A01N043-04

ICS: A61K031-70

EXF 536/26.4; 536/26.44; 514/52

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 193 OF 588 USPATFULL on STN

AN 1998:147391 USPATFULL

TI \*\*\*Insulin\*\*\* -like growth factor binding protein 3 (IGF-BP3) in  
treatment of p53-related tumors

IN Buckbinder, Leonard R., Doylestown, PA, United States

Kley, Nikolai, Princeton Junction, NJ, United States

Seizinger, Bernd R., Stockton, NJ, United States

PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S.  
corporation)

PI US 5840673 19981124 <--

LN.CNT 4160

INCL INCLM: 435/069.100

INCLS: 435/320.100; 435/325.000; 435/252.300; 536/023.500; 935/077.000;  
935/078.000

NCL NCLM: 435/069.100

NCLS: 435/252.300; 435/320.100; 435/325.000; 536/023.500

IC [6]

ICM: C12N015-00

ICS: C12N015-63; C12N015-85; C12N001-21; C07H021-04

EXF 435/69.1; 435/320.1; 435/242.7; 435/325; 435/252.3; 536/23.5; 530/350;  
530/399

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 195 OF 588 USPATFULL on STN

AN 1998:147232 USPATFULL

TI Protease and related nucleic acid compounds

IN Ni, Binhui, Carmel, IN, United States

Paul, Marc, Carmel, IN, United States

Wu, Xin, Carmel, IN, United States

PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)

PI US 5840509 19981124

<--

AI US 1997-890542 19970709 (8)

DT Utility

FS Granted

LN.CNT 1761

INCL INCLM: 435/023.000

INCLS: 435/212.000; 435/219.000; 435/226.000

NCL NCLM: 435/007.350

NCLS: 424/139.100; 424/150.100; 424/164.100; 530/327.000; 530/387.900;  
530/388.200; 530/388.400; 530/389.500; 530/391.300; 530/391.700

IC [6]

ICM: C12N009-48

ICS: C12N009-64; C12N009-14; C12Q001-37

(U.S. corporation)

PI US 5837693 19981117 <--  
AI US 1995-410660 19950324 (8)  
DT Utility  
FS Granted  
LN.CNT 1540  
INCL INCLM: 514/044.000  
INCLS: 424/093.210; 435/320.100; 435/325.000; 435/172.300; 536/023.100  
NCL NCLM: 514/044.000  
NCLS: 424/093.210; 435/320.100; 435/325.000; 536/023.100  
IC [6]  
ICM: A01N043-04  
EXF 424/93.21; 435/320.1; 435/325; 435/172.3; 514/49; 935/2; 935/33; 935/52;  
536/23.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 198 OF 588 USPATFULL on STN  
AN 1998:144075 USPATFULL  
TI Synergistic effect of \*\*\*insulin\*\*\* -like growth factor-I and  
erythropoietin  
IN Brox, Alan G., 3547 Vendome, Montreal, Quebec, Canada H4A 3M6  
PI US 5837675 19981117 <--  
AI US 1995-383012 19950203 (8)  
DT Utility  
FS Granted  
LN.CNT 762  
INCL INCLM: 514/008.000  
INCLS: 514/012.000  
NCL NCLM: 514/008.000  
NCLS: 514/012.000  
IC [6]  
ICM: A61K038-30  
ICS: A61K038-42; A61K038-00; C07K014-00  
EXF 514/8; 514/12

Markland, William, Milford, MA, United States

Ley, Arthur Charles, Newton, MA, United States

Kent, Rachel Baribault, Boxborough, MA, United States

PA Dyax, Corp., Cambridge, MA, United States (U.S. corporation)

PI US 5837500 19981117 <--

AI US 1995-415922 19950403 (8)

RLI Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, now patented, Pat. No. US 5403484 which is a division of Ser. No. US 1991-664989, filed on 1 Mar 1991, now patented, Pat. No. US 5223409 which is a continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988, now abandoned

DT Utility

FS Granted

LN.CNT 15973

INCL INCLM: 435/069.700

INCLS: 435/172.300; 530/350.000; 530/412.000; 536/023.400

NCL NCLM: 435/069.700

NCLS: 435/091.100; 435/091.200; 435/471.000; 530/350.000; 530/412.000;  
536/023.400

IC [6]

ICM: C12N015-62

ICS: C07K019-00

EXF 435/69.7; 435/172.3; 530/350; 530/412; 536/23.4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 201 OF 588 USPATFULL on STN

AN 1998:143883 USPATFULL

TI Method of identifying modulators of binding between and VCAM-1

IN Gallatin, W. Michael, Mercer Island, WA, United States

Van der Vieren, Monica, Seattle, WA, United States

PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)

PI US 5837478 19981117 <--

AI US 1997-943363 19971003 (8)

DT Utility

FS Granted

LN.CNT 1685

INCL INCLM: 424/136.100

INCLS: 424/141.100; 424/145.100; 424/152.100; 424/156.100; 424/158.100;  
435/332.000; 435/336.000; 530/387.100; 530/388.200; 530/388.240;  
530/388.850; 530/389.200

NCL NCLM: 424/130.100

NCLS: 424/141.100; 424/145.100; 424/152.100; 424/156.100; 424/158.100;  
435/332.000; 435/336.000; 530/387.100; 530/388.200; 530/388.240;  
530/388.850; 530/389.200

IC [6]

ICM: A61K039-395

ICS: C12N005-12; C07K016-18; C07K016-22

EXF 530/388.23; 530/388.24; 530/350; 530/300; 530/387.1; 530/388.2;  
530/388.85; 530/389.2; 435/240.27; 435/172.2; 435/70.21; 435/332;  
435/336; 514/9-11; 424/158.1; 424/145.1; 424/130.1; 424/141.1;  
424/152.1; 424/156.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 203 OF 588 USPATFULL on STN

AN 1998:139028 USPATFULL

TI \*\*\*Human\*\*\* \*\*\*growth\*\*\* \*\*\*hormone\*\*\* variants

IN Lowman, Henry B., Hercules, CA, United States

Wells, James A., Burlingame, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S.  
corporation)

PI US 5834598 19981110 <--

AI US 1995-463667 19950605 (8)

RLI Division of Ser. No. US 1993-50058, filed on 30 Apr 1993 which is a  
continuation-in-part of Ser. No. US 1991-743614, filed on 9 Aug 1991,  
now abandoned which is a continuation-in-part of Ser. No. US  
1991-715300, filed on 14 Jun 1991, now abandoned which is a  
continuation-in-part of Ser. No. US 1991-683400, filed on 10 Apr 1991,



DT Utility

FS Granted

LN.CNT 5299

INCL INCLM: 435/172.300

INCLS: 435/320.100; 435/325.000; 435/366.000; 536/234.000

NCL NCLM: 435/456.000

NCLS: 435/320.100; 435/325.000; 435/366.000; 435/463.000; 435/465.000;  
536/023.400

IC [6]

ICM: C12N015-62

ICS: C12N015-63; C12N015-79; C12N005-10

EXF 424/93.21; 514/44; 435/69.7; 435/240.2; 435/320.1; 435/23.4; 435/23.5;  
435/325; 435/366; 435/372.3; 435/172.3; 536/23.4; 536/23.5

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 205 OF 588 USPATFULL on STN

AN 1998:138691 USPATFULL

TI Compositions and methods using rchd534, a gene uregulated by shear  
stress

IN Falb, Dean, Wellesley, MA, United States

PA Millennium Pharmaceuticals Inc., Cambridge, MA, United States (U.S.  
corporation)

PI US 5834248 19981110 <--

AI US 1995-480994 19950607 (8)

RLI Division of Ser. No. US 1995-485573, filed on 7 Jun 1995 And a  
continuation-in-part of Ser. No. US 1995-386844, filed on 10 Feb 1995

DT Utility

FS Granted

LN.CNT 4877

INCL INCLM: 435/070.100

INCLS: 435/325.000; 435/172.300; 435/320.100; 536/023.100; 536/023.500

NCL NCLM: 435/070.100

NCLS: 435/320.100; 435/325.000; 536/023.100; 536/023.500

IC [6]

AN 1998:135170 USPATFULL  
TI Human .beta.2 integrin .alpha. subunit  
IN Gallatin, W. Michael, Mercer Island, WA, United States  
Van der Vieren, Monica, Seattle, WA, United States  
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)  
PI US 5831029 19981103 <--  
AI US 1995-482293 19950607 (8)  
RLI Continuation-in-part of Ser. No. US 1994-362652, filed on 21 Dec 1994  
which is a continuation-in-part of Ser. No. US 1994-286889, filed on 5  
Aug 1994, now patented, Pat. No. US 5470953 which is a  
continuation-in-part of Ser. No. US 1993-173497, filed on 23 Dec 1993,  
now patented, Pat. No. US 5437958  
DT Utility  
FS Granted  
LN.CNT 5481  
INCL INCLM: 530/387.200  
INCLS: 530/387.900; 530/388.100; 530/388.220; 530/388.700; 530/389.600;  
435/331.000; 435/334.000; 435/346.000  
NCL NCLM: 530/387.200  
NCLS: 435/331.000; 435/334.000; 435/346.000; 530/387.900; 530/388.100;  
530/388.220; 530/388.700; 530/389.600  
IC [6]  
ICM: C07K016-28  
ICS: C12P021-08  
EXF 530/387.1; 530/387.2; 530/387.9; 530/388.1; 530/388.22; 530/388.7;  
530/389.1; 530/389.6; 435/350; 435/331; 435/334; 435/346  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 208 OF 588 USPATFULL on STN  
AN 1998:135155 USPATFULL  
TI Bacterial receptor structures  
IN Nilsson, Bjorn, Sollentuna, Sweden  
Nygren, Per-.ANG.ke, Skarpnack, Sweden  
Uhlen, Mathias, Upsala, Sweden

IN Mascarenhas, Desmond, San Rafael, CA, United States  
 Zhang, Yang, Sunnyvale, CA, United States  
 Olson, Pamela S., Cupertino, CA, United States  
 Olsen, David R., Menlo Park, CA, United States  
 Carrillo, Pedro A., San Francisco, CA, United States  
 PA Celtrix Pharmaceuticals, Inc., Santa Clara, CA, United States (U.S.  
 corporation)  
 PI US 5830706 19981103 <--  
 AI US 1995-460915 19950605 (8)  
 RLI Continuation of Ser. No. US 1993-100744, filed on 2 Aug 1993, now  
 patented, Pat. No. US 5563046  
 DT Utility  
 FS Granted  
 LN.CNT 1903  
 INCL INCLM: 435/069.700  
 INCLS: 435/252.300; 435/320.100; 530/350.000; 536/023.400  
 NCL NCLM: 435/069.700  
 NCLS: 435/252.300; 435/320.100; 530/350.000; 536/023.400  
 IC [6]  
 ICM: C07K019-00  
 ICS: C12N015-62  
 EXF 435/69.7; 435/202.3; 435/320.1; 435/69.52; 536/23.4; 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L5 ANSWER 210 OF 588 USPATFULL on STN  
 AN 1998:134626 USPATFULL  
 TI Regulated transcription of targeted genes and other biological events  
 IN Crabtree, Gerald R., Woodside, CA, United States  
 Schreiber, Stuart L., Cambridge, MA, United States  
 Spencer, David M., Los Altos, CA, United States  
 Wandless, Thomas J., Cambridge, MA, United States  
 Belshaw, Peter, Cambridge, MA, United States  
 PA President & Fellows of Harvard College, Cambridge, MA, United States  
 (U.S. corporation)

PI US 5830448 19981103 <--  
AI US 1995-470777 19950606 (8)  
RLI Division of Ser. No. US 1994-260850, filed on 16 Jun 1994  
DT Utility  
FS Granted  
LN.CNT 1698  
INCL INCLM: 424/085.200  
INCLS: 514/002.000; 530/351.000; 530/381.000; 424/085.500; 424/085.100  
NCL NCLM: 424/085.200  
NCLS: 424/085.100; 424/085.500; 514/002.000; 530/351.000; 530/381.000  
IC [6]  
ICM: A61K045-05  
ICS: A61K038-00  
EXF 514/2; 530/351; 530/381; 424/85.2; 424/85.5; 424/85.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 212 OF 588 USPATFULL on STN  
AN 1998:131606 USPATFULL  
TI Materials and methods for determining ob protein in a biological sample  
IN Weigle, David S., Bainbridge Island, WA, United States  
Kuijper, Joseph L., Bothell, WA, United States  
Forstrom, John W., Seattle, WA, United States  
Lehner, Joyce M., Seattle, WA, United States  
PA University of Washington, Seattle, WA, United States (U.S. corporation)  
Zymogenetics, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 5827734 19981027 <--  
AI US 1995-540242 19951004 (8)  
RLI Continuation-in-part of Ser. No. US 1995-486459, filed on 7 Jun 1995,  
now abandoned Ser. No. Ser. No. US 1995-486450, filed on 7 Jun 1995, now  
abandoned And Ser. No. US 1995-487111, filed on 7 Jun 1995 , each Ser.  
No. US which is a continuation-in-part of Ser. No. US 1995-419214, filed  
on 10 Apr 1995, now abandoned which is a continuation-in-part of Ser.  
No. US 1995-377068, filed on 20 Jan 1995, now abandoned  
DT Utility

530/350; 530/387.1; 530/387.3

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 214 OF 588 USPATFULL on STN  
AN 1998:124383 USPATFULL  
TI E6 binding proteins  
IN Androphy, Elliot, Natick, MA, United States  
Chen, Jason J., Boston, MA, United States  
PA New England Medical Center Hospitals, Boston, MA, United States (U.S.  
corporation)  
PI US 5821051 19981013 <--  
AI US 1997-840683 19970429 (8)  
RLI Continuation of Ser. No. US 1994-273059, filed on 8 Jul 1994, now  
abandoned  
DT Utility  
FS Granted  
LN.CNT 3004  
INCL INCLM: 435/005.000  
INCLS: 530/350.000; 530/352.000; 530/357.000; 530/358.000  
NCL NCLM: 435/005.000  
NCLS: 530/350.000; 530/352.000; 530/357.000; 530/358.000  
IC [6]  
ICM: C12Q001-70  
EXF 435/5; 530/350; 530/352; 530/357; 530/358

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 215 OF 588 USPATFULL on STN  
AN 1998:122270 USPATFULL  
TI Human B2 integrin alpha subunit antibodies  
IN Gallatin, W. Michael, Mercer Island, WA, United States  
Van der Vieren, Monica, Seattle, WA, United States  
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)  
PI US 5817515 19981006 <--  
AI US 1996-605672 19960222 (8)

AI US 1996-700575 19960807 (8)

DT Utility

FS Granted

LN.CNT 2025

INCL INCLM: 435/069.100

INCLS: 435/091.400; 435/320.100; 435/325.000; 435/252.100; 536/023.200;  
536/023.500

NCL NCLM: 435/069.100

NCLS: 435/091.400; 435/252.100; 435/320.100; 435/325.000; 536/023.200;  
536/023.500

IC [6]

ICM: C12P021-06

ICS: C12N015-64

EXF 536/23.1; 536/23.2; 536/23.5; 435/91.4; 435/325; 435/320.1; 435/69.1;  
435/252.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 217 OF 588 USPATFULL on STN

AN 1998:119134 USPATFULL

TI Methods for regulating gene expression

IN Bujard, Hermann, Heidelberg, Germany, Federal Republic of  
Gossen, Manfred, El Cerrito, CA, United States

PA BASF Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of  
(non-U.S. corporation)

Knoll Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of  
(non-U.S. corporation)

PI US 5814618 19980929 <--

AI US 1995-485978 19950607 (8)

RLI Continuation-in-part of Ser. No. US 1994-260452, filed on 14 Jun 1994,  
now patented, Pat. No. US 5650298 Ser. No. Ser. No. US 1993-76726, filed  
on 14 Jun 1993, now patented, Pat. No. US 5464758 Ser. No. Ser. No. US  
1995-383754, filed on 6 Feb 1995 And Ser. No. US 1994-275876, filed on  
15 Jul 1994, now patented, Pat. No. US 5654168 which is a  
continuation-in-part of Ser. No. US 1994-270637, filed on 1 Jul 1994,

NCLS: 530/399.000; 530/402.000

IC [6]

ICM: A61K038-29

ICS: C07K001-113

EXF 424/562; 514/2; 514/12; 530/324; 530/399; 530/402; 435/69.1; 435/69.4;  
435/252.3; 435/320.1; 536/22.1; 536/23.1; 536/23.4; 536/23.5; 536/23.51

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 219 OF 588 USPATFULL on STN

AN 1998:119004 USPATFULL

TI Eukaryotic layered vector initiation systems

IN Dubensky, Jr., Thomas W., P.O. Box 675205, Rancho Sante Fe, CA, United  
States 92067

Polo, John M., 1222 Reed Ave., Number 4, San Diego, CA, United States  
92109

Jolly, Douglas J., 277 Hillcrest Dr., Leucadia, CA, United States 92024

Driver, David A., 5142 Biltmore St., San Diego, CA, United States 92117

PI US 5814482 19980929 <--

AI US 1996-739158 19961030 (8)

RLI Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a  
continuation-in-part of Ser. No. US 1995-376184, filed on 18 Jan 1995,  
now abandoned which is a continuation-in-part of Ser. No. US  
1994-348472, filed on 30 Nov 1994, now abandoned which is a  
continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994,  
now abandoned which is a continuation-in-part of Ser. No. US  
1993-122791, filed on 15 Sep 1993, now abandoned

DT Utility

FS Granted

LN.CNT 10431

INCL INCLM: 435/069.300

INCLS: 435/320.100; 536/023.100; 536/024.100

NCL NCLM: 435/069.300

NCLS: 435/320.100; 536/023.100; 536/024.100

IC [6]

EXF 435/69.4; 435/69.1; 435/240.2; 435/172.1; 435/172.3; 435/320.1;  
435/252.3; 435/325; 530/350; 530/399; 530/303; 530/418-420; 530/421-442;  
530/424

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 221 OF 588 USPATFULL on STN

AN 1998:111793 USPATFULL

TI Method for making heteromultimeric polypeptides

IN Carter, Paul J., San Francisco, CA, United States

Presta, Leonard G., San Francisco, CA, United States

Ridgway, John B., San Francisco, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S.  
corporation)

PI US 5807706 19980915 <--

AI US 1995-433105 19950503 (8)

RLI Division of Ser. No. US 1995-399106, filed on 1 Mar 1995

DT Utility

FS Granted

LN.CNT 2576

INCL INCLM: 435/069.100

INCLS: 435/172.100; 435/172.300; 435/069.700; 435/070.100; 435/071.100;  
530/300.000; 530/350.000; 530/387.100; 530/387.300

NCL NCLM: 435/069.100

NCLS: 435/069.700; 435/070.100; 435/071.100; 530/300.000; 530/350.000;  
530/387.100; 530/387.300

IC [6]  
ICM: C12P021-06

EXF 435/172.1; 435/172.3; 435/69.1; 435/69.7; 435/70.1; 435/71.1; 530/300;  
530/350; 530/387.1; 530/387.3

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 222 OF 588 USPATFULL on STN

AN 1998:108251 USPATFULL

TI Recombinant production of proteins using 7B2 protein



AI US 1993-129930 19930930 (8)  
RLI Continuation-in-part of Ser. No. US 1992-977696, filed on 16 Nov 1992  
DT Utility  
FS Granted  
LN.CNT 5440  
INCL INCLM: 424/134.100  
INCLS: 424/133.100; 424/138.100; 435/007.230; 435/328.000; 435/330.000;  
530/387.300; 530/387.700  
NCL NCLM: 424/134.100  
NCLS: 424/133.100; 424/138.100; 435/007.230; 435/328.000; 435/330.000;  
530/387.300; 530/387.700  
IC [6]  
ICM: A61K039-395  
ICS: A61K039-40; A61K039-42; G01N033-574  
EXF 530/387.3; 530/388.85; 424/133.1; 424/134.1; 424/156.1; 424/1.11;  
435/240.27

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 224 OF 588 USPATFULL on STN  
AN 1998:104803 USPATFULL  
TI Nucleic acid compositions encoding acetyl-coa carboxylase and uses  
therefor  
IN Haselkorn, Robert, Chicago, IL, United States  
Gornicki, Piotr, Chicago, IL, United States  
PA Arch Development Corporation, Chicago, IL, United States (U.S.  
corporation)  
PI US 5801233 19980901 <--  
AI US 1996-611107 19960305 (8)  
RLI Continuation-in-part of Ser. No. US 1995-422560, filed on 14 Apr 1995  
which is a continuation-in-part of Ser. No. US 1992-956700, filed on 2  
Oct 1992, now patented, Pat. No. US 5539092  
DT Utility  
FS Granted  
LN.CNT 5674

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 226 OF 588 USPATFULL on STN  
AN 1998:104592 USPATFULL  
TI DNA encoding fused alpha-beta globin pseudodimer and production of  
pseudotetrameric hemoglobin  
IN Anderson, David C., Lafayette, CO, United States  
Mathews, Antony James, Louisville, CO, United States  
PA Somatogen, Inc., Boulder, CO, United States (U.S. corporation)  
PI US 5801019 19980901 <--  
AI US 1995-444939 19950519 (8)  
RLI Division of Ser. No. US 1991-789179, filed on 8 Nov 1991, now patented,  
Pat. No. US 5545727 which is a continuation-in-part of Ser. No. US  
1991-671707, filed on 1 Apr 1991, now abandoned which is a  
continuation-in-part of Ser. No. US 1989-374161, filed on 30 Jun 1989,  
now abandoned And Ser. No. US 1989-379116, filed on 13 Jul 1989, now  
abandoned And Ser. No. US 1989-349623, filed on 10 May 1989, now  
abandoned  
DT Utility  
FS Granted  
LN.CNT 6736  
INCL INCLM: 435/069.600  
INCLS: 435/069.700; 435/069.100; 530/385.000; 536/023.400  
NCL NCLM: 435/069.600  
NCLS: 435/069.100; 435/069.700; 530/385.000; 536/023.400  
IC [6]  
ICM: C12P021-06  
ICS: C07H017-00; C07K014-805  
EXF 530/385; 536/23.1; 536/23.4; 435/69.1; 435/69.6

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 227 OF 588 USPATFULL on STN  
AN 1998:101519 USPATFULL  
TI Co-expression of alpha and beta globins

PA Baylor College of Medicine, Houston, TX, United States (U.S.  
corporation)

PI US 5798209 19980825 <--

AI US 1995-451883 19950526 (8)

RLI Division of Ser. No. US 1993-149103, filed on 8 Nov 1993

DT Utility

FS Granted

LN.CNT 1606

INCL INCLM: 435/006.000

INCLS: 536/023.100; 536/024.300; 536/024.330; 435/091.200

NCL NCLM: 435/006.000

NCLS: 435/091.200; 536/023.100; 536/024.300; 536/024.330

IC [6]

ICM: C12Q001-68

ICS: C12P019-34; C07H021-04; C07H021-02

EXF 536/23.1; 536/24.3-24.33; 435/6; 435/91.2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 229 OF 588 USPATFULL on STN

AN 1998:98981 USPATFULL

TI Lymphotoxin-beta and lymphotoxin-beta complexes

IN Browning, Jeffrey, Brookline, MA, United States

Ware, Carl F., Riverside, CA, United States

PA Biogen, Inc., Cambridge, MA, United States (U.S. corporation)

University of California, Oakland, CA, United States (U.S. corporation)

PI US 5795964 19980818 <--

AI US 1995-467070 19950606 (8)

RLI Division of Ser. No. US 1994-222614, filed on 1 Apr 1994, now abandoned  
which is a continuation-in-part of Ser. No. US 1990-544862, filed on 27  
Jun 1990, now abandoned

DT Utility

FS Granted

LN.CNT 2597

INCL INCLM: 530/351.000

L5 ANSWER 231 OF 588 USPATFULL on STN  
AN 1998:98752 USPATFULL  
TI Expression of neurogenic bHLH genes in primitive neuroectodermal tumors  
IN Tapscott, Stephen J., Seattle, WA, United States  
Olson, James M., Seattle, WA, United States  
PA Fred Hutchinson Cancer Research Center, Seattle, WA, United States (U.S.  
corporation)  
PI US 5795723 19980818 <--  
AI US 1997-910973 19970807 (8)  
RLI Continuation-in-part of Ser. No. US 1995-552142, filed on 2 Nov 1995,  
now patented, Pat. No. US 5695995 which is a continuation-in-part of  
Ser. No. US 1994-239238, filed on 6 May 1994, now abandoned  
DT Utility  
FS Granted  
LN.CNT 3095  
INCL INCLM: 435/006.000  
INCLS: 435/034.000; 435/069.100; 536/023.100  
NCL NCLM: 435/006.000  
NCLS: 435/034.000; 435/069.100; 536/023.100  
IC [6]  
ICM: C12Q001-68  
ICS: C12Q001-04; C12P021-02; C07H021-04  
EXF 435/6; 435/29; 435/325; 435/34; 435/69.1; 435/69.4; 435/172.3;  
435/257.33; 435/320.1; 435/357; 435/360; 536/23.1; 536/23.5; 536/23.51  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 232 OF 588 USPATFULL on STN  
AN 1998:95622 USPATFULL  
TI Polynucleotides encoding modified antibodies with human milk fat globule  
specificity  
IN do Couto, Fernando J. R., Pleasanton, CA, United States  
Ceriani, Roberto L., Lafayette, CA, United States  
Peterson, Jerry A., Lafayette, CA, United States

IC [6]  
ICM: C07K014-00  
EXF 530/350; 530/300  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 234 OF 588 USPATFULL on STN  
AN 1998:92164 USPATFULL  
TI Method of producing \*\*\*insulin\*\*\* -like growth factor-I (IGF-I) and  
\*\*\*insulin\*\*\* -like growth factor binding protein-3 (IGFBP-3) with  
correct folding and disulfide bonding  
IN Sommer, Andreas, Danville, CA, United States  
Ogawa, Yasushi, Pacifica, CA, United States  
Tao, Peggy, San Jose, CA, United States  
PA Celtrix Pharmaceuticals, Inc., Santa Clara, CA, United States (U.S.  
corporation)  
PI US 5789547 19980804 <--  
AI US 1995-482271 19950607 (8)  
DT Utility  
FS Granted  
LN.CNT 1095  
INCL INCLM: 530/351.000  
INCLS: 530/350.000; 530/324.000; 530/344.000; 530/399.000; 530/408.000;  
530/412.000; 435/069.500; 435/172.300  
NCL NCLM: 530/351.000  
NCLS: 435/069.500; 530/324.000; 530/344.000; 530/350.000; 530/399.000;  
530/408.000; 530/412.000  
IC [6]  
ICM: C07K001-14  
ICS: C07K014-435; C07K014-65; C12N015-12  
EXF 435/69.5; 435/172.3; 530/399; 530/412; 530/408; 530/324; 530/344;  
530/350; 530/351  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 235 OF 588 USPATFULL on STN

now abandoned which is a continuation-in-part of Ser. No. US  
1994-348472, filed on 30 Nov 1994, now abandoned which is a  
continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994,  
now abandoned which is a continuation-in-part of Ser. No. US  
1993-122791, filed on 15 Sep 1993, now abandoned

DT Utility

FS Granted

LN.CNT 10270

INCL INCLM: 435/320.100

INCLS: 435/691.000; 435/325.000; 536/023.720

NCL NCLM: 435/320.100

NCLS: 435/069.100; 435/325.000; 536/023.720

IC [6]

ICM: C12N015-63

ICS: C12N015-40; C12N005-10; C12P021-02

EXF 435/320.1; 435/69.1; 435/325; 536/23.72

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 237 OF 588 USPATFULL on STN

AN 1998:91857 USPATFULL

TI Stranded RNA virus particles

IN Wertz, Gail W., Birmingham, AL, United States

Yu, Qingzhong, Birmingham, AL, United States

Ball, Laurence A., Birmingham, AL, United States

Barr, John N., Birmingham, AL, United States

Whelan, Sean P. J., Birmingham, AL, United States

PA UAB Research Foundation, Birmingham, AL, United States (U.S.  
corporation)

PI US 5789229 19980804

<--

AI US 1995-514975 19950929 (8)

RLI Continuation-in-part of Ser. No. US 1995-475587, filed on 7 Jun 1995,  
now abandoned which is a continuation-in-part of Ser. No. US  
1994-316438, filed on 30 Sep 1994, now patented, Pat. No. US 5716821

DT Utility

L5 ANSWER 239 OF 588 USPATFULL on STN

AN 1998:91815 USPATFULL

TI Yeast cells engineered to produce pheromone system protein surrogates,  
and uses therefor

IN Fowlkes, Dana M., Chapel Hill, NC, United States  
Broach, Jim, Princeton, NJ, United States  
Manfredi, John, Ossining, NY, United States  
Klein, Christine, Ossining, NY, United States  
Murphy, Andrew J., Montclair, NJ, United States  
Paul, Jeremy, South Nyack, NY, United States  
Trueheart, Joshua, South Nyack, NY, United States

PA Cadus Pharmaceutical Corporation, Tarrytown, NY, United States (U.S.  
corporation)

PI US 5789184 19980804 <--

AI US 1995-464531 19950605 (8)

RLI Continuation-in-part of Ser. No. US 1994-322137, filed on 13 Oct 1994  
which is a continuation-in-part of Ser. No. US 1994-309313, filed on 20  
Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US  
1994-190328, filed on 31 Jan 1994, now abandoned which is a  
continuation-in-part of Ser. No. US 1993-41431, filed on 31 Mar 1993,  
now abandoned

DT Utility

FS Granted

LN.CNT 6731

INCL INCLM: 435/007.310  
INCLS: 435/254.110; 435/254.200; 435/254.210

NCL NCLM: 435/007.310  
NCLS: 435/254.110; 435/254.200; 435/254.210; 435/DIG.007; 435/DIG.027

IC [6]  
ICM: G01N033-53

EXF 435/4; 435/7.1; 435/64; 435/252.3; 435/320.1; 435/254.21; 435/254.2;  
435/254.11

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 241 OF 588 USPATFULL on STN  
AN 1998:88936 USPATFULL  
TI Hormone-nuclease compounds and method for regulating hormone related diseases  
IN Nett, Torrance M., Ft. Collins, CO, United States  
Glode, Leonard Michael, Aurora, CO, United States  
Karpeisky, Marat, Boulder, CO, United States  
PA Colorado State University Research Foundation, Ft. Collins, CO, United States (U.S. corporation)  
PI US 5786457 19980728 <--  
AI US 1995-481128 19950607 (8)  
RLI Continuation-in-part of Ser. No. US 1992-837639, filed on 14 Feb 1992, now patented, Pat. No. US 5378688, issued on 3 Jan 1995 which is a continuation-in-part of Ser. No. US 1989-314653, filed on 23 Feb 1989, now abandoned , said Ser. No. US 481128 which is a continuation-in-part of Ser. No. US 1993-88434, filed on 7 Jul 1993 Ser. No. Ser. No. US 1993-94250, filed on 20 Jul 1993, now patented, Pat. No. US 5492893 And Ser. No. US 1993-94625, filed on 20 Jul 1993, now patented, Pat. No. US 5488036  
DT Utility  
FS Granted  
LN.CNT 2002  
INCL INCLM: 530/402.000  
INCLS: 530/324.000; 514/015.000; 514/012.000  
NCL NCLM: 530/402.000  
NCLS: 530/324.000  
IC [6]  
ICM: A61K038-00  
ICS: C07K005-00; C07K007-00  
EXF 514/15; 514/12; 530/402; 530/324

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



corporation)

PI US 5783664 19980721 <--  
AI US 1994-250975 19940531 (8)  
RLI Continuation-in-part of Ser. No. US 1993-123175, filed on 17 Sep 1993,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 2063  
INCL INCLM: 530/350.000  
INCLS: 530/395.000; 435/069.100; 435/194.000  
NCL NCLM: 530/350.000  
NCLS: 435/069.100; 435/194.000; 530/395.000  
IC [6]  
ICM: C07K014-435  
ICS: C07K014-705; C12N015-12; C12N009-12  
EXF 530/350; 530/395; 435/69.1; 435/194  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 244 OF 588 USPATFULL on STN  
AN 1998:85574 USPATFULL  
TI Therapeutic uses of \*\*\*fusion\*\*\* \*\*\*proteins\*\*\* between mutant  
IL 4/IL13 antagonists and immunoglobulins  
IN Browne, Michael Joseph, Welwyn Garden, England  
Young, Peter Ronald, Lawrenceville, NJ, United States  
Shatzman, Allan Richard, King of Prussia, PA, United States  
Murphy, Kay Elizabeth, Hertford, England  
Chapman, Conrad Gerald, Orpington, England  
Clinkenbeard, Helen Elizabeth, Hertford, England  
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S.  
corporation)  
SmithKline Beecham p.l.c., Brentford, England (non-U.S. corporation)  
PI US 5783181 19980721 <--  
AI US 1995-470299 19950606 (8)  
PRAI GB 1994-15379 19940729

DT Utility

FS Granted

LN.CNT 2062

INCL INCLM: 536/024.310

INCLS: 536/024.300

NCL NCLM: 536/024.310

NCLS: 536/024.300

IC [6]

ICM: C07H021-04

EXF 536/23.5; 536/23.1; 536/24.3; 536/24.31; 435/320.1; 435/69.1; 435/172.3;  
435/240.1; 435/252.3

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 246 OF 588 USPATFULL on STN

AN 1998:78974 USPATFULL

TI Recombinant production of glucagon receptors

IN Kindsvogel, Wayne R., Seattle, WA, United States

Jelinek, Laura J., Seattle, WA, United States

Sheppard, Paul O., Redmond, WA, United States

Grant, Francis J., Seattle, WA, United States

Kuijper, Joseph L., Bothell, WA, United States

Foster, Donald C., Seattle, WA, United States

Lok, Si, Seattle, WA, United States

O'Hara, Patrick J., Seattle, WA, United States

PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5776725 19980707

<--

AI US 1993-86631 19930701 (8)

RLI Continuation-in-part of Ser. No. US 1992-938331, filed on 28 Aug 1992,  
now abandoned

DT Utility

FS Granted

LN.CNT 3276

INCL INCLM: 435/069.100

INCLS: 536/023.500; 536/024.310; 435/320.100; 435/325.000; 435/252.300;

ICS: C07K014-475

EXF 530/402; 530/399; 530/350; 424/194.1; 424/195.11; 424/185.1; 424/198.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 248 OF 588 USPATFULL on STN

AN 1998:72720 USPATFULL

TI Peptides comprising repetitive units of amino acids and DNA sequences  
encoding the same

IN Ferrari, Franco A., La Jolla, CA, United States

Richardson, Charles, Florence, MT, United States

Chambers, James, San Diego, CA, United States

Causey, Stuart, Palo Alto, CA, United States

Pollock, Thomas J., San Diego, CA, United States

Cappello, Joseph, San Diego, CA, United States

Crissman, John W., San Diego, CA, United States

PA Protein Polymer Technologies, Inc., San Diego, CA, United States (U.S.  
corporation)

PI US 5770697 19980623 <--

AI US 1995-477509 19950607 (8)

RLI Continuation-in-part of Ser. No. US 1993-175155, filed on 29 Dec 1993,  
now patented, Pat. No. US 5641648, issued on 24 Jun 1997 which is a  
continuation-in-part of Ser. No. US 1993-53049, filed on 22 Apr 1993;  
now abandoned which is a continuation of Ser. No. US 1987-114618, filed  
on 29 Oct 1987, now patented, Pat. No. US 5243038, issued on 7 Sep 1993  
which is a continuation-in-part of Ser. No. US 1986-927258, filed on 4  
Nov 1986; now abandoned

DT Utility

FS Granted

LN.CNT 3242

INCL INCLM: 530/353.000

INCLS: 435/069.100; 530/356.000; 530/357.000

NCL NCLM: 530/353.000

NCLS: 435/069.100; 530/356.000; 530/357.000

IC [6]

TI      Glucagon receptor proteins, peptides, and antibodies

IN      Kindsvogel, Wayne R., Seattle, WA, United States  
Jelinek, Laura J., Seattle, WA, United States  
Sheppard, Paul O., Redmond, WA, United States  
Grant, Francis J., Seattle, WA, United States  
Kuijper, Joseph L., Bothell, WA, United States  
Foster, Donald C., Seattle, WA, United States  
Lok, Si, Seattle, WA, United States  
O'Hara, Patrick J., Seattle, WA, United States

PA      ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)

PI      US 5770445                      19980623                      <--

AI      US 1995-453956                      19950530 (8)

RLI      Division of Ser. No. US 1993-86631, filed on 1 Jul 1993 which is a  
continuation-in-part of Ser. No. US 1992-938331, filed on 28 Aug 1992,  
now abandoned

DT      Utility

FS      Granted

LN.CNT 3238

INCL      INCLM: 435/334.000  
INCLS: 530/350.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000;  
530/328.000; 530/338.220; 530/389.100; 514/002.000

NCL      NCLM: 435/334.000  
NCLS: 514/002.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000;  
530/328.000; 530/350.000; 530/388.220; 530/389.100

IC      [6]  
ICM: C07K014-72  
ICS: C07K016-28; C12N015-12

EXF      530/350; 530/324; 530/325; 530/326; 530/327; 530/328; 530/387.2;  
530/388.22; 530/389.1; 435/240.27; 435/24; 514/2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5      ANSWER 251 OF 588    USPATFULL on STN

AN      1998:72453    USPATFULL

TI      Human ALK protein tyrosine kinase

435/252.800; 435/320.100; 536/023.100; 536/023.500; 536/024.310

NCL NCLM: 435/069.500

NCLS: 435/071.100; 435/071.200; 435/252.300; 435/252.800; 435/320.100;  
435/325.000; 536/023.100; 536/023.500; 536/024.310

IC [6]

ICM: C12N015-19

ICS: C07K014-52

EXF 435/69.5; 435/70.1; 435/71.1; 435/71.2; 435/172.3; 435/240.2; 435/252.3;  
435/252.8; 435/325; 435/320.1; 536/23.1; 536/23.5; 536/24.31; 935/11;  
935/22; 935/52; 935/66; 935/72; 935/73

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 253 OF 588 USPATFULL on STN

AN 1998:72417 USPATFULL

TI Method for determining compound interaction with E2 binding proteins

IN Androphy, Elliot J., Natick, MA, United States  
Breiding, David E., Somerville, MA, United States

PA New England Medical Center Hospitals, Inc, Boston, MA, United States  
(U.S. corporation)

PI US 5770384 19980623 <--

AI US 1996-612986 19960306 (8)

RLI Division of Ser. No. US 1994-361806, filed on 22 Dec 1994

DT Utility

FS Granted

LN.CNT 4248

INCL INCLM: 435/007.800

INCLS: 435/007.930; 435/007.100; 435/005.000; 435/069.100; 435/069.700;  
514/002.000; 536/023.720; 530/300.000; 530/350.000

NCL NCLM: 435/007.800

NCLS: 435/005.000; 435/007.100; 435/007.930; 435/069.100; 435/069.700;  
514/002.000; 530/300.000; 530/350.000; 536/023.720

IC [6]

ICM: C12Q001-00

ICS: C12P021-06; C07K014-025

PA Texas A & M University, College Station, TX, United States (U.S.  
corporation)

PI US 5766885 19980616 <--

AI US 1995-468067 19950606 (8)

RLI Continuation-in-part of Ser. No. US 1993-146881, filed on 1 Nov 1993,  
now patented, Pat. No. US 5491076

DT Utility

FS Granted

LN.CNT 1200

INCL INCLM: 435/070.100  
INCLS: 435/069.100; 435/069.400; 435/069.520; 435/069.600; 435/091.100;  
435/091.330; 435/410.000; 435/419.000

NCL NCLM: 435/070.100  
NCLS: 435/069.100; 435/069.400; 435/069.520; 435/069.600; 435/091.100;  
435/091.330; 435/410.000; 435/419.000

IC [6]  
ICM: C12N007-01  
ICS: C12N015-01; C12P021-00

EXF 435/172.3; 435/69.4; 435/69.52; 435/69.1; 435/69.6; 435/70.1; 435/91.1;  
435/91.33; 435/240.1; 435/240.4; 435/320.1; 435/410; 435/419; 935/6;  
935/11; 935/22-25; 935/47; 935/51; 935/67

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 256 OF 588 USPATFULL on STN

AN 1998:68788 USPATFULL

TI Kinase receptor activation assay

IN Godowski, Paul J., Burlingame, CA, United States  
Mark, Melanie R., Burlingame, CA, United States  
Sadick, Michael D., El Cerrito, CA, United States  
Shelton, David L., Pacifica, CA, United States  
Wong, Wai Lee Tan, Los Altos Hills, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S.  
corporation)

PI US 5766863 19980616 <--

DT Utility

FS Granted

LN.CNT 3283

INCL INCLM: 435/006.000

INCLS: 435/007.200; 435/007.800; 536/025.400; 935/019.000

NCL NCLM: 435/006.000

NCLS: 435/007.200; 435/007.800; 536/025.400

IC [6]

ICM: C12N015-00

ICS: C12N015-02; C12N015-10; C12N015-12

EXF 435/6; 435/7.2; 435/7.8; 536/25.4; 935/19

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 258 OF 588 USPATFULL on STN

AN 1998:65525 USPATFULL

TI Production of heterologous protein in plants and plant cells

IN Sijmons, Peter Christiaan, Amsterdam, Netherlands

Hoekema, Andreas, Oegstgeest, Netherlands

Dekker, Bernardus Martinus M., Gouda, Netherlands

Schrammeijer, Barbara, Rotterdam, Netherlands

Verwoerd, Teunis Cornelius, Leiden, Netherlands

Van Den Elzen, Peturs Josephus M., Voorhout, Netherlands

PA Mogen International N.V., Leiden, Netherlands (non-U.S. corporation)

PI US 5763748 19980609 <--

AI US 1997-829057 19970331 (8)

RLI Continuation of Ser. No. US 1991-659287, filed on 21 May 1991

PRAI NL 1989-1932 19890726

DT Utility

FS Granted

LN.CNT 876

INCL INCLM: 800/205.000

INCLS: 800/DIG.009; 800/DIG.042; 800/DIG.043; 800/DIG.056; 435/069.100;  
435/069.600; 435/069.700; 435/172.100; 435/172.300; 435/320.100;  
435/375.000; 435/419.000; 530/364.000; 536/023.500

EXF 424/185.1; 424/195.11; 424/198.1; 424/194.1; 435/68.1; 530/402; 530/399  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 260 OF 588 USPATFULL on STN  
AN 1998:65039 USPATFULL  
TI Chimeric toxins  
IN Williams, Diane, Franklin, MA, United States  
Murphy, John R., Boston, MA, United States  
PA Boston Medical Center Corporation, Boston, MA, United States (U.S.  
corporation)  
PI US 5763250 19980609 <--  
AI US 1995-479107 19950607 (8)  
RLI Continuation of Ser. No. US 1994-231397, filed on 22 Apr 1994, now  
patented, Pat. No. US 5616482 which is a continuation of Ser. No. US  
1992-886715, filed on 21 May 1992, now abandoned which is a continuation  
of Ser. No. US 1990-537430, filed on 13 Jun 1990, now abandoned which is  
a continuation-in-part of Ser. No. US 1990-488608, filed on 2 Mar 1990,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 1018  
INCL INCLM: 435/194.000  
INCLS: 530/350.000; 530/351.000; 935/047.000  
NCL NCLM: 435/194.000  
NCLS: 530/350.000; 530/351.000  
IC [6]  
ICM: C12N009-12  
ICS: C07K014-34; C07K014-52  
EXF 435/69.1; 435/69.7; 435/71.1; 435/71.3; 435/172.1; 435/320.1; 435/194;  
514/12; 530/350; 530/351; 530/399; 536/23.1; 935/47  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 261 OF 588 USPATFULL on STN  
AN 1998:64720 USPATFULL



PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

PI US 5762921 19980609 <--

AI US 1996-594360 19960130 (8)

RLI Continuation of Ser. No. US 1994-260850, filed on 16 Jun 1994, now abandoned

DT Utility

FS Granted

LN.CNT 1824

INCL INCLM: 424/085.100  
 INCLS: 424/198.100; 424/085.200; 424/085.500; 424/158.100; 514/012.000; 530/350.000; 530/351.000; 530/381.000

NCL NCLM: 424/085.100  
 NCLS: 424/085.200; 424/085.500; 424/158.100; 424/198.100; 514/012.000; 530/350.000; 530/351.000; 530/381.000

IC [6]  
 ICM: A61K045-05  
 ICS: A61K038-19; A61K038-06; C07K001-00

EXF 424/198.1; 424/85.2; 424/85.5; 424/85.1; 424/158.1; 514/12; 530/350; 530/351; 530/381

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 263 OF 588 USPATFULL on STN

AN 1998:61137 USPATFULL

TI Hemoglobins as drug delivery agents

IN Anderson, David C., San Bruno, CA, United States  
 Mathews, Antony James, Louisville, CO, United States

PA Somatogen, Inc., Boulder, CO, United States (U.S. corporation)

PI US 5759517 19980602 <--

AI US 1995-457753 19950601 (8)

RLI Division of Ser. No. US 1994-240711, filed on 12 Jul 1994 which is a continuation-in-part of Ser. No. US 1991-789177, filed on 8 Nov 1991, now abandoned And a continuation-in-part of Ser. No. US 1991-789179, filed on 8 Nov 1991, now patented, Pat. No. US 5545727

ICS: A61K038-22

EXF 435/69.4; 435/69.1; 435/260.2; 435/172.1; 435/172.3; 435/320.1;  
435/252.3; 435/325; 530/350; 530/399; 530/303; 530/418-420; 530/421-422;  
530/424; 530/423

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 265 OF 588 USPATFULL on STN

AN 1998:57762 USPATFULL

TI Aspergillus niger vacuolar aspartyl protease

IN Buxton, Frank, Muttentz, Switzerland

Jarai, Gabor, Oberwil, Switzerland

Visser, Jacob, Wageningen, Netherlands

PA Novartis Corporation, Summit, NJ, United States (U.S. corporation)

PI US 5756338 19980526 <--

AI US 1996-731045 19961008 (8)

RLI Division of Ser. No. US 1994-328314, filed on 24 Oct 1994, now patented,  
Pat. No. US 5674728, issued on 7 Oct 1997

PRAI GB 1993-810764 19931103

DT Utility

FS Granted

LN.CNT 1957

INCL INCLM: 435/219.000

INCLS: 435/254.300; 536/023.200

NCL NCLM: 435/219.000

NCLS: 435/254.300; 536/023.200

IC [6]

ICM: C12N009-62

ICS: C12N015-57; C12N015-63; C12N015-80

EXF 435/219; 435/254.3; 435/2; 536/23.2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 266 OF 588 USPATFULL on STN

AN 1998:57716 USPATFULL

TI Aptamers specific for biomolecules and methods of making

DT Utility

FS Granted

LN.CNT 2522

INCL INCLM: 514/396.000

INCLS: 514/397.000; 548/311.100; 548/311.700; 548/312.100; 548/314.700;  
548/315.400; 548/335.100; 548/338.100; 548/343.500

NCL NCLM: 514/396.000

NCLS: 514/397.000; 548/311.100; 548/311.700; 548/312.100; 548/314.700;  
548/315.400; 548/335.100; 548/338.100; 548/343.500

IC [6]

ICM: A61K031-415

ICS: C07D233-54; C07D233-56; C07D233-66

EXF 548/311.1; 548/335.1; 548/343.5; 514/396; 514/397

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 268 OF 588 USPATFULL on STN

AN 1998:54709 USPATFULL

TI Secretion leader trap cloning method

IN Lok, Si, Seattle, WA, United States

PA Zymogenetics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5753462 19980519 <--

AI US 1997-796508 19970206 (8)

RLI Continuation of Ser. No. US 1995-472806, filed on 7 Jun 1995, now  
abandoned

DT Utility

FS Granted

LN.CNT 984

INCL INCLM: 435/069.100

INCLS: 435/172.300; 536/023.100

NCL NCLM: 435/006.000

NCLS: 435/069.100; 536/023.100

IC [6]

ICM: C12N015-66

ICS: C12N015-11; C12P021-02

1994-270412, filed on 5 Jul 1994, now abandoned Ser. No. Ser. No. US  
1993-149508, filed on 9 Nov 1993, now abandoned And Ser. No. US  
1994-311099, filed on 23 Sep 1994, now abandoned , each Ser. No. US -  
which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8  
Jul 1991, now abandoned

DT Utility

FS Granted

LN.CNT 4339

INCL INCLM: 435/069.520

INCLS: 435/069.100; 435/172.300; 435/325.000; 435/368.000; 435/377.000;  
435/384.000; 435/392.000; 435/395.000

NCL NCLM: 435/069.520

NCLS: 435/069.100; 435/325.000; 435/368.000; 435/377.000; 435/384.000;  
435/392.000; 435/395.000; 435/455.000; 435/456.000; 435/458.000;  
435/461.000

IC [6]

ICM: C12N005-00

ICS: C12N005-08; C12N005-10; C12P001-00

EXF 435/240.2; 435/172.3; 435/69.1; 435/69.52; 435/325; 435/368; 435/377;  
435/384; 435/392; 435/395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 270 OF 588 USPATFULL on STN

AN 1998:51458 USPATFULL

TI Methods of producing secreted receptor analogs and biologically active  
dimerized polypeptide fusions

IN Sledziewski, Andrzej Z., Seattle, WA, United States

Bell, Lillian Anne, Seattle, WA, United States

Kindsvogel, Wayne R., Seattle, WA, United States

PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5750375 19980512 <--

AI US 1995-477329 19950607 (8)

RLI Continuation of Ser. No. US 1994-180175, filed on 11 Jan 1994, now  
patented, Pat. No. US 5567584 which is a continuation of Ser. No. US

NCLS: 435/069.600; 435/070.100; 435/070.300; 435/071.100; 435/243.000;  
435/320.100; 435/325.000; 435/410.000; 536/023.100; 536/023.500;  
536/024.100

IC [6]

ICM: C07H021-02

ICS: C12N005-00; C12N015-12; C12P021-06

EXF 536/23.1; 536/23.5; 536/24.1; 536/24.2; 435/172.3; 435/320.1; 435/69.1;  
435/69.7; 435/70.1; 435/70.3; 435/71.1; 435/243; 435/325; 435/410;  
935/22; 935/33

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 272 OF 588 USPATFULL on STN

AN 1998:48256 USPATFULL

TI Method and construct for screening for inhibitors of transcriptional  
activation

IN Giese, Klaus, Castro Valley, CA, United States

Escobedo, Jaime, Alamo, CA, United States

PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

PI US 5747338 19980505 <--

AI US 1996-719577 19960925 (8)

RLI Continuation of Ser. No. US 1996-689926, filed on 15 Aug 1996

PRAI US 1995-3708P 19950913 (60)

DT Utility

FS Granted

LN.CNT 1791

INCL INCLM: 435/348.000

INCLS: 435/367.000; 435/252.300; 435/254.210; 435/320.100; 536/024.500

NCL NCLM: 435/348.000

NCLS: 435/252.300; 435/254.210; 435/320.100; 435/367.000; 536/024.500

IC [6]

ICM: C12N005-10

EXF 435/348; 435/367; 435/252.3; 435/252.33; 435/254.21; 435/320.1; 536/24.5

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



NCLS: 435/069.100; 435/069.700; 530/385.000; 536/023.400

IC [6]

ICM: C12P021-06

ICS: C07H017-00; C07K014-805

EXF 530/385; 536/23.1; 536/23.4; 435/69.1; 435/69.6

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 277 OF 588 USPATFULL on STN

AN 1998:45070 USPATFULL

TI Production of proteins in procaryotes

IN Krivi, Gwen G., St. Louis, MO, United States

PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)

PI US 5744328 19980428 <--

AI US 1995-402088 19950310 (8)

RLI Division of Ser. No. US 1992-975205, filed on 22 Nov 1992, now patented,  
Pat. No. US 5399489 which is a continuation of Ser. No. US 1989-299376,  
filed on 23 Jan 1989, now abandoned which is a continuation of Ser. No.  
US 1985-704362, filed on 22 Feb 1985, now patented, Pat. No. US 4861868

DT Utility

FS Granted

LN.CNT 1556

INCL INCLM: 435/069.400

NCL NCLM: 435/069.400

IC [6]

ICM: C12N015-18

EXF 435/69.4; 536/23.51

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 278 OF 588 USPATFULL on STN

AN 1998:45056 USPATFULL

TI Periplasmic membrane-bound system for detecting protein-protein  
interactions

IN Menzel, Rolf, Princeton Junction, NJ, United States

Taylor, Scott T., West Windsor, NJ, United States

now abandoned

DT Utility

FS Granted

LN.CNT 5113

INCL INCLM: 424/078.080

INCLS: 436/501.000; 514/001.000

NCL NCLM: 424/078.080

NCLS: 436/501.000; 514/001.000

IC [6]

ICM: A61K031-74

ICS: G01N033-566; G01N033-558

EXF 536/23.1; 536/27.1; 546/109; 436/501; 514/1; 424/78.08

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 280 OF 588 USPATFULL on STN

AN 1998:42237 USPATFULL

TI Light-regulated promoters for production of heterologous proteins in  
filamentous fungi

IN Kato, Elie K., Honolulu, HI, United States

Stuart, W. Dorsey, Kaneohe, HI, United States

PA University of Hawaii, Honolulu, HI, United States (U.S. corporation)

PI US 5741665 19980421 <--

AI US 1994-240372 19940510 (8)

DT Utility

FS Granted

LN.CNT 649

INCL INCLM: 435/069.100

INCLS: 435/254.400; 536/024.100

NCL NCLM: 435/069.100

NCLS: 435/254.400; 536/024.100

IC [6]

ICM: C12N001-15

ICS: C12N015-09; C12N015-11; C07H021-04

EXF 435/69.1; 435/254.4; 536/24.1



Cantor, Charles R., Boston, MA, United States

Andrews, Beth M., Maynard, MA, United States

PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

PI US 5738990 19980414 <--

AI US 1995-475221 19950607 (8)

RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned

DT Utility

FS Granted

LN.CNT 5040

INCL INCLM: 435/006.000

INCLS: 435/691.000; 435/172.300; 435/320.100; 536/024.100; 935/036.000;  
935/039.000

NCL NCLM: 435/006.000

NCLS: 435/069.100; 435/320.100; 536/024.100

IC [6]

ICM: C12P021-02

ICS: C12N015-67; C07H021-04

EXF 435/172.1; 435/69.1; 435/6; 435/320.1; 435/172.3; 536/24.1; 935/36;  
935/39

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 283 OF 588 USPATFULL on STN

AN 1998:39246 USPATFULL

TI Interleukin-3 (IL-3) variant \*\*\*fusion\*\*\* \*\*\*proteins\*\*\* , their recombinant production, and therapeutic compositions comprising them

IN Bauer, S. Christopher, New Haven, MO, United States

Abrams, Mark Allen, St. Louis, MO, United States

Braford-Goldberg, Sarah Ruth, St. Louis, MO, United States

Caparon, Maire Helena, Chesterfield, MO, United States

Easton, Alan Michael, Maryland Heights, MO, United States

Klein, Barbara Kure, St. Louis, MO, United States

DT Utility  
FS Granted  
LN.CNT 2215  
INCL INCLM: 435/320.100  
INCLS: 424/093.600; 435/172.300; 435/235.100; 514/044.000  
NCL NCLM: 435/320.100  
NCLS: 424/093.600; 435/235.100; 514/044.000  
IC [6]  
ICM: C12N015-85  
ICS: C12N015-88; A61K048-00  
EXF 435/320.1; 435/172.3; 435/240.1; 435/235.1; 514/2; 514/44; 424/93.21  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 285 OF 588 USPATFULL on STN  
AN 1998:36573 USPATFULL  
TI IGF-II analogues  
IN Edwards, Richard Mark, Oxford, England  
Bawden, Lindsay, Oxford, England  
PA British Bio-technology Limited, England (non-U.S. corporation)  
PI US 5736363 19980407 <--  
WO 9303152 19930218 <--  
AI US 1994-190029 19940228 (8)  
WO 1992-GB1389 19920727  
19940228 PCT 371 date  
19940228 PCT 102(e) date  
PRAI GB 1991-16325 19910729  
GB 1992-2401 19920205

DT Utility  
FS Granted  
LN.CNT 1079  
INCL INCLM: 435/069.400  
INCLS: 514/002.000; 530/303.000; 530/399.000  
NCL NCLM: 435/069.400  
NCLS: 514/002.000; 530/303.000; 530/399.000

L5 ANSWER 287 OF 588 USPATFULL on STN

AN 1998:33765 USPATFULL

TI Polypeptide-induced monoclonal receptors to protein ligands

IN Niman, Henry L., Carlsbad, CA, United States

PA Ligand Pharmaceuticals, San Diego, CA, United States (U.S. corporation)

PI US 5733738 19980331 <--

AI US 1995-418898 19950407 (8)

RLI Continuation of Ser. No. US 1992-925815, filed on 4 Aug 1992, now abandoned which is a continuation of Ser. No. US 1991-779143, filed on 21 Oct 1991, now abandoned which is a continuation of Ser. No. US 1989-393267, filed on 12 Aug 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-232395, filed on 12 Aug 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-118823, filed on 9 Nov 1987, now abandoned which is a continuation-in-part of Ser. No. US 1987-39534, filed on 16 Apr 1987, now patented, Pat. No. US 5015571 which is a continuation-in-part of Ser. No. US 1985-736545, filed on 21 May 1985, now abandoned which is a continuation-in-part of Ser. No. US 1985-701954, filed on 15 Feb 1985, now patented, Pat. No. US 5030565 which is a continuation-in-part of Ser. No. US 1983-524804, filed on 17 Aug 1983, now abandoned

DT Utility

FS Granted

LN.CNT 4502

INCL INCLM: 435/007.230

INCLS: 436/503.000; 436/548.000; 436/813.000

NCL NCLM: 435/007.230

NCLS: 436/503.000; 436/548.000; 436/813.000

IC [6]

ICM: G01N033-574

EXF 424/138.1; 424/155.1; 424/174.1; 435/7.23; 435/240.27; 436/503; 436/548; 436/64; 436/813; 530/324; 530/325; 530/326; 530/327; 530/328; 530/329; 530/387.7; 530/388.8; 530/389.7; 530/808; 530/828

Stern, Warren, Gainesville, FL, United States

Wong, Gregory J., San Leandro, CA, United States

PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

PI US 5730969 19980324 <--

AI US 1995-474178 19950607 (8)

RLI Division of Ser. No. US 1989-373928, filed on 29 Jun 1989 which is a continuation-in-part of Ser. No. US 1988-253720, filed on 5 Oct 1988, now abandoned

DT Utility

FS Granted

LN.CNT 1753

INCL INCLM: 424/085.100

INCLS: 424/085.200; 424/085.400; 424/085.600; 424/094.300; 514/002.000;  
514/003.000; 514/012.000; 514/021.000

NCL NCLM: 424/085.100

NCLS: 424/085.200; 424/085.400; 424/085.600; 424/094.300; 514/002.000;  
514/003.000; 514/012.000; 514/021.000

IC [6]

ICM: A61K038-17

ICS: A61K038-19; A61K038-20; A61K038-49

EXF 435/188; 424/85.1; 424/85.2; 424/85.4; 424/85.5; 424/85.6; 424/85.7;  
424/94.3; 530/303; 530/351; 530/399; 514/2; 514/3; 514/12; 514/21

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 290 OF 588 USPATFULL on STN

AN 1998:28183 USPATFULL

TI Use of cyclodextrins for protein renaturation

IN Sharma, Ajit, Mount Pleasant, MI, United States

Karuppiah, Nadarajah, Mount Pleasant, MI, United States

PA Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S. corporation)

PI US 5728804 19980317 <--

AI US 1995-460234 19950602 (8)

DT Utility

ICS: G01N033-573; G01N033-53; G01N033-543

EXF 435/7.21; 435/7.4; 435/7.72; 436/518

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 292 OF 588 USPATFULL on STN

AN 1998:27915 USPATFULL

TI Human .beta..sub.2 integrin .alpha.subunit

IN Gallatin, W. Michael, Mercer Island, WA, United States

Van der Vieren, Monica, Seattle, WA, United States

PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)

PI US 5728533 19980317 <--

AI US 1995-485618 19950607 (8)

RLI Continuation-in-part of Ser. No. US 1994-362652, filed on 21 Dec 1994  
which is a continuation-in-part of Ser. No. US 1994-286889, filed on 5  
Aug 1994, now patented, Pat. No. US 5470953 which is a  
continuation-in-part of Ser. No. US 1993-173497, filed on 23 Dec 1993,  
now patented, Pat. No. US 5437958

DT Utility

FS Granted

LN.CNT 3915

INCL INCLM: 435/007.100

INCLS: 435/007.800; 530/350.000; 530/380.000

NCL NCLM: 435/007.100

NCLS: 435/007.800; 530/350.000; 530/380.000

IC [6]

ICM: C12Q001-00

ICS: G01N033-53; C07K014-00; A61K035-14

EXF 435/7.1; 435/7.8; 530/350; 530/380; 536/22.1; 536/23.1; 536/23.4;  
536/23.8

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 293 OF 588 USPATFULL on STN

AN 1998:25086 USPATFULL

TI Assay and reagents for detecting inhibitors of ubiquitin-dependent

which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned

DT Utility

FS Granted

LN.CNT 5659

INCL INCLM: 435/006.000

INCLS: 435/091.200; 436/501.000

NCL NCLM: 435/006.000

NCLS: 435/091.200; 436/501.000

IC [6]

ICM: C12Q001-68

ICS: C12P019-34; G01N033-566

EXF 435/6; 435/235; 435/91.1; 435/91.2; 435/91.5; 536/23.1; 536/23.2;  
436/501

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 295 OF 588 USPATFULL on STN

AN 1998:22344 USPATFULL

TI Method of purifying cardiac hypertrophy factor

IN Baker, Joffre, El Granada, CA, United States

Chien, Kenneth, La Jolla, CA, United States

King, Kathleen, Pacifica, CA, United States

Pennica, Diane, Burlingame, CA, United States

Wood, William, San Mateo, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S.  
corporation)

PI US 5723585 19980303 <--

AI US 1995-443130 19950517 (8)

RLI Division of Ser. No. US 1994-286304, filed on 5 Aug 1994, now patented,  
Pat. No. US 5571893 which is a continuation-in-part of Ser. No. US  
1994-233609, filed on 25 Apr 1994, now patented, Pat. No. US 5534615

DT Utility

FS Granted

LN.CNT 4213

L5 ANSWER 297 OF 588 USPATFULL on STN  
 AN 1998:14655 USPATFULL  
 TI Production of heterologous proteins in plants and plant cells  
 IN Sijmons, Peter Christiaan, Amsterdam, Netherlands  
 Hoekema, Andreas, Oegstgeest, Netherlands  
 Dekker, Bernardus Martinus M., Gouda, Netherlands  
 Schrammeijer, Barbara, Rotterdam, Netherlands  
 Verwoerd, Teunis Cornelius, Leiden, Netherlands  
 Van Den Elzen, Peturs Josephus M., Voorhout, Netherlands  
 PA Mogen International, n.v., Netherlands (non-U.S. corporation)  
 PI US 5716802 19980210 <--  
 WO 9102066 19910221 <--  
 AI US 1991-659287 19910521 (7)  
 WO 1990-NL108 19900726  
 19910321 PCT 371 date  
 19910321 PCT 102(e) date  
 PRAI NL 1989-1932 19890726  
 DT Utility  
 FS Granted  
 LN.CNT 898  
 INCL INCLM: 435/069.100  
 INCLS: 435/070.100; 435/172.300; 435/240.400; 435/320.100; 800/205.000;  
 800/250.000; 800/255.000; 800/DIG.042; 800/DIG.043; 800/DIG.056;  
 536/023.400; 536/023.500; 047/058.000; 530/363.000  
 NCL NCLM: 435/069.100  
 NCLS: 435/070.100; 435/320.100; 530/363.000; 536/023.400; 536/023.500;  
 800/288.000; 800/317.200; 800/320.100  
 IC [6]  
 ICM: C12N015-82  
 ICS: C12N015-14; A01H005-00; A01H001-00  
 EXF 530/363; 530/364; 800/205; 800/200; 800/250; 800/255; 800/DIG.42;  
 800/DIG.43; 800/DIG.56; 935/30; 935/33-36; 935/47; 935/48; 935/66;  
 935/67; 935/10; 935/22; 935/51; 435/69.1; 435/70.1; 435/172.3;

Hammill, Linda, Townsend,, MA, United States

Ferenz, Catherine R., Belchertown, MA, United States

PA BASF Aktiengesellschaft, Federal Republic of Germany, Germany, Federal  
Republic of (non-U.S. corporation)

PI US 5712114 19980127 <--

AI US 1995-466265 19950606 (8)

DT Utility

FS Granted

LN.CNT 1421

INCL INCLM: 435/069.100

INCLS: 435/254.200; 435/255.700; 435/320.100; 435/325.000; 536/023.100;  
536/024.100

NCL NCLM: 435/069.100

NCLS: 435/254.200; 435/255.700; 435/320.100; 435/325.000; 536/023.100;  
536/024.100

IC [6]

ICM: C12P021-02

ICS: C07H021-04; C12N015-81; C12N015-85

EXF 435/69.1; 435/320.1; 435/255.1; 435/255.7; 435/240.1; 435/254.2;  
435/325; 536/23.1; 536/24.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 300 OF 588 USPATFULL on STN

AN 1998:6946 USPATFULL

TI Polynucleotides that encode the calcitonin gene-related peptide receptor  
coponent factor (HOUNDC44)

IN Adamou, John E., Exton, PA, United States

Elshourbagy, Nabil, West Chester, PA, United States

PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S.  
corporation)

PI US 5710024 19980120 <--

AI US 1996-686178 19960723 (8)

DT Utility

FS Granted



EXF 530/350; 530/333

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 302 OF 588 USPATFULL on STN

AN 1998:4732 USPATFULL

TI Human AlaGlu-IGF-1

IN Skriver, Lars, Vedb.ae butted.k, Denmark  
Hejn.ae butted.s, Kim Ry, Lyngby, Denmark  
Dalb.o slashed.ge, Henrik, Virum, Denmark

PA Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

PI US 5708134 19980113 <--

AI US 1995-444131 19950518 (8)

RLI Division of Ser. No. US 1993-87477, filed on 2 Jul 1993, now patented,  
Pat. No. US 5459052 which is a continuation of Ser. No. US 1991-746827,  
filed on 19 Aug 1991, now abandoned

PRAI DK 1990-1989 19900820

DK 1990-2497 19901016

DT Utility

FS Granted

LN.CNT 838

INCL INCLM: 530/303.000

INCLS: 530/399.000; 530/324.000

NCL NCLM: 530/303.000

NCLS: 530/324.000; 530/399.000

IC [6]

ICM: C07K014-65

EXF 530/303; 530/399; 530/324; 435/69.4; 435/69.8; 435/71.1; 435/71.2;  
435/240.1; 435/320.1; 536/23.51; 536/24.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 303 OF 588 USPATFULL on STN

AN 1998:4429 USPATFULL

TI Enzymatic method for modification of recombinant polypeptides

IN Wagner, Fred W., Walton, NE, United States

INCLS: 435/383.000; 435/395.000; 435/375.000

NCL NCLM: 435/070.300

NCLS: 435/375.000; 435/383.000; 435/395.000

IC [6]

ICM: C12N005-06

EXF 435/70.3; 435/240.2; 435/240.27; 435/240.3; 435/375; 435/383; 435/395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 305 OF 588 USPATFULL on STN

AN 1997:124181 USPATFULL

TI Expression of polypeptides in yeast

IN Hitzeman, Ronald A., Pacifica, CA, United States  
Hagie, IV, Franklin E., Foster City, CA, United States  
Hall, Benjamin D., Bellevue, WA, United States  
Ammerer, Gustav, Seattle, WA, United States

PA Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)  
Washington Research Foundation, Seattle, WA, United States (U.S. corporation)

PI US 5618676 19970408 <--

AI US 1995-474333 19950607 (8)

RLI Continuation of Ser. No. US 1995-383668, filed on 3 Feb 1995, now abandoned which is a continuation of Ser. No. US 1994-198535, filed on 18 Feb 1994, now abandoned which is a continuation of Ser. No. US 1993-89419, filed on 9 Jul 1993, now abandoned which is a continuation of Ser. No. US 1991-708828, filed on 29 May 1991, now abandoned which is a continuation of Ser. No. US 1989-349918, filed on 9 May 1989, now abandoned which is a continuation of Ser. No. US 1988-284774, filed on 12 Dec 1988, now abandoned which is a continuation of Ser. No. US 1988-173008, filed on 28 Mar 1988, now abandoned which is a continuation of Ser. No. US 1985-764145, filed on 9 Aug 1985, now abandoned which is a continuation of Ser. No. US 1981-237913, filed on 25 Feb 1981, now abandoned

DT Utility

FS Granted

INCL INCLM: 514/012.000  
INCLS: 514/002.000; 514/893.000; 514/894.000; 514/838.000; 530/350.000;  
530/399.000; 435/360.000; 935/013.000  
NCL NCLM: 514/012.000  
NCLS: 435/360.000; 514/002.000; 514/838.000; 514/893.000; 514/894.000;  
530/350.000; 530/399.000  
IC [6]  
ICM: A61K038-18  
ICS: C07K014-475; C12N015-12; C07H021-04  
EXF 514/12; 514/893; 514/894; 514/838; 514/2; 424/130.1; 530/350; 530/399;  
435/360; 935/13

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 307 OF 588 USPATFULL on STN  
AN 97:123177 USPATFULL  
TI Chimeric toxins  
IN Williams, Diane P., Franklin, MA, United States  
Murphy, John R., Boston, MA, United States  
PA The University Hospital, Boston, MA, United States (U.S. corporation)  
PI US 5703039 19971230 <--  
AI US 1995-483726 19950607 (8)  
RLI Division of Ser. No. US 1994-231397, filed on 22 Apr 1994 which is a  
continuation of Ser. No. US 1992-886715, filed on 21 May 1992, now  
abandoned which is a continuation of Ser. No. US 1990-537430, filed on  
13 Jun 1990, now abandoned which is a continuation-in-part of Ser. No.  
US 1990-488608, filed on 2 Mar 1990, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1164  
INCL INCLM: 514/002.000  
NCL NCLM: 514/002.000  
IC [6]  
ICM: A61K038-16  
EXF 514/2; 530/350

435/252.34; 435/320.1; 536/23.1; 536/23.7

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 309 OF 588 USPATFULL on STN  
AN 97:120734 USPATFULL  
TI Serpin derived from human hypothalamus  
IN Braxton, Scott Michael, San Mateo, CA, United States  
Diep, Dinh, San Francisco, CA, United States  
Stuart, Susan G., Montara, CA, United States  
PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.  
corporation)  
PI US 5700924 19971223 <--  
AI US 1995-487823 19950607 (8)  
DT Utility  
FS Granted  
LN.CNT 1487  
INCL INCLM: 536/023.100  
INCLS: 435/240.200; 435/320.100; 435/091.400; 435/069.100  
NCL NCLM: 536/023.100  
NCLS: 435/069.100; 435/091.400; 435/320.100  
IC [6]  
ICM: C12N015-85  
ICS: C12N015-63; C07H021-04; C12P019-34  
EXF 435/6; 435/91.4; 435/69.1; 435/240.2; 435/320.1; 514/44; 536/23.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 310 OF 588 USPATFULL on STN  
AN 97:115159 USPATFULL  
TI Neurogenic differentiation (neurod) genes  
IN Weintraub, deceased, Harold M., late of Seattle, WA, United States by  
Nancy Weintraub, executrix  
Lee, Jacqueline E., Denver, CO, United States  
Hollenberg, Stanley M., Portland, OR, United States  
Tapscott, Stephen J., Seattle, WA, United States

LN.CNT 596

INCL INCLM: 530/350.000

INCLS: 530/395.000; 530/399.000; 435/007.100; 435/007.210

NCL NCLM: 530/350.000

NCLS: 435/007.100; 435/007.210; 530/395.000; 530/399.000

IC [6]

ICM: C07K014-435

ICS: C07K014-65; G01N033-566

EXF 530/399; 530/387.1; 530/350; 530/395; 514/8; 514/2; 514/12; 435/7.1;  
435/7.21

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 312 OF 588 USPATFULL on STN

AN 97:112300 USPATFULL

TI Method of ordering sequence binding preferences of a DNA-binding  
molecule

IN Edwards, Cynthia A., Menlo Park, CA, United States

Fry, Kirk E., Palo Alto, CA, United States

Cantor, Charles R., Boston, MA, United States

Andrews, Beth M., Maynard, MA, United States4)

PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S.  
corporation)

PI US 5693463 19971202 <--

AI US 1992-996783 19921223 (7)

RLI Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991,  
now abandoned

DT Utility

FS Granted

LN.CNT 4908

INCL INCLM: 435/006.000

INCLS: 435/007.230; 536/023.100; 935/076.000; 935/077.000

NCL NCLM: 435/006.000

NCLS: 435/007.230; 536/023.100

IC [6]

PA Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)  
PI US 5691168 19971125 <--  
AI US 1995-444142 19950518 (8)  
RLI Division of Ser. No. US 1993-87477, filed on 2 Jul 1993, now patented,  
Pat. No. US 5459052 which is a continuation of Ser. No. US 1991-746827,  
filed on 19 Aug 1991, now abandoned  
PRAI DK 1990-1989 19900820  
DK 1990-2497 19901016  
DT Utility  
FS Granted  
LN.CNT 853  
INCL INCLM: 435/069.400  
INCLS: 435/069.700; 435/243.000; 435/252.330; 435/320.100; 435/325.000;  
536/023.400; 536/023.510  
NCL NCLM: 435/069.400  
NCLS: 435/069.700; 435/243.000; 435/252.330; 435/320.100; 435/325.000;  
536/023.400; 536/023.510  
IC [6]  
ICM: C12N015-18  
ICS: C12N015-63; C12N005-10; C12N001-21  
EXF 530/303; 530/399; 435/69.4; 435/69.8; 435/71.1; 435/71.2; 435/240.1;  
435/320.1; 435/69.7; 435/243; 435/252.33; 435/325; 536/23.51; 536/24.1;  
536/23.4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 315 OF 588 USPATFULL on STN  
AN 97:109711 USPATFULL  
TI CDK4 binding assay  
IN Draetta, Giulio, Winchester, MA, United States  
Gyuris, Jeno, Winchester, MA, United States  
PA Mitotix, Inc., Cambridge, MA, United States (U.S. corporation)  
PI US 5691147 19971125 <--  
AI US 1994-253155 19940602 (8)  
DT Utility

IC [6]

ICM: C07C057-145

ICS: A61K031-19; A61K031-195; A61K038-00

EXF 514/14; 514/561; 514/563; 562/565; 560/82

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 317 OF 588 USPATFULL on STN

AN 97:107050 USPATFULL

TI Compositions and methods for the synthesis of \*\*\*growth\*\*\*  
\*\*\*hormone\*\*\* receptor and \*\*\*growth\*\*\* \*\*\*hormone\*\*\* binding  
protein

IN Hammonds, Jr., R. Glenn, 5955 Almaden La., Oakland, CA, United States  
94611

Leung, David W., 7625 E. Mercer Way, Mercer Island, WA, United States  
98040

Spencer, Steven A., 1967 Ticonderoga Dr., San Mateo, CA, United States  
94402

Wood, William I., 1400 Tarrytown St., San Mateo, CA, United States  
94402

Colosi, Peter Cameron, 1240 Alameda Delas Pugas, No. 312, Belmont, CA,  
United States 94002

PI US 5688763 19971118 <--

AI US 1994-248832 19940525 (8)

RLI Continuation of Ser. No. US 1993-2489, filed on 8 Jan 1993, now  
abandoned which is a continuation-in-part of Ser. No. US 1991-723358,  
filed on 28 Jun 1991, now abandoned which is a division of Ser. No. US  
1987-62542, filed on 12 Jun 1987, now patented, Pat. No. US 5057417

DT Utility

FS Granted

LN.CNT 2534

INCL INCLM: 514/012.000

INCLS: 514/002.000; 530/350.000

NCL NCLM: 514/012.000

NCLS: 514/002.000; 530/350.000

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 319 OF 588 USPATFULL on STN  
AN 97:104146 USPATFULL  
TI Uses of inorganic pyrophosphates  
IN Welsh, Michael J., Riverside, IA, United States  
PA University of Iowa Research Foundation, Iowa City, IA, United States  
(U.S. corporation)  
PI US 5686114 19971111 <--  
AI US 1995-484847 19950602 (8)  
DT Utility  
FS Granted  
LN.CNT 1394  
INCL INCLM: 424/601.000  
INCLS: 514/851.000  
NCL NCLM: 424/601.000  
NCLS: 514/851.000  
IC [6]  
ICM: A61K033-42  
EXF 424/601; 514/851

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 320 OF 588 USPATFULL on STN  
AN 97:101887 USPATFULL  
TI Chimeric hepatocyte growth factor (HGF) ligand variants  
IN Godowski, Paul J., Burlingame, CA, United States  
PA Genentech, Inc., South San Francisco, CA, United States (U.S.  
corporation)  
PI US 5684136 19971104 <--  
AI US 1995-435501 19950505 (8)  
RLI Continuation of Ser. No. US 1993-87784, filed on 13 Jul 1993, now  
abandoned which is a continuation-in-part of Ser. No. US 1992-950572,  
filed on 21 Sep 1992, now abandoned which is a continuation-in-part of  
Ser. No. US 1992-884811, filed on 18 May 1992, now patented, Pat. No. US



ICM: A61K038-28

ICS: C07K014-00

EXF 530/303; 514/3

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 322 OF 588 USPATFULL on STN

AN 97:99260 USPATFULL

TI \*\*\*Growth\*\*\* \*\*\*hormone\*\*\* antagonists

IN Kopchick, John J., Athens, OH, United States

Chen, Wen Y., Athens, OH, United States

PA Ohio University, Athens, OH, United States (U.S. corporation)

PI US 5681809 19971028 <--

AI US 1994-313505 19940926 (8)

RLI Continuation of Ser. No. US 1992-878703, filed on 4 May 1992, now patented, Pat. No. US 5350836 which is a continuation-in-part of Ser. No. US 1991-693305, filed on 1 May 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-419561, filed on 12 Oct 1989, now abandoned

DT Utility

FS Granted

LN.CNT 1634

INCL INCLM: 514/002.000

INCLS: 530/399.000

NCL NCLM: 514/002.000

NCLS: 530/399.000

IC [6]

ICM: C07K014-61

EXF 530/399; 514/2; 435/69.1; 435/69.4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 323 OF 588 USPATFULL on STN

AN 97:96965 USPATFULL

TI Hemoglobins as drug delivery agents

IN Anderson, David C., San Bruno, CA, United States

abandoned

PRAI AU 1990-8586 19900213

DT Utility

FS Granted

LN.CNT 1144

INCL INCLM: 530/324.000

INCLS: 514/012.000; 530/399.000

NCL NCLM: 530/324.000

NCLS: 530/399.000

IC [6]

ICM: A61K038-30

EXF 514/12; 514/2; 530/324

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 325 OF 588 USPATFULL on STN

AN 97:96751 USPATFULL

TI Process for preparing a desired protein

IN Dalb.o slashed.ge, Henrik, Virum, Denmark

Pedersen, John, Kokkedal, Denmark

Christensen, Thorkild, Aller.o slashed.d, Denmark

Ringsted, J.o slashed.rli Winnie, Br.o slashed.ndby, Denmark

Jessen, Torben Ehler, Holbaek, Denmark

PA Novo Nordisk A/S, Denmark (non-U.S. corporation)

PI US 5679552 19971021

<--

AI US 1995-450837 19950525 (8)

RLI Division of Ser. No. US 1995-402455, filed on 10 Mar 1995 which is a continuation of Ser. No. US 1995-372692, filed on 13 Jan 1995, now patented, Pat. No. US 5618597 which is a continuation of Ser. No. US 1992-959856, filed on 12 Nov 1992, now abandoned which is a continuation of Ser. No. US 1991-759106, filed on 6 Sep 1991, now abandoned which is a continuation of Ser. No. US 1988-215602, filed on 1 Jul 1988, now abandoned which is a continuation-in-part of Ser. No. US 1986-910230, filed on 2 Oct 1986, now abandoned which is a continuation-in-part of Ser. No. US 1984-640081, filed on 8 Aug 1984, now abandoned

INCL INCLM: 435/069.100

ICS: C12N015-31

EXF 536/23.4; 536/23.7; 435/69.7; 435/240.1; 435/240.2; 435/240.4;  
435/252.3; 435/320.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 329 OF 588 USPATFULL on STN

AN 97:91713 USPATFULL

TI Isolation and characterization of an actin gene from abalone

IN Powers, Dennis Alpha, Pacific Grove, CA, United States

Hereford, deceased, Lynna Madsen, late of Port Angeles, WA, United  
States by Anne Madsen, legal representative

Gomez-Chiarri, Marta, Pacific Grove, CA, United States

PA The Board of Trustees of the Leland Stanford Junior University,  
Stanford, CA, United States (U.S. corporation)

PI US 5675061 19971007 <--

AI US 1994-286872 19940805 (8)

RLI Continuation-in-part of Ser. No. US 1994-192272, filed on 4 Feb 1994,  
now abandoned

DT Utility

FS Granted

LN.CNT 1176

INCL INCLM: 800/002.000

INCLS: 800/DIG.001; 435/172.100; 435/172.300; 435/173.600; 435/320.100;  
536/023.100; 536/023.500; 536/024.100; 119/234.000; 935/027.000;  
935/055.000; 935/063.000

NCL NCLM: 800/013.000

NCLS: 119/234.000; 435/173.600; 435/320.100; 536/023.100; 536/023.500;  
536/024.100; 800/021.000

IC [6]

ICM: C12N005-00

ICS: C12N015-00

EXF 435/172.1; 435/172.3; 435/320.1; 435/69.1; 435/173.6; 800/2; 800/DIG.1;  
536/23.1; 536/23.5; 536/24.1; 119/234; 935/27; 935/55; 935/63

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

RLI Continuation of Ser. No. US 1991-646875, filed on 28 Jan 1991, now  
abandoned which is a continuation-in-part of Ser. No. US 1990-575394,  
filed on 29 Aug 1990, now abandoned

DT Utility

FS Granted

LN.CNT 786

INCL INCLM: 435/069.100

INCLS: 435/240.200; 536/023.510; 536/023.530; 536/023.400; 536/023.100

NCL NCLM: 435/069.100

NCLS: 435/325.000; 435/365.000; 435/366.000; 435/372.100; 435/372.200;  
536/023.100; 536/023.400; 536/023.510; 536/023.530

IC [6]

ICM: C12N015-00

ICS: C12N005-00; C12P021-06; C07H021-04

EXF 435/69.1; 435/240.2; 935/1; 935/10; 935/15; 536/23.51; 536/23.53;  
536/23.4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 332 OF 588 USPATFULL on STN

AN 97:88861 USPATFULL

TI Methods of identifying compounds useful for treating autoimmune diseases

IN Glimcher, Laurie H., W. Newton, MA, United States

Zhou, Hong, Watertown, MA, United States

Douhan, III, John, Boston, MA, United States

PA President and Fellows of Harvard College, Cambridge, MA, United States  
(U.S. corporation)

PI US 5672473 19970930

<--

AI US 1994-295502 19940824 (8)

DT Utility

FS Granted

LN.CNT 1291

INCL INCLM: 435/006.000

INCLS: 435/007.240; 435/007.800; 435/029.000; 435/172.300; 436/501.000;  
530/358.000; 536/023.500

AN 97:86585 USPATFULL  
TI Method to enhance permeability of the blood/brain blood/nerve barriers to  
therapeutic agents  
IN Poduslo, Joseph F., 5719 St. Mary's Dr. NW, Rochester, MN, United States  
55901  
Curran, Geoffrey L., 629 23rd St. NE, Rochester, MN, United States  
55906  
PA Poduslo, Joseph F., Rochester, MN, United States (U.S. individual)  
Curran, Geoffrey L., Rochester, MN, United States (U.S. individual)  
PI US 5670477 19970923 <--  
AI US 1995-425576 19950420 (8)  
DT Utility  
FS Granted  
LN.CNT 1978  
INCL INCLM: 514/002.000  
NCL NCLM: 514/002.000  
IC [6]  
ICM: A61K023-02  
EXF 514/2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 335 OF 588 USPATFULL on STN  
AN 97:86481 USPATFULL  
TI Biological containment  
IN Molin, S.o slashed.ren, Holte, Denmark  
Andersson, Poul Kirketerp, Frederiksberg, Denmark  
Gerdes, Kenn Ax.o slashed., Virum, Denmark  
Klemm, Per, Frederiksberg, Denmark  
PA GX BioSystems A/S, Copenhagen, Denmark (non-U.S. corporation)  
PI US 5670370 19970923 <--  
AI US 1995-452494 19950530 (8)  
RLI Continuation of Ser. No. US 1994-205824, filed on 4 Mar 1994, now  
abandoned which is a continuation of Ser. No. US 1992-947910, filed on  
21 Sep 1992, now abandoned which is a continuation of Ser. No. US

LN.CNT 2504

INCL INCLM: 424/130.100

INCLS: 424/133.100; 424/139.100; 424/141.100; 424/142.100; 424/145.100;  
424/158.100; 435/069.500; 530/388.220; 530/388.240

NCL NCLM: 424/130.100

NCLS: 424/133.100; 424/139.100; 424/141.100; 424/142.100; 424/145.100;  
424/158.100; 435/069.500; 530/388.220; 530/388.240

IC [6]

ICM: A61K039-395

EXF 435/69.5; 435/172.1; 435/320.1; 530/388.22; 530/388.24; 424/130.1;  
424/133.1; 424/139.1; 424/141.1; 424/142.1; 424/145.1; 424/158.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 337 OF 588 USPATFULL on STN

AN 97:84079 USPATFULL

TI Hybrid molecules having translocation region and cell-binding region

IN Murphy, John R., Wayland, MA, United States

PA Seragen, Inc., Hopkinton, MA, United States (U.S. corporation)

PI US 5668255 19970916 <--

AI US 1993-102387 19930804 (8)

RLI Continuation of Ser. No. US 1991-722484, filed on 27 Jun 1991, now  
abandoned which is a continuation-in-part of Ser. No. US 1990-538276,  
filed on 14 Jun 1990, now abandoned which is a continuation-in-part of  
Ser. No. US 1989-456095, filed on 22 Dec 1989, now abandoned which is a  
continuation-in-part of Ser. No. US 1985-742554, filed on 7 Jun 1985,  
now abandoned which is a continuation-in-part of Ser. No. US  
1985-726808, filed on 25 Apr 1985, now abandoned which is a continuation  
of Ser. No. US 1984-618199, filed on 7 Jun 1984, now abandoned

DT Utility

FS Granted

LN.CNT 977

INCL INCLM: 530/350.000

INCLS: 435/069.700

NCL NCLM: 530/350.000

AN 97:78572 USPATFULL

TI Refolding of misfolded \*\*\*insulin\*\*\* -like growth factor-I

IN Builder, Stuart, Belmont, CA, United States  
Hart, Roger, Burlingame, CA, United States  
Lester, Philip, San Lorenzo, CA, United States  
Reifsnyder, David, San Mateo, CA, United States

PA Genentech, Inc., San Francisco, CA, United States (U.S. corporation)

PI US 5663304 19970902 <--

AI US 1993-110664 19930820 (8)

DT Utility

FS Granted

LN.CNT 2464

INCL INCLM: 530/399.000  
INCLS: 530/418.000; 530/420.000; 530/422.000; 530/424.000; 435/069.400;  
435/172.300; 435/252.300; 435/320.100

NCL NCLM: 530/399.000  
NCLS: 435/069.400; 435/252.300; 435/320.100; 530/418.000; 530/420.000;  
530/422.000; 530/424.000

IC [6]  
ICM: C07K014-475  
ICS: C12N015-18

EXF 435/69.4; 435/69.1; 435/240.2; 435/172.1; 435/172.3; 435/252.3;  
435/320.1; 530/350; 530/399; 530/303; 530/418-420; 530/421-422; 530/424

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 340 OF 588 USPATFULL on STN

AN 97:75994 USPATFULL

TI Recombinant production of consensus human leukocyte interferon

IN Stabinsky, Yitzhak, Boulder, CO, United States

PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)

PI US 5661009 19970826 <--

AI US 1996-686822 19960726 (8)

RLI Continuation of Ser. No. US 1990-472328, filed on 30 Jan 1990, now  
patented, Pat. No. US 5541293 which is a division of Ser. No. US



LN.CNT 2578

INCL INCLM: 435/069.100

INCLS: 435/240.200; 536/023.500

NCL NCLM: 435/069.100

NCLS: 435/325.000; 435/358.000; 435/366.000; 435/372.300; 536/023.500

IC [6]

ICM: C12N015-00

ICS: C12N015-11; C12N015-85

EXF 435/69.5; 435/69.1; 435/240.2; 536/23.5

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 342 OF 588 USPATFULL on STN

AN 97:73468 USPATFULL

TI Polynucleotides encoding cytostatin I

IN Ni, Jian, 305 West Side Dr., Apt. 204, Gaithersburg, MD, United States  
20878

Gentz, Reiner, 13404 Fairland Park Dr., Silver Spring, MD, United States  
20904

Yu, Guo-Liang, 13524 Straw Bale La., Darnestown, MD, United States  
20878

Rosen, Craig A., 22400 Rolling Hill Rd., Laytonsville, MD, United States  
20882

PI US 5658758 19970819

<--

AI US 1995-409731 19950324 (8)

DT Utility

FS Granted

LN.CNT 1658

INCL INCLM: 435/069.100

INCLS: 435/070.100; 435/252.230; 435/320.100; 435/172.300; 435/325.000;  
435/348.000; 435/419.000; 435/358.000; 435/365.000; 935/011.000;  
935/022.000; 935/066.000; 935/070.000; 536/023.100; 536/023.500

NCL NCLM: 435/069.100

NCLS: 435/070.100; 435/252.300; 435/320.100; 435/325.000; 435/348.000;  
435/358.000; 435/365.000; 435/419.000; 435/466.000; 536/023.100;

EXF 435/188.5; 435/219; 435/226; 435/68.1; 530/389.2; 530/388.24

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 344 OF 588 USPATFULL on STN

AN 97:68570 USPATFULL

TI Protection against liver damage by HGF

IN Roos, Filip, Brisbane, CA, United States

Schwall, Ralph, Pacifica, CA, United States

PA Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)

PI US 5654404 19970805 <--

AI US 1995-419654 19950410 (8)

RLI Division of Ser. No. US 1994-310361, filed on 21 Sep 1994 which is a continuation of Ser. No. US 1992-968711, filed on 30 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-946263, filed on 16 Sep 1992, now abandoned

DT Utility

FS Granted

LN.CNT 2330

INCL INCLM: 530/387.300

INCLS: 530/350.000; 424/134.100; 424/136.100; 424/178.100

NCL NCLM: 530/387.300

NCLS: 424/134.100; 424/136.100; 424/178.100; 530/350.000

IC [6]

ICM: C07K014-435

ICS: C12P021-08; A61K039-00; A61K038-16

EXF 530/389.2; 530/387.3; 530/399; 530/350; 424/138.1; 424/124.1; 424/145.1; 514/12; 514/2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 345 OF 588 USPATFULL on STN

AN 97:68349 USPATFULL

TI Production of human somatomedin C

IN Buell, Gary N., Geneva, Switzerland

Movva, Nageswararao, Geneva, Switzerland

PA BASF Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of  
(non-U.S. corporation)  
Knoll Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of  
(non-U.S. corporation)

PI US 5654168 19970805 <--

AI US 1994-275876 19940715 (8)

RLI Continuation-in-part of Ser. No. US 1994-270637, filed on 1 Jul 1994,  
now abandoned

DT Utility

FS Granted

LN.CNT 2613

INCL INCLM: 435/069.100  
INCLS: 435/172.300; 435/320.100; 536/023.700; 536/024.100

NCL NCLM: 435/069.100  
NCLS: 435/320.100; 536/023.700; 536/024.100

IC [6]  
ICM: C12P021-00  
ICS: C12N015-00; C12N015-63; C07H021-04

EXF 435/69.1; 435/172.3; 435/320.1; 536/23.7; 536/24.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 347 OF 588 USPATFULL on STN

AN 97:66228 USPATFULL

TI Method for purification of L-selectin ligands

IN Lasky, Laurence A., Sausalito, CA, United States  
Imai, Yasuyuki, Tokyo, Japan  
Rosen, Steven D., San Francisco, CA, United States  
Singer, Mark S., Berkeley, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S.  
corporation)  
The Regents of the University of California, Berkeley, CA, United States  
(U.S. corporation)

PI US 5652343 19970729 <--

AI US 1994-294675 19940823 (8)

NCLS: 435/069.700; 530/399.000; 536/023.400; 536/023.510

. IC [6]

ICM: C12N001-21

ICS: C12N015-18; C07K014-65

EXF 536/23.5; 536/23.51; 435/69.1; 435/69.8; 435/172.3; 435/252.33;  
435/320.1; 530/303; 530/324; 530/399; 530/808; 935/47; 935/48

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 349 OF 588 USPATFULL on STN

AN 97:66026 USPATFULL

TI Substrate assisted catalysis

IN Carter, Paul John, San Francisco, CA, United States

Wells, James Allen, Burlingame, CA, United States

PA Genencor International, Inc., Palo Alto, CA, United States (U.S.  
corporation)

PI US 5652136 19970729 <--

AI US 1995-488096 19950607 (8)

RLI Division of Ser. No. US 1994-287964, filed on 22 Sep 1994, now patented,  
Pat. No. US 5472855 which is a division of Ser. No. US 1993-90902, filed  
on 12 Jul 1993, now patented, Pat. No. US 5371190 which is a  
continuation of Ser. No. US 1992-823039, filed on 14 Jan 1992, now  
abandoned which is a continuation-in-part of Ser. No. US 1987-35652,  
filed on 6 Apr 1987, now abandoned which is a continuation-in-part of  
Ser. No. US 1986-858594, filed on 30 Apr 1986, now abandoned , said Ser.  
No. US 1992-823039, filed on 14 Jan 1992, now abandoned which is a  
continuation of Ser. No. US 1989-334081, filed on 4 Apr 1989, now  
abandoned which is a continuation-in-part of Ser. No. US 1987-127134,  
filed on 1 Dec 1987, now abandoned which is a continuation-in-part of  
Ser. No. US 1986-846627, filed on 1 Apr 1986, now abandoned which is a  
continuation-in-part of Ser. No. US 1984-614615, filed on 29 May 1984,  
now abandoned And a continuation-in-part of Ser. No. US 1986-858594,  
filed on 30 Apr 1986, now abandoned which is a continuation-in-part of  
Ser. No. US 1984-614612, filed on 29 May 1984, now patented, Pat. No. US  
4760025 And a continuation-in-part of Ser. No. US 1984-614615, filed on

INCL INCLM: 435/172.300  
INCLS: 435/069.100; 435/070.100; 800/205.000; 800/250.000; 800/255.000;  
800/DIG.042; 800/DIG.043; 530/363.000; 530/387.300; 047/058.000  
NCL NCLM: 435/069.600  
NCLS: 435/069.100; 435/070.100; 530/363.000; 530/387.300  
IC [6]  
ICM: C12N015-63  
ICS: C12N015-82; A01H005-00; C07K014-765  
EXF 800/205; 800/250; 800/255; 800/DIG.42; 800/DIG.43; 435/172.3; 435/69.1;  
435/69.6; 435/69.8; 435/70.1; 435/240.2; 530/363; 530/387.3; 935/10;  
935/11; 935/35; 935/67; 047/58

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 351 OF 588 USPATFULL on STN  
AN 97:61590 USPATFULL  
TI Co-expression in eukaryotic cells  
IN Mulvihill, Eileen R., Seattle, WA, United States  
Kumar, A. Ashok, Flemington, NJ, United States  
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 5648254 19970715 <--  
AI US 1994-275076 19940714 (8)  
RLI Continuation of Ser. No. US 1991-785865, filed on 28 Oct 1991, now  
abandoned which is a continuation of Ser. No. US 1989-445302, filed on 4  
Dec 1989, now abandoned which is a continuation-in-part of Ser. No. US  
1988-144357, filed on 15 Jan 1988, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1540  
INCL INCLM: 435/217.000  
INCLS: 435/254.200; 435/172.300; 435/352.000  
NCL NCLM: 435/217.000  
NCLS: 435/254.200; 435/352.000  
IC [6]  
ICM: C12N009-68

process for making and a method of using

IN Walsh, Terence A., Zionsville, IN, United States  
Hey, Timothy D., Zionsville, IN, United States  
Morgan, Alice E. R., Midland, MI, United States

PA DowElanco, Indianapolis, IN, United States (U.S. corporation)

PI US 5646026 19970708 <--

AI US 1995-485286 19950607 (8)

RLI Division of Ser. No. US 1995-378761, filed on 26 Jan 1995 which is a  
continuation of Ser. No. US 1992-987927, filed on 9 Dec 1992, now  
abandoned which is a continuation-in-part of Ser. No. US 1990-535636,  
filed on 11 Jun 1990, now patented, Pat. No. US 5248606

DT Utility

FS Granted

LN.CNT 2377

INCL INCLM: 435/199.000  
INCLS: 435/069.100; 435/252.300; 435/254.210; 435/320.100; 435/412.000;  
435/325.000; 536/023.200; 536/023.600; 530/376.000

NCL NCLM: 435/199.000  
NCLS: 435/069.100; 435/252.300; 435/254.210; 435/320.100; 435/325.000;  
435/412.000; 530/376.000; 536/023.200; 536/023.600

IC [6]  
ICM: C12N009-22  
ICS: C12P021-06

EXF 435/69.1; 435/240.2; 435/240.4; 435/252.3; 435/254.21; 435/320.1;  
536/23.6; 536/23.2; 530/376

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 354 OF 588 USPATFULL on<sup>o</sup> STN

AN 97:59072 USPATFULL

TI Methods and compositions for expression of competent eukaryotic gene  
products

IN Bromley, Peter, Chene-Bougeries, Switzerland  
Voellmy, Richard, Miami, FL, United States

PA Rockwell Property Limited, Isle of Man, United Kingdom (non-U.S.

L5 ANSWER 355 OF 588 USPATFULL on STN  
AN 97:56524 USPATFULL  
TI Production and purification of a protein fused to a binding protein  
IN Guan, Chudi, Wenham, MA, United States  
Inouye, deceased,, Hiroshi, late of Philadelphia, PA, United States  
Chang, administrator, Frank N., Dresher, PA, United States  
PA New England Biolabs, Inc., Beverly, MA, United States (U.S. corporation)  
Temple University, Philadelphia, PA, United States (U.S. corporation)  
PI US 5643758 19970701 <--  
AI US 1995-374145 19950112 (8)  
RLI Continuation of Ser. No. US 1993-19981, filed on 17 Feb 1993 which is a  
continuation of Ser. No. US 1991-737596, filed on 25 Jul 1991, now  
abandoned which is a continuation of Ser. No. US 1988-196988, filed on  
20 May 1988, now abandoned which is a continuation-in-part of Ser. No.  
US 1987-24053, filed on 10 Mar 1987, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1313  
INCL INCLM: 435/069.700  
INCLS: 435/320.100  
NCL NCLM: 435/069.700  
NCLS: 435/320.100  
IC [6]  
ICM: C12P021-00  
ICS: C12N015-70  
EXF 435/69.1; 435/69.7; 435/172.3; 435/320.1; 536/23.1; 536/23.4; 935/23  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 356 OF 588 USPATFULL on STN  
AN 97:56492 USPATFULL  
TI Methods for modulating transcription from the amyloid .beta.-protein  
precursor (APP) promoter  
IN Tanzi, Rudolph E., Canton, MA, United States  
Kovacs, Dora M., Cambridge, MA, United States

DT Utility  
FS Granted  
LN.CNT 3894  
INCL INCLM: 530/413.000  
INCLS: 530/412.000; 530/415.000; 530/416.000; 530/417.000; 530/418.000  
NCL NCLM: 530/413.000  
NCLS: 530/412.000; 530/415.000; 530/416.000; 530/417.000; 530/418.000  
IC [6]  
ICM: C07K001-14  
ICS: C07K001-18; C07K001-20; C07K001-22  
EXF 530/415; 530/412; 530/413; 530/416; 530/417; 530/418  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 358 OF 588 USPATFULL on STN  
AN 97:54117 USPATFULL  
TI Plasmids suitable for IL-2 expression  
IN Hobart, Peter M., Poway, CA, United States  
Margalith, Michal, Solana Beach, CA, United States  
Parker, Suezanne E., San Diego, CA, United States  
Khatibi, Shirin, Carlsbad, CA, United States  
PA Vical Incorporated, San Diego, CA, United States (U.S. corporation)  
PI US 5641665 19970624 <--  
AI US 1994-345913 19941128 (8)  
DT Utility  
FS Granted

LN.CNT 2408  
INCL INCLM: 435/172.300  
INCLS: 435/069.520; 435/325.000; 435/243.000; 435/320.100; 435/348.000;  
435/252.330; 514/044.000; 530/351.000; 536/024.100  
NCL NCLM: 514/044.000  
NCLS: 435/069.520; 435/091.400; 435/243.000; 435/252.330; 435/320.100;  
435/325.000; 435/348.000; 530/351.000; 536/024.100  
IC [6]  
ICM: A61K048-00



PI US 5639635 19970617 <--  
AI US 1994-333912 19941103 (8)  
DT Utility  
FS Granted  
LN.CNT 1347  
INCL INCLM: 435/069.100  
INCLS: 536/023.700; 536/023.500; 536/023.600  
NCL NCLM: 435/069.100  
NCLS: 536/023.500; 536/023.600; 536/023.700  
IC [6]  
ICM: C12P021-06  
EXF 435/69.7; 435/69.1; 435/252.3; 435/252.33; 435/320.1; 536/27; 536/23.7;  
536/23.5; 536/23.6

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 361 OF 588 USPATFULL on STN  
AN 97:51869 USPATFULL  
TI Isolated nucleic acid encoding a ubiquitous nuclear receptor  
IN Liao, Shutsung, Chicago, IL, United States  
Song, Ching, Durham, NC, United States  
PA Arch Development Corporation, Chicago, IL, United States (U.S.  
corporation)  
PI US 5639616 19970617 <--  
AI US 1994-342411 19941118 (8)  
RLI Continuation-in-part of Ser. No. US 1993-152003, filed on 10 Nov 1993,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 4472  
INCL INCLM: 435/007.100  
INCLS: 435/069.100; 435/252.300; 435/320.100; 536/023.500; 536/024.300  
NCL NCLM: 435/007.100  
NCLS: 435/069.100; 435/252.300; 435/320.100; 536/023.500; 536/024.300  
IC [6]

\*\*\*hormone\*\*\* ( \*\*\*HGH\*\*\* )

IN Dalb.o slashed.ge, Henrik, Virum, Denmark

Pedersen, John, Kokkedal, Denmark

Christensen, Thorkild, Aller.o slashed.d, Denmark

Ringsted, J.o slashed.rli W., Br.o slashed.ndby, Denmark

Jessen, Torben E., Holbaek, Denmark

PA Novo Nordisk A/S, Denmark (non-U.S. corporation)

PI US 5635604 19970603 <--

AI US 1995-450094 19950525 (8)

RLI Division of Ser. No. US 1995-402286, filed on 10 Mar 1995 which is a continuation of Ser. No. US 1995-372692, filed on 13 Jan 1995 which is a continuation of Ser. No. US 1992-959856, filed on 12 Nov 1992, now abandoned which is a continuation of Ser. No. US 1991-759106, filed on 6 Sep 1991, now abandoned which is a continuation of Ser. No. US 1988-215602, filed on 1 Jul 1988, now abandoned which is a continuation-in-part of Ser. No. US 1986-910230, filed on 2 Oct 1986, now abandoned which is a continuation-in-part of Ser. No. US 1984-640081, filed on 8 Aug 1984, now abandoned

PRAI DK 1982-5493 19821210

DK 1985-556 19850207

DT Utility

FS Granted

LN.CNT 479

INCL INCLM: 530/399.000

INCLS: 530/402.000; 530/412.000

NCL NCLM: 530/399.000

NCLS: 530/402.000; 530/412.000

IC [6]

ICM: C07K014-61

EXF 530/399; 530/402; 530/412; 530/427; 530/335; 530/337

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 364 OF 588 USPATFULL on STN

AN 97:47297 USPATFULL

PI US 5635384 19970603 <--  
 AI US 1995-378761 19950126 (8)  
 RLI Continuation of Ser. No. US 1992-987927, filed on 9 Dec 1992, now  
 abandoned which is a continuation-in-part of Ser. No. US 1990-535636,  
 filed on 11 Jun 1990, now patented, Pat. No. US 5248606  
 DT Utility  
 FS Granted  
 LN.CNT 2458  
 INCL INCLM: 435/199.000  
 INCLS: 435/068.100; 435/069.100; 435/069.700; 435/252.300; 435/320.100;  
 536/023.200; 530/370.000; 530/379.000; 530/395.000; 530/396.000;  
 530/376.000  
 NCL NCLM: 435/199.000  
 NCLS: 435/068.100; 435/069.100; 435/069.700; 435/252.300; 435/320.100;  
 530/370.000; 530/376.000; 530/379.000; 530/395.000; 530/396.000;  
 536/023.200  
 IC [6]  
 ICM: C12N007-04  
 EXF 435/68.1; 435/69.1; 435/69.7; 435/252.3; 435/320.1; 435/199; 536/23.2;  
 530/370; 530/379; 530/395; 530/396; 530/376  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L5 ANSWER 366 OF 588 USPATFULL on STN  
 AN 97:45112 USPATFULL  
 TI Biosynthetic \*\*\*human\*\*\* \*\*\*growth\*\*\* \*\*\*hormone\*\*\*  
 IN Dalb.o slashed.ge, Henrik, Virum, Denmark  
 Pedersen, John, Kokkedal, Denmark  
 Christensen, Thorkild, Aller.o slashed.d, Denmark  
 Ringsted, J.o slashed.rli W., Br.o slashed.ndby, Denmark  
 Jessen, Torben E., Holbaek, Denmark  
 PA Novo Nordisk A/S, Denmark (non-U.S. corporation)  
 PI US 5633352 19970527 <--  
 AI US 1995-402286 19950310 (8)  
 RLI Continuation of Ser. No. US 1995-372692, filed on 13 Jan 1995 which is a

LN.CNT 2755

INCL INCLM: 435/064.700

INCLS: 435/069.100; 435/252.300; 435/320.100; 530/315.000; 536/023.400

NCL NCLM: 435/069.700

NCLS: 435/069.100; 435/252.300; 435/320.100; 530/350.000; 536/023.400

IC [6]

ICM: C12N001-19

ICS: C12N015-62; C07K014-00

EXF 435/69.7; 435/252.3; 435/320.1; 530/350; 530/23.4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 368 OF 588 USPATFULL on STN

AN 97:38416 USPATFULL

TI Hybridomas producing antibodies to cardiac hypertrophy factor

IN Baker, Joffre, El Granada, CA, United States

Chien, Kenneth, La Jolla, CA, United States

King, Kathleen, Pacifica, CA, United States

Pennica, Diane, Burlingame, CA, United States

Wood, William, San Mateo, CA, United States

PA Genentech, Inc., United States (U.S. corporation)

The Regents of the University of California, United States (U.S. corporation)

PI US 5627073 19970506 <--

AI US 1995-443129 19950517 (8)

RLI Division of Ser. No. US 1994-286304, filed on 5 Aug 1994 which is a continuation-in-part of Ser. No. US 1994-233609, filed on 25 Apr 1994, now abandoned

DT Utility

FS Granted

LN.CNT 4258

INCL INCLM: 435/331.000

INCLS: 435/070.210; 435/172.100; 435/069.600; 435/252.330; 435/332.000;  
435/336.000; 530/387.900; 530/388.230; 530/387.300; 530/391.300;  
424/139.100; 424/145.100

NCL NCLM: 435/007.100  
 NCLS: 435/331.000; 435/344.100; 530/387.300; 530/387.900; 530/388.850;  
 530/391.300  
 IC [6]  
 ICM: G01N033-53  
 ICS: C12N005-12; C07K016-22  
 EXF 530/387.1; 530/389.1; 530/389.2; 530/388.24; 530/387.24; 530/387.9;  
 530/388.85; 530/391.3; 530/888.1; 530/388.15; 530/387.3; 424/130.1;  
 424/145.1; 424/139.1; 424/7.24; 424/156.1; 424/141.1; 424/142.1;  
 424/133.1; 424/178.1; 424/136.1; 435/240.27; 435/70.21; 435/7.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 370 OF 588 USPATFULL on STN  
 AN 97:33727 USPATFULL  
 TI IGF-1 superagonists  
 IN DiMarchi, Richard D., Carmel, IN, United States  
 Fan, Li, Lombard, IL, United States  
 Long, Harlan B., Carmel, IN, United States  
 PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
 corporation)  
 PI US 5622932 19970422 <--  
 AI US 1995-435252 19950505 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 900  
 INCL INCLM: 514/012.000  
 INCLS: 514/021.000; 530/324.000; 530/399.000  
 NCL NCLM: 514/012.000  
 NCLS: 514/021.000; 530/324.000; 530/399.000  
 IC [6]  
 ICM: C07K014-65  
 EXF 514/12; 514/21; 530/399; 530/324  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PA Syntex (U.S.A.) Inc., Palo Alto, CA, United States (U.S. corporation)  
PI US 5622712 19970422 <--  
AI US 1994-237807 19940504 (8)  
RLI Division of Ser. No. US 1993-15738, filed on 10 Feb 1993, now patented,  
Pat. No. US 5336502 which is a division of Ser. No. US 1990-614412,  
filed on 16 Nov 1990, now patented, Pat. No. US 5208036 which is a  
division of Ser. No. US 1990-524257, filed on 15 May 1990, now patented,  
Pat. No. US 5049386 which is a division of Ser. No. US 1989-428815,  
filed on 27 Oct 1989, now patented, Pat. No. US 4946787 which is a  
division of Ser. No. US 1987-114809, filed on 29 Oct 1987, now patented,  
Pat. No. US 4897355 which is a continuation-in-part of Ser. No. US  
1986-877916, filed on 24 Jun 1986, now abandoned which is a  
continuation-in-part of Ser. No. US 1985-689407, filed on 7 Jan 1985,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 3038  
INCL INCLM: 424/450.000  
INCLS: 424/423.000; 424/427.000; 424/428.000; 424/449.000; 435/829.000;  
264/004.100; 264/004.330; 264/004.600  
NCL NCLM: 424/450.000  
NCLS: 264/004.100; 264/004.330; 264/004.600; 424/423.000; 424/427.000;  
424/428.000; 424/449.000; 435/829.000  
IC [6]  
ICM: A61F002-02  
ICS: A61K009-70; A61K009-127; B01J013-02  
EXF 424/423; 424/427; 424/428; 424/449; 424/450; 435/829; 264/4.1; 264/4.33;  
264/4.6  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L5 ANSWER 373 OF 588 USPATFULL on STN  
AN 97:29356 USPATFULL  
TI Process for preparing a desired protein  
IN Dalb.o slashed.ge, Henrik, Virum, Denmark

Seebboth, Peter, Inzlingen, Germany, Federal Republic of

Riezman, Howard, Biel-Benken, Switzerland

PA CIBA-Geigy Corporation, Tarrytown, NY, United States (U.S. corporation)

PI US 5618690 19970408 <--

AI US 1995-462397 19950605 (8)

RLI Division of Ser. No. US 1994-328961, filed on 24 Oct 1994, now patented,  
Pat. No. US 5501975 which is a continuation of Ser. No. US 1992-989260,  
filed on 11 Dec 1992, now abandoned

PRAI DE 1991-810984 19911216

DT Utility

FS Granted

LN.CNT 1412

INCL INCLM: 435/068.100

INCLS: 435/069.100; 435/069.700; 435/219.000; 435/223.000

NCL NCLM: 435/068.100

NCLS: 435/069.100; 435/069.700; 435/219.000; 435/223.000

IC [6]

ICM: C12P021-06

ICS: C12N009-50

EXF 435/68.1; 435/69.1; 435/69.7; 435/219; 435/223

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 375 OF 588 USPATFULL on STN

AN 97:27072 USPATFULL

TI Chimeric toxins

IN Williams, Diane, 22 Danforth Way, Franklin, MA, United States 02038

PI US 5616482 19970401 <--

AI US 1994-231397 19940422 (8)

RLI Continuation of Ser. No. US 1992-886715, filed on 21 May 1992, now  
abandoned which is a continuation of Ser. No. US 1990-537430, filed on  
13 Jun 1990, now abandoned which is a continuation-in-part of Ser. No.  
US 1990-488608, filed on 2 Mar 1990, now abandoned

DT Utility

FS Granted

ICS: C12N001-19

EXF 435/69.1; 435/69.7; 435/69.8; 435/69.9; 435/320.1; 435/172.3;  
435/254.11; 435/254.21; 435/255.5; 435/254.23; 435/255.4; 435/255.6;  
536/23.4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 377 OF 588 USPATFULL on STN

AN 97:22476 USPATFULL

TI Tissue plasminogen activator glycosylation variants with improved  
therapeutic properties

IN Bennett, William F., San Mateo, CA, United States

Keyt, Bruce A., Pacifica, CA, United States

Paoni, Nicholas F., Moraga, CA, United States

PA Genentech, Inc., San Francisco, CA, United States (U.S. corporation)

PI US 5612029 19970318 <--

AI US 1995-436697 19950508 (8)

RLI Division of Ser. No. US 1995-389611, filed on 13 Feb 1995, now abandoned  
which is a continuation of Ser. No. US 1994-275462, filed on 13 Jul  
1994, now abandoned which is a continuation of Ser. No. US 1992-894213,  
filed on 3 Jun 1992, now abandoned

DT Utility

FS Granted

LN.CNT 2044

INCL INCLM: 424/094.640

INCLS: 424/094.630; 435/212.000; 435/226.000; 435/068.100

NCL NCLM: 424/094.640

NCLS: 424/094.630; 435/068.100; 435/212.000; 435/226.000

IC [6]

ICM: A61K038-49

ICS: C12N009-48; C12N009-64

EXF 424/94.63; 424/94.64; 435/172.3; 435/212; 435/219; 435/226; 435/68.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 378 OF 588 USPATFULL on STN



TI Method to enhance permeability of the blood/brain blood/nerve barriers  
to therapeutic agents

IN Poduslo, Joseph F., 5719 St. Mary's Dr. NW., Rochester, MN, United  
States 55901

Curran, Geoffrey L., 629 23rd St. NE., Rochester, MN, United States  
55906

PI US 5604198 19970218 <--

AI US 1994-241621 19940512 (8)

DT Utility

FS Granted

LN.CNT 1292

INCL INCLM: 514/006.000

INCLS: 514/008.000; 514/012.000; 514/021.000; 530/327.000; 424/094.200

NCL NCLM: 514/006.000

NCLS: 424/094.200; 514/008.000; 514/012.000; 514/021.000; 530/327.000

IC [6]

ICM: A61K038-16

EXF 514/6; 514/8; 514/12; 514/21; 530/327; 424/94.2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 380 OF 588 USPATFULL on STN

AN 97:14592 USPATFULL

TI Liver enriched transcription factor

IN Sladek, Frances M., Riverside, CA, United States

Zhong, Weimin, New York, NY, United States

Darnell, Jr., James E., Larchmont, NY, United States

PA The Rockefeller University, New York, NY, United States (U.S.  
corporation)

PI US 5604115 19970218 <--

WO 9211365 19920907 <--

AI US 1993-78222 19931028 (8)

WO 1991-US9733 19911223

19931028 PCT 371 date

19931028 PCT 102(e) date

NCL NCLM: 435/254.110  
NCLS: 435/069.900; 435/320.100; 536/024.100  
IC [6]  
ICM: C12N001-15  
ICS: C12N015-09; C12N015-63; C12N015-81  
EXF 435/172.3; 435/320.1; 435/69.9; 435/254.2; 435/254.11; 536/23.4;  
536/24.1; 536/24.2; 935/28; 935/37; 935/48; 935/69

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 382 OF 588 USPATFULL on STN  
AN 97:12349 USPATFULL  
TI Dominant negative chimeras of the steroid/thyroid superfamily of  
receptors  
IN Evans, Ronald M., La Jolla, CA, United States  
Hollenberg, Stanley M., Seattle, WA, United States  
Oro, Anthony E., San Diego, CA, United States  
Damm, Klaus, Munich, Germany, Federal Republic of  
Heyman, Richard A., Encinitas, CA, United States  
PA The Salk Institute for Biological Studies, La Jolla, CA, United States  
(U.S. corporation)  
PI US 5602009 19970211 <--  
AI US 1993-777232 19930510 (7)  
WO 1990-US3113 19900525  
19930510 PCT 371 date  
19930510 PCT 102(e) date  
RLI Continuation-in-part of Ser. No. US 1989-358696, filed on 26 May 1989,  
now abandoned which is a continuation-in-part of Ser. No. US  
1988-289561, filed on 23 Dec 1988, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1444  
INCL INCLM: 435/069.700  
INCLS: 435/252.300; 435/320.100; 530/350.000; 536/023.400  
NCL NCLM: 435/069.700

L5 ANSWER 384 OF 588 USPATFULL on STN  
 AN 97:5723 USPATFULL  
 TI Methods for using monoclonal antibodies specific for cell-surface bound  
 LAM-1  
 IN Tedder, Thomas F., South Natick, MA, United States  
 Schleiffenbaum, Boris, Brookline, MA, United States  
 Spertini, Olivier, Assens, Switzerland  
 PA Dana-Farber Cancer Institute, Inc., Boston, MA, United States (U.S.  
 corporation)  
 PI US 5595737 19970121 <--  
 AI US 1995-477394 19950607 (8)  
 RLI Division of Ser. No. US 1994-334191, filed on 4 Nov 1994 which is a  
 division of Ser. No. US 1992-862483, filed on 2 Apr 1992, now patented,  
 Pat. No. US 5389520, issued on 14 Feb 1995 which is a  
 continuation-in-part of Ser. No. US 1991-730503, filed on 8 Jul 1991,  
 now abandoned which is a continuation of Ser. No. US 1989-313109, filed  
 on 21 Feb 1989, now abandoned And a continuation-in-part of Ser. No. US  
 1991-700773, filed on 15 May 1991, now abandoned Ser. No. Ser. No. US  
 1991-737092, filed on 29 Jul 1991, now abandoned And Ser. No. US  
 1991-770608, filed on 3 Oct 1991, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 1089  
 INCL INCLM: 424/130.100  
 INCLS: 530/388.220; 530/388.730; 530/388.750; 435/240.270  
 NCL NCLM: 424/130.100  
 NCLS: 530/388.220; 530/388.730; 530/388.750  
 IC [6]  
 ICM: A61K039-395  
 ICS: C07K016-28; C12N005-20  
 EXF 530/387.9; 530/388.2; 530/388.22; 530/388.73; 530/389.7; 530/389.6;  
 530/388.75; 435/70.21; 435/172.2; 435/240.27; 435/7.24; 424/139.1;  
 424/144.1; 424/153.1; 424/173.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

corporation)

PI US 5589367 19961231 <--

AI US 1994-184237 19940119 (8)

RLI Continuation of Ser. No. US 1992-923692, filed on 31 Jul 1992, now patented, Pat. No. US 5316931 which is a continuation-in-part of Ser. No. US 1990-600244, filed on 22 Oct 1990, now abandoned Ser. No. Ser. No. US 1991-641617, filed on 16 Jan 1991, now abandoned Ser. No. Ser. No. US 1991-737899, filed on 26 Jul 1991, now abandoned And Ser. No. US 1991-739143, filed on 1 Aug 1991, now abandoned , said Ser. No. US -600244 which is a continuation of Ser. No. US 1989-310881, filed on 17 Feb 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-160766, filed on 26 Feb 1988, now abandoned And Ser. No. US 1988-160771, filed on 26 Feb 1988, now abandoned , said Ser. No. US -641617 which is a continuation of Ser. No. US 1989-347637, filed on 5 May 1989, now abandoned , said Ser. No. US -737899 which is a continuation of Ser. No. US 1989-363138, filed on 8 Jun 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-219279, filed on 15 Jul 1988, now abandoned

DT Utility

FS Granted

LN.CNT 2986

INCL INCLM: 435/172.300

INCLS: 435/069.100; 435/070.100; 435/320.100; 536/023.720; 536/024.100;  
800/205.000; 935/025.000; 935/057.000; 935/064.000; 935/067.000

NCL NCLM: 435/320.100

NCLS: 435/069.100; 435/070.100; 536/023.720; 536/024.100

IC [6]

ICM: C12N015-83

ICS: C12N015-33; C12N015-68

EXF 435/320.1; 435/69.1; 435/70.1; 536/24.1; 536/23.72; 800/205; 935/25;  
935/57; 935/64; 935/67

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 387 OF 588 USPATFULL on STN

EXF 435/69.1; 435/172.3; 536/23.4; 536/24.1; 935/6; 935/10; 935/34; 935/36;  
935/47

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 388 OF 588 USPATFULL on STN  
AN 96:108831 USPATFULL  
TI Gene manipulation and expression using genomic elements  
IN Sherwin, Stephen, San Francisco, CA, United States  
Klapholz, Sue, Stanford, CA, United States  
Skoultchi, Arthur, Larchmont, NY, United States  
PA Cell Genesys, Inc., Foster City, CA, United States (U.S. corporation)  
PI US 5578461 19961126 <--  
AI US 1993-102567 19930805 (8)  
RLI Continuation of Ser. No. US 1993-1898, filed on 7 Jan 1993, now  
abandoned which is a continuation-in-part of Ser. No. US 1989-432069,  
filed on 6 Nov 1989, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1363  
INCL INCLM: 435/069.100  
INCLS: 435/172.300; 435/240.200; 435/244.000; 435/320.100; 935/028.000;  
935/033.000; 935/055.000; 536/231.000; 536/241.000  
NCL NCLM: 435/069.100  
NCLS: 435/244.000; 435/320.100; 435/464.000; 536/023.100; 536/024.100  
IC [6]  
ICM: C12N015-00  
ICS: C12N005-00; C12N001-38; C07H021-04  
EXF 435/69.1; 435/172.3; 536/24.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 389 OF 588 USPATFULL on STN  
AN 96:108816 USPATFULL  
TI Sequence-directed DNA-binding molecules compositions and methods  
IN Edwards, Cynthia A., Menlo Park, CA, United States

AI US 1995-372236 19950113 (8)

DT Utility

FS Granted

LN.CNT 1024

INCL INCLM: 435/091.100

INCLS: 435/091.200; 435/006.000; 435/005.000; 435/007.900

NCL NCLM: 435/091.100

NCLS: 435/005.000; 435/006.000; 435/007.900; 435/091.200

IC [6]

ICM: C12P019-34

ICS: C12Q001-68; C12Q001-70; G01N033-53

EXF 435/6; 435/5; 435/7.9; 435/91.1; 435/91.2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 391 OF 588 USPATFULL on STN

AN 96:103892 USPATFULL

TI Porcine vasoactive intestinal peptide receptor and DNA

IN Hsiung, Hansen M., Carmel, IN, United States

Smith, Dennis P., Indianapolis, IN, United States

Zhang, Xing-Yue, Indianapolis, IN, United States

PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

PI US 5573928 19961112

<--

AI US 1993-112817 19930825 (8)

DT Utility

FS Granted

LN.CNT 1567

INCL INCLM: 435/069.100

INCLS: 435/064.700; 435/252.300; 435/320.100; 530/350.000; 536/023.400;  
536/023.500

NCL NCLM: 435/069.100

NCLS: 435/069.700; 435/252.300; 435/320.100; 530/350.000; 536/023.400;  
536/023.500

IC [6]

L5 ANSWER 393 OF 588 USPATFULL on STN  
 AN 96:101657 USPATFULL  
 TI Cardiac hypertrophy factor  
 IN Baker, Joffre, El Granada, CA, United States  
 Chien, Kenneth, La Jolla, CA, United States  
 King, Kathleen, Pacifica, CA, United States  
 Pennica, Diane, Burlingame, CA, United States  
 Wood, William, San Mateo, CA, United States  
 PA Genentech, Inc., South San Francisco, CA, United States (U.S.  
 corporation)  
 Regents of the Univ. of California, Oakland, CA, United States (U.S.  
 corporation)  
 PI US 5571893 19961105 <--  
 AI US 1994-286304 19940805 (8)  
 RLI Continuation of Ser. No. US 1994-233609, filed on 25 Apr 1994, now  
 patented, Pat. No. US 5534615  
 DT Utility  
 FS Granted  
 LN.CNT 4056  
 INCL INCLM: 530/350.000  
 INCLS: 530/399.000; 530/351.000; 930/140.000  
 NCL NCLM: 530/350.000  
 NCLS: 530/351.000; 530/399.000; 930/140.000  
 IC [6]  
 ICM: C07K014-52  
 ICS: A61K038-19  
 EXF 530/350; 530/399; 530/351; 514/12; 930/140  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 394 OF 588 USPATFULL on STN  
 AN 96:101466 USPATFULL  
 TI Directed evolution of novel binding proteins  
 IN Ladner, Robert C., Ijamsville, MD, United States  
 Guterman, Sonia K., Belmont, MA, United States

corporation)

Regents of the Univ. of California, Oakland, CA, United States (U.S. corporation)

PI US 5571675 19961105 <--  
AI US 1995-444083 19950517 (8)  
RLI Division of Ser. No. US 1994-286304, filed on 5 Aug 1994 which is a  
continuation-in-part of Ser. No. US 1994-233609, filed on 25 Apr 1994  
DT Utility  
FS Granted  
LN.CNT 4298  
INCL INCLM: 435/006.000  
INCLS: 435/091.200; 435/091.210; 536/024.300; 536/024.310; 536/024.320;  
536/024.330  
NCL NCLM: 435/006.000  
NCLS: 435/091.200; 435/091.210; 536/024.300; 536/024.310; 536/024.320;  
536/024.330  
IC [6]  
ICM: C12Q001-68  
ICS: C12P019-34; C07H021-04  
EXF 435/6; 435/91.2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 396 OF 588 USPATFULL on STN  
AN 96:96925 USPATFULL  
TI Methods of using biologically active dimerized polypeptide fusions to  
detect PDGF  
IN Sledziewski, Andrzej Z., Seattle, WA, United States  
Bell, Lillian A., Seattle, WA, United States  
Kindsvogel, Wayne R., Seattle, WA, United States  
PA Zymogenetics, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 5567584 19961022 <--  
AI US 1994-180195 19940111 (8)  
RLI Continuation of Ser. No. US 1990-634510, filed on 27 Dec 1990, now  
abandoned which is a continuation-in-part of Ser. No. US 1989-347291,



IC [6]  
ICM: C12N015-00  
ICS: C07H021-00  
EXF 435/320.1; 435/172.3; 435/69.1; 435/317.1; 800/2; 800/DIG.1; 536/23.1;  
935/111

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 398 OF 588 USPATFULL on STN  
AN 96:94483 USPATFULL  
TI Deubiquitinating enzyme: compositions and methods  
IN Hochstrasser, Mark, Chicago, IL, United States  
Papa, Feroz, Chicago, IL, United States  
PA Arch Development Corporation, Chicago, IL, United States (U.S.  
corporation)  
PI US 5565352 19961015 <--  
AI US 1993-159340 19931124 (8)  
DT Utility  
FS Granted  
LN.CNT 2953

INCL INCLM: 435/240.100  
INCLS: 435/252.300; 435/201.000; 435/254.110; 435/254.200; 435/254.210;  
435/255.200; 435/255.100; 435/320.100; 435/172.300; 536/023.200;  
935/069.000; 935/010.000; 935/014.000

NCL NCLM: 435/255.100  
NCLS: 435/201.000; 435/252.300; 435/254.110; 435/254.200; 435/254.210;  
435/255.200; 435/320.100; 536/023.200

IC [6]  
ICM: C12N015-53  
ICS: C12N001-19; C12N001-18; C12N001-16; C12N001-21; C12N005-10;  
C12N015-63  
EXF 435/320.1; 435/252.3; 435/252.33; 435/254.2; 435/254.21; 435/255.2;  
435/255.1; 435/69.1; 435/240.1; 435/201; 536/23.2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Kalbach, Cathy E., Newark, DE, United States

PA E. I. Du Pont de Nemours and Company, Wilmington, DE, United States  
(U.S. corporation)

PI US 5552301 19960903 <--

AI US 1994-233158 19940426 (8)

RLI Continuation of Ser. No. US 1993-38380, filed on 29 Mar 1993, now  
abandoned

DT Utility

FS Granted

LN.CNT 1021

INCL INCLM: 435/069.100  
INCLS: 435/069.400; 435/252.330

NCL NCLM: 435/069.100  
NCLS: 435/069.400; 435/252.330

IC [6]  
ICM: C12N015-00  
ICS: C12N015-73; C12P021-00; C12P021-02

EXF 435/69.1; 435/172.1; 435/172.3; 435/69.4; 435/252.3-252.35; 435/320.1;  
935/72; 935/73

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 401 OF 588 USPATFULL on STN

AN 96:77939 USPATFULL

TI N-(1, (1-1)-dialkyloxy)-and N-(1, (1-1)-dialkenyloxy alk-1-yl-N,N,N-  
tetrasubstituted ammonium lipids and uses therefor

IN Eppstein, Deborah A., Menlo Park, CA, United States  
Felgner, Philip L., Los Altos, CA, United States  
Gadek, Thomas R., Oakland, CA, United States  
Jones, Gordon H., Cupertino, CA, United States  
Roman, Richard B., Fairhope, AL, United States

PA Syntex (U.S.A.) Inc., Palo Alto, CA, United States (U.S. corporation)

PI US 5550289 19960827 <--

AI US 1995-415963 19950403 (8)

RLI Division of Ser. No. US 1994-237807, filed on 4 May 1994 which is a

Nagai, Kiyoshi, Cambridge, England

PA Somatogen, Inc., Boulder, CO, United States (U.S. corporation)

PI US 5545727 19960813 <--

AI US 1991-789179 19911108 (7)

RLI Continuation-in-part of Ser. No. US 1991-671707, filed on 1 Apr 1991,  
now abandoned which is a continuation-in-part of Ser. No. US  
1989-374161, filed on 30 Jun 1989, now abandoned And a  
continuation-in-part of Ser. No. US 1989-379116, filed on 13 Jul 1989,  
now abandoned And a continuation-in-part of Ser. No. US 1989-349623,  
filed on 10 May 1989, now abandoned

DT Utility

FS Granted

LN.CNT 7153

INCL INCLM: 536/234.000  
INCLS: 536/023.500; 530/385.000

NCL NCLM: 536/023.400  
NCLS: 530/385.000; 536/023.500

IC [6]  
ICM: C12N015-12  
ICS: C07K014-805

EXF 536/23.4; 536/23.5; 435/69.1; 435/69.6; 435/69.7; 435/71.1; 530/385

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 403 OF 588 USPATFULL on STN

AN 96:72662 USPATFULL

TI N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-  
tetrasubstituted ammonium lipids and uses therefor

IN Eppstein, Deborah A., Menlo Park, CA, United States  
Felgner, Philip L., Los Altos, CA, United States  
Gadek, Thomas R., Oakland, CA, United States  
Jones, Gordon H., Cupertino, CA, United States  
Roman, Richard B., Fairhope, AL, United States

PA Syntex (U.S.A.) Inc., Palo Alto, CA, United States (U.S. corporation)

PI US 5545412 19960813 <--

AI US 1990-472328 19900130 (7)

RLI Division of Ser. No. US 1987-99096, filed on 21 Sep 1987, now patented,  
Pat. No. US 4897471 which is a continuation of Ser. No. US 1983-560495,  
filed on 12 Dec 1983, now patented, Pat. No. US 4695623 which is a  
division of Ser. No. US 1983-483451, filed on 13 Apr 1983 which is a  
continuation-in-part of Ser. No. US 1982-375494, filed on 6 May 1982,  
now abandoned

DT Utility

FS Granted

LN.CNT 1693

INCL INCLM: 530/351.000  
INCLS: 424/085.700; 435/069.510

NCL NCLM: 530/351.000  
NCLS: 424/085.700; 435/069.510

IC [6]  
ICM: C07K014-56

EXF 530/351; 424/85.7; 435/69.51

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 405 OF 588 USPATFULL on STN

AN 96:67890 USPATFULL

TI Mammalian adipocyte protein P154, nucleic acids coding therefor and uses  
thereof

IN Serrero, Ginette, Lake Placid, NY, United States

PA W. Alton Jones Cell Science Center, inc., Lake Placid, NY, United States  
(U.S. corporation)

PI US 5541068 19960730 <--

AI US 1993-127995 19931122 (8)

RLI Division of Ser. No. US 1991-708038, filed on 31 May 1991, now patented,  
Pat. No. US 5268295

DT Utility

FS Granted

LN.CNT 2126

INCL INCLM: 435/000.710

L5 ANSWER 407 OF 588 USPATFULL on STN  
AN 96:65321 USPATFULL  
TI Isolation, growth, differentiation and genetic engineering of human  
muscle cells  
IN Blau, Helen M., Menlo Park, CA, United States  
Hughes, Simon M., Palo Alto, CA, United States  
PA Stanford University, Stanford, CA, United States (U.S. corporation)  
PI US 5538722 19960723 <--  
AI US 1991-748348 19910822 (7)  
RLI Continuation-in-part of Ser. No. US 1989-365374, filed on 13 Jun 1989,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 1019  
INCL INCLM: 424/093.210  
INCLS: 435/069.400; 435/240.200; 435/172.300  
NCL NCLM: 424/093.210  
NCLS: 435/069.400  
IC [6]  
ICM: A61K048-00  
ICS: C12N015-00  
EXF 424/93B; 424/93U; 435/240.2; 435/172.3; 435/69.4; 935/62; 935/70; 935/71  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 408 OF 588 USPATFULL on STN  
AN 96:60800 USPATFULL  
TI \*\*\*Human\*\*\* \*\*\*growth\*\*\* \*\*\*hormone\*\*\* variants having  
greater affinity for \*\*\*human\*\*\* \*\*\*growth\*\*\* \*\*\*hormone\*\*\*  
receptor at site 1  
IN Cunningham, Brian C., Piedmont, CA, United States  
Lowman, Henry, Hercules, CA, United States  
Wells, James A., Burlingame, CA, United States  
PA Genentech, Inc., South San Francisco, CA, United States (U.S.

Pennice, Diane, Burlingame, CA, United States

Wood, William, San Mateo, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

PI US 5534615 19960709 <--

AI US 1994-233609 19940425 (8)

DT Utility

FS Granted

LN.CNT 3897

INCL INCLM: 530/350.000

INCLS: 530/380.000; 424/569.000; 424/570.000

NCL NCLM: 530/350.000

NCLS: 424/569.000; 424/570.000; 530/380.000

IC [6]

ICM: C07K001-00

ICS: A61K035-14; A61K035-30

EXF 530/350; 530/380; 424/569; 424/570

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 410 OF 588 USPATFULL on STN

AN 96:58313 USPATFULL

TI Tumor suppressor protein PRB2, related gene products, and DNA encoding therefor

IN Giordano, Antonio, Willow Grove, PA, United States

PA Temple University of The Commonwealth System of Higher Education, Philadelphia, PA, United States (U.S. corporation)

PI US 5532340 19960702 <--

AI US 1995-429264 19950425 (8)

RLI Division of Ser. No. US 1993-106493, filed on 12 Aug 1993, now patented, Pat. No. US 5457049

DT Utility

FS Granted

IN Sechler, Joan M., Silver Spring, MD, United States  
PA The United States of America as represented by the Department of Health  
and Human Services, Washington, DC, United States (U.S. government)  
PI US 5523232 19960604 <--  
AI US 1994-257625 19940608 (8)  
RLI Continuation-in-part of Ser. No. US 1992-861938, filed on 2 Apr 1992,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 1184  
INCL INCLM: 435/236.000  
INCLS: 435/199.000; 424/094.600; 424/094.300  
NCL NCLM: 435/236.000  
NCLS: 424/094.300; 424/094.600; 435/199.000  
IC [6]  
ICM: C12N007-04  
ICS: A61K038-46  
EXF 435/236; 435/199; 424/94.6; 424/94.3  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
  
L5 ANSWER 413 OF 588 USPATFULL on STN  
AN 96:45926 USPATFULL  
TI Periplasmic membrane-bound system for detecting protein-protein  
interactions  
IN Menzel, Rolf, Princeton Junction, NJ, United States  
Taylor, Scott T., West Windsor, NJ, United States  
PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S.  
corporation)  
PI US 5521066 19960528 <--  
AI US 1993-121201 19930913 (8)  
DT Utility  
FS Granted  
LN.CNT 824  
INCL INCLM: 435/007.200

ICS: C12N015-70; C12N015-12

EXF 530/330; 435/172.3; 435/69.1; 435/320.1; 435/252.3; 435/252.33; 576/27;  
536/23.5; 536/23.4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 415 OF 588 USPATFULL on STN

AN 96:36656 USPATFULL

TI Multitrophic and multifunctional chimeric neurotrophic factors

IN Shooter, Eric M., Portola Valley, CA, United States

Suter, Ulrich, Menlo Park, CA, United States

Ip, Nancy P., Hong Kong, Hong Kong

Squinto, Stephen P., Irvington, NY, United States

Furth, Mark E., Chapel Hill, NC, United States

Lindsay, Ronald M., Briarcliff Manor, NY, United States

PA Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States (U.S.  
corporation)

PI US 5512661 19960430 <--

AI US 1994-308625 19940919 (8)

RLI Continuation of Ser. No. US 1992-923334, filed on 31 Jul 1992, now  
abandoned which is a division of Ser. No. US 1990-564929, filed on 8 Aug  
1990, now patented, Pat. No. US 5169764

DT Utility

FS Granted

LN.CNT 2139

INCL INCLM: 530/399.000

INCLS: 530/350.000; 530/839.000; 930/120.000

NCL NCLM: 530/399.000

NCLS: 530/350.000; 530/839.000; 930/120.000

IC [6]

ICM: C07K014-475

ICS: C07K014-48; C07K019-00

EXF 530/350; 530/399; 530/839; 930/120

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



RLI Continuation of Ser. No. US 1992-825522, filed on 29 Jan 1992, now  
abandoned which is a continuation-in-part of Ser. No. US 1991-650054,  
filed on 4 Feb 1991, now abandoned

DT Utility

FS Granted

LN.CNT 1133

INCL INCLM: 424/196.110  
INCLS: 424/193.100; 424/281.100; 424/450.000; 424/215.100; 424/852.000;  
424/085.500; 514/012.000; 530/391.100

NCL NCLM: 424/196.110  
NCLS: 424/085.200; 424/085.500; 424/193.100; 424/215.100; 424/281.100;  
424/450.000; 514/012.000; 530/391.100

IC [6]  
ICM: C07K016-00  
ICS: A61K039-15; A61K039-385; A61K045-05

EXF 530/391.1; 424/85.5; 424/85.2; 424/196.11; 424/215.1; 424/281.1;  
424/450; 424/499; 424/193.1; 424/391.1; 514/12

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 418 OF 588 USPATFULL on STN

AN 96:24862 USPATFULL

TI DNA molecules encoding an ER-located endoprotease

IN Chaudhuri, Bhabatosh, Munchenstein, Switzerland  
Stephan, Christine, Kingersheim, France  
Seeboth, Peter, Inzlingen, Germany, Federal Republic of  
Riezman, Howard, Biel-Benken, Switzerland

PA Ciba-Geigy Corporation, Tarrytown, NY, United States (U.S. corporation)

PI US 5501975 19960326 <--

AI US 1994-328961 19941024 (8)

RLI Continuation of Ser. No. US 1992-989260, filed on 11 Dec 1992, now  
abandoned

PRAI EP 1991-810984 19911216

DT Utility

FS Granted

L5 ANSWER 420 OF 588 USPATFULL on STN  
AN 96:17074 USPATFULL  
TI Recombinant purified protease nexin  
IN McGrogan, Michael P., San Carlos, CA, United States  
Scott, Randy W., San Carlos, CA, United States  
Baker, Joffre B., Lawrence, KS, United States  
Simonsen, Sr., Christian C., San Jose, CA, United States  
PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.  
corporation)  
PI US 5495001 19960227 <--  
AI US 1994-288596 19940810 (8)  
RLI Continuation of Ser. No. US 1993-111111, filed on 24 Aug 1993 which is a  
division of Ser. No. US 1987-25450, filed on 13 Mar 1987, now patented,  
Pat. No. US 5278049 which is a continuation-in-part of Ser. No. US  
1986-871501, filed on 6 Jun 1986, now abandoned which is a  
continuation-in-part of Ser. No. US 1986-870232, filed on 3 Jun 1986,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 993  
INCL INCLM: 530/350.000  
INCLS: 530/395.000; 435/069.200; 435/172.300; 435/320.100; 536/023.500  
NCL NCLM: 530/350.000  
NCLS: 435/069.200; 435/320.100; 530/395.000; 536/023.500  
IC [6]  
ICM: C07K014-81  
ICS: C12N015-15  
EXF 435/69.2; 435/172.3; 530/350; 530/395; 536/23.5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 421 OF 588 USPATFULL on STN  
AN 96:12798 USPATFULL  
TI Expression of foreign genes using a replicating polyprotein producing  
virus vector

abandoned And Ser. No. US 1990-619827, filed on 28 Nov 1990, now  
patented, Pat. No. US 5260201

DT Utility

FS Granted

LN.CNT 1464

INCL INCLM: 435/243.000

INCLS: 435/069.400; 435/252.330; 935/044.000; 935/045.000; 536/023.510

NCL NCLM: 435/243.000

NCLS: 435/069.400; 435/252.330; 536/023.510

IC [6]

ICM: C12N015-18

ICS: C12N015-70

EXF 435/69.1-71.3; 435/91.1; 435/172.1; 435/172.3; 435/252.3-252.35;  
435/321; 435/243; 935/10; 935/44; 935/45; 935/46; 935/61; 935/72;  
935/73; 536/23.51

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 423 OF 588 USPATFULL on STN

AN 96:11064 USPATFULL

TI Secretion of \*\*\*insulin\*\*\* -like growth factor-I in E. coli

IN Wong, Edith, Chesterfield, MO, United States

Bittner, Michael L., Naperville, IL, United States

PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)

PI US 5489517 19960206 <--

AI US 1991-704486 19910523 (7)

RLI Continuation of Ser. No. US 1990-522399, filed on 10 May 1990, now  
patented, Pat. No. US 5084384 which is a continuation of Ser. No. US  
1987-41896, filed on 23 Apr 1987, now abandoned

DT Utility

FS Granted

LN.CNT 896

INCL INCLM: 435/069.400

INCLS: 435/069.700; 435/069.800; 435/071.200; 935/048.000

NCL NCLM: 435/069.400

ICM: C07K014-435

ICS: C07K019-00; C12N015-12; C12N015-62

EXF 536/23.4; 530/395; 530/350; 435/69.7; 435/69.1; 435/252.3; 435/320.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 425 OF 588 USPATFULL on STN

AN 96:5890 USPATFULL

TI Selectin ligands

IN Lasky, Laurence A., Sausalito, CA, United States

Imai, Yasuyuki, Tokyo, Japan

Rosen, Steven D., San Francisco, CA, United States

Singer, Mark S., Berkeley, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S.  
corporation)

The Regents of the University of California, Berkeley, CA, United States  
(U.S. corporation)

PI US 5484891 19960116 <--

AI US 1993-18994 19930218 (8)

RLI Division of Ser. No. US 1992-834902, filed on 13 Feb 1992, now patented,  
Pat. No. US 5304640 which is a continuation-in-part of Ser. No. US  
1991-695805, filed on 6 May 1991, now patented, Pat. No. US 5318890

DT Utility

FS Granted

LN.CNT 2415

INCL INCLM: 530/387.300

INCLS: 530/350.000; 530/395.000; 435/007.200

NCL NCLM: 530/387.300

NCLS: 435/007.200; 530/350.000; 530/395.000

IC [6]

ICM: C07K013-00

ICS: C07K015-14

EXF 530/350; 530/387.3; 530/395; 435/7.2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 427 OF 588 USPATFULL on STN  
AN 95:105943 USPATFULL  
TI Human .beta..sub.2 integrin .alpha. subunit  
IN Gallatin, W. Michael, Seattle, WA, United States  
Van der Vieren, Monica, Seattle, WA, United States  
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)  
PI US 5470953 19951128 <--  
AI US 1994-286889 19940805 (8)  
RLI Continuation-in-part of Ser. No. US 1993-173497, filed on 23 Dec 1993  
DT Utility  
FS Granted  
LN.CNT 2422  
INCL INCLM: 530/350.000  
INCLS: 536/022.100; 536/023.100; 536/023.400; 536/023.500  
NCL NCLM: 530/350.000  
NCLS: 536/022.100; 536/023.100; 536/023.400; 536/023.500  
IC [6]  
ICM: C07K001-00  
ICS: C07K002-00; C07H019-00; C07H021-00  
EXF 530/350; 530/380; 536/22.1; 536/23.1; 536/23.4; 536/23.5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 428 OF 588 USPATFULL on STN  
AN 95:105711 USPATFULL  
TI Production of human somatomedin C  
IN Buell, Gary N., Geneva, Switzerland  
Movva, Nageswararao, Geneva, Switzerland  
PA Biogen, Inc., Cambridge, MA, United States (U.S. corporation)  
PI US 5470721 19951128 <--  
AI US 1993-81979 19930623 (8)  
RLI Division of Ser. No. US 1992-965047, filed on 21 Oct 1992, now patented,  
Pat. No. US 5242811 which is a continuation of Ser. No. US 1990-496086,

patented, Pat. No. US 4956455 And Ser. No. US 1986-940524, filed on 10  
Dec 1986, now patented, Pat. No. US 4785079

PRAI WO 1986-US1318 19860618

DT Utility

FS Granted

LN.CNT 1272

INCL INCLM: 536/023.510

INCLS: 530/399.000

NCL NCLM: 536/023.510

NCLS: 530/399.000

IC [6]

ICM: C12N015-18

EXF 435/68; 435/70; 435/71; 435/91; 435/169; 435/170; 435/171; 435/172.1;  
435/172.3; 435/240.1; 435/240.2; 435/320; 435/849; 435/940; 435/253;  
435/254; 435/255; 435/256; 435/257; 435/258; 536/27; 536/23.51; 935/9;  
935/10; 935/11; 935/22; 935/23; 935/24; 935/27; 935/28; 935/29; 935/33;  
935/34; 935/38; 935/59; 935/60; 935/61; 935/66; 935/68; 935/69; 935/70;  
935/71; 935/72; 935/73; 935/74; 935/75

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 430 OF 588 USPATFULL on STN

AN 95:99069 USPATFULL

TI Processes and compositions for the isolation of human relaxin

IN Henner, Dennis J., Pacifica, CA, United States

Vandlen, Richard L., Hillsborough, CA, United States

Wilkins, James A., San Mateo, CA, United States

Yansura, Daniel G., Pacifica, CA, United States

PA Genentech, San Francisco, CA, United States (U.S. corporation)

PI US 5464756 19951107 <--

AI US 1992-908766 19920701 (7)

RLI Continuation of Ser. No. US 1989-347550, filed on 4 May 1989, now  
abandoned

DT Utility

FS Granted

IC [6]  
ICM: C07K015-26  
ICS: A61K037-66  
EXF 530/351; 424/85.6; 424/85.4  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 432 OF 588 USPATFULL on STN  
AN 95:92700 USPATFULL  
TI Method of producing IGF-1  
IN Skriver, Lars, Vedb k, Denmark  
Hejn s, Kim R., Lyngby, Denmark  
Dalboge, Henrik, Virum, Denmark  
PA Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)  
PI US 5459052 19951017 <--  
AI US 1993-87477 19930702 (8)  
RLI Continuation of Ser. No. US 1991-746827, filed on 19 Aug 1991, now  
abandoned  
PRAI DK 1990-1989 19900820  
DK 1990-2497 19901016  
DT Utility  
FS Granted  
LN.CNT 909  
INCL INCLM: 435/071.200  
INCLS: 435/069.400; 435/320.100; 530/303.000; 530/399.000; 530/402.000;  
530/412.000; 530/416.000; 530/417.000; 530/422.000; 530/427.000;  
530/414.000; 436/161.000  
NCL NCLM: 435/071.200  
NCLS: 435/069.400; 435/320.100; 436/161.000; 530/303.000; 530/399.000;  
530/402.000; 530/412.000; 530/414.000; 530/416.000; 530/417.000;  
530/422.000; 530/427.000  
IC [6]  
ICM: C12P021-04  
ICS: A61K038-28; C07K014-00; C12N015-17  
EXF 530/303; 530/399; 435/69.4; 435/69.8; 435/320.1; 435/71.2; 436/161

AI US 1993-106493 19930812 (8)

DT Utility

FS Granted

LN.CNT 615

INCL INCLM: 435/252.330

INCLS: 435/252.300; 435/320.100; 435/172.300; 435/091.100; 435/849.000;  
536/023.100; 536/023.500; 530/350.000; 935/009.000; 935/029.000;  
935/073.000

NCL NCLM: 435/252.330

NCLS: 435/091.100; 435/252.300; 435/320.100; 435/849.000; 530/350.000;  
536/023.100; 536/023.500

IC [6]

ICM: C12N001-21

ICS: C12N015-12; C12N015-70

EXF 435/320.1; 435/252.3; 435/252.83; 435/91.1; 435/91.4; 435/91.41;  
536/23.1; 536/23.5; 935/9; 935/11; 935/22; 935/29; 935/56; 935/60;  
935/73

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 435 OF 588 USPATFULL on STN

AN 95:62455 USPATFULL

TI Rotavirus VP6 as a diagnostic and targeting agent

IN Redmond, Mark J., Saskatoon, Canada

Campos, Manuel, Saskatoon, Canada

Matte, Gilbert G., Saskatoon, Canada

Haines, Deborah M., Saskatoon, Canada

PA University of Saskatchewan, Saskatchewan, Canada (non-U.S. corporation)

PI US 5431899 19950711 <--

AI US 1991-650041 19910204 (7)

DT Utility

FS Granted

LN.CNT 419

INCL INCLM: 424/001.570

INCLS: 435/005.000; 435/007.240; 435/235.100; 436/501.000; 436/519.000;



NCLS: 424/188.100; 424/208.100; 435/069.400; 435/069.600; 435/358.000;  
530/388.350; 536/023.100

IC [6]

ICM: C12N015-00

ICS: A61K039-00; C07K003-00

EXF 435/69.4; 435/69.6; 435/172.3; 435/320.1; 530/386.35; 424/88; 536/23.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 437 OF 588 USPATFULL on STN

AN 95:50087 USPATFULL

TI DNA encoding the Trichinella spirals 53kD excretory/secretory antigen  
for use as immunodiagnostic reagents

IN Zarlenga, Jr., Dante S., Ellicott City, MD, United States  
Gamble, H. Ray, Bowie, MD, United States

PA The United States of America as represented by the Secretary of  
Agriculture, Washington, DC, United States (U.S. government)

PI US 5422263 19950606 <--

AI US 1993-70645 19930601 (8)

RLI Continuation of Ser. No. US 1989-366844, filed on 15 Jun 1989, now  
abandoned

DT Utility

FS Granted

LN.CNT 1094

INCL INCLM: 435/240.100

INCLS: 424/191.100; 424/265.100; 435/069.300; 435/320.100; 435/172.300;  
530/388.600; 536/023.100; 536/024.300

NCL NCLM: 435/252.330

NCLS: 424/191.100; 424/265.100; 435/069.300; 435/252.300; 435/320.100;  
530/388.600; 536/023.100; 536/024.300

IC [6]

ICM: C07K015-28

ICS: C12N015-30; C12P021-08; A61K039-002

EXF 424/8; 424/191.1; 435/69.3; 435/240.1; 435/320.1; 435/172.3; 530/350.1;  
530/387.6; 935/12; 536/23.1

AI US 1993-161044 19931202 (8)  
RLI Continuation of Ser. No. US 1991-808451, filed on 6 Dec 1991, now  
patented, Pat. No. US 5288931  
DT Utility  
FS Granted  
LN.CNT 1736  
INCL INCLM: 530/408.000  
INCLS: 530/399.000; 530/350.000; 530/409.000; 530/422.000; 530/412.000  
NCL NCLM: 530/408.000  
NCLS: 530/350.000; 530/399.000; 530/409.000; 530/412.000; 530/422.000  
IC [6]  
ICM: C12N015-00  
ICS: C07K007-04  
EXF 530/399; 530/350; 530/408; 530/409; 530/422; 530/825; 530/826; 530/412;  
435/69.1; 435/172.3; 930/10  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
  
L5 ANSWER 440 OF 588 USPATFULL on STN  
AN 95:29292 USPATFULL  
TI Viruses expressing chimeric binding proteins  
IN Ladner, Robert C., Ijamsville, MD, United States  
Guterman, Sonia K., Belmont, MA, United States  
Roberts, Bruce L., Milford, MA, United States  
Markland, William, Milford, MA, United States  
Ley, Arthur C., Newton, MA, United States  
Kent, Rachel B., Boxborough, MA, United States  
PA Protein Engineering Corporation, Cambridge, MA, United States (U.S.  
corporation)  
PI US 5403484 19950404 <--  
AI US 1993-9319 19930126 (8)  
RLI Division of Ser. No. US 1991-664989, filed on 1 Mar 1991, now patented,  
Pat. No. US 5223409 which is a continuation-in-part of Ser. No. US  
1990-487063, filed on 2 Mar 1990, now abandoned which is a  
continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988,

ICM: C12P021-02

ICS: C12P021-00

EXF 435/172.3; 435/69.4; 435/320.1; 435/252.3-252.35; 536/23.51; 935/13  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 442 OF 588 USPATFULL on STN

AN 95:13762 USPATFULL

TI Modified lam.beta. signal sequence and processes for producing  
recombinant neurotrophins

IN Panayotatos, Nikos, Orangeburg, NY, United States  
Fandl, James P., La Grangeville, NY, United States

PA Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States (U.S.  
corporation)

PI US 5389529 19950214 <--

AI US 1991-796106 19911121 (7)

RLI Continuation-in-part of Ser. No. US 1991-715185, filed on 12 Jun 1991,  
now abandoned

DT Utility

FS Granted

LN.CNT 1479

INCL INCLM: 435/069.800

INCLS: 435/172.100; 435/320.100; 435/069.400; 435/071.200; 536/023.100;  
536/023.400; 935/048.000

NCL NCLM: 435/069.800

NCLS: 435/069.400; 435/071.200; 435/320.100; 536/023.100; 536/023.400

IC [6]

ICM: C12N015-11

EXF 435/69.4; 435/69.7; 435/69.8; 435/71.2; 435/172.1; 435/320.1; 530/399  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 443 OF 588 USPATFULL on STN

AN 95:13753 USPATFULL

TI Specific detection of cell surface receptor leukocyte adhesion  
molecule-1

AI US 1991-782113 19911025 (7)

DT Utility

FS Granted

LN.CNT 449

INCL INCLM: 536/023.200

INCLS: 536/023.100; 536/023.700

NCL NCLM: 536/023.200

NCLS: 536/023.100; 536/023.700

IC [6]

ICM: C12N015-31

ICS: C12N015-52

EXF 536/27; 536/23.1; 536/23.2; 536/23.7; 435/69.1; 435/71.1; 435/320.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 445 OF 588 USPATFULL on STN

AN 94:110684 USPATFULL

TI Chitinase-producing bacteria and plants

IN Suslow, Trevor, El Cerrito, CA, United States

Jones, Jonathan D. G., Norwich, United Kingdom

PA DNA Plant Technology Corporation, Mt. Kisco, NY, United States (U.S. corporation)

PI US 5374540 19941220

<--

AI US 1990-550253 19900709 (7)

RLI Continuation-in-part of Ser. No. US 1986-888033, filed on 18 Jul 1986, now patented, Pat. No. US 4940840 which is a continuation-in-part of Ser. No. US 1984-593691, filed on 26 Mar 1984, now patented, Pat. No. US 4751081

DT Utility

FS Granted

LN.CNT 1356

INCL INCLM: 435/069.800

INCLS: 435/069.700; 435/070.100; 435/172.300; 435/240.400; 435/320.100;  
935/030.000; 935/035.000; 935/047.000; 935/048.000; 935/067.000

NCL NCLM: 435/069.800

AN 94:106888 USPATFULL

TI Substrate assisted catalysis

IN Carter, Paul J., San Francisco, CA, United States  
Wells, James A., Burlingame, CA, United States

PA Genencor International, Inc., South San Francisco, CA, United States  
(U.S. corporation)

PI US 5371190 19941206 <--

AI US 1993-90902 19930712 (8)

RLI Continuation of Ser. No. US 1992-823039, filed on 14 Jan 1992, now  
abandoned And a continuation-in-part of Ser. No. US 1987-35652, filed on  
6 Apr 1987, now abandoned which is a continuation-in-part of Ser. No. US  
1986-858594, filed on 30 Apr 1986, now abandoned , said Ser. No. US  
-823039 which is a continuation of Ser. No. US 1989-334081, filed on 4  
Apr 1989, now abandoned which is a continuation-in-part of Ser. No. US  
1987-127134, filed on 1 Dec 1987, now abandoned which is a  
continuation-in-part of Ser. No. US 1986-846627, filed on 1 Apr 1986,  
now abandoned which is a continuation-in-part of Ser. No. US  
1984-614615, filed on 29 May 1984, now abandoned And Ser. No. US  
1986-858594, filed on 30 Apr 1986, now abandoned which is a  
continuation-in-part of Ser. No. US 1984-614612, filed on 29 May 1984,  
now patented, Pat. No. US 4760025 And Ser. No. US 1984-614615, filed on  
29 May 1984, now abandoned And Ser. No. US 1984-614617, filed on 29 May  
1984, now abandoned And Ser. No. US 1984-614491, filed on 29 May 1984,  
now abandoned

DT Utility

FS Granted

LN.CNT 2496

INCL INCLM: 530/350.000  
INCLS: 435/222.000; 435/221.000

NCL NCLM: 530/350.000  
NCLS: 435/221.000; 435/222.000

IC [5]  
ICM: C07K015-00  
ICS: C12N009-56

NCL NCLM: 435/222.000  
NCLS: 435/221.000; 530/358.000  
IC [5]  
ICM: C12N009-56  
ICS: C12N009-54  
EXF 435/222; 435/221; 435/183; 530/350  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 449 OF 588 USPATFULL on STN  
AN 94:102323 USPATFULL  
TI Structure, production and use of heregulin  
IN Vandlen, Richard L., Hillsborough, CA, United States  
Holmes, William E., Pacifica, CA, United States  
PA Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)  
PI US 5367060 19941122 <--  
AI US 1992-847743 19920306 (7)  
RLI Continuation-in-part of Ser. No. US 1991-790801, filed on 8 Nov 1991,  
now abandoned which is a continuation-in-part of Ser. No. US  
1991-765212, filed on 25 Sep 1991, now abandoned which is a  
continuation-in-part of Ser. No. US 1991-705256, filed on 24 May 1991,  
now abandoned  
DT Utility  
FS Granted

LN.CNT 3698

INCL INCLM: 530/399.000  
INCLS: 530/350.000  
NCL NCLM: 530/399.000  
NCLS: 530/350.000  
IC [5]  
ICM: C07K013-00  
ICS: A61K037-36  
EXF 435/69.1; 530/350; 530/399; 530/389.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 451 OF 588 USPATFULL on STN  
AN 94:86498 USPATFULL  
TI Hydrolysis of peptide bonds using Pt (II) and Pd (II) complexes  
IN Kostic, Nenad M., Ames, IA, United States  
Zhu, Longgen, Ames, IA, United States  
PA Iowa State University Research Foundation Inc., Ames, IA, United States  
(U.S. corporation)  
PI US 5352771 19941004 <--  
AI US 1992-938436 19920831 (7)  
DT Utility  
FS Granted  
LN.CNT 970  
INCL INCLM: 530/345.000  
INCLS: 530/343.000  
NCL NCLM: 530/345.000  
NCLS: 530/343.000  
IC [5]  
ICM: C07K001-12  
ICS: C07K003-10  
EXF 514/492; 530/333; 530/343; 530/345; 424/646; 424/649; 424/617  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 452 OF 588 USPATFULL on STN  
AN 94:84343 USPATFULL  
TI \*\*\*Growth\*\*\* \*\*\*hormone\*\*\* antagonists  
IN Kopchick, John J., Athens, OH, United States  
Chen, Wen Y., Athens, OH, United States  
PA Ohio University, Athens, OH, United States (U.S. corporation)  
PI US 5350836 19940927 <--  
AI US 1992-878703 19920504 (7)  
RLI Continuation-in-part of Ser. No. US 1991-693305, filed on 1 May 1991,

NCL NCLM: 435/353.000  
NCLS: 435/252.300; 435/320.100; 536/024.100

IC [5]  
ICM: C12N005-10  
ICS: C12N005-16; C12N001-00; C12N015-63

EXF 536/24.1; 435/69.1; 435/69.6; 435/172.3; 435/252.3; 435/240.2;  
435/240.1; 435/320.1; 935/34; 935/36; 935/71

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 454 OF 588 USPATFULL on STN

AN 94:60142 USPATFULL

TI \*\*\*Insulin\*\*\* -like growth factor binding protein and pharmaceutical  
compositions

IN Baxter, Robert C., Glebe, Australia  
Wood, William I., San Mateo, CA, United States

PA Genentech, Inc., S. San Francisco, CA, United States (U.S. corporation)  
Central Sydney Area Health Service, Camperdown, Australia (non-U.S.  
corporation)

PI US 5328891 19940712 <--

AI US 1993-3710 19930113 (8)

RLI Division of Ser. No. US 1988-171623, filed on 22 Mar 1988, now patented,  
Pat. No. US 5258287

DT Utility

FS Granted

LN.CNT 1653

INCL INCLM: 514/002.000  
INCLS: 514/012.000; 530/350.000; 530/402.000

NCL NCLM: 514/002.000  
NCLS: 514/012.000; 530/350.000; 530/402.000

IC [5]  
ICM: A61K037-00  
ICS: C07K013-00

EXF 530/350; 530/324; 530/395; 530/402; 514/2; 514/8; 514/12

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



IN Brierley, Russell A., San Diego, CA, United States  
Davis, Geneva R., San Diego, CA, United States  
Holtz, Gregory C., San Diego, CA, United States

PA The Salk Institute Biotechnology/Industrial Assoc, Inc., La Jolla, CA,  
United States (U.S. corporation)

PI US 5324639 19940628 <--

AI US 1993-23463 19930225 (8)

RLI Continuation of Ser. No. US 1990-578728, filed on 4 Sep 1990, now  
abandoned

DT Utility

FS Granted

LN.CNT 1674

INCL INCLM: 435/069.400  
INCLS: 536/023.500; 536/023.400; 536/023.510; 435/320.100; 435/069.100;  
435/069.700; 435/069.800; 435/069.900; 435/254.230

NCL NCLM: 435/069.400  
NCLS: 435/069.100; 435/069.700; 435/069.800; 435/069.900; 435/254.230;  
435/320.100; 536/023.400; 536/023.500; 536/023.510

IC [5]  
ICM: C12P021-06  
ICS: C12N001-16; C12N015-00

EXF 435/69.4; 435/69.7; 435/69.8; 435/69.9; 435/69.1; 435/320.1; 435/255;  
435/256; 435/172.3; 536/23.4; 536/23.5; 536/23.51

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 457 OF 588 USPATFULL on STN

AN 94:49252 USPATFULL

TI Soluble interleukin-1 receptors

IN Dower, Steven K., Redmond, WA, United States  
March, Carl J., Winslow, WA, United States  
Sims, John, Seattle, WA, United States  
Urdal, David L., Seattle, WA, United States

PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)

PI US 5319071 19940607 <--

AI US 1992-923692 19920731 (7)

RLI Continuation-in-part of Ser. No. US 1990-600244, filed on 22 Oct 1990, now abandoned Ser. No. Ser. No. US 1991-641617, filed on 16 Jan 1991, now abandoned Ser. No. Ser. No. US 1991-737899, filed on 26 Jul 1991, now abandoned And Ser. No. US 1991-739143, filed on 1 Aug 1991, now abandoned , said Ser. No. 600244 which is a continuation of Ser. No. US 1989-310881, filed on 17 Feb 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-160766, filed on 26 Feb 1988, now abandoned And Ser. No. US 1988-160771, filed on 26 Feb 1988, now abandoned , said Ser. No. 641617 which is a continuation of Ser. No. US 1989-347637, filed on 5 May 1989, now abandoned , said Ser. No. 737899 which is a continuation of Ser. No. US 1989-363138, filed on 8 Jun 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-219279, filed on 15 Jul 1988, now abandoned

DT Utility

FS Granted

LN.CNT 2961

INCL INCLM: 435/172.300

INCLS: 435/069.100; 435/070.100; 435/320.100; 536/023.720; 536/024.100;  
800/205.000; 935/025.000; 935/057.000; 935/064.000; 935/067.000

NCL NCLM: 800/288.000

NCLS: 435/069.100; 435/070.100; 435/320.100; 536/023.720; 536/024.100;  
800/301.000; 800/317.300

IC [5]

ICM: C12N015-83

ICS: A01H005-00; C07H021-04

EXF 435/69.1; 435/70.1; 435/172.3; 435/320.1; 536/23.72; 536/24.1; 800/205;  
935/25; 935/57; 935/64; 935/67

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 459 OF 588 USPATFULL on STN

AN 94:39982 USPATFULL

TI Affinity peptides

IN Dobeli, Heinz, Ziefen, Switzerland

DT Utility

FS Granted

LN.CNT 2371

INCL INCLM: 536/023.500

INCLS: 435/069.100; 435/320.100; 435/172.300; 435/240.200

NCL NCLM: 536/023.500

NCLS: 435/069.100; 435/320.100; 435/369.000

IC [5]

ICM: C12N015-12

ICS: C12N005-10; C12N015-85

EXF 435/320.1; 435/69.1; 435/172.3; 536/27

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 461 OF 588 USPATFULL on STN

AN 94:33155 USPATFULL

TI DNA sequences to target proteins to the mammary gland for efficient secretion

IN Rosen, Jeffrey M., Houston, TX, United States

PA GenPharm International, Inc., Mountain View, CA, United States (U.S. corporation)

PI US 5304489 19940419

<--

AI US 1990-602066 19901024 (7)

RLI Continuation of Ser. No. US 1987-14952, filed on 17 Feb 1987, now abandoned

DT Utility

FS Granted

LN.CNT 893

INCL INCLM: 435/320.100

INCLS: 435/172.300; 435/069.100; 800/002.000; 800/DIG.001

NCL NCLM: 435/320.100

NCLS: 435/069.100; 536/023.500

IC [5]

ICM: C12N015-00

ICS: C07H021-00

Jones, Jonathan D. G., Norwich, United Kingdom

PA DNA Plant Technology Corporation, Mt. Kisco, NY, United States (U.S. corporation)

PI US 5290687 19940301 <--

AI US 1992-930970 19920814 (7)

RLI Continuation of Ser. No. US 1990-550253, filed on 9 Jul 1990 which is a continuation-in-part of Ser. No. US 1986-888033, filed on 18 Jul 1986, now patented, Pat. No. US 4940840 which is a continuation-in-part of Ser. No. US 1984-593691, filed on 26 Mar 1984, now patented, Pat. No. US 4751081

DT Utility

FS Granted

LN.CNT 1289

INCL INCLM: 435/069.100

INCLS: 435/070.100; 435/172.300; 800/205.000

NCL NCLM: 435/069.100

NCLS: 435/070.100; 800/279.000; 800/301.000

IC [5]

ICM: C12P021-00

ICS: C12P021-04; C12N015-00; A01H001-04

EXF 435/69.1; 435/70.1; 435/172.3; 800/205

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 464 OF 588 USPATFULL on STN

AN 94:15954 USPATFULL

TI Method for refolding insoluble, misfolded \*\*\*insulin\*\*\* -like growth factor-I into an active conformation

IN Chang, Judy Y., Hillsborough, CA, United States

McFarland, Nancy C., Hillsborough, CA, United States

Swartz, James R., Menlo Park, CA, United States

PA Genentech, Inc., S. San Francisco, CA, United States (U.S. corporation)

PI US 5288931 19940222 <--

AI US 1991-808451 19911206 (7)

DT Utility

EXF 435/69.7; 435/252.3; 435/320.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 466 OF 588 USPATFULL on STN  
AN 94:11500 USPATFULL  
TI Affinity peptides  
IN Dobeli, Heinz, Ziefen, Switzerland  
Eggimann, Bernhard, Basel, Switzerland  
Gentz, Reiner, Rheinfelden, Germany, Federal Republic of  
Hochuli, Erich, Arisdorf, Switzerland  
Stuber, Dietrich, Grenzach-Wyhlen, Germany, Federal Republic of  
PA Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)  
PI US 5284933 19940208 <--  
AI US 1988-158962 19880222 (7)  
PRAI CH 1987-895 19870310  
DT Utility  
FS Granted  
LN.CNT 1400  
INCL INCLM: 530/350.000  
INCLS: 530/324.000; 530/413.000; 530/409.000; 435/069.700  
NCL NCLM: 530/350.000  
NCLS: 435/069.700; 530/324.000; 530/409.000; 530/413.000  
IC [5]  
ICM: C07K013-00  
EXF 530/350; 530/324; 530/413; 530/409; 435/69.7  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 467 OF 588 USPATFULL on STN  
AN 94:9572 USPATFULL  
TI Systemic delivery of polypeptides through the eye  
IN Chiou, George C. Y., College Station, TX, United States  
PA Orbon Corporation, Palo Alto, CA, United States (U.S. corporation)  
PI US 5283236 19940201 <--  
AI US 1992-966706 19921026 (7)

ICS: A61K037-64; A61K047-06

EXF 514/3; 514/12; 514/2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 469 OF 588 USPATFULL on STN

AN 94:3673 USPATFULL

TI Recombinant molecule encoding human protease nexin

IN Baker, Joffre B., Lawrence, KS, United States

Scott, Randy W., San Carlos, CA, United States

PA Incyte Pharmaceuticals, Inc., Redwood City, CA, United States (U.S.  
corporation)

PI US 5278049 19940111 <--

AI US 1987-25450 19870313 (7)

RLI Continuation-in-part of Ser. No. US 1986-871501, filed on 6 Jun 1986,  
now abandoned which is a continuation-in-part of Ser. No. US  
1986-870232, filed on 3 Jun 1986, now abandoned

DT Utility

FS Granted

LN.CNT 924

INCL INCLM: 435/068.100

INCLS: 435/091.400; 435/172.300; 435/212.000; 435/219.000; 435/235.100;  
435/320.100; 435/252.300; 435/240.200; 435/254.210; 536/023.500;  
536/024.310; 530/350.000; 935/018.000; 935/032.000; 935/041.000;  
935/057.000; 935/061.000; 935/070.000; 935/082.000

NCL NCLM: 435/069.200

NCLS: 435/091.400; 435/212.000; 435/219.000; 435/235.100; 435/252.300;  
435/254.210; 435/320.100; 435/358.000; 435/364.000; 435/367.000;  
530/350.000; 536/023.500; 536/024.310

IC [5]

ICM: C12P021-00

ICS: C12P019-34; C12N015-00; C12N009-48; C12N009-50; C12N007-00;

C12N005-00; C12N001-21; C12N001-16; C12N001-18; C07H015-12; C07K003-00

EXF 435/68; 435/70; 435/172.3; 435/212; 435/219; 435/69.1; 435/71.1; 435/91;  
435/252.33; 435/235.1; 435/320.1; 435/240.2; 435/255; 435/256; 536/27;

AI US 1991-708038 19910531 (7)

DT Utility

FS Granted

LN.CNT 2018

INCL INCLM: 435/252.300

INCLS: 435/069.100; 435/070.100; 435/070.300; 435/071.100; 435/172.300;  
435/240.200; 435/320.100; 536/023.500; 935/011.000; 935/027.000;  
935/056.000; 935/066.000

NCL NCLM: 435/252.300

NCLS: 435/069.100; 435/070.100; 435/070.300; 435/071.100; 435/320.100;  
536/023.500

IC [5]

ICM: C12N015-12

ICS: C12N015-63

EXF 536/27; 536/23.5; 435/69.1; 435/70.1; 435/70.3; 435/71.1; 435/172.3;  
435/240.2; 435/252.3; 435/320.1; 935/8; 935/11; 935/12; 935/24; 935/27;  
935/56; 935/66

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 472 OF 588 USPATFULL on STN

AN 93:98309 USPATFULL

TI Protease-deficient bacterial strains for production of proteolytically  
sensitive polypeptides

IN Georgiou, George, Austin, TX, United States

Baneyx, Francois, Thenon, France

PA Board of Regents, The University of Texas System, Austin, TX; United  
States (U.S. corporation)

PI US 5264365 19931123

<--

AI US 1990-612696 19901109 (7)

DT Utility

FS Granted

LN.CNT 903

INCL INCLM: 435/252.800

INCLS: 435/069.100; 435/172.300

L5 ANSWER 474 OF 588 USPATFULL on STN  
AN 93:96021 USPATFULL  
TI Recombinant HTLV-III proteins and uses thereof  
IN Putney, Scott D., Arlington, MA, United States  
Lynn, Debra, Arlington, MA, United States  
Javaherian, Kashayar, Lexington, MA, United States  
Mueller, William T., Watertown, MA, United States  
Farley, John, Rochester, NY, United States  
PA Repligen Corporation, Cambridge, MA, United States (U.S. corporation)  
PI US 5262301 19931116 <--  
AI US 1992-817025 19920103 (7)  
RLI Division of Ser. No. US 1990-588514, filed on 24 Sep 1990, now abandoned  
which is a continuation-in-part of Ser. No. US 1986-892680, filed on 1  
Aug 1986, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1588  
INCL INCLM: 435/005.000  
INCLS: 435/007.100; 422/056.000; 436/504.000; 530/350.000  
NCL NCLM: 435/005.000  
NCLS: 422/056.000; 435/007.100; 436/504.000; 530/350.000  
IC [5]  
ICM: C12Q001-70  
ICS: C12Q001-00; G01N033-567; C07K005-00  
EXF 435/7.1; 435/5; 422/56; 436/504  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 475 OF 588 USPATFULL on STN  
AN 93:93692 USPATFULL  
TI Methods and products for facile microbial expression of DNA sequences  
IN de Boer, Herman A., Pacifica, CA, United States  
Heynerer, Herbert L., Burlingame, CA, United States  
Seeburg, Peter H., San Francisco, CA, United States  
PA Genentech, Inc., South San Francisco, CA, United States (U.S.



FS Granted

LN.CNT 1665

INCL INCLM: 435/069.100

INCLS: 536/023.500; 435/006.000; 435/069.800; 435/240.100; 435/240.200;  
435/252.300; 435/254.110; 435/254.200; 435/320.100

NCL NCLM: 435/069.100

NCLS: 435/006.000; 435/069.800; 435/252.300; 435/254.110; 435/254.200;  
435/320.100; 435/365.000; 435/369.000; 536/023.500

IC [5]

ICM: C12N005-10

ICS: C12N001-15; C12N001-21; C12N015-12

EXF 435/69.1; 435/6; 435/172.3; 435/69.8; 435/320.1; 435/254; 435/255;  
435/256; 435/240.2; 435/240.1; 536/27

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 477 OF 588 USPATFULL on STN

AN 93:87250 USPATFULL

TI Method for expression of bovine \*\*\*growth\*\*\* \*\*\*hormone\*\*\*

IN de Boer, Herman A., Pacifica, CA, United States

Heyneker, Herbert L., Burlingame, CA, United States

Seeburg, Peter H., San Francisco, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S.  
corporation)

PI US 5254463 19931019 <--

AI US 1990-582590 19900912 (7)

RLI Continuation of Ser. No. US 1988-178824, filed on 5 Apr 1988, now  
abandoned which is a continuation of Ser. No. US 1984-632361, filed on  
19 Jul 1984, now abandoned which is a continuation of Ser. No. US  
1981-303687, filed on 18 Sep 1981, now abandoned

DT Utility

FS Granted

LN.CNT 1121

INCL INCLM: 435/069.400

INCLS: 435/252.300; 435/252.330; 435/320.100; 935/045.000

L5 ANSWER 479 OF 588 USPATFULL on STN  
 AN 93:80680 USPATFULL  
 TI DNA encoding inactive precursor and active forms of maize ribosome  
 inactivating protein  
 IN Walsh, Terence A., Midland, MI, United States  
 Hey, Timothy D., Midland, MI, United States  
 Morgan, Alice E. R., Midland, MI, United States  
 PA DowElanco, Indianapolis, IN, United States (U.S. corporation)  
 PI US 5248606 19930928 <--  
 AI US 1990-535636 19900611 (7)  
 DT Utility  
 FS Granted  
 LN.CNT 1260  
 INCL INCLM: 435/240.400  
 INCLS: 536/023.600; 435/320.100; 435/240.200; 435/252.300; 435/254.210;  
 530/376.000; 935/010.000; 935/011.000; 935/067.000  
 NCL NCLM: 435/412.000  
 NCLS: 435/252.300; 435/254.210; 435/320.100; 530/376.000; 536/023.600  
 IC [5]  
 ICM: C12N005-10  
 ICS: C12N015-29; C12N015-63; C12N001-21  
 EXF 536/27; 536/23.6; 435/320.1; 435/252.3; 435/240.2; 435/240.4; 435/255;  
 934/9; 934/11; 934/60; 934/67; 934/10; 530/376  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 480 OF 588 USPATFULL on STN  
 AN 93:74193 USPATFULL  
 TI Production of human somatomedin C  
 IN Buell, Gary N., Geneva, Switzerland  
 Movva, Nageswararao, Geneva, Switzerland  
 PA Biogen, Inc., Cambridge, MA, United States (U.S. corporation)  
 PI US 5242811 19930907 <--  
 AI US 1992-965047 19921021 (7)

INCL INCLM: 435/069.100  
INCLS: 435/069.400; 435/071.200; 435/172.300; 435/252.300; 435/252.330;  
435/252.340  
NCL NCLM: 435/069.100  
NCLS: 435/069.400; 435/071.200; 435/252.300; 435/252.330; 435/252.340  
IC [5]  
ICM: C12P021-00  
ICS: C12N015-18; C12N015-67; C12N001-21  
EXF 435/69.1; 435/69.4; 435/252.3; 435/252.34; 435/252.33; 435/172.1;  
435/172.3; 435/71.2; 935/45  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 482 OF 588 USPATFULL on STN  
AN 93:59044 USPATFULL  
TI Catalytic antibody components  
IN Paul, Sudhir, Omaha, NE, United States  
Powell, Michael J., Gaithersburg, MD, United States  
Massey, Richard J., Rockville, MD, United States  
Kenten, John H., Gaithersburg, MD, United States  
PA Igen, Inc., Rockville, MD, United States (U.S. corporation)  
PI US 5229272 19930720 <--  
AI US 1990-498225 19900323 (7)  
RLI Continuation-in-part of Ser. No. US 1989-343081, filed on 25 Apr 1989  
DT Utility  
FS Granted  
LN.CNT 2439  
INCL INCLM: 435/068.100  
INCLS: 435/188.500; 435/219.000; 435/226.000; 530/389.200; 530/387.100;  
530/388.240  
NCL NCLM: 435/068.100  
NCLS: 435/188.500; 435/219.000; 435/226.000; 530/387.100; 530/388.240;  
530/389.200  
IC [5]  
ICM: C12N009-00

AI US 1988-277963 19881130 (7)  
RLI Continuation-in-part of Ser. No. US 1987-34203, filed on 2 Apr 1987, now  
abandoned  
DT Utility  
FS Granted  
LN.CNT 765  
INCL INCLM: 435/240.200  
INCLS: 435/252.300; 435/252.330; 435/255.000; 435/256.000; 435/320.100;  
536/023.200  
NCL NCLM: 435/358.000  
NCLS: 435/252.300; 435/252.330; 435/320.100; 536/023.200  
IC [5]  
ICM: C12N005-10  
ICS: C12N001-21; C12N001-19; C12N015-12  
EXF 435/252.3; 435/69.1; 435/172.3; 435/320.1; 435/183; 536/27  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
  
L5 ANSWER 485 OF 588 USPATFULL on STN  
AN 93:52487 USPATFULL  
TI Directed evolution of novel binding proteins  
IN Ladner, Robert C., Ijamsville, MD, United States  
Guterman, Sonia K., Belmont, MA, United States  
Roberts, Bruce L., Milford, MA, United States  
Markland, William, Milford, MA, United States  
Ley, Arthur C., Newton, MA, United States  
Kent, Rachel B., Boxborough, MA, United States  
PA Protein Engineering Corp., Cambridge, MA, United States (U.S.  
corporation)  
PI US 5223409 19930629 <--  
AI US 1991-664989 19910301 (7)  
RLI Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,  
now abandoned And a continuation-in-part of Ser. No. US 1988-240160,  
filed on 2 Sep 1988, now abandoned  
DT Utility

NCLS: 435/235.100; 435/320.100; 435/348.000; 435/349.000; 435/352.000;  
435/357.000; 435/362.000; 435/367.000; 536/023.720; 536/024.100

IC [5]

ICM: C12P021-00

ICS: C12N007-01; C12N015-86; C12N005-10

EXF 435/235.1; 435/320.1; 435/240.2; 435/172.3; 435/69.1; 435/69.2; 435/91;  
935/32; 935/36; 935/57; 935/70; 536/27

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 487 OF 588 USPATFULL on STN

AN 93:39900 USPATFULL

TI Genetic material encoding new \*\*\*insulin\*\*\* -like growth factor  
binding protein IGFBP-6

IN Kiefer, Michael C., Clayton, CA, United States  
Masiarz, Frank R., San Francisco, CA, United States

PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

PI US 5212074 19930518 <--

AI US 1990-576629 19900831 (7)

RLI Division of Ser. No. US 1990-574613, filed on 28 Aug 1990, now abandoned

DT Utility

FS Granted

LN.CNT 1731

INCL INCLM: 435/069.600

INCLS: 435/069.100; 435/252.300; 435/240.100; 435/243.000; 435/254.000;  
536/023.500; 935/009.000; 935/011.000; 935/066.000; 530/395.000

NCL NCLM: 435/069.600

NCLS: 435/069.100; 435/243.000; 435/252.300; 435/361.000; 530/395.000;  
536/023.500

IC [5]

ICM: C12P021-02

ICS: C07H021-04; C12N001-00

EXF 514/44; 530/303; 530/399; 435/69.1; 435/70.1; 435/71.1; 435/252.3;  
435/252.33; 435/255; 435/240.2; 435/69.5; 435/240.1; 435/240.2;  
435/240.4; 435/254; 435/255; 435/243; 435/69.6; 935/13; 935/9; 800/2;

EXF 424/422; 424/423; 424/427; 424/428; 424/449; 424/450; 435/829; 264/4.1;  
264/4.33; 264/4.6

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 489 OF 588 USPATFULL on STN

AN 93:22794 USPATFULL

TI Molecular recognition units

IN Rodwell, John D., Yardley, PA, United States

McKearn, Thomas J., New Hope, PA, United States

Alvarez, Vernon L., Morrisville, PA, United States

Radcliffe, Robert D., Titusville, NJ, United States

PA Cytogen Corporation, Princeton, NJ, United States (U.S. corporation)

PI US 5196510 19930323 <--

AI US 1990-519702 19900507 (7)

RLI Continuation-in-part of Ser. No. US 1988-291730, filed on 29 Dec 1988,  
now abandoned

DT Utility

FS Granted

LN.CNT 1684

INCL INCLM: 530/324.000

INCLS: 530/326.000; 424/001.100; 424/002.000; 436/545.000; 436/546.000

NCL NCLM: 530/324.000

NCLS: 436/545.000; 436/546.000; 530/326.000

IC [5]

ICM: C07K007-08

ICS: C07K007-10; A61K043-00; G01N033-533

EXF 436/513; 436/545; 436/546; 530/324; 530/326; 424/2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 490 OF 588 USPATFULL on STN

AN 93:18576 USPATFULL

TI Method to produce recombinant proteins using an expression vector  
comprising transcriptional and translational activating sequences

IN Schoner, Brigitte E., Monrovia, IN, United States

INCL INCLM: 435/212.000  
INCLS: 435/218.000  
NCL NCLM: 435/212.000  
NCLS: 435/218.000  
IC [5]  
ICM: C12N009-48  
ICS: C12N009-66  
EXF 435/218; 435/212; 435/184; 435/69.2; 530/350  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 492 OF 588 USPATFULL on STN  
AN 93:7090 USPATFULL  
TI Systemic delivery of polypeptides through the eye  
IN Chiou, George C. Y., College Station, TX, United States  
PA Orbon Corporation, Palo Alto, CA, United States (U.S. corporation)  
PI US 5182258 19930126 <--  
AI US 1989-412979 19890926 (7)  
RLI Continuation-in-part of Ser. No. US 1989-326200, filed on 20 Mar 1989,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 1226  
INCL INCLM: 514/003.000  
NCL NCLM: 514/003.000  
IC [5]  
ICM: A61K037-26  
ICS: A61K037-64; A61K047-00  
EXF 514/3; 514/954  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 493 OF 588 USPATFULL on STN  
AN 93:3675 USPATFULL  
TI Human relaxin polypeptides  
IN Hudson, Peter J., Victoria, Australia

DT Utility

FS Granted

LN.CNT 1464

INCL INCLM: 530/391.300

INCLS: 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000;  
530/329.000; 530/330.000; 530/377.000; 530/391.100; 530/391.500;  
530/391.700; 530/391.900; 530/306.000; 530/307.000; 530/308.000;  
530/313.000; 530/323.000; 530/351.000; 530/395.000; 530/399.000;  
530/403.000; 530/408.000; 530/409.000; 530/410.000; 424/001.100;  
424/009.000; 424/085.910; 435/188.000; 514/002.000; 514/008.000;  
514/012.000; 514/021.000; 514/013.000; 514/014.000; 514/015.000;  
514/016.000; 514/017.000; 514/018.000

NCL NCLM: 530/391.300

NCLS: 424/001.410; 424/001.450; 424/001.530; 424/001.690; 424/009.100;  
424/180.100; 530/306.000; 530/307.000; 530/308.000; 530/313.000;  
530/323.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000;  
530/328.000; 530/329.000; 530/330.000; 530/351.000; 530/377.000;  
530/391.100; 530/391.500; 530/391.700; 530/391.900; 530/395.000;  
530/399.000; 530/403.000; 530/408.000; 530/409.000; 530/410.000

IC [5]

ICM: C07K017-02

ICS: C07K007-06; C07K007-08; C07K007-10; C07K007-34; C07K007-36;  
C07K007-38; A61K049-02

EXF 424/1.1; 424/9; 424/85.91; 530/395; 530/324; 530/325; 530/326; 530/327;  
530/328; 530/329; 530/330; 530/377; 530/399; 530/403; 530/408; 530/409;  
435/188

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 495 OF 588 USPATFULL on STN

AN 92:100920 USPATFULL

TI Multitrophic and multifunctional chimeric neurotrophic factors, and  
nucleic acids and plasmids encoding the chimeras

IN Shooter, Eric M., Portola Valley, CA, United States  
Suter, Ulrich, Menlo Park, CA, United States



LN.CNT 1122

INCL INCLM: 435/069.100

INCLS: 435/069.700; 435/069.800; 435/172.300; 435/240.100; 435/240.200;  
435/240.400; 435/252.300; 435/252.330; 435/252.350; 435/255.000;  
435/256.000; 435/320.100; 536/027.000; 935/010.000; 935/011.000

NCL NCLM: 435/069.100

NCLS: 435/069.700; 435/069.800; 435/252.300; 435/252.330; 435/252.350;  
435/254.110; 435/254.200; 435/320.100; 435/366.000

IC [5]

ICM: C12N015-00

ICS: C12N015-03; C12N015-04; C12N015-05; C12N015-06; C12N015-11;  
C12N015-31; C12N015-70; C12P021-00; C12P021-02

EXF 435/68; 435/70; 435/71; 435/91; 435/172.1; 435/172.3; 435/252.3;  
435/252.31-252.35; 435/255; 435/256; 435/320; 435/69.1; 435/71.2;  
435/320.1; 514/2; 536/27; 935/10; 935/11; 935/22; 935/29; 935/33;  
935/38; 935/39; 935/47; 935/48; 935/66-75

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 497 OF 588 USPATFULL on STN

AN 92:84971 USPATFULL

TI Basic fibroblast growth factor

IN Baird, Andrew J., San Diego, CA, United States

Esch, Frederick S., Foster City, CA, United States

Gospodarowicz, Denis, San Francisco, CA, United States

Bohlen, Peter, Cortland, NY, United States

Ling, Nicholas C., San Diego, CA, United States

PA The Salk Institute for Biological Studies, San Diego, CA, United States  
(U.S. corporation)

PI US 5155214 19921013 <--

AI US 1990-462126 19900108 (7)

RLI Division of Ser. No. US 1987-139953, filed on 31 Dec 1987 which is a  
continuation-in-part of Ser. No. US 1986-940524, filed on 10 Dec 1986,  
now patented, Pat. No. US 4785079 which is a continuation-in-part of  
Ser. No. US 1985-747154, filed on 20 Jun 1985, now patented, Pat. No. US

ICM: C12N015-62

EXF 435/68; 435/70; 435/235; 435/320; 435/243; 435/253; 435/272; 435/240.27;  
435/240.2; 435/240.1; 435/69.1; 435/69.7; 435/172.3; 530/356; 530/387

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 499 OF 588 USPATFULL on STN

AN 92:74541 USPATFULL

TI Polyhedrin gene and genetic engineering thereof

IN Yamada, Nobutoshi, Kusatsu, Japan

Matsuo, Norifusa, Kusatsu, Japan

Araki, Takaaki, Kusatsu, Japan

PA Research Association for Biotechnology of Agricultural Chemicals, Tokyo,  
Japan (non-U.S. corporation)

PI US 5145775 19920908 <--

AI US 1990-483823 19900223 (7)

PRAI JP 1989-46736 19890228

DT Utility

FS Granted

LN.CNT 815

INCL INCLM: 435/069.100

INCLS: 435/412.300; 435/320.700; 435/240.100; 537/027.000

NCL NCLM: 435/069.100

NCLS: 435/235.100; 435/320.100; 435/348.000; 435/456.000; 435/463.000;  
435/465.000; 536/023.400; 536/023.720

IC [5]

ICM: C12P021-02

ICS: C12N015-34; C12N015-86; C12N015-00

EXF 536/27; 435/320.1; 435/172.3; 435/69.1; 435/240.2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 500 OF 588 USPATFULL on STN

AN 92:72398 USPATFULL

TI Construction of an IgG binding protein to facilitate downstream  
processing using protein engineering

NCL NCLM: 530/350.000

IN Anderson, David C., Seattle, WA, United States  
Morgan, Jr., A. C., Edmonds, WA, United States  
Abrams, Paul G., Seattle, WA, United States  
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)  
PI US 5135736 19920804 <--  
AI US 1988-232337 19880815 (7)  
DT Utility  
FS Granted  
LN.CNT 1134  
INCL INCLM: 424/001.100  
INCLS: 424/009.000; 424/085.910; 424/094.300; 514/008.000; 514/012.000;  
514/021.000; 530/395.000; 530/391.700; 530/389.700; 530/288.150;  
530/388.800; 530/387.100; 530/391.300; 435/188.000  
NCL NCLM: 424/001.490  
NCLS: 424/094.300; 424/182.100; 435/188.000; 514/008.000; 514/012.000;  
514/021.000; 530/387.100; 530/388.150; 530/388.800; 530/389.700;  
530/391.300; 530/391.700; 530/395.000; 530/409.000  
IC [5]  
ICM: A61K039-44  
ICS: A61K049-02; A61K049-04  
EXF 530/390; 530/391; 530/388; 530/395; 424/1.1; 424/9; 424/85.91; 424/94.3;  
514/12; 514/21; 514/8; 435/188  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L5 ANSWER 505 OF 588 USPATFULL on STN  
AN 92:57665 USPATFULL  
TI Method for enhancing growth of mammary parenchyma  
IN Collier, Robert J., University City, MO, United States  
McGrath, Michael F., Chesterfield, MO, United States  
PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)  
PI US 5130300 19920714 <--  
AI US 1990-493256 19900314 (7)  
RLI Continuation-in-part of Ser. No. US 1987-92009, filed on 2 Sep 1987, now  
patented, Pat. No. US 5059586 which is a continuation-in-part of Ser.

NCL NCLM: 530/395.000  
NCLS: 530/350.000; 530/380.000; 530/387.200; 530/387.900; 530/389.100  
IC [5]  
ICM: C07K003-00  
ICS: A61K035-14  
EXF 435/6; 536/27; 530/395; 530/386; 530/387  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 507 OF 588 USPATFULL on STN  
AN 92:40826 USPATFULL  
TI Variant proteins and polypeptides possessing enhanced affinity for  
immobilized-metal affinity matrices  
IN Haymore, Barry L., Creve Coeur, MO, United States  
Bild, Gary S., Chesterfield, MO, United States  
Krivi, Gwen G., St. Louis, MO, United States  
PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)  
PI US 5115102 19920519 <--  
AI US 1989-383778 19890721 (7)  
DT Utility  
FS Granted

LN.CNT 1176

INCL INCLM: 530/399.000  
INCLS: 530/350.000; 530/413.000; 435/069.100  
NCL NCLM: 530/399.000  
NCLS: 435/069.100; 530/350.000; 530/413.000  
IC [5]  
ICM: C07K003-18  
ICS: C07K015-00; C12N015-09  
EXF 530/350; 530/399; 530/413; 435/68; 435/69.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 508 OF 588 USPATFULL on STN  
AN 92:36291 USPATFULL  
TI Derivatives of soluble T-4

DT Utility

FS Granted

LN.CNT 2214

INCL INCLM: 435/224.000

INCLS: 435/172.300; 435/240.200; 435/252.330; 435/252.300; 435/255.000;  
435/320.100; 536/027.000

NCL NCLM: 435/224.000

NCLS: 435/252.300; 435/252.330; 435/254.200; 435/254.210; 435/320.100;  
435/365.000; 536/023.200; 536/023.600

IC [5]

ICM: C12N009-60

ICS: C12N015-00; C07H015-12

EXF 435/91; 435/195; 435/224; 435/240.1; 435/252.3; 435/252.33; 435/255;  
435/320; 536/27

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 510 OF 588 USPATFULL on STN

AN 92:29613 USPATFULL

TI High titer production of human somatomedin C

IN Keith, Paula M., Terre Haute, IN, United States

Cain, Wendy, Terre Haute, IN, United States

PA International Minerals & Chemical Corp., Northbrook, IL, United States  
(U.S. corporation)

PI US 5104796 19920414 <--

AI US 1987-34847 19870406 (7)

DT Utility

FS Granted

LN.CNT 596

INCL INCLM: 435/069.400

INCLS: 435/069.100; 435/320.100; 435/172.300; 435/252.330; 435/071.200;  
536/027.000; 530/399.000; 935/033.000; 935/038.000; 935/039.000;  
935/044.000; 935/061.000; 935/043.000; 935/073.000

NCL NCLM: 435/069.400

NCLS: 435/069.100; 435/071.200; 435/252.330; 435/320.100; 530/399.000

L5 ANSWER 512 OF 588 USPATFULL on STN  
AN 92:10613 USPATFULL  
TI Purified protease nexin  
IN Scott, Randy W., Sunnyvale, CA, United States  
Baker, Joffre B., El Granada, CA, United States  
PA Incyte Pharmaceuticals, Palo Alto, CA, United States (U.S. corporation)  
University of Kansas, Lawrence, KS, United States (U.S. corporation)  
PI US 5087368 19920211 <--  
AI US 1990-577887 19900905 (7)  
RLI Continuation of Ser. No. US 1989-378434, filed on 10 Jul 1989, now  
patented, Pat. No. US 5006252 which is a continuation of Ser. No. US  
1986-871501, filed on 6 Jun 1986, now abandoned which is a  
continuation-in-part of Ser. No. US 1986-870232, filed on 3 Jun 1986,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 626  
INCL INCLM: 210/635.000  
INCLS: 210/656.000; 530/413.000; 530/417.000  
NCL NCLM: 210/635.000  
NCLS: 210/656.000; 530/413.000; 530/417.000  
IC [5]  
ICM: B01D015-08  
EXF 210/635; 210/656; 210/659; 210/198.2; 210/502.1; 530/413; 530/417  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 513 OF 588 USPATFULL on STN  
AN 92:7274 USPATFULL  
TI Secretion of \*\*\*insulin\*\*\* -like growth factor-I  
IN Wong, Edith, Chesterfield, MO, United States  
Bittner, Michael L., Naperville, IL, United States  
PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)  
PI US 5084384 19920128 <--

INCLS: 435/061.400; 435/069.500; 435/069.800; 435/069.900; 435/212.000;  
435/219.000; 435/069.300; 536/027.000; 935/048.000; 935/037.000;  
935/047.000

NCL NCLM: 435/069.100

NCLS: 435/069.300; 435/069.400; 435/069.500; 435/069.800; 435/069.900;  
435/212.000; 435/219.000; 435/320.100; 536/024.100

IC [5]

ICM: C07H015-12

ICS: C12P021-00; C12N001-16

EXF 435/69.1; 435/69.2; 435/69.3; 435/69.4; 435/69.5; 435/69.9; 435/69.6;  
435/69.8; 435/172.3; 435/255; 435/212; 435/256; 435/219; 435/254;  
435/320; 435/252.3; 435/252.33; 935/47; 935/48; 935/37; 536/27

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 515 OF 588 USPATFULL on STN

AN 92:3765 USPATFULL

TI Interleukin-1 receptors

IN Dower, Steven K., Redmond, WA, United States

March, Carl J., Seattle, WA, United States

Sims, John E., Seattle, WA, United States

Urdal, David L., Seattle, WA, United States

PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)

PI US 5081228 19920114 <--

AI US 1988-258756 19881013 (7)

RLI Continuation-in-part of Ser. No. US 1988-160550, filed on 25 Feb 1988,  
now patented, Pat. No. US 4968607 which is a continuation-in-part of  
Ser. No. US 1987-125627, filed on 25 Nov 1987, now abandoned

DT Utility

FS Granted

LN.CNT 1540

INCL INCLM: 530/035.100

INCLS: 530/350.000; 530/395.000; 530/820.000; 435/069.500; 435/069.100;  
424/085.100; 424/085.200; 514/002.000; 514/008.000

NCL NCLM: 530/351.000



CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 517 OF 588 USPATFULL on STN  
AN 91:100166 USPATFULL  
TI Rotavirus nucleocapsid protein VP6 as a carrier in vaccine compositions  
IN Sabara, Marta I., Saskatoon, Canada  
Frenchick, Patrick J., Saskatoon, Canada  
Mullin-Ready, Kerry F., Saskatoon, Canada  
PA University of Saskatchewan, Saskatoon, Canada (non-U.S. corporation)  
PI US 5071651 19911210 <--  
AI US 1990-489790 19900305 (7)  
RLI Continuation of Ser. No. US 1987-92120, filed on 2 Sep 1987, now  
abandoned which is a continuation-in-part of Ser. No. US 1986-903222,  
filed on 3 Sep 1986, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1399  
INCL INCLM: 424/089.000  
INCLS: 514/008.000; 530/403.000; 530/402.000; 530/816.000; 530/807.000;  
530/324.000  
NCL NCLM: 424/186.100  
NCLS: 424/196.110; 424/215.100; 514/008.000; 530/324.000; 530/402.000;  
530/403.000; 530/807.000; 530/816.000  
IC [5]  
ICM: A61K039-385  
ICS: C07K017-00  
EXF 424/89; 530/403; 530/402; 530/816; 530/807; 530/324; 514/8  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 518 OF 588 USPATFULL on STN  
AN 91:90692 USPATFULL  
TI Recombinant DNA expression vector comprising both transcriptional and  
translational activating sequences  
IN Schoner, Brigitte E., Monrovia, IN, United States

DT Utility

FS Granted

LN.CNT 2119

INCL INCLM: 435/069.100

INCLS: 435/172.300; 435/240.200; 435/252.330; 435/317.100; 536/027.000;  
935/070.000; 935/073.000; 935/011.000

NCL NCLM: 435/069.100

NCLS: 435/252.330; 435/317.100; 435/360.000; 435/369.000; 435/461.000;  
435/464.000; 435/488.000; 536/023.510

IC [5]

ICM: C12P021-00

ICS: C12N015-00; C12N005-00; C07H021-00

EXF 536/27; 435/320; 435/240.2; 435/68; 435/172.3; 435/317.1; 435/252.33;  
435/69.1; 935/70; 935/73; 935/11

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 520 OF 588 USPATFULL on STN

AN 91:75533 USPATFULL

TI N-.omega., (.omega.-1)-dialkyloxy)- and N-(.omega., (.omega.-1)-  
dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses  
therefor

IN Eppstein, Deborah A., Menlo Park, CA, United States

Felgner, Philip L., Los Altos, CA, United States

Gadek, Thomas R., Oakland, CA, United States

Jones, Gordon H., Cupertino, CA, United States

Roman, Richard B., Fairhope, AL, United States

PA Syntex (U.S.A.) Inc., Palo Alto, CA, United States (U.S. corporation)

PI US 5049386 19910917 <--

AI US 1990-524257 19900515 (7)

RLI Division of Ser. No. US 1989-428815, filed on 27 Oct 1989, now patented,  
Pat. No. US 4946787 which is a division of Ser. No. US 1987-114809,  
filed on 29 Oct 1987, now patented, Pat. No. US 4897355 which is a  
continuation-in-part of Ser. No. US 1986-877916, filed on 24 Jun 1986,  
now abandoned which is a continuation-in-part of Ser. No. US

AN 91:62706 USPATFULL  
TI BAR1 secretion signal  
IN Welch, Susan K., Los Altos Hills, CA, United States  
MacKay, Vivian L., Seattle, WA, United States  
Yip, Carli L., Bellevue, WA, United States  
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 5037743 19910806 <--  
AI US 1988-270933 19881114 (7)  
RLI Continuation-in-part of Ser. No. US 1988-229074, filed on 5 Aug 1988,  
now abandoned which is a continuation-in-part of Ser. No. US  
1987-104316, filed on 2 Oct 1987, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1692  
INCL INCLM: 435/069.100  
INCLS: 435/240.200; 435/255.000; 435/172.300; 435/320.100; 536/027.000;  
935/048.000; 935/060.000; 935/069.000; 935/070.000  
NCL NCLM: 435/069.100  
NCLS: 435/254.200; 435/320.100; 435/325.000; 536/023.200; 536/023.700;  
536/024.100  
IC [5]  
ICM: C12N001-16  
ICS: C12N005-06; C12N015-11; C12N015-79  
EXF 435/68; 435/69.1; 935/320; 935/32; 935/48; 935/57; 935/70; 935/71;  
935/28; 536/27; 536/240.2; 536/255; 536/172.3  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 523 OF 588 USPATFULL on STN  
AN 91:58865 USPATFULL  
TI Chimeric genes suitable for expression in plant cells  
IN Rogers, Stephen G., Webster Groves, MO, United States  
Fraley, Robert T., Glendale, MO, United States  
PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)  
PI US 5034322 19910723 <--

INCL INCLM: 435/069.100  
INCLS: 435/172.300  
NCL NCLM: 435/069.100  
NCLS: 435/461.000; 435/466.000  
IC [5]  
ICM: C12N015-67  
EXF 435/68; 435/172.3; 435/235; 435/320; 435/69.1; 935/32; 935/34; 935/27;  
935/56

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 525 OF 588 USPATFULL on STN  
AN 91:46779 USPATFULL  
TI Molecular cloning and characterization of a further gene sequence coding  
for human relaxin  
IN Hudson, Peter J., Bulleen, Australia  
Niall, High D., Elwood, Australia  
Tregear, Geoffrey W., Hawthorn, Australia  
PA Howard Florey Institute of Experimental Physiology & Medicine, Victoria,  
Australia (non-U.S. corporation)  
PI US 5023321 19910611 <--  
AI US 1987-21885 19870304 (7)  
RLI Division of Ser. No. US 1983-560790, filed on 13 Dec 1983, now patented,  
Pat. No. US 4758516  
PRAI AU 1982-7247 19821213  
DT Utility  
FS Granted  
LN.CNT 963  
INCL INCLM: 530/324.000  
INCLS: 530/303.000; 530/851.000; 530/853.000; 514/012.000  
NCL NCLM: 530/324.000  
NCLS: 530/303.000; 530/851.000; 530/853.000  
IC [5]  
ICM: C07K007-10  
EXF 530/324; 530/851; 530/853

TI Composite yeast vectors  
IN Strausberg, Robert L., Silver Spring, MD, United States  
Strausberg, Susan L., Silver Spring, MD, United States  
PA Genex Corporation, Gaithersburg, MD, United States (U.S. corporation)  
PI US 5013652 19910507 <--  
AI US 1986-918147 19861014 (6)  
DT Utility  
FS Granted  
LN.CNT 1521  
INCL INCLM: 435/069.200  
INCLS: 435/069.100; 435/172.300; 435/254.000; 435/255.000; 435/256.000;  
435/320.100; 935/037.000; 935/056.000; 935/069.000; 935/011.000;  
935/028.000; 536/027.000  
NCL NCLM: 435/069.200  
NCLS: 435/069.100; 435/254.210; 435/320.100; 435/483.000; 536/024.100  
IC [5]  
ICM: C12P021-00  
ICS: C12P021-02; C12N015-00  
EXF 935/28; 935/29; 935/37; 935/41; 935/42; 935/48; 935/56; 935/69; 435/68;  
435/942; 435/317.1; 435/320; 435/172.3; 536/27

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 528 OF 588 USPATFULL on STN  
AN 91:34207 USPATFULL  
TI Thrombus specific conjugates  
IN Pang, Roy H. L., Medway, MA, United States  
PA Creative Biomolecules, Inc., Hopkinton, MA, United States (U.S. corporation)  
PI US 5011686 19910430 <--  
AI US 1989-437769 19891115 (7)  
RLI Continuation of Ser. No. US 1987-99242, filed on 21 Sep 1987, now abandoned  
DT Utility  
FS Granted

NCL NCLM: 435/069.900  
NCLS: 435/069.100; 435/069.500; 435/069.510; 435/069.800; 435/254.210;  
435/320.100; 435/483.000; 536/023.200; 536/023.520; 536/024.100  
IC [5]  
ICM: C12P021-00  
ICS: C12P021-02; C12N015-00  
EXF 435/69.1; 435/69.5; 435/69.51; 435/172.3; 435/255; 435/256; 435/320;  
536/27; 935/37; 935/47; 935/48  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 530 OF 588 USPATFULL on STN  
AN 91:28320 USPATFULL  
TI Purified protease nexin  
IN Scott, Randy W., Sunnyvale, CA, United States  
Baker, Joffre B., El Granada, CA, United States  
PA Invitron, St. Louis, MO, United States (U.S. corporation)  
University of Kansas, Lawrence, KS, United States (U.S. corporation)  
PI US 5006252 19910409 <--  
AI US 1989-378434 19890710 (7)  
RLI Continuation of Ser. No. US 1986-871501, filed on 6 Jun 1986, now  
abandoned which is a continuation-in-part of Ser. No. US 1986-870232,  
filed on 3 Jun 1986, now abandoned  
DT Utility  
FS Granted  
LN.CNT 624  
INCL INCLM: 210/635.000  
INCLS: 210/656.000; 530/413.000; 530/417.000  
NCL NCLM: 210/635.000  
NCLS: 210/656.000; 530/413.000; 530/417.000  
IC [5]  
ICM: B01D015-08  
EXF 210/635; 210/636; 210/659; 210/198.2; 210/502.1; 530/413; 530/417  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AI US 1989-391709 19890810 (7)  
RLI Continuation of Ser. No. US 1986-939043, filed on 1 Dec 1986, now  
abandoned  
PRAI GB 1985-8340 19850329  
DT Utility  
FS Granted  
LN.CNT 486  
INCL INCLM: 530/412.000  
INCLS: 530/413.000; 530/415.000; 530/416.000; 530/417.000; 530/820.000;  
530/408.000; 530/409.000; 530/410.000; 435/069.100; 435/069.700  
NCL NCLM: 530/412.000  
NCLS: 435/069.100; 435/069.700; 530/408.000; 530/409.000; 530/410.000;  
530/413.000; 530/415.000; 530/416.000; 530/417.000; 530/820.000  
IC [5]  
ICM: C07K003-20  
EXF 530/412-413; 530/415; 530/416; 530/417; 530/820; 530/408-410; 435/69.1;  
435/69.7  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L5 ANSWER 533 OF 588 USPATFULL on STN  
AN 90:95022 USPATFULL  
TI Vector comprising signal peptide-encoding DNA for use in Bacillus and  
other microorganisms  
IN Kovacevic, Steven, Indianapolis, IN, United States  
Miller, James R., Indianapolis, IN, United States  
Veal, Loraine E., Phoenix, AZ, United States  
Wood, John S., Indianapolis, IN, United States  
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)  
PI US 4977089 19901211 <--  
AI US 1987-10245 19870130 (7)  
DT Utility  
FS Granted  
LN.CNT 1176

EXF 536/27; 435/68; 435/172.3; 435/235; 435/320; 435/240.1; 435/69.1;  
435/252.8; 435/255; 530/387; 530/399

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 535 OF 588 USPATFULL on STN

AN 90:76644 USPATFULL

TI Modified antibiotic resistance gene

IN Ingolia, Thomas D., Indianapolis, IN, United States

Kaster, Kevin R., Indianapolis, IN, United States

Rao, R. Nagaraja, Indianapolis, IN, United States

PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)

PI US 4960704 19901002 <--

AI US 1988-205011 19880531 (7)

RLI Continuation of Ser. No. US 1983-535508, filed on 26 Sep 1983, now  
abandoned which is a continuation-in-part of Ser. No. US 1983-533189,  
filed on 19 Sep 1983, now abandoned which is a continuation-in-part of  
Ser. No. US 1983-516222, filed on 22 Jul 1983, now abandoned

DT Utility

FS Granted

LN.CNT 1432

INCL INCLM: 435/252.330

INCLS: 435/172.300; 435/194.000; 435/320.000; 536/027.000; 935/014.000;  
935/029.000; 935/069.000; 935/073.000

NCL NCLM: 435/252.330

NCLS: 435/194.000; 435/254.210; 435/320.100; 536/023.200; 536/024.100

IC [5]

ICM: C12N001-20

ICS: C12N015-00; C12N009-12; C07H015-12

EXF 435/68; 435/172.3; 435/194; 435/320; 435/252.33; 536/27; 935/9; 935/14;  
935/22; 935/27; 935/29; 935/47; 935/73; 935/69

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 536 OF 588 USPATFULL on STN



PA Gist-brocades NV, Delft, Netherlands (non-U.S. corporation)  
PI US 4943529 19900724 <--  
AI US 1987-78539 19870728 (7)  
RLI Continuation-in-part of Ser. No. US 1984-572414, filed on 19 Jan 1984,  
now patented, Pat. No. US 4859596  
DT Utility  
FS Granted  
LN.CNT 1715  
INCL INCLM: 435/172.300  
INCLS: 435/255.000; 435/256.000; 435/320.000; 435/091.000; 935/028.000;  
935/037.000; 935/056.000  
NCL NCLM: 435/006.000  
NCLS: 435/254.200; 435/320.100; 435/483.000  
IC [5]  
ICM: C12N015-00  
ICS: C12N001-20; C12N005-00  
EXF 435/68; 435/20; 435/172.3; 435/226; 435/255; 435/64; 435/91; 435/240.1;  
435/317; 435/253; 435/320; 435/317.1; 435/320; 935/28; 935/37; 935/56;  
536/27

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 538 OF 588 USPATFULL on STN  
AN 90:7749 USPATFULL  
TI Consensus human leukocyte interferon  
IN Stabinsky, Yitzhak, Boulder, CO, United States  
PA Amgen, Thousand Oaks, CA, United States (U.S. corporation)  
PI US 4897471 19900130 <--  
AI US 1987-99096 19870921 (7)  
RLI Continuation of Ser. No. US 1983-560495, filed on 12 Dec 1983, now  
patented, Pat. No. US 4695623 which is a division of Ser. No. US  
1983-483451, filed on 15 Apr 1983 which is a continuation-in-part of  
Ser. No. US 1982-375494, filed on 6 May 1982, now abandoned  
DT Utility  
FS Granted

EXF 435/240.2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 540 OF 588 USPATFULL on STN

AN 89:100553 USPATFULL

TI Hybrid proteins produced by an ultrahigh prokaryotic expression

IN Palmer, John L., Arlington, MA, United States

Anilionis, Algis, Arlington, MA, United States

PA Repligen Corporation, Cambridge, MA, United States (U.S. corporation)

PI US 4888280 19891219 <--

AI US 1986-899699 19860825 (6)

RLI Division of Ser. No. US 1984-686342, filed on 26 Dec 1984, now patented,  
Pat. No. US 4691009

DT Utility

FS Granted

LN.CNT 969

INCL INCLM: 435/069.700

INCLS: 435/172.300; 435/320.000; 435/252.330; 435/069.400; 435/069.510;  
435/069.520; 935/047.000

NCL NCLM: 435/069.700

NCLS: 435/069.400; 435/069.510; 435/069.520; 435/252.330; 435/320.100;  
536/024.200

IC [4]

ICM: C12P021-02

ICS: C12N015-00; C12N001-20; C12N001-00

EXF 435/68; 435/172.3; 435/320; 935/47

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 541 OF 588 USPATFULL on STN

AN 89:92617 USPATFULL

TI Fused polypeptides and methods for their detection

IN Brewer, Stephen J., High Wycombe, England

Sassenfeld, Helmut M., Benson, England

PA G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)

EXF 260/112.5R; 514/12; 530/350

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 543 OF 588 USPATFULL on STN

AN 89:80733 USPATFULL

TI Bacterial methionine N-terminal peptidase

IN Ben-Bassat, Arie, Concord, CA, United States

Bauer, Keith A., Oakland, CA, United States

Chang, Shing, Oakland, CA, United States

Chang, Sheng-Yung, Oakland, CA, United States

PA Cetus Corporation, Emeryville, CA, United States (U.S. corporation)

PI US 4870017 19890926 <--

AI US 1985-778414 19850920 (6)

DT Utility

FS Granted

LN.CNT 795

INCL INCLM: 435/212.000

INCLS: 435/068.000; 435/172.300; 435/252.330; 435/317.100

NCL NCLM: 435/212.000

NCLS: 435/069.400; 435/069.500; 435/252.330; 435/489.000; 930/010.000;  
930/200.000; 930/240.000

IC [4]

ICM: C12N009-48

ICS: C12N015-00

EXF 260/112.5; 530/409; 530/339; 530/402; 935/11; 935/28; 935/69; 935/79;  
435/70; 435/71; 435/91; 435/212; 435/255; 435/256; 435/317

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 544 OF 588 USPATFULL on STN

AN 89:78679 USPATFULL

TI Gram-positive expression control sequences

IN Bujard, Hermann, Heidelberg, Germany, Federal Republic of

Le Grice, Stuart, Basel, Switzerland

PA Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

DT Utility  
FS Granted  
LN.CNT 1025  
INCL INCLM: 435/068.000  
INCLS: 435/212.000; 435/172.300; 935/060.000  
NCL NCLM: 435/068.100  
NCLS: 435/212.000; 435/320.100; 930/010.000; 930/141.000; 930/230.000;  
930/240.000; 930/300.000  
IC [4]  
ICM: C12P071-06  
ICS: C12N009-48; C12N001-00; C12N015-00  
EXF 435/70; 435/69; 435/172.3; 435/233; 435/68; 435/69; 435/317; 530/402;  
530/339; 260/112.5; 935/60  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 546 OF 588 USPATFULL on STN  
AN 89:72121 USPATFULL  
TI Production of proteins in procaryotes  
IN Krivi, Gwen G., St. Louis, MO, United States  
PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)  
PI US 4861868 19890829 <--  
AI US 1985-704362 19850222 (6)  
DT Utility  
FS Granted  
LN.CNT 1331  
INCL INCLM: 530/399.000  
NCL NCLM: 530/399.000  
IC [4]  
ICM: C07K013-00  
EXF 530/324; 530/399  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 547 OF 588 USPATFULL on STN  
AN 89:69698 USPATFULL

AI US 1987-61942 19870612 (7)  
 RLI Continuation-in-part of Ser. No. US 1986-861236, filed on 7 May 1986  
 which is a continuation of Ser. No. US 1985-737302, filed on 22 May  
 1985, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 1104  
 INCL INCLM: 530/403.000  
 INCLS: 530/402.000; 530/810.000; 424/088.000; 430/519.000; 430/543.000  
 NCL NCLM: 424/185.100  
 NCLS: 436/519.000; 436/543.000; 530/402.000; 530/403.000; 530/810.000;  
 930/010.000; 930/300.000  
 IC [4]  
 ICM: C12P021-00  
 ICS: C12P019-34; C12N015-00; C07H015-12  
 EXF 424/85; 424/86; 424/87; 424/88; 530/402; 530/403; 530/810; 436/519;  
 436/543  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
  
 L5 ANSWER 549 OF 588 USPATFULL on STN  
 AN 89:65024 USPATFULL  
 TI Regulatory region for heterologous gene expression in yeast  
 IN Stroman, David W., Bartlesville, OK, United States  
 Brust, Paul F., San Diego, CA, United States  
 Ellis, Steven B., La Jolla, CA, United States  
 Gingeras, Thomas R., Encinitas, CA, United States  
 Harpold, Michael M., San Diego, CA, United States  
 Tschopp, Juerg F., San Diego, CA, United States  
 PA Phillips Petroleum Company, Bartlesville, OK, United States (U.S.  
 corporation)  
 PI US 4855231 19890808 <--  
 AI US 1985-780102 19850925 (6)  
 RLI Continuation-in-part of Ser. No. US 1984-666391, filed on 30 Oct 1984  
 DT Utility

INCL INCLM: 435/068.000  
INCLS: 435/172.300; 435/243.000; 435/255.000; 435/320.000; 435/252.310;  
435/252.330  
NCL NCLM: 435/069.600  
NCLS: 435/243.000; 435/252.310; 435/252.330; 435/254.210; 435/320.100;  
435/475.000; 930/010.000  
IC [4]  
ICM: C12P021-00  
ICS: C12N015-00; C12N001-00; C12N001-20  
EXF 435/68; 435/172.3; 435/243; 435/320; 435/253; 435/255  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 551 OF 588 USPATFULL on STN  
AN 89:17246 USPATFULL  
TI Microbial production of mature human leukocyte interferon K and L  
IN Goeddel, David V., Burlingame, CA, United States  
Pestka, Sidney, North Caldwell, NJ, United States  
PA Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)  
Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)  
PI US 4810645 19890307 <--  
AI US 1986-822984 19860127 (6)  
RLI Division of Ser. No. US 1981-293044, filed on 14 Aug 1981, now abandoned  
DT Utility  
FS Granted

LN.CNT 1517

INCL INCLM: 435/068.000  
INCLS: 435/172.300; 435/320.000; 435/252.330; 536/027.000; 424/085.700  
NCL NCLM: 435/069.510  
NCLS: 424/085.700; 435/252.330; 435/320.100; 536/023.520; 536/024.100;  
930/142.000; 930/300.000  
IC [4]  
ICM: C12P021-00  
ICS: C12N015-00; C07H021-04  
EXF 435/68; 435/172.3; 435/253; 435/320; 536/27; 424/88; 424/85

IN Goeddel, David V., Burlingame, CA, United States  
Pestka, Sidney, North Caldwell, NJ, United States  
PA Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)  
Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)  
PI US 4801685 19890131 <--  
AI US 1987-56623 19870601 (7)  
RLI Continuation of Ser. No. US 1986-894076, filed on 5 Aug 1986, now  
abandoned which is a continuation of Ser. No. US 1981-293044, filed on  
14 Aug 1981, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1464  
INCL INCLM: 530/351.000  
INCLS: 424/085.700; 435/068.000; 435/811.000  
NCL NCLM: 530/351.000  
NCLS: 424/085.700; 435/069.510; 435/811.000; 930/142.000  
IC [4]  
ICM: C07K013-00  
ICS: C07K015-26; A61K045-02; C12P021-00  
EXF 424/85; 530/351; 435/68; 435/811  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 554 OF 588 USPATFULL on STN  
AN 89:7503 USPATFULL  
TI Vector for expression of polypeptides in bacilli  
IN Nagarajan, Vasantha, Rockville, MD, United States  
Rhodes, Craig S., Washington, DC, United States  
Banner, Carl D. B., Bethesda, MD, United States  
PA Genex Corporation, Gaithersburg, MD, United States (U.S. corporation)  
PI US 4801537 19890131 <--  
AI US 1985-717800 19850329 (6)  
RLI Continuation-in-part of Ser. No. US 1984-618902, filed on 8 Jun 1984,  
now abandoned which is a continuation-in-part of Ser. No. US  
1983-511198, filed on 6 Jul 1983, now abandoned

NCLS: 435/069.400; 435/069.800; 435/320.100; 536/023.100; 536/023.400;  
536/024.100; 930/200.000

IC [4]

ICM: C12P021-00

ICS: C12N015-00

EXF 435/68; 435/172.3; 935/48

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 556 OF 588 USPATFULL on STN

AN 89:3075 USPATFULL

TI Solubilization of protein aggregates

IN Patroni, Joseph J., Preston West, Australia

Brandon, Malcolm R., Ivanhoe East, Australia

PA Bunge (Australia) Pty. Ltd., Australia (non-U.S. corporation)

PI US 4797474 19890110 <--

AI US 1986-939578 19861209 (6)

PRAI AU 1985-3818 19851211

DT Utility

FS Granted

LN.CNT 440

INCL INCLM: 530/351.000

INCLS: 530/355.000; 530/417.000; 530/418.000; 530/419.000; 530/422.000;  
530/423.000

NCL NCLM: 530/351.000

NCLS: 530/355.000; 530/417.000; 530/418.000; 530/419.000; 530/422.000;  
530/423.000

IC [4]

ICM: C07K003-12

EXF 530/417; 530/418; 530/419; 530/422; 530/423; 530/351; 530/355

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 557 OF 588 USPATFULL on STN

AN 89:1186 USPATFULL

TI Novel expression control sequences



RLI Continuation-in-part of Ser. No. US 1985-777117, filed on 17 Sep 1985,  
now abandoned

DT Utility

FS Granted

LN.CNT 1090

INCL INCLM: 530/350.000  
INCLS: 530/324.000; 530/399.000

NCL NCLM: 530/350.000  
NCLS: 530/324.000; 530/399.000; 930/120.000; 930/DIG.821

IC [4]  
ICM: C07K013-00

EXF 530/350; 530/399; 530/827; 530/830; 530/324; 514/12; 514/21

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 559 OF 588 USPATFULL on STN

AN 88:70969 USPATFULL

TI Synthesis of protein with an identification peptide, and hybrid  
polypeptide incorporating same

IN Hopp, Thomas P., Seattle, WA, United States  
Bektesh, Susan L., Seattle, WA, United States  
Conlon, III, Paul J., Seattle, WA, United States  
March, Carl J., Seattle, WA, United States

PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)

PI US 4782137 19881101 <--

AI US 1987-76811 19870723 (7)

RLI Division of Ser. No. US 1984-573825, filed on 24 Jan 1984, now patented,  
Pat. No. US 4703004

DT Utility

FS Granted

LN.CNT 1513

INCL INCLM: 530/328.000  
INCLS: 530/330.000; 530/350.000; 435/068.000

NCL NCLM: 530/328.000  
NCLS: 435/069.300; 435/069.700; 530/330.000; 530/350.000; 930/010.000;

for human relaxin

IN Hudson, Peter J., Bulleen, Australia

Niall, Hugh D., Elwood, Australia

Tregear, Geoffrey W., Hawthorn, Australia

PA Howard Florey Institute of Experimental Physiology and Medicine,  
Australia (non-U.S. corporation)

PI US 4758516 19880719 <--

AI US 1983-560790 19831213 (6)

PRAI AU 1982-7247 19821213

DT Utility

FS Granted

LN.CNT 1017

INCL INCLM: 435/253.000

INCLS: 435/070.000; 435/172.300; 435/320.000; 536/027.000; 935/013.000;  
935/029.000; 935/031.000; 935/072.000

NCL NCLM: 435/252.300

NCLS: 435/069.400; 435/252.330; 435/320.100; 536/023.200; 536/023.500;  
536/023.510; 536/024.100

IC [4]

ICM: C12N001-20

ICS: C12N015-00; C12N001-00; C12P021-02; C07H017-00

EXF 435/68; 435/70; 435/317; 435/172.3; 435/320; 536/27; 935/9; 935/13;  
935/23; 935/24; 935/27; 935/72; 935/29; 935/31

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 562 OF 588 USPATFULL on STN

AN 88:42303 USPATFULL

TI Secretion of correctly processed \*\*\*human\*\*\* \*\*\*growth\*\*\*  
\*\*\*hormone\*\*\* in E. coli and Pseudomonas

IN Gray, Gregory L., San Francisco, CA, United States

Heyneker, Herbert L., Burlingame, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S.  
corporation)

PI US 4755465 19880705 <--

EXF 530/303; 530/308; 530/344; 530/345; 530/397; 530/399; 530/406; 530/410;  
530/408; 530/329

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 564 OF 588 USPATFULL on STN

AN 88:31001 USPATFULL

TI Fused protein for enzyme immunoassay system

IN Schenk, Dale B., Campbell, CA, United States

Spratt, Sharon K., Sunnyvale, CA, United States

PA California Biotechnology Inc., Mountain View, CA, United States (U.S.  
corporation)

PI US 4745055 19880517 <--

AI US 1986-868393 19860528 (6)

RLI Continuation-in-part of Ser. No. US 1985-731853, filed on 7 May 1985,  
now abandoned

DT Utility

FS Granted

LN.CNT 824

INCL INCLM: 435/007.000

INCLS: 435/014.000; 435/068.000; 435/070.000; 435/172.300; 435/188.000;  
435/810.000; 435/320.000; 530/350.000; 935/010.000; 935/011.000;  
935/029.000; 935/047.000

NCL NCLM: 435/007.600

NCLS: 435/007.900; 435/014.000; 435/069.700; 435/069.800; 435/188.000;  
435/320.100; 435/488.000; 435/810.000; 530/350.000; 930/050.000;  
930/220.000; 930/240.000

IC [4]

ICM: G01N033-535

ICS: C12N015-00

EXF 435/7; 435/14; 435/68; 435/70; 435/172.3; 435/188; 435/317; 435/810;  
935/10; 935/11; 935/29; 935/47; 530/350

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 565 OF 588 USPATFULL on STN

products

IN Belagaje, Ramamoorthy, Indianapolis, IN, United States  
Epp, Janet K., Indianapolis, IN, United States  
Hoskins, JoAnn, Indianapolis, IN, United States  
Hsiung, Hansen M., Indianapolis, IN, United States  
Long, George L., Indianapolis, IN, United States  
Schoner, Brigitte E., Zionsville, IN, United States  
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)

PI US 4738921 19880419 <--

AI US 1984-655183 19840927 (6)

DT Utility

FS Granted

LN.CNT 1086

INCL INCLM: 435/068.000

INCLS: 435/070.000; 435/172.300; 435/253.000; 435/320.000; 435/849.000;  
536/027.000; 935/041.000; 935/047.000; 935/048.000

NCL NCLM: 435/069.700

NCLS: 435/069.400; 435/069.800; 435/252.330; 435/320.100; 435/488.000;  
435/849.000; 530/351.000; 536/023.200; 536/023.400; 536/023.500;  
536/023.510; 536/023.520; 536/024.100; 536/024.200; 930/120.000;  
930/260.000

IC [4]

ICM: C12P021-00

ICS: C12P021-02; C12N015-00; C12N001-20; C12N007-00; C07H015-12

EXF 435/68; 435/70; 435/172.3; 435/317; 435/253; 935/39; 935/40; 935/41;  
935/73; 536/27

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 567 OF 588 USPATFULL on STN

AN 88:17912 USPATFULL

TI Polypeptides having \*\*\*growth\*\*\* \*\*\*hormone\*\*\* releasing  
activity

IN Felix, Arthur M., West Caldwell, NJ, United States

935/075.000; 935/079.000

NCL NCLM: 435/252.330

NCLS: 435/069.400; 435/193.000; 435/195.000; 435/252.300; 435/252.310;  
435/252.340; 435/252.350; 435/320.100; 930/010.000; 930/180.000

IC [4]

ICM: C12N009-14

ICS: C12N001-20; C12N001-00; C12N015-00; C12N009-10; C12P021-00

EXF 435/68; 435/70; 435/91; 435/172.3; 435/253; 435/317; 435/317.1; 435/193;  
435/195; 435/172.1; 935/29; 935/72-75; 935/79

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 569 OF 588 USPATFULL on STN

AN 87:74973 USPATFULL

TI Expression vector carrying a gene coding for a phosphate-binding  
protein, a method for preparing the same and a method for preparing the  
same and a method for producing a polypeptide using the same

IN Nakata, Atsuo, Toyonaka, Japan  
Shinagawa, Hideo, Minoo, Japan

PA The Research Foundation for Microbial Diseases of Osaka University,  
Osaka, Japan (non-U.S. corporation)

PI US 4703005 19871027 <--

AI US 1983-501559 19830606 (6)

PRAI JP 1982-96775 19820604

DT Utility

FS Granted

LN.CNT 1100

INCL INCLM: 435/068.000

INCLS: 435/091.000; 435/172.300; 435/253.000; 435/320.000; 935/029.000;  
935/041.000; 935/060.000; 935/073.000

NCL NCLM: 435/069.100

NCLS: 435/091.410; 435/091.420; 435/320.100; 435/488.000; 435/849.000;  
536/023.100

IC [4]

ICM: C12P021-00

AI US 1983-560495 19831212 (6)  
RLI Division of Ser. No. US 1983-483451, filed on 15 Apr 1983 which is a  
continuation-in-part of Ser. No. US 1982-375494, filed on 6 May 1982  
DT Utility  
FS Granted  
LN.CNT 1630  
INCL INCLM: 530/351.000  
INCLS: 435/068.000; 435/811.000; 424/085.000  
NCL NCLM: 530/351.000  
NCLS: 424/085.700; 435/069.510; 435/811.000; 930/142.000  
IC [4]  
ICM: C07K015-26  
ICS: C07K013-00; A61K045-02; C12P021-00  
EXF 260/112R; 260/112.5R; 435/172.3; 435/68; 530/351  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 572 OF 588 USPATFULL on STN  
AN 87:32195 USPATFULL  
TI Method of altering double-stranded DNA  
IN Kleid, Dennis G., San Mateo, CA, United States  
Yansura, Daniel G., San Francisco, CA, United States  
Heyneker, Herbert L., Burlingame, CA, United States  
Miozzari, Giuseppe F., San Carlos, CA, United States  
PA Genentech, Inc., South San Francisco, CA, United States (U.S.  
corporation)  
PI US 4663283 19870505 <--  
AI US 1983-543682 19831020 (6)  
RLI Division of Ser. No. US 1981-307473, filed on 1 Oct 1981, now abandoned  
which is a continuation of Ser. No. US 1980-133296, filed on 24 Mar  
1980, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1041  
INCL INCLM: 435/091.000

EXF 435/68; 435/70; 435/172.3; 435/71; 435/91; 435/253; 435/834; 435/839;  
435/317; 536/27; 935/41; 935/29; 935/48; 935/49; 935/74

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 574 OF 588 USPATFULL on STN

AN 87:20719 USPATFULL

TI Manufacture and expression of structural genes

IN Stabinsky, Yitzhak, Boulder, CO, United States

PA Amgen, Thousand Oaks, CA, United States (U.S. corporation)

PI US 4652639 19870324 <--

AI US 1982-375493 19820506 (6)

DT Utility

FS Granted

LN.CNT 1010

INCL INCLM: 536/027.000

INCLS: 536/028.000; 536/029.000; 435/068.000; 435/070.000; 435/091.000;  
435/172.300; 435/317.000; 935/016.000; 935/017.000

NCL NCLM: 435/091.520

NCLS: 435/069.400; 435/091.530; 435/320.100; 536/023.100; 930/080.000

IC [4]

ICM: C07H021-04

ICS: C07H021-02; C12P021-00; C12P021-02; C12P019-34; C12N015-00;  
C12N001-00

EXF 435/68; 435/70; 435/91; 435/172; 435/253; 435/317; 435/172.3; 536/27;  
536/28; 536/29; 935/16; 935/17

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 575 OF 588 USPATFULL on STN

AN 87:18713 USPATFULL

TI Method for stabilizing and selecting recombinant DNA containing host  
cell

IN Hershberger, Charles L., New Palestine, IN, United States

Rosteck, Jr., Paul R., Beech Grove, IN, United States

PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.

DT Utility  
FS Granted  
LN.CNT 194  
INCL INCLM: 530/409.000  
INCLS: 435/176.000; 435/177.000; 435/207.000; 530/345.000; 530/812.000  
NCL NCLM: 530/409.000  
NCLS: 435/176.000; 435/177.000; 435/207.000; 530/345.000; 530/812.000  
IC [4]  
ICM: C07K017-00  
ICS: C12N009-99; C12N011-02  
EXF 260/112R; 260/112B; 260/112.5R; 435/176; 435/177; 435/207; 530/409;  
530/345; 530/812

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 577 OF 588 USPATFULL on STN  
AN 85:65304 USPATFULL  
TI Microbial hybrid promoters  
IN DeBoer, Herman A., Pacifica, CA, United States  
PA Genentech, Inc., San Francisco, CA, United States (U.S. corporation)  
PI US 4551433 19851105 <--  
AI US 1982-338397 19820111 (6)  
RLI Continuation-in-part of Ser. No. US 1981-264306, filed on 18 May 1981,  
now abandoned And a continuation-in-part of Ser. No. US 1981-328174,  
filed on 7 Dec 1981, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1015  
INCL INCLM: 435/253.000  
INCLS: 435/068.000; 435/070.000; 435/071.000; 435/172.300; 435/317.000;  
435/849.000; 536/027.000; 935/038.000; 935/041.000; 935/061.000;  
935/073.000  
NCL NCLM: 435/252.330  
NCLS: 435/069.100; 435/069.200; 435/069.300; 435/069.400; 435/320.100;  
435/849.000; 536/024.100



435/172.3; 935/51; 935/47

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 579 OF 588 USPATFULL on STN

AN 85:43207 USPATFULL

TI Method for conferring bacteriophage resistance to bacteria

IN Hershberger, Charles L., New Palestine, IN, United States

Rosteck, Jr., Paul R., Beech Grove, IN, United States

PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)

PI US 4530904 19850723 <--

AI US 1982-414290 19820903 (6)

DT Utility

FS Granted

LN.CNT 1251

INCL INCLM: 435/172.300

INCLS: 435/068.000; 435/070.000; 435/071.000; 435/091.000; 435/253.000;  
435/317.000; 435/029.000; 435/072.000; 435/073.000; 435/083.000

NCL NCLM: 435/006.000

NCLS: 435/069.100; 435/069.300; 435/069.400; 435/069.500; 435/069.510;  
435/069.520; 435/069.600; 435/091.410; 435/252.200; 435/252.300;  
435/252.310; 435/252.330; 435/252.340; 435/252.350; 435/320.100;  
435/488.000; 435/849.000; 536/023.200; 536/024.200; 930/010.000;  
930/180.000

IC [3]

ICM: C12P019-34

ICS: C12P021-00; C12P021-02; C12P021-04; C12N001-20; C12N001-00;  
C12N015-00

EXF 435/68; 435/70; 435/91; 435/172; 435/253; 435/317; 435/172.3

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 580 OF 588 USPATFULL on STN

AN 85:16402 USPATFULL

TI Stabilizing and selecting recombinant DNA host cells

PI	US 4436815	19840313	<--
AI	US 1981-325511	19811127 (6)	
DT	Utility		
FS	Granted		
LN.CNT 1344			
INCL	INCLM: 435/172.000		
	INCLS: 435/068.000; 435/070.000; 435/253.000; 435/317.000; 536/027.000		
NCL	NCLM: 435/034.000		
	NCLS: 435/069.100; 435/069.200; 435/069.300; 435/069.400; 435/069.510;		
	435/252.330; 435/320.100; 435/473.000; 536/023.100; 536/024.100;		
	536/024.200; 930/180.000		
IC	[3]		
	ICM: C12N015-00		
	ICS: C12N001-20; C12N001-00; C12P021-00; C12P021-02; C07H021-04		
EXF	435/172; 435/317; 435/253; 435/68; 435/70; 536/27		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
L5	ANSWER 582 OF 588 USPATFULL on STN		
AN	84:8943 USPATFULL		
TI	DNA Transfer vector and transformed microorganism containing human proinsulin and pre-proinsulin genes		
IN	Bell, Graeme, San Francisco, CA, United States		
	Pictet, Raymond, San Francisco, CA, United States		
	Goodman, Howard M., San Francisco, CA, United States		
	Rutter, William J., San Francisco, CA, United States		
PA	The Regents of the University of California, Berkeley, CA, United States (U.S. corporation)		
PI	US 4431740	19840214	<--
AI	US 1982-386338	19820608 (6)	
RLI	Continuation of Ser. No. US 1979-75192, filed on 12 Sep 1979, now abandoned		
DT	Utility		
FS	Granted		
LN.CNT 1066			

EXF 435/68; 435/70; 435/71; 435/91; 435/196; 435/172; 435/253; 435/317;  
435/820; 435/849; 435/881

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 584 OF 588 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

AN 1997-226231 [20] WPIDS

DNC C1997-072567

TI Nucleic acid segment encoding one subunit of a coiled dimer protein - also  
derived \*\*\*fusion\*\*\* \*\*\*proteins\*\*\* that can be detected or  
purified by reaction with the complementary second subunit.

DC B04 D16

IN BAUTISTA, D; CACHIA, P J; HODGES, R S; HOUSTON, M E; IRVIN, R T; TRIPET,  
B; YU, L

PA (PENC-N) PENCE

CYC 22

PI WO 9712988 A1 19970410 (199720)\* EN 80 C12P021-06 <--

RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

W: AU CA JP US

AU 9672584 A 19970428 (199733) C12P021-06 <--

EP 854931 A1 19980729 (199834) EN C12P021-06 <--

R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AU 695679 B 19980820 (199845) C12P021-06 <--

JP 11512620 W 19991102 (200003) 97 C12N015-00

ADT WO 9712988 A1 WO 1996-US16032 19961004; AU 9672584 A AU 1996-72584  
19961004; EP 854931 A1 EP 1996-934080 19961004, WO 1996-US16032 19961004;  
AU 695679 B AU 1996-72584 19961004; JP 11512620 W WO 1996-US16032  
19961004, JP 1997-514507 19961004

FDT AU 9672584 A Based on WO 9712988; EP 854931 A1 Based on WO 9712988; AU  
695679 B Previous Publ. AU 9672584, Based on WO 9712988; JP 11512620 W  
Based on WO 9712988

PRAI US 1995-540397 19951006

IC ICM C12N015-00; C12P021-06

ICS C07H021-02; C07H021-04; C07K001-22; C07K007-06; C07K016-00;  
C07K019-00; C12N001-19; C12N001-21; C12P021-02; C12P021-04

19941117, WO 1994-US14210 19941209, US 1996-652521 19960605; EP 1087016 A2  
 Div ex EP 1995-905888 19941209, EP 2000-127662 19941209; EP 731632 B1 WO  
 1994-US14210 19941209, EP 1995-905888 19941209, Related to EP 2000-127662  
 19941209; DE 69429012 E DE 1994-629012 19941209, WO 1994-US14210 19941209,  
 EP 1995-905888 19941209; ES 2164759 T3 EP 1995-905888 19941209; CA 2177267  
 C CA 1994-2177267 19941209, WO 1994-US14210 19941209  
 FDT AU 9514333 A Based on WO 9515678; EP 731632 A1 Based on WO 9515678; JP  
 09508786 W Based on WO 9515678; AU 693506 B Previous Publ. AU 9514333,  
 Based on WO 9515678; US 5792935 A Based on WO 9515678; EP 1087016 A2 Div  
 ex EP 731632; EP 731632 B1 Related to EP 1087016, Based on WO 9515678; DE  
 69429012 E Based on EP 731632, Based on WO 9515678; ES 2164759 T3 Based on  
 EP 731632; CA 2177267 C Based on WO 9515678  
 PRAI US 1994-341461 19941117; US 1993-164296 19931209;  
 US 1996-652521 19960605  
 IC A01H005-08; C12N005-14; C12N015-64; C12N015-82  
 ICM A01H005-00; C12N015-82; C12N015-84  
 ICS A01H005-08; C12N005-10; C12N005-14; C12N015-09; C12N015-18;  
 C12N015-24; C12N015-64  
 L5 ANSWER 586 OF 588 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN  
 AN 1990-269426 [36] WPIDS  
 DNC C1990-116468  
 TI Polyhedrin gene of Spodoptera-litura nuclear polyhedrosis virus - which  
 allows efficient transformation when cloning heterologous DNA sequences.  
 DC B04 D16  
 IN ARAKI, T; MATSUO, N; YAMADA, N  
 PA (NOYA-N) NOYAKU BIOTECHN KAI; (REAS-N) RES ASSOC BIOTECHN; (REAS-N) RES  
 ASSOC BIOTECHNOLOGY AGRIC CHEM  
 CYC 13  
 PI EP 385394 A 19900905 (199036)\* <--  
 R: AT BE CH DE ES FR GB IT LI NL SE  
 JP 02291272 A 19901203 (199103) <--  
 US 5145775 A 19920908 (199239) 22 C12P021-02 <--  
 ADT EP 385394 A EP 1990-103793 19900227; JP 02291272 A JP 1990-44559 19900227;

ICS A61K035-74; A61K037-00; C07H021-04; C07K013-00; C07K015-00;  
C07K019-00; C12N001-20; C12N001-21; C12N015-09; C12R001-19  
ICI C12N001-20, C12R001:19; C12P021-02, C12R001:19; C12N001-21, C12R001:19;  
C12N001-21, C12R001:

L5 ANSWER 588 OF 588 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN  
AN 1987-108702 [15] WPIDS  
DNC C1987-045201

TI Drug delivery system - comprises target specific peptide having low  
density lipoprotein receptor-binding region bound to drug or carrier.

DC B04 D16

IN KANE, J P; PROTTER, A A

PA (BIOT-N) BIOTECHN RES PARTN

CYC 13

PI WO 8702061 A 19870409 (198715)\* EN 52 <--

RW: AT BE CH DE FR GB IT LU NL SE

W: AU JP

AU 8664085 A 19870424 (198728) <--

EP 238645 A 19870930 (198739) EN <--

R: AT BE CH DE FR GB IT LI LU NL SE

ADT WO 8702061 A WO 1986-US2074 19861002; EP 238645 A EP 1986-906200 19861002

PRAI US 1985-783787 19851003

IC C12P021-00

STN INTERNATIONAL LOGOFF AT 16:37:12 ON 18 APR 2005